Pharmacogenetics of Tamoxifen in Asian Breast Cancer Patients by LIM SIOK LIU
 











LIM SIOK LIU 





A THESIS SUBMITTED  





DEPARTMENT OF PHARMACOLOGY 







I would like to express my heartfelt gratitude to Prof Balram Chowbay, National 
Cancer Centre, Singapore. This project was carried out in National Cancer 
Centre Singapore under his direct supervision. Without his guidance and 
unwavering support, this project and thesis would not be possible. I would also 
like to thank Prof Edmund Lee for his encouragement and advice during the 
course of my study. I would also like to sincerely thank my fellow colleagues, 
Xiangai, Onkar, Sin Chi and Koilan for their contributions and technical support. I 
would like to express my gratitude towards Dr Flockhart David (Indiana University 
School of Medicine, Indianapolis, IN, USA) and Dr Lazarus Phillips (Pennsylvania 
State University College of Medicine, PA, USA) for their generous gifts of the 
pure metabolites, endoxifen. In addition, I would like to express appreciation for 
the help that our collaborators from Dr. Margarete Fischer-Bosch-Institut für 
Klinische Pharmakologie, Germany, rendered in the analyses of the phase II 
metabolites: Drs Matthias Schwab, Thomas Muerdter, Hiltrud Brauch and Boian 
Ganchev. I am also greatly indebted to Drs Yap Yoon Sim, Raymond Ng and 
Wong Nan Soon as well as other clinicians from the breast team in National 
Cancer Centre Singapore for their clinical support in study recruitment. I sincerely 
thank all patients who took part in this study. Without them, the study would not 
be possible. This study was supported by grants from the Singapore Cancer 
Syndicate (SCS-PS0023R) and National Medical Research Council 
(NMRC/1159/2008 and NMRCB1011).  In addition, I would like express my 
appreciation for A/Prof Go Mei Lin for her invaluable advice during the turning 
point of my life. Last but not least, I would also like to thank my family for their 




Declaration         i 
Acknowledgements        ii  
Summary         xii 
Publications and Abstracts       xv 
List of Tables         xvii 
List of Figures        xxii 
 
Chapter 1: Introduction       1 
1.1 Breast Cancer        1 
1.1.1 Epidemiology       1 
1.1.2 Types of Breast Cancer      2 
1.1.3 Available Treatment Modalities     6 
1.1.4 Endocrine Therapies: Tamoxifen versus Aromatase Inhibitors  8 
1.2 Pharmacology of Tamoxifen      11 
1.2.1 Introduction        11 
1.2.2 Chemistry        11 
1.2.3 Mechanism of Action      13 
1.2.4 Pharmacokinetics       16 
 iv
1.2.4.1 Absorption and Distribution     16 
1.2.4.2 Metabolism       17 
1.2.4.3 Excretion       22 
1.2.5 Pharmacodynamics       25 
1.2.5.1 Endocrine Effect      25 
1.2.5.2 Effects on Breast      27 
1.2.5.3 Effects on Other Tissues     30 
1.3 Pharmacogenetics of Tamoxifen     32 
1.3.1 Phase I Drug Metabolizing Enzymes: Cytochrome P450 (CYP) 34 
1.3.1.1 Cytochrome P450, family 1, subfamily A, polypeptide 2 
(CYP1A2)       35 
1.3.1.2 Cytochrome P450, family 2, subfamily C (CYP2C)  40 
1.3.1.2.1 Cytochrome P450, family 2, subfamily C, polypeptide 9 
(CYP2C9)      40 
1.3.1.2.2 Cytochrome P450, family 2, subfamily C, polypeptide 19 
(CYP2C19)      42 
1.3.1.3 Cytochrome P450, family 2, subfamily D, polypeptide 6 
(CYP2D6)       45 
1.3.1.3.1 Effect of CYP2D6 on Disposition of Tamoxifen 52 
1.3.1.3.2 Effect of CYP2D6 on Treatment Outcome of Tamoxifen
        55 
1.3.1.4 Cytochrome P450, family 3, subfamily A (CYP3A)  58 
1.3.1.4.1 Cytochrome P450, family 3, subfamily A, polypeptide 4 
(CYP3A4)      59 
1.3.1.4.2 Cytochrome P450, family 3, subfamily A, polypeptide 5 
(CYP3A5)      60 
 v
1.3.2 Phase II Drug Metabolizing Enzymes    62 
1.3.2.1 Uridine 5′-diphosphate-glucuronosyltransferase (UDP-
glucuronosyltransferase, UGT)    62 
1.3.2.1.1 UDP glucuronosyltransferase 1 family, polypeptide A4 
(UGT1A4)      65 
1.3.2.1.2 UDP glucuronosyltransferase 2 family, polypeptide B7 
(UGT2B7)      68 
1.3.2.1.3 UDP glucuronosyltransferase 2 family, polypeptide B15 
(UGT2B15)      70 
1.3.2.2 Sulfotransferase (SULT)     73 
1.3.2.2.1 Sulfotransferase family, cytosolic, 1A, phenol-preferring, 
member 1 (SULT1A1)     74 
1.4 Hypothesis        78 
1.5 Aims         79 
Chapter 2: Materials and Methods      81 
2.1 Study Design        81 
2.2 Study Populations       82 
2.2.1 Healthy Subjects       82 
2.2.2 Breast Cancer Patients      82 
2.2.2.1 Inclusion criteria      82 
2.2.2.2 Exclusion criteria      83 
2.2.2.3 Baseline Evaluations      83 
2.2.2.4 Tamoxifen Administration and Monitoring of Treatment 
Compliance       84  
 vi
2.3 Chemicals and Reagents      85 
2.4 Pharmacogenetic Analysis      87 
2.4.1 DNA extraction (from whole blood)    87 
2.4.2 Polymerase Chain Reaction (PCR)    89 
2.4.3 Purification of PCR Amplicons     90 
2.4.4 DNA Sequencing       90 
2.4.5 Pharmacogenetics of Phase I Drug Metabolizing Enzymes 93 
2.4.5.1 Cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) 
         93 
2.4.5.2 Cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) 
         96 
2.4.5.3 Cytochrome P450, family 2, subfamily C, polypeptide 19 
(CYP2C19)       97 
2.4.5.4 Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) 
         100 
2.4.5.5 Cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5) 
         102 
2.4.6 Pharmacogenetics of Phase II Drug Metabolizing Enzymes 103 
2.4.6.1 UDP glucuronosyltransferase 1 family, polypeptide A4 (UGT1A4) 
         103 
2.4.6.2 UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7) 
         105 
2.4.6.3 UDP glucuronosyltransferase 2 family, polypeptide B15 (UGT2B15)
         108 
2.4.6.4 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 
1 (SULT1A1)       110 
 vii
2.5 Pharmacokinetic Analysis      111  
2.5.1 HPLC-fluorescence Assay      111 
2.5.1.1 Instrumentation and chromatographic conditions  112 
2.5.1.2 Standard Stock Solutions, Calibration and Quality Control (QC) 
Samples       113 
2.5.1.3 Sample Preparation and Analysis of Plasma Concentrations of 
Analytes using HPLC-fluorescence    113 
2.5.2 LC-MS Assay       115 
2.5.2.1 Instrumentation and chromatographic conditions  115 
2.5.2.2 Standard Stock Solutions, Calibration and Quality Control (QC) 
Samples       116 
2.5.2.3 Sample Preparation and Analysis of Plasma Concentrations of 
Analytes using LC-MS      116 
2.5.3 Calculation of Metabolic Ratios (MRs)    116 
2.6 Statistical Analysis       118 
2.6.1 Genetic Analysis       118 
2.6.2 Pharmacokinetics-Pharmacogenetics Correlations  118 
Chapter 3: Results and Discussions     120 
3.1 Patient Demographics and Characteristics    120 
3.2 Plasma Concentrations of Tamoxifen and its Metabolites  122 
3.3 Pharmacogenetics of Phase I Drug Metabolizing Enzymes  136 
3.3.1 Cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) 
         136 
3.3.1.1 Genetic Analysis of CYP1A2     136 
 viii
3.3.1.2 Linkage disequilibrium (LD) Analysis of CYP1A2 Polymorphisms 
         141 
3.3.1.3 Haplotypes, Network and tag-SNP Analysis of CYP1A2 
Polymorphisms      143 
3.3.1.4 Pharmacogenetic-pharmacokinetic Associations of CYP1A2 
Polymorphisms      146 
3.3.1.5 Discussion       151 
3.3.2 Cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) 
         157 
3.3.2.1 Genetic Analysis of CYP2C9     157 
3.3.2.2 Influence of CYP2C9 Polymorphisms on the Plasma Levels of 
Tamoxifen and its Metabolites    157 
3.3.2.3 Discussion       160 
3.3.3 Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) 
         165 
3.3.3.1 Genetic Profile of CYP2C19 Polymorphisms   165 
3.3.3.2 LD Analysis of CYP2C19 Polymorphisms   177 
3.3.3.3 Selection of CYP2C19 tag-SNPs    177 
3.3.3.4 Influence of CYP2C19 Polymorphisms on the Plasma Levels of 
Tamoxifen and its Metabolites    180 
3.3.3.5 Influence of CYP2C19 Polymorphisms on the Metabolic Ratios of 
Tamoxifen and its Metabolites    180 
3.3.3.6 Discussion       189 
3.3.4 Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) 
         195 
3.3.4.1 Genetic Profile of CYP2D6     195 
 ix
3.3.4.2 Influence of CYP2D6 Polymorphisms on the Plasma Levels of 
Tamoxifen and its Metabolites    199 
3.3.4.3 Influence of CYP2D6 Polymorphisms on the Metabolic Ratios of 
Tamoxifen and its Metabolites    201 
3.3.4.4 Discussion       210 
3.3.5 Cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5) 
         216 
3.3.5.1 Genetic Profile of CYP3A5     216 
3.3.5.2 Influence of CYP3A5*3 (6986A>G; rs776746) on the Plasma 
Levels of Tamoxifen and its Metabolites as well as its Metabolic 
Ratios        216 
3.3.5.3 Discussion       218 
3.4 Pharmacogenetics of Phase II Drug Metabolizing Enzymes 222 
3.4.1 UDP glucuronosyltransferase 1 family, polypeptide A4 (UGT1A4) 
         222 
3.4.1.1 Genetic Profile of UGT1A4     222 
3.4.1.2 LD Pattern of UGT1A4     234 
3.4.1.3 Genetic Profile of UGT1A4 tag-SNPs in Asian Breast Cancer 
Patients       237 
3.4.1.4 Genotypic-phenotypic Associations of UGT1A4 Polymorphic 
Variants       239 
3.4.1.5 Discussion       257 
3.4.2 UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7) 
         263 
3.4.2.1 Genetic Profile of UGT2B7     263 
3.4.2.2 LD Pattern of UGT2B7     276 
 x
3.4.2.3 Genetic Profile of UGT2B7 tag-SNPs in Asian Breast Cancer 
Patients       278 
3.4.2.4 Genotypic-phenotypic Associations of UGT2B7 Polymorphisms 
         280 
3.4.2.5 Discussion       294 
3.4.3 UDP glucuronosyltransferase 2 family, polypeptide B15 (UGT2B15) 
         299 
3.4.3.1 Genetic Profile of UGT2B15     299 
3.4.3.2 LD Pattern of UGT2B15     309 
3.4.3.3 Genetic Profile of UGT2B15 tag-SNPs in Asian Breast 
Cancer Patients      311 
3.4.3.4 Genotypic-phenotypic Associations of UGT2B15 tag-SNPs 313 
3.4.3.5 Discussion       337 
3.4.4 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 
(SULT1A1)        342 
3.4.4.1 Genetic Profile of SULT1A1     342 
3.4.4.2 Genotypic-phenotypic Associations Between SULT1A1 
Polymorphisms and Steady State Concentrations of Tamoxifen 
Metabolites       342 
3.4.4.3 Discussion       344 
Chapter 4: Conclusions       347 
Chapter 5: Future Directions      352  
Bibliography         355 
 xi
Appendices         400 
Appendix A: Institutional Review Board (IRB) Approval of Population 
Genetic Studies of Candidate Genes.     400 
Appendix B: IRB Approval of Pharmacogenetic Study of Tamoxifen in 
Asian Breast Cancer Patients.      401 
Appendix C: Post-hoc Power Analysis.     402 
 xii
Summary 
Tamoxifen is the cornerstone in endocrine treatment of breast cancer. However, 
wide variation in treatment response is observed and has been partially attributed 
to differential exposure to the active metabolites of tamoxifen. The current project 
aimed to comprehensively evaluate the pharmacogenetic effects of candidate 
genes along the biochemical pathway of tamoxifen on the variations in steady 
state plasma levels of tamoxifen and its metabolites in Asian breast cancer 
patients.  
The metabolic pathway of tamoxifen was found to be extremely complex with 29 
metabolites detected and wide variations in steady state plasma concentrations 
of tamoxifen and its metabolites were observed. Phase I analyses investigated 
the effects of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 on the 
plasma levels and metabolic ratios (MRs) of tamoxifen, NDM, (Z)-endoxifen and 
(Z)-4-OHT. Plasma disposition of the parent drug and these primary metabolites 
were not found to vary with polymorphic variants in CYP1A2, CYP2C9/19 and 
CYP3A5. Among the phase I pharmacogenes, CYP2D6 was the only factor 
found to influence the disposition of tamoxifen and its metabolites.  
The most prevalent CYP2D6 polymorphisms in the Asian breast cancer patients 
were CYP2D6*5 (CYP2D6del) and *10 (100C>T, rs1065852). The plasma 
concentrations of endoxifen and NDM were found to be lower and higher 
respectively among patients carrying the defective variant CYP2D6*5 
(CYP2D6del) and *10 (100C>T, rs1065852) alleles. Correspondingly, the MRZ-
END/NDM, was lower among patients carrying the variant genotypes CYP2D6*5/*10 
or CYP2D6*10/*10 compared to patients who were wild-type, indicating lower 
 xiii
relative formation of (Z)-endoxifen from NDM in the presence of reduced 
CYP2D6 activity. Although these CYP2D6 variant alleles were found to influence 
the MRZ-4-OHT/TAM, no association with the steady state plasma concentrations of 
the respective metabolites was observed. This indicated that CYP2D6 
polymorphisms exert greater impact on the formation of (Z)-endoxifen via NDM, 
compared to that of (Z)-4-OHT from tamoxifen, in agreement with available 
reports. 
The second phase of analyses involved investigating the impact of major hepatic 
phase II conjugating enzymes, namely UGT1A4, UGT2B7, UGT2B15 and 
SULT1A1, on the disposition of tamoxifen and its metabolites. The plasma 
concentrations of glucuronides of the primary metabolites at steady state were 
additionally quantified for this investigation. Pharmacogenetic investigations of 
the phase II pharmacogenes identified UGT1A4 but not UGT2B7, UGT2B15 and 
SULT1A1 to be an important determinant of the disposition of tamoxifen and its 
metabolites. Prior to investigation in tamoxifen-treatment patients, the genetic 
profiles of the UGT genes were elucidated in our healthy populations (Chinese, 
Malays, Indians) and representative tag-SNPs were identified. All UGT genes 
were found to be highly polymorphic with high LD between polymorphisms. 
UGT1A4*3 (142T>G, rs2011425) and the associated haplotype [-1548G, -1531C, 
-419A, -219T, -163A, 142G, 448C, 804A, IVS1+196C, IVS1+346T, IVS1+414G 
and IVS2+307G] were associated with higher plasma concentrations of Tam-N-
Gluc and MRTAM-N-GLUC/TAM which indicated higher rate of formation of tamoxifen 
N-glucuronidation among carriers of the variant haplotype. A modest decrease in 
(E)-endoxifen plasma concentration and increase in the MRZ-NDM-4-O-GLUC/E-END 
were observed among patients harboring the haplotype comprising of five SNPs 
 xiv
in the LD block 3 of UGT2B15 [1568C, *168T, *186A, *+630G and *+888G] in 
comparison to patients who carried the wild-type haplotype. However, variations 
in plasma concentrations of the analytes or the MRs were not found to differ 
significantly with tag-SNPs or functional polymorphisms of UGT2B7. Both 
UGT2B7 and UGT2B15 mediate the O-glucuronidation of (E)- and (Z)-isomers of 
4-OHT and endoxifen.  
However, the plasma levels of tamoxifen and its metabolites were still highly 
variable after taking into account the significant factors (CYP2D6 and UGT1A4 
polymorphisms). Hence, the impact of other pharmacogenes involved in the 
biochemical pathway of tamoxifen should be evaluated. Subsequent studies 
should also evaluate the effects of the significant genetic determinants of the 
plasma disposition of the analytes, identified in this study, on the therapeutic 
outcome of tamoxifen treatment.  
 xv 
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Chapter 1: Introduction 
1.1 Breast Cancer 
1.1.1 Epidemiology 
Cancer is the principal cause of death across the world especially in 
economically developed countries. The incidence rate of all cancers in the 
developed nations has been reported to be almost double of that observed in the 
economically developing countries (1). Several causes have been proposed for 
this trend including smoking, physical inactivity and “westernized’ dietary habits. 
Among the different types of cancer, breast cancer is the most prevalent breast 
cancer in females and has been described as a worldwide epidemic affecting 
1.38 million (23% of all new cancer cases) and causing the death of 458 400 
(14% of total cancer deaths) women in 2008 (1). It has been estimated that one 
in eight women with a life expectancy of 80 years will develop breast cancer with 
a mean 5-year recurrence free survival rate of 60% (2). In Singapore, breast 
cancer remains the most common female cancer and accounts for 29.3% of all 
cancers diagnosed in women between 2006 and 2010 (3). Ethnic-specific 
differences in the disease incidence have also been observed with Singaporean 
Chinese carrying the greatest risk followed by Malays and Indians who harbored 
10% and 20% lower risk than Chinese individuals (3). Comparable to the pattern 
observed in the developed countries, rapid escalation of the breast cancer 
incidence rate has been observed in tandem with a fairly constant breast cancer 
mortality rate since the 1980s (4). This observation has been attributed to earlier 
disease detection due to routine mammographic screening and greater 
availability of novel and more effective treatment options (4, 5).  
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Several predisposing characteristics have been identified as possible causative 
factors for the high prevalence rate of breast cancer: old age, dense breast tissue 
on mammogram, developed countries, early menarche (before 11 years of age), 
late menopause (after 54 years of age), first childbirth at late age (after 40 years 
of age), previous benign breast disease, contralateral breast cancer, high or low 
socioeconomic status, high body mass index (BMI; especially in postmenopausal 
females), alcohol consumption, exposure to ionizing radiation, no previous 
breastfeeding and use of hormonal preparation (6). In addition, familial 
inheritance of genetic mutations such as BRCA1/2 has also been implicated. In 
high risk individuals predispose to breast cancer, preventive measures such as 
maintenance of healthy body weight, increasing physical activity and minimizing 
alcohol intake are recommended (1, 7). The use of hormonal therapy like 
tamoxifen has also been shown to reduce the risk of hormone receptor positive 
breast cancer by almost half (8). Subsequently, raloxifene has been reported to 
exhibit similar efficacy as tamoxifen (9). 
1.1.2 Types of Breast Cancer 
Breast cancer is a highly heterogeneous disease with diverse histopathological 
features (10, 11). The clinical presentation, prognosis and treatment response 
differ across various breast tumors and this diversity in the disease has attracted 
numerous attempts to create meaningful categories with prognostic values (12). 
Traditionally, breast tumors were segregated based on the architectural and 
cytological patterns that have been correlated to the clinical course and outcome 
of the disease. On this basis, the WHO classification identified more than 17 
distinct types of breast adenocarcinoma (13) which are currently known as 
“histological special types” and represents 25% of all breast cancer. The 
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remaining 50% to 80% of the breast tumors which do not satisfy the criteria of the 
special type are classified as invasive ductal carcinomas not otherwise specified 
(IDS-NOS). Tumors of special histological types are associated with specific 
biological characteristics and are generally more homogenous than IDS-NOS (12, 
13). However, use of this classification system in clinical decision is limited due to 
the absence of standardized classification scheme and inter-observer 
reproducibility. Furthermore, tumors of the special types are rare in the general 
patient population. 
Besides tumor histological subtypes, tumor size, histological grade, expression of 
hormone receptors [estrogen receptor, (ER) and progesterone receptor, (PR)] 
and human epidermal growth factor receptor 2 (HER-2), presence of 
lymphovascular metastasis and lymph node invasion provide additional 
information that distinguish between tumors (14, 15). These factors as well as 
baseline characteristics including age, co-morbidities and menopausal status, 
have been routinely employed in treatment decision (15). Histological tumor 
grade and tumor type are among the most important parameters which indicate 
the intrinsic differences between parameters (12, 16, 17). However, predictive 
power of histological classification of tumors is low as only 2% to 15% of the 
patients receiving chemotherapy derived therapeutic benefit and almost 50% of 
tamoxifen-treated patients relapsed (18). These observations highlighted the 
need for better biomarkers with higher predictive values. 
The tumor molecular expression profile has been proposed to be more a rigorous 
depiction of tumor diversity. Seminal studies conducted by Perou et al (19) and 
Sorlie et al (20) demonstrated the vast disparity between tumors at the sub-
cellular level when tumor gene expression were analyzed using microarray. This 
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sparked interest in the molecular classification of breast tumors. Among the 65 
surgical samples included in the study, Perou et al (19) identified four subtypes of 
breast cancer based on hierarchical cluster analysis of the expression patterns of 
intrinsic genes, that is, genes that displayed greater variation between tumors 
compared to multiple samples from the same tumors. The four subtypes were 
luminal, HER2-enriched, basal-like and normal breast-like breast tumors with the 
most distinct difference between the basal-like and other subtypes (21, 22).  
Luminal tumors which are typically found in the luminal epithelium of normal 
mammary glands, are generally characterized by expression of the hormone 
receptors and ER activated (19, 20). Subsequent studies further segregated this 
subtype to luminal A and B (23, 24) with luminal A tumors being the most 
common accounting for 50% to 60% of all tumors while luminal B represents 
another 10% to 20% (19, 20). Compared to luminal A tumors, higher expression 
of proliferation-related genes has been observed in luminal B samples leading to 
higher proliferative index as indicated by Ki67 (23, 24). Additionally, luminal B 
consists of a subset of HER-2 expressing tumors (25). Thus, luminal B tumors 
adopt a more aggressive phenotype with higher histological grade and poorer 
prognosis compared to luminal A tumors (26). Patients with luminal A tumors 
have a more favorable prognosis compared to all other subtypes with low relapse 
rate (26) and usually respond well to endocrine therapies such as tamoxifen, 
aromatase inhibitors (AIs) and fulvestrant (27).  
HER2–enriched tumor subtype contributes to 15% to 20% of all breast cancers 
(19, 20). Tumors belonging to this subtype typically over-express HER2 and 
other genes associated with the HER2 signaling pathway. While genes involved 
in cellular proliferation are over-expressed, majority of these tumors do not 
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express ER. As a result, these tumors are highly proliferative with high 
histological grade (28, 29). However, the correlation between this tumor subtype 
as identified via microarray and immunohisto-staining has not been found to be 
high. Only 70% of the HER2–enriched tumors as indicated via microarray 
expressed HER2 on immunohistochemistry (IHC) (23, 30). Fortunately, HER2–
enriched tumors respond well to anti-HER2 therapy as well as chemotherapy (23, 
28). 
Another 10% to 20% of the breast tumors are classified as basal-like which 
display high expression of genes involved in cell proliferation and present in 
normal breast myoepithelium (19, 20). Expression of ER and ER-regulated genes 
is low and frequently accompanied by the lack of HER2 expression. Hence, 
basal-like tumors are frequently referred as triple-negative breast cancer 
although up to 30% deviance between the two tumor types has been observed 
(31). Mutations in p53 and BRCA1 (20, 32) are often reported in these tumors 
which attributebasal-like tumors to be associated with an aggressive phenotype 
with worst prognosis and high relapse rate (20, 32, 33). Clinical features 
associated with this subtype are early age of tumor occurrence, African ethnic 
origin, large tumor size, high histological grade and frequent involvement of 
lymph nodes (34). Compared to other subtypes, relapse rate is high in the first 
three years (33) though these tumors are highly chemosensitive (35). The 
expression profile of the remaining 5% to 10% of the breast carcinomas is highly 
similar to that of normal breast tissues and fibroadenomas (19, 24, 32, 36). 
Therefore, these tumors are labeled as normal breast-like tumors. However, 
recent studies have suggested that this subtype is likely an experimental artifact 
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as investigators failed to isolate tumors of this subtype in large series of 
microdissected samples (22, 23). 
More recently, additional tumor subtypes namely molecular apocrine and claudin-
low tumors were identified (37-39). As the name implies, molecular apocrine 
tumors typically exhibits apocrine-differentiated features and expression of 
androgen receptor. Preponderance of tumors in this subclass over-express 
HER2 leading to significant overlap with HER2–enriched subtypes (37, 38). On 
the contrary, claudin-low tumors which are usually triple negative cancers, exhibit 
expression profile which is typical of that observed in cancer stem cells (23, 39, 
40). It is characterized by high expression of genes involved in epithelial-
mesenchymal transition (EMT) and low expression of genes implicated in cell 
adhesion. Long term prognosis of this relatively rare subset (12% and 14%) is 
poor and insufficient response to neoadjuvant chemotherapy has been observed 
(40, 41).  
The intrinsic subtype classification of breast tumors has provided much insight 
into the diversity of breast tumor biology. Its utility in the therapeutic decision has 
been acknowledged by the St Gallen International Expert Consensus which 
noted that the microarray classification of tumors complements that achieved by 
IHC (42). However, it has not been widely integrated into treatment guidelines 
(43). This is likely due to the lack of standardization of the model and validation 
from prospective studies (23, 44-49). 
1.1.3 Available Treatment Modalities 
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A combination of multiple treatment modalities is warranted to successfully 
eradicate the disease (15). Upon confirmation of the breast tumor via cytological 
or histological means, bulk of the tumor mass is removed via mastectomy or 
breast conservation surgery. Systemic therapies can also be administered before 
surgical procedures. This type of regimen known as neoadjuvant therapy is 
administered to reduce the mass of large tumors and facilitate its removal by 
subsequent surgical means. Subsequent to breast conservation surgery, 
radiotherapy is employed to reduce local recurrence, particularly in patients with 
high risk of recurrence. This treatment modality may be followed by adjuvant 
systemic therapies which are prescribed to eradicate micro-metastases, prevent 
disease relapse and increase survival (50). In patients with advanced disease, 
surgery to remove the tumor or radiotherapy may not be a suitable initial choice 
of treatment as the disease burden is likely to be high. Systemic chemotherapy is 
primarily used to control disease progression and to improve the quality of life 
(51). The efficacy of systemic therapies for this indication can be monitored 
following short term exposure to the drug. Commonly employed systemic 
therapies include chemotherapeutic agents (doxorubicin, epirubicin, 
cyclophosphamide and 5-fluorouracil), HER-2 antagonist (trastuzumab) (52) and 
hormonal therapies (tamoxifen, AIs and fulvestrant) (53).  
The choice of systemic therapies is dependent on the molecular subtypes of the 
cancer and the biomarkers expressed on the tumor (15). Approximately 70% of 
the tumor expresses the hormone receptors, ER and/or PR (54), which are highly 
predictive of the response to hormone modulating agents (18). Trastuzumab is 
indicated for a subgroup of patients with tumors overexpressing HER2 (15) and 
accounts for about 20% of all breast tumors (55). The remaining basal-like or 
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triple-negative tumors which do not express the three receptors listed previously 
have been demonstrated to be highly sensitive to chemotherapy (35). However, it 
should be noted that tumors expressing hormone receptors can also be 
responsive to chemotherapy although the probability of achieving a complete 
eradication is lower compared with hormone receptor negative tumors (6). 
Although endocrine therapies have demonstrated efficacy in neoadjuvant 
indications, its use is mainly reserved for adjuvant purposes (15). Chemotherapy 
remains the treatment of choice for neoadjuvant treatment.  
1.1.4 Endocrine Therapies: Tamoxifen versus Aromatase Inhibitors 
Tamoxifen is the first targeted hormonal agent which is FDA-approved for the 
treatment of a wide spectrum of breast cancer (56). As a selective estrogen 
receptor modulator (SERM), it inhibits ER-stimulated growth of the malignant 
tissues but exhibits mixed estrogenic and anti-estrogenic activity at other tissues 
(57). The role of tamoxifen in the adjuvant treatment of early breast cancer was 
established in the collaborative meta-analyses conducted by the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) (18). Results of the meta-
analyses indicated a reduction of 31% in breast cancer mortality and 39% in risk 
of disease recurrence regardless of age, use of chemotherapy, PR status or 
other tumor characteristics. 
A new class of hormonal therapy, the third generation AIs, was recently 
introduced. The AIs which consist of anastrazole, letrozole and exemestane 
inhibit the activity of aromatase (CYP19A1) that catalyzes the biosynthesis of 
estrogen (58). Thus, the use of the AIs leads to almost complete abrogation of 
the estrogenic activity. In a series of landmark trials, the AIs alone were found to 
 9 
be slightly superior to tamoxifen in terms of disease-free survival, risk of distant 
or locoregional recurrence and risk of contralateral breast cancer (<5% difference) 
in post-menopausal women (59-61). No difference in overall survival, however, 
was noted between the two therapies. Surprisingly, the sequential therapy of AIs 
followed by tamoxifen or vice versa was found to exhibit greater efficacy than 
either agents alone (62-64). In view of the demonstrated benefits, the American 
Society of Clinical Oncology and the National Comprehensive Cancer Network 
now recommends the upfront use of AIs for five years or sequential use of AIs 
after tamoxifen for a total of five years (15, 65).  
However, the introduction of AIs does not negate the place of tamoxifen in breast 
cancer therapy. The benefits of AIs are not without its disadvantages. Use of AIs 
has been demonstrated to be linked to development of benign ovarian pathology 
(66, 67) and do not effectively suppress the synthesis of ovarian estrogen. Hence, 
AIs are not indicated for treatment of breast cancer in premenopausal patients 
while tamoxifen remained the treatment of choice for breast cancer in pre- and 
peri- menopausal female as well as male (15). 
The side effect profiles of AIs and tamoxifen have also been shown to differ 
widely (15, 65). AIs are associated with increased risk of cardiovascular disease, 
hypercholesterolemia and hypertension while tamoxifen is associated with 
greater risk of venous thromboembolism (68, 69). Compared to tamoxifen, AIs 
have also been found to lead to greater loss of bone mineral density, fractures 
and a musculoskeletal/arthralgia syndrome manifested as symmetric joint pain 
and stiffiness (70, 71). In contrast, tamoxifen has been reported to have 
beneficial effects on bone health inclusive of increased bone mineral density (70, 
71). Nevertheless, tamoxifen has been associated with heightened risk of uterine 
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cancer, benign endometrial pathology, hysterectomy and vaginal discharge (72-
77). Therefore, individuals contraindicated for AIs can be offered tamoxifen as an 
alternative treatment. The converse is true.  
Besides, tamoxifen has a long history of usage with well-established adverse 
effect profile and is a much economical and viable treatment option (78). In the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) P1 trial (8), use of 
tamoxifen in females over 35 years of age at high risk for breast cancer was 
shown to decrease the incidence of invasive carcinoma of the breast by 49%. On 
the contrary, the chemopreventive efficacy of the AIs has not been found (15, 65). 
Therefore, tamoxifen continues to play central role in the treatment and 
prevention of breast cancer. 
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1.2 Pharmacology of Tamoxifen 
1.2.1 Introduction 
Tamoxifen initially known as ICI 46,474 was developed as a post-coital 
contraceptive in the early 1960s (79). However, subsequent studies revealing 
efficacy of tamoxifen for the treatment of metastatic breast cancer led to its 
approval as a palliative option in metastatic breast cancer patients in 1970s (80). 
Since then, tamoxifen has been successively approved by FDA for the treatment 
and prevention of various types of ER and/or PR positive breast cancers which 
include adjuvant therapy for early breast cancer and treatment of metastatic 
breast cancer in both pre- and post-menopausal women (78).  
Tamoxifen is generally well-tolerated and the side effects are mainly menopausal 
symptoms such as hot flashes and vaginal discharge which mostly affect 
patients’ quality of life (78, 81). However, hot flashes and vaginal discharge were 
commonly cited as reasons for withdrawal among patients withdrawal due to 
medical reasons which constitute 15% of the entire study cohort in Breast Cancer 
Prevention Trial (BCPT) (8). The frequency of hot flashes in tamoxifen-treated 
patient varies between 3% and 80% with a higher percentage of pre-menopausal 
women being affected while vaginal discharge was reported to be present in 13% 
to 55% of the treated patients recruited to various studies (8). Severe side-effects 
such as thromboembolism and endometrial cancer are rare. Apart from these 
adverse effects, tamoxifen has also been associated with favorable change in 
lipid profile as well as increases in bone mass density (78, 81). 
1.2.2 Chemistry 
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Tamoxifen or Z-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine 
(ICI 46,474) is a triphenylethylene-derived, non-steroidal mixed estrogen agonist-
antagonist which is structurally related to clomiphene (Fig 1.1). It is commercially 
available as the monocitrate salt of trans- or (Z)-tamoxifen which is hygroscopic 
at high humidity. Tamoxifen citrate takes the form of a white, odorless, crystalline 
powder with a molecular weight of 563.6, molecular formula of C26H29NOC6H8O7 
and pKa of 8.85 (82). Although the powder is only slightly water-soluble at 
0.5mg/ml (37°C), it is soluble in the organic solvents including ethanol, methanol 
and acetone (83). Besides, ultraviolet photolysis of tamoxifen to the 
corresponding E-isomer followed by cyclisation of the isomers to form 
phenanthrenes has been observed especially when the compound is in solution. 









1.2.3 Mechanism of Action 
Although originally developed as an antagonist for estrogen receptor (84), 
tamoxifen has been demonstrated to be a SERM with activity ranging from 
agonist, partial agonist and antagonist for ER (81, 85-88). Tamoxifen and its 
active metabolites have been shown to exhibit anti-estrogenic effects in the 
breast and central nervous system but estrogenic effects predominate in the 
endometrium and bone (81, 88). Additionally, these compounds also 
competitively inhibit the binding of estradiol to estrogen receptors in the uterine 
tissue, anterior pituitary gland and ERα-expressing tumors (81, 88). 
Estrogen receptors or ERs consist of α and β isoforms which are mapped onto 
distinct genomic regions. ERs are ligand-activated nuclear transcription factors 
that regulate the transcription of genes involved in normal growth and 
development (80). As with other nuclear receptors, the general structure of the 
ER consists of an N-terminal DNA binding domain and a C-terminal ligand 
binding domain (80). ERα is frequently overexpressed in breast tumors and has 
been found to be crucial in the development and progression of breast 
malignancies (89). On the contrary, the role of ERβ in the development of breast 
cancer remains controversial though low expression of ERβ was associated with 
resistance to tamoxifen (90, 91). Despite the capacity to bind and modulate the 
activities of both α and β isoforms of ER, the therapeutic effects of tamoxifen are 
believed to be mainly mediated by ERα (92).  
In the absence of ligand, ER associates with a heat shock protein complex in the 
cytosol or nucleus (93). Upon binding to its ligand, the receptor dissociates from 
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the protein complex and undergoes conformational changes that cause receptor 
dimerization. The DNA binding domains of the receptors preferentially interact 
with specific regulatory regions, termed estrogen response elements (EREs) 
located at the 5′ regulatory regions of its target genes. ERs which bind to the 
EREs (94) serve as the nucleating point where co-regulatory proteins are 
recruited to modify the transcriptional complex and influence the expression of its 
downstream genes (95). When the ER is bound to an agonist such as its 
endogenous ligand, estrogen, the conformation of ER is modified to 
accommodate the interaction with co-activators such as steroid receptor 
coactivator-1 (SRC-1), SRC-2 and SRC-3 (96, 97) (Fig 1.2). Addition of these 
proteins to the transcriptional complex recruits the histone acetyltransferases 
(HAT) which loosen the tightly coiled chromatin structure and allow the general 
transcriptional complex to access and transcribe the gene of interest (92).  
However, in the presence of tamoxifen and its active metabolites, 4-
hydroxyltamoxifen (4-OHT) and endoxifen, these compounds compete with 
estrogen for ER occupancy. Although the ER-ligand complex still associates with 
EREs in the target genes, binding of tamoxifen and its metabolites affect the 
position of helix 12 in ER leading to differential conformational changes in the 
receptor which favor the binding of the co-repressor proteins such as nuclear 
receptor co-repressor 1(NCoR1) and NCoR2 (96, 97) (Fig 1.2). This complex 
instead recruits histone deacetylases (HDACs) to the transcriptional machinery. 
HDAC deacetylates the histone molecules and further compact the histone-DNA 
structure. The highly dense structure makes the target genes inaccessible to 
transcriptional activity, thereby repressing its expression (92). Thus, tamoxifen 
and its active metabolites inhibit the expression of estrogen-regulated 
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proliferative genes such as insulin-like growth factor 1 receptor (IGF-1R), cyclin 
D1 and B-cell lymphoma 2 (Bcl-2) (92) and induces cell cycle arrest mainly at the 
G1 phase (78, 98). Tumor regression ensues due to the disturbance in the 
balance of cell proliferation and cell death.  
 
Fig 1.2 Mechanism of action of tamoxifen. Adapted from NCI Understanding 
Cancer Series: Estrogen Receptors/ SERMs. 
(http://www.cancer.gov/cancertopics/understandingcancer/estrogenreceptors) 
 
In addition, tamoxifen has been suggested to act as an agonist for the non-
genomic activity of ER, also known as membrane-initiated steroid signaling (92). 
It has been revealed that both estrogen and tamoxifen exert rapid stimulatory 
effects on various signaling pathway and the associated proteins. The ER in the 
membrane can interact with a variety of tyrosine kinase receptors (IGF-1R, 
epidermal growth factor receptor or EGFR, HER-2), G-protein coupled receptor 
(GPCR), SHC-transforming protein 1 (Shc) or p85 subunit of phosphatidylinositol 
3-kinases (PI3K) directly or indirectly to trigger downstream cascade of events 
which lead to cell proliferation and survival (99, 100). However, this mechanism 
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of action is dependent on the activity of these signalling proteins in addition to 
that of ER. Hence, it is likely to be important only in cells which overexpress 
these growth factor receptors. 
Of note, tamoxifen has often been referred to as a prodrug which requires 
metabolic activation to its active counterpart, 4-OHT and endoxifen. This mainly 
stems from in vitro assays which examined and compared the ER binding affinity 
and inhibition of E2-induced gene expression of tamoxifen against its metabolites. 
The ER binding affinity of tamoxifen has been demonstrated to be only 30% of 
that obtained with estradiol (E2) (84, 101). At the same time, tamoxifen associates 
4 times slower with and dissociates 100 faster from ER compared to E2 (88). In 
terms of binding affinity for ER and inhibition of ER, both 4-OHT and endoxifen 
are similar with 100-fold greater affinity for ER and 30- to 100- fold higher 
potency compared to tamoxifen (101, 102). Both endoxifen and 4-OHT have also 
been found to cause similar changes in the global gene expression profile of 
MCF-7 cells (103). Most of the genes affected are regulated by estrogen. In 
addition, endoxifen but not 4-OHT has been shown to target ER for proteosomal 
degradation in a concentration-dependent manner (104). Thus, endoxifen has 
been considered to be at least as important as 4-OHT as the active metabolite of 
tamoxifen. 
1.2.4 Pharmacokinetics 
1.2.4.1 Absorption and Distribution  
Tamoxifen is commonly administered as 20 mg orally (82). Following oral 
administration, tamoxifen is rapidly absorbed (105, 106) and undergoes 
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extensive first pass metabolism. Hence, the oral bioavailability of tamoxifen is 
only 40% (56). As tamoxifen is highly lipophilic, extensive plasma protein binding 
of about 98%, in particular to albumin, (56, 107, 108) is observed with apparent 
volume of distribution estimated to range between 50 to 60 L/kg (109). The drug 
has been found to be highly concentrated in the liver, lung, brain, ovaries and 
breast tissues (110). Tamoxifen and its metabolites were found to be 10- to 60- 
fold higher in the various tissues, including breast, salivary glands and bile, 
compared to the serum (110-114). 
1.2.4.2 Metabolism 
Tamoxifen undergoes extensive phase I metabolism to form several metabolites 
inclusive of its E- and Z- isomers with varying estrogenic and anti-estrogenic 
properties. Subsequently, the parent drug as well as the metabolites undergo 
phase II conjugative reactions to facilitate the removal of these exogenous 
compounds from the in vivo system (Fig 1.3). Previous studies reported the 
presence of eight metabolites in the human plasma (115-117). However, current 
technologies have led to the further elucidation of 14 more metabolites including 
the glucuronides (Fig 1.4) with the use of HPLC electrospray–tandem mass 
spectrometry (ESI-MS/MS) (118). 
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Fig 1.3 General overview of drug biotransformation. The schematic diagram 
above shows the fate of tamoxifen in the hepatocyte. Tamoxifen undergoes 
phase I oxidative reaction to form an array of metabolites before phase II 
conjugation that forms inactive metabolites. Entrance to and exit from the 
hepatocytes are governed by the efflux and influx transporters which constitute 
phase III reactions. 
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In the in vivo system, tamoxifen undergoes metabolic activation to form two 
highly potent metabolites, namely 4-OHT formed via 4-hydroxylation of tamoxifen 
and 4-hydroxy-N-desmethyltamoxifen (endoxifen) (101) resulting from the N-
demethylation of 4-OHT. The formation of endoxifen via N-demethylation of 4-
OHT is an enzyme-mediated pathway which is a minor contributor to the overall 
formation of endoxifen. The 4-hydroxylation of tamoxifen is principally mediated 
by CYP2D6 with minor contribution from CYP2B6, CYP2C9/19 and CYP3A4 
(119, 120) while N-demethylation of 4-OHT is primarily catalyzed by CYP3A4/5 
(119). Up to 97% of endoxifen is formed via an alternative pathway involving 
sequential CYP3A4/5 mediated N-demethylation of tamoxifen to form N-
desmethyltamoxifen (NDM) (119, 121) and subsequent CYP2D6 catalyzed 4-
hydroxylation of NDM (Fig 1.4) (119, 122). Other enzymes found to play minor 
roles in these metabolic pathways include CYP1A2, CYP2C9 and CYP2C19 (119, 
120, 123).  
In addition to the above-mentioned metabolic pathways, tamoxifen is also 
subjected to biotransformation to other metabolites such as tamoxifen-N-oxide, 
α-hydroxytamoxifen as well as Z- and E- isomers of 4′-OHT as indicated in Fig 
1.4 (88, 117-119). N-oxidation of tamoxifen is mediated by the flavin 
monooxygenases (FMO1 and FMO3) (124, 125) while α-, 3- and 4′-
hydroxylations of tamoxifen are attributed to the activity of CYP2B6, CYP2D6 
and CYP3A4/5 (119, 126). Similarly, NDM also undergoes hydroxylation and 
demethylation to form α-hydroxy-NDM, 3-hydroxy-NDM, 4′-hydroxy-NDM (E- and 
Z- isomers) and N,N-didesmethyltamoxifen (118, 119, 126). 
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Phase II disposition reactions involve sulfonation and glucuronidation; the latter 
accounting for approximately 75% of the metabolism (117). All primary 
metabolites of tamoxifen except NDM have been established to undergo 
glucuronidation (117, 127). While tamoxifen only undergoes N-glucuronidation by 
UGT1A4 to form tamoxifen-N-glucuronide (128), 4-OHT has been found to be 
subjected to both N- and O-glucuronidation (129, 130). The N-glucuronidation of 
4-OHT to 4-hydroxytamoxifen-N-glucuronide is mediated by UGT1A4 (130) whilst 
the O-glucuronidation pathway to form tamoxifen-4-O-glucuronide implicates 
multiple UGT isoforms (129). In contrast to 4-OHT, endoxifen is not N-
glucuronidated but O-glucuronidated possibly due to the absence of the tertiary 
amine group (129).  
The O-glucuronidating pathways of both endoxifen and 4-OHT have been 
previously investigated in baculosomes overexpressing the enzymes of interest 
(129). Among the eight enzymes included in the kinetic assay, UGT1A8 and 
UGT2B7 exhibited the highest activity against (Z)-4-OHT followed by UGT1A10 
as indicated by the Vmax/Km ratios (129, 131). However, the catalytic activity of 
UGT1A8 for (Z)-endoxifen has been found to be comparable with that of 
UGT1A10 and higher than UGT2B7. Other enzymes such as UGT1A1 and 
UGT1A3 have been observed to have low enzymatic activity against both the 
trans-metabolites. Of note, UGT2B15 has been found to specifically catalyze the 
O-glucuronidation of the cis-isomers of both endoxifen and 4-OHT (131, 132). 
Thus, O-glucuronidation of 4-OHT and endoxifen is predominantly mediated by 
hepatic UGTs, UGT2B7 and UGT2B15, as well as UGT1A8 and UGT1A10 which 













Fig 1.4 Metabolic pathway  of tamoxifen (118, 122, 127-129, 133, 134). 
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Sulfonation represents the alternative phase II conjugative reaction involved in 
the tamoxifen biochemical pathway and both active metabolites, 4-OHT and 
endoxifen, are subjected to sulfonation (133, 135). The affinity and activity of the 
various SULT isoforms (SULT1A1, SULT1A3, SULT1B1, SULT1C2, SULT1E1, 
SULT2A1 and SULT2B1) on 4-OHT has been previously studied (135). Among 
the seven SULT isozymes under investigation, only SULT1A1, SULT1E1 and 
SULT2A1 were found to exhibit activity against 4-OHT. The affinity of SULT1E1 
(Km: 0.2 ± 0.1 µM) for 4-OHT was found to be the highest followed by SULT1A1 
(Km: 0.8 ± 0.1 µM) and SULT2A1 (Km: 1.6 ± 0.3 µM). However, the hepatic 
expression of SULT1A1 is twice as high as that of SULT2A1 and 8.8-fold higher 
than SULT1E1. Hence, SULT1A1 may be a more important isoform in the 
sulfonation of 4-OHT compared to SULT1E1 although the substrate affinity of 
SULT1E1 is higher (135). 
1.2.4.3 Excretion 
The biological half-life of tamoxifen is relatively long at 7 days while the half-life of 
NDM has been estimated to be approximately 14 days (136, 137). Given the long 
circulating time of these metabolites in the body, once daily dosing is sufficient to 
maintain steady state plasma levels which require approximately 4 − 6 weeks to 
be established (138). Conversely, more than 6 weeks after the termination of 
therapy is needed for complete elimination of tamoxifen and its metabolites from 
the body. Subsequent to the oral administration of 40mg of tamoxifen, the peak 
plasma level of about 65 ng/ml of tamoxifen has been observed within 3 – 4 hrs 
(139). However, wide degrees of inter-individual and inter-ethnic differences in 
the steady state plasma concentrations of tamoxifen and its metabolites have 
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been consistently reported (122, 140). The steady state plasma concentrations of 
tamoxifen and its three main metabolites after daily administration of 20mg of 
tamoxifen have been reported to vary between the following ranges: 190 − 420 
nM for tamoxifen, 280 − 800 nM for NDM, 3 − 17 nM for 4-OHT and 14 − 130nM 
for endoxifen (141). It should be noted that endoxifen has been frequently 
reported at plasma concentrations 6− to 12− fold higher than that of 4-OHT (118, 
122, 140, 142). Since the binding affinity and inhibitory potency for ER are similar 
between endoxifen and 4-OHT, the presence of elevated levels of endoxifen 
suggests that endoxifen may be more important than 4-OHT as the activity 
metabolite mediating the activity of tamoxifen (140). The plasma levels of other 
metabolites are listed in Table 1.1. 
Biliary excretion represents the main route of excretion (107, 143, 144). Animal 
studies in rats and dogs estimated that 53% of tamoxifen was excreted via the 
bile (145), and urinary excretory pathway only accounted for 9 to 14% of the drug 
excretion (143). More than 60% of the metabolites were recovered in free, 
unconjugated form and majority of the remaining dose was in the form of phase II 
conjugates (145). It was believed that this is due to the action of the β-
glucuronidases present in the intestinal microflora. Up to 69% of the excreted 
drugs were re-absorbed via enterohepatic circulation (106). Thus, the elimination 
kinetics of tamoxifen has been observed to display a biphasic profile.  
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Effect on ER 
Affinity for ER 
(compared to E2, 
100%) 
Tamoxifen Tam 190 – 429 Weak antagonist  2 
Tamoxifen-N-glucuronide Tam-N-Gluc 2.5 Weak antagonist  1 
N-desmethyltamoxifen NDM 280 – 800 Weak antagonist  – 
(Z)-Endoxifen (Z)-END 14 – 130 Strong antagonist similar to (Z)-4-OHT 
(E)-Endoxifen (E)-END 1.17 Strong antagonist 35- to 67- fold lower 
than (Z)-END 
(Z)-4-hydroxy-tamoxifen (Z)-4-OHT 3 – 17 Strong antagonist 188 
(E)-4-hydroxytamoxifen† (E)-4-OHT 0.56 Strong antagonist 35- to 67- fold lower 
than (Z)-4-OHT 
Tamoxifen-N-Oxide Tam-NO 15 – 32 Weak antagonist  
a-hydroxytamoxifen a-OHT 1 No effect – 
3-hydroxytamoxifen 3-OHT  No effect – 
3-hydroxy-N-desmethyltamoxifen 3-OH-NDM 3.16 No effect – 
(Z)-4'-hydroxytamoxifen (Z)-4'-OHT  No effect – 
(Z)-4'-hydroxy-N-desmethyltamoxifen (Z)-4'-OH-NDM 21.3 No effect – 
(E)-N-desmethyltamoxifen-4-O-glucuronide (E)-NDM-4-O-Gluc 1.77 No effect – 
(Z)-N-desmethyltamoxifen-4-O-glucuronide (Z)-NDM-4-O-Gluc 0.53 No effect – 
(E)-tamoxifen-4-O-glucuronide (E)-Tam-4-O-Gluc 0.6 No effect – 
(Z)-tamoxifen-4-O-glucuronide† (Z)-Tam-4-O-Gluc 0.56 No effect – 
(Z)-4-hydroxytamoxifen-N-glucuronide (Z)-4-OHT-N-Gluc NA No effect – 
Adapted from Brauch et al (141), Murdter et al (118), Lazarus et al (131).   
†More than 10% of the samples were below the limit of quantification when reported by Murdter el al (118). 
§ER, Estrogen Receptor; E2, Estradiol; NA, Not Available     
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1.2.5 Pharmacodynamics 
The pharmacodynamic effects of tamoxifen are the result of a complex interplay 
between the ligand (estrogen, tamoxifen), ER (α and β isoforms) and the co-
regulators in the tumor microenvironment (78, 92). The effects elicited by 
tamoxifen-receptor complex are affected by the transcriptional co-regulators 
binding to the complex which influence the overall conformation of the ER 
leading to transcriptional activation or repression of target genes. Moreover, 
differential levels of these transcriptional regulators between cells would 
determine the nature of the co-regulators binding to the complex (92, 93, 97). 
This mechanism has been proposed to contribute to the difference in tamoxifen 
activity among different organs. 
1.2.5.1 Endocrine Effect 
As an agent that modulates the activity of ER, the administration of tamoxifen 
was found to influence the relative levels of certain hormones (78, 88). In the 
post-menopausal women whose estrogen and progesterone concentrations are 
low while gonadotropins are high, tamoxifen has been found to decrease the 
secretion of luteinizing hormone and follicle-stimulating hormone (146-148), with 
variations within normal concentration ranges observed in postmenopausal 
women. The concentrations of these gonadotropins were observed to return to 
baseline levels between four to twelve weeks following the initiation of therapy 
(149-151). No effects on serum androgen and progesterone levels have been 
observed (88, 150, 152, 153). Although majority of the studies indicated that 
tamoxifen had no effect on serum estrogen concentration, Willis et al (150) 
observed a minor rise in estrogen level in nonresponders compared to 
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responders of tamoxifen therapy. Furthermore, Daxenbichler et al (153), 
observed a significant decrease in estrogen levels in tamoxifen-treated 
postmenopausal patients with plasma concentration of tamoxifen above 50 pg/ml. 
In contrast, tamoxifen has been reported to marginally increase the serum levels 
of both luteinizing and follicle-stimulating hormones in pre-menopausal women 
(147, 148, 154) although other investigators observed null associations (155, 
156). Increases in serum estradiol and progesterone levels independent of serum 
gonadotropin levels which are indicative of direct stimulatory effect on the 
follicular activity, had also been reported in premenopausal women. At a daily 
dose of 40mg, several studies reported approximately two-fold increase in 
circulating estradiol concentration (155, 157, 158). 
With regard to LHRH, mixed effects have been reported in postmenopausal 
women. While some investigators declared no change in the response of 
gonadotropins to LHRH (152), others have reported blunted responses to LHRH 
stimulation (156). Furthermore, several studies claimed decreased response with 
either LH or FSH (150, 159). The relationship between LHRH and gonadotropins 
was more defined in premenopausal subjects in whom the response to LHRH 
was either unchanged or slightly increased (156, 157). Thus far, this difference 
has not been found to influence treatment outcomes as survival benefits of pre- 
and post- menopausal patients treated with tamoxifen are similar (18).  
Interestingly, several tamoxifen metabolites which include endoxifen and NDM 
have been found to exhibit varying degrees of inhibitory effects on aromatase, 
the enzyme essential for the synthesis of estrogens in peripheral tissues (160). 
Among these metabolites, the newly identified metabolite, norendoxifen or N,N-
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didesmethyl-4-hydroxytamoxifen, is the most inhibitor of aromastase with in vitro 
inhibitory potency similar to that observed in letrozole (161). At the concentration 
of 10 µM, norendoxifen completely inhibits aromatase activity while endoxifen 
and NDM lead to 60% and 40% reductions in aromatase activity (161). These 
findings illustrate the complexity in the metabolic pathway and 
pharmacodynamics of tamoxifen.  
1.2.5.2 Effects on Breast 
In breast tissue, tamoxifen and its metabolites compete with estradiol for the 
binding to estrogen receptor and inhibit the expression of its downstream genes 
(78, 88). Several investigators have examined the pharmacodynamic effects of 
tamoxifen and 4-OHT using microarray assays. Both tamoxifen and 4-OHT have 
been shown to influence the expression of a set of E2-regulated genes which are 
related to cell proliferation and survival (103, 162). It was further shown by Lim et 
al (103) that the expression profile of endoxifen-treated breast cancer cell lines 
paralleled that seen in 4-OHT-treated cells thereby suggesting the similarity in 
the mechanistic effects of the two metabolites.  
Furthermore, in vitro experiments using MCF-7 breast cancer cells have 
demonstrated functional equivalence between endoxifen and 4-OHT in terms of 
their binding affinity for ERα and ERβ, ability to inhibit E2-stimulated cell growth 
and mRNA expression of progesterone receptor (PGR) (101, 102). The apparent 
relative affinity of both metabolites for ERα was estimated to be similar to E2 and 
the half maximal ER inhibition was approximately 50 nM. Both endoxifen and 4-
OHT were observed to be pure estrogen antagonist with almost null agonist 
activity in the in vitro breast cancer cell system (101, 102). Compared to the 
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parent compound, tamoxifen, the ER binding affinities as well as inhibitory 
potencies of both endoxifen and 4-OHT were observed to be 30- to 100-fold 
higher than tamoxifen depending on the assay employed (101, 102). Besides 
being a pure ER-antagonist, endoxifen in the concentration range of 10 to 1000 
nM has been shown to target the ERα for proteosomal degradation leading to 
suppression of E2 regulated gene expression in breast cancer cell lines (104). 
The investigators also examined the endometrial cancer cells but similar effect 
was not observed. In addition, this phenomenon was not observed with 
tamoxifen, NDM and 4-OHT. Hence, therapeutic efficacy has only been observed 
in breast tumors expressing estrogen receptors (18).  
Tamoxifen is reported to increase the production of transforming growth factor 
(TGF)-β which inhibit the growth of breast cancer cells while simultaneously 
decrease the secretion of TGF-α and insulin-like growth factor-1 (IGF-1). Both 
TGF-α and IGF-1 stimulate the growth of breast cancer cells (163-165). Early 
studies examining the therapeutic efficacy of tamoxifen tried to identify 
biomarkers indicating patients who are most likely to respond to endocrine 
therapy. Almost half of the patients who were ER-positive responded to 
tamoxifen while only 33% of the unselected cohort responded (88, 166). Since 
then, ER has been the most widely employed biomarker for tamoxifen response. 
Despite 4-OHT and endoxifen being the metabolites with the greatest 
antagonism on ER, other metabolites also exhibit varying degrees of inhibitory 
effects on ER (Table 1.1). Thus, the observed therapeutic effect is attributed to 
the combined effect of multiple metabolites and unchanged parent drug though 
the relative contribution of these metabolites to the observed effect remains 
unknown (88).  
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The role of tamoxifen in the treatment of early breast cancer has been 
established via several randomized trials. In the meta-analysis of 194 
unconfounded trial conducted by the EBCTCG (18), it has been revealed that the 
annual breast cancer death rate was reduced by 31% among ER-positive 
patients receiving tamoxifen for five years. This observation was independent of 
the use of chemotherapy, age, status of progesterone receptor and other tumor 
characteristics. When tamoxifen therapy was preceded by anthracycline-based 
chemotherapy, the net reduction in breast cancer mortality ranged between 45% 
and 57% depending on the age of patients. A greater reduction in death rate has 
been observed for patients younger than 50 years old compared to patients 
between 50 to 69 years of age (18). It was also shown that the use of five years 
of tamoxifen was significantly more efficacious compared to 1-2 years of 
treatment with regard to disease recurrence and breast cancer mortality and the 
treatment benefit extended well beyond the treatment duration (167). However, 
trials conducted in North American and Scotland demonstrated no additional 
benefit when tamoxifen was administered for longer than five years (168-171). In 
particular, two of these studies indicated a tendency towards a detrimental effect 
for treatment duration of longer than five years (169, 171). Thus, optimal 
treatment duration of five years has been selected (78). However, relapse to 
therapy is frequently observed in up to 50% of all treated women. Causes of 
treatment relapse are diverse and not well understood (92, 93). 
A previous randomized trial had shown that tamoxifen given at the daily dose of 
30 mg or 90 mg exhibited similar therapeutic profile in terms of tumor regression 
and duration of response (88, 172). Although there is a case report of a single 
patient experiencing long term disease remission upon dose escalation of 20 mg 
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to 40 mg, response to this dose increase was not observed in majority of the 
patients (173). Thus far, no correlation was detected among subsequent studies 
attempting to identify possible relationships between serum levels of tamoxifen 
and treatment responses. Since an increase in dose beyond 20 mg was not 
found to increase efficacy, an optimal dose of 20 mg was selected (88). In recent 
times, Madlensky et al (174) suggested that the plasma concentration of 
endoxifen should be above a minimum threshold of 5.97 ng/ml to be effective. 
The study estimated that the plasma endoxifen levels of approximately 80% of 
patients who were receiving tamoxifen exceeded this threshold and recurrence 
rate was found to be 26% lower in this group of patients compared to patients 
with endoxifen levels below threshold. This study also found other contributory 
factors that led to poorer response rates including poor or intermediate CYP2D6 
metabolizing genotype status, higher BMI and lower tamoxifen concentrations 
(174).  
1.2.5.3 Effects on Other Tissues 
Tamoxifen acts like an estrogen agonist in the bone tissue (175). Similar to the 
effects of estrogen, in vitro experiments have shown that tamoxifen inhibits the 
resorptive activity of osteoclast (81). Two years of treatment of tamoxifen was 
associated with a preservation of bone mass in the lumbar spine compared to 
placebo in NSABP (8). However, when the effect of tamoxifen on skeletal 
metabolism was examined separately in pre- and post-menopausal women, 
relative increase in the bone mineral density of lumbar spine and hip was 
observed in post-menopausal women while a slight decrease was reported in 
pre-menopausal women (8). These observations suggested that post-
menopausal women are more likely to benefit from tamoxifen treatment and that 
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the risk of osteoporosis in pre-menopausal women cannot be excluded. In line 
with the observation with estrogen, the maximal benefit of tamoxifen on bone 
metabolism has been observed within the first year of initiation of therapy. 
The use of tamoxifen has also been associated with lower mortality rate due to 
myocardial infarction in post-menopausal women (176, 177). However, tamoxifen 
exerts a positive impact on the lipid profile as well as antioxidant effect on the 
arteries. In parallel with estrogen, reductions in plasma concentrations of low-
density lipoprotein and total cholesterol have been demonstrated (178, 179). 
Simultaneously, moderate decrease in high-density lipoprotein cholesterol and 
insignificant increase in triglyceride levels have been observed. These effects 
appeared to be more evident in post-menopausal compared to pre-menopausal 
women. Additionally, in vitro experiments supported protective roles of tamoxifen 
and 4-OHT for low-density lipoprotein against lipid peroxidation given at 
suprapharmacological and conventional doses (81).  
Additionally, heightened incidences of endometrial changes such as hyperplasia 
and polyps, especially in post-menopausal women, have been reported with the 
use of tamoxifen (180). Neven et al (81, 181) reported a relative risk of 6.7 in 
post-menopausal women for the development of endometrial polyps which has 
been described in patients with uterine bleeding. More importantly, increased 
incidence of endometrial cancer has been reported, typically within five years of 
therapeutic initiation and is likely due to the estrogenic effect of tamoxifen on the 
endometrial tissues (182, 183). The relative risk of this secondary cancer has 
been reported to be 2.2 with an annual hazard rate of 1.7 per 1000 women 
compared to population rates of endometrial cancer (182).  
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1.3 Pharmacogenetics of tamoxifen 
The efficacy and activity of tamoxifen have been found to be highly varied. 
Although the expression of ER is highly predictive of the response to tamoxifen, 
approximately 50% of all patients receiving tamoxifen subsequently relapsed (92, 
184). Moreover, tolerance to tamoxifen is highly variable and adverse effects of 
tamoxifen (hot flashes, thromboembolic events and endometrial cancer) do not 
manifest in a predictable manner (78). Several causative factors have been 
suggested for the wide variability in tamoxifen pharmacodynamics which can be 
broadly classified into host factors or tumor factors (185). Tumor factors include 
overexpression or amplification of HER-2, epigenetic silencing of ER, presence 
of variant ER, gene ratio of homeobox 13 (HOXB13)/ interleukin-17B receptor 
(IL17BR), and cross-talk between ER with other growth-factor signaling pathways 
(186, 187). Host factors mainly influence the drug handling capacity of individuals 
thereby affecting the amount of active metabolites available at the target site. 
Common host factors implicated in variability in treatment response are treatment 
adherence, food-drug or drug-drug interactions, dietary factors, body size and 
genetics (188, 189). Interestingly, it has been recently suggested that a minimal 
concentration of endoxifen is required to achieve therapeutic efficacy (174). In 
particular, high inter-individual variability in the plasma concentrations of 
tamoxifen and its metabolites have been frequently observed with the standard 
dose of tamoxifen 20 mg (122, 140). It has been estimated that between 20% 
and 95% of the variations in drug disposition and effects can be attributed to 
genetic factors (190).  
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Pharmacogenetics refers to the study of the contributions of genetic factors to the 
variation in drug response experienced by different individuals (188). On average, 
one genetic variant have been observed every 1000 bp along the genome (191). 
Genetic variants which are frequently present in the genome in more than 1% of 
the population are termed polymorphisms while variants present at frequency of 
less than 1% are referred as mutations (192). Genetic variants can be present in 
the form of single nucleotide polymorphisms (SNPs), deletions, insertions and 
gene copy number variations. Thus far, SNPs are the most frequent with over 12 
million SNPs discovered across the whole genome and at least 60 000 SNPs in 
the coding regions (190). Genetic variations present in the coding regions can 
alter the amino acid sequences, shift the open reading frames or introduce 
premature stop codons leading to changes in the protein functions (193). Beside 
the exonic variants, intronic polymorphisms can introduce alternative splice 
variants with different activity or stability compared to the wild-type protein. Other 
polymorphisms present in the 5′ regulatory and 3′ untranslated regions (UTR) 
can potentially influence the expression of the gene products by affecting the 
gene transcription or stability of the mRNA transcript respectively. The net effect 
is the alteration in the overall activity of the protein (193). 
The metabolism of tamoxifen is complex and involves several phase I and II drug 
metabolizing enzymes. Genes encoding these enzymes have been reported to 
be highly polymorphic with functional polymorphisms previously demonstrated to 
influence the formation of tamoxifen metabolites in vitro (134, 194, 195) and in 
vivo (118, 133, 140). Hence, alterations in the plasma concentrations of 
tamoxifen and its metabolites are likely due to the combinatorial effects of 
polygenic determinants involved in the disposition of tamoxifen. Understanding 
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the role of the various polygenic determinants in affecting tamoxifen disposition 
would help to elucidate the pharmacokinetic-pharmacodynamic relationship of 
tamoxifen. 
1.3.1 Phase I Drug Metabolizing Enzymes: Cytochrome P450 (CYP)  
Cytochrome P450 (CYP) is the largest and most important class of enzymes 
involved in the phase I oxidative reactions responsible for transforming putative 
drug substrates into more hydrophilic compounds (196). Compared to other 
phase I metabolizing enzymes, CYP have been found to be involved in the 
metabolism of more than 90% of the clinically used drugs (197). The substrates 
of CYP include both endobiotics (eicosanoids and steroids) and xenobiotics 
(environmental carcinogens, dietary compound and drugs). Currently, 57 
functional genes and 58 pseudogenes of CYPs have been reported (198). These 
genes are divided into families and subfamilies based on sequence similarities. 
Among the various CYP isoforms, enzymes belonging to CYPs 4, 7, 11, 17, 19, 
and 21 are mainly involved in the catalysis of endogenous substrates such as 
leukotrienes, bile acids and steroids. In contrast, CYPs 1, 2 and 3 consist of 
isozymes which are highly involved in the metabolism of xenobiotics with 
substantial variations in substrate specificity across different isoforms. The CYP 
isoforms which have been widely implicated in drug metabolism are CYP1A2 
(4%), CYP2A6 (2%), CYP2C9 (10%), CYP2C19 (2%), CYP2D6 (30%), CYP2E1 
(2%), and CYP3A4 (50%) (199). 
The CYP enzymes are mainly expressed in the liver, the main organ involved in 
metabolism. Nevertheless they have also been found to be present in 
extrahepatic tissues inclusive of gastrointestinal mucosa, kidney, lung, placenta, 
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skin and brain (200, 201). Interestingly, their relative contributions to drug 
metabolism are not correlated to the relative enzyme expression in the liver. The 
relative protein expression of the hepatic CYPs has been established as such: 
CYP1A2 (13%), CYP2A6 (4%), CYP2C9/19 (20%), CYP2D6 (2%), CYP2E1 (7%), 
and CYP3A4 (30%) (202). Interestingly, significant variability in the CYP 
enzymatic activities has been frequently observed (202) and partially attributed to 
inhibition and induction by dietary components, environmental carcinogens as 
well as drugs (203-205). In addition, CYP genes have been reported to be highly 
polymorphic (206). Genetic variants present along these pharmacogenes have 
been found to influence the protein expression and enzymatic activities of the 
candidate CYP enzymes (205, 207). Thus, these polymorphisms are of clinical 
relevance as they affect the disposition of CYP substrates which are commonly 
used drugs. 
The phase I drug metabolizing enzymes involved in the metabolism of tamoxifen 
include the flavin monooxygenases (FMO) (124) and CYP enzymes (119). In 
particular, several CYP enzymes have been shown to play important roles in the 
biotransformation of tamoxifen to its metabolites (122) with the liver being the 
major site of tamoxifen oxidation. A comprehensive in vitro assay conducted by 
Desta et al (119) screened the activity of a panel of common CYP isoforms 
(CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6, CYP2E1, CYP3A4 
and CYP3A5) and demonstrated the involvement of several CYP enzymes in the 
metabolism of tamoxifen with CYP2D6 and CYP3A4/5 playing important roles .  
1.3.1.1 Cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) 
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CYP1A2 is constitutively expressed in the liver (202, 208) and is involved in the 
metabolism of several clinically important drugs such as caffeine, olanzapine, 
clozapine, imipramine and theophylline (209). In addition, this enzyme is also 
involved in the catalytic activation of several carcinogenic heterocyclic amines to 
reactive metabolites that are implicated in the development of various cancers 
(210). A wide degree of interindividual as well as interethnic variability in CYP1A2 
activity exists (211, 212), which may affect the efficacy as well as toxicity profiles 
of putative drugs metabolized by CYP1A2, particularly those with narrow 
therapeutic indices. The sources of this variability are multifactorial and include 
both genetic and environmental factors such as induction of CYP1A2 by cigarette 
smoking, aromatic hydrocarbons and omeprazole and inhibition by grapefruit 
juice, ciprofloxacin, enoxacin, cimetidine, fluoxetine, fluvoxamine and estrogens 
(210, 213). However, these factors have been shown to account for 
approximately 28% of the total variation in CYP1A2 activity (212). It has been 
estimated that approximately 39% to 72% of the variation in CYP1A2 activity are 
due to genetic factors (212).   
The CYP1A2 gene is mapped onto chromosome 15, spans 7.8kb and consists of 
7 exons including a non-coding exon 1 (214). To date, more than 150 variant 
alleles have been reported, of which approximately 26 are non-synonymous 
polymorphisms present at frequencies of less than 0.01 (196, 215). Although 
certain non-synonymous alleles [CYP1A2*2 (63C>G, F21L, rs56160784), 
CYP1A2*3 (2116G>A, D348N, rs56276455), CYP1A2*4 (2499A>T, I386F, 
rs72547516), CYP1A2*5 (3497G>A, C406Y, rs55889066), CYP1A2*6 (5090C>T, 
R431W, rs28399424), CYP1A2*8 (5166G>A, R456H, rs72547517), CYP1A2*9 
(248C>T, T83M, rs17861153), CYP1A2*10 (502G>C, E168Q, rs72547512), 
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CYP1A2*11 (558C>A, F186L, rs72547513), CYP1A2*12 (634A>T, S212C), 
CYP1A2*13 (1514G>A, G299S, rs35796837), CYP1A2*14 (5112C>T, T438I, 
rs45486893), CYP1A2*15 (125C>G, P42R, rs72547511), CYP1A2*16 (2473G>A, 
R377Q, rs72547515)] have been shown to influence CYP1A2 expression and 
function in vitro, the in vivo impact of these SNPs remains largely unknown due 
to its rarity (210, 216, 217). 
Conversely, the polymorphic variants present in the 5′ transcriptional regulatory 
regions [CYP1A2*1C (-3860G>A, rs2069514), -3113A>G (rs2069521), 
CYP1A2*1D (-2467delT, rs35694136)] and intron 1 [CYP1A2*1E (-739T>G, 
rs2069526), -729C>T (rs12720461) and CYP1A2*1F (-163C>A, rs762551)] are 
associated with functional changes in enzyme activity (218, 219). Caffeine has 
been considered the gold standard probe substrate for CYP1A2 activity as the 
N3-demethylation of caffeine is predominantly mediated by the enzyme (210, 
220). Thus, the metabolic ratio of 1,7-dimethylxanthine to caffeine has been 
widely used as an indicator of CYP1A2 catalytic activity. A higher caffeine 
metabolic ratio is indicative of greater CYP1A2 activity. Sachse et al. (220) first 
associated the CYP1A2*1F (-163C>A, rs762551) polymorphism with higher 
caffeine metabolic ratio (MR) in smokers of Caucasian ethnic origin. The 
frequency of this polymorphism, CYP1A2*1F (-163C>A, rs762551) was not found 
to differ significantly in Asians, Africans and Caucasians (minor allelic frequency, 
MAF: 0.29 − 0.51) (221, 222). Smoking individuals who were homozygous wild-
type were found to exhibit 40% lower caffeine MR than carriers of the 
homozygous variant genotype (220). The polymorphism was suggested to 
heighten the inducibility of CYP1A2 resulting in higher catalytic activity in the 
presence of inducers of CYP1A2 such as omeprazole and cigarette smoke as 
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this observation was not replicated in the non-smokers. A subsequent study by 
Aklillu E et al (223) identified 4 haplotypes [CYP1A2*1A, CYP1A2*1F (-163C>A, 
rs762551), CYP1A2*1J and CYP1A2*1K) based on the linkage disequilibrium 
between CYP1A2*1F (-163C>A, rs762551), CYP1A2*1E (-739T>G, rs2069526) 
and -729C>T (rs12720461) in the Ethiopian population. CYP1A2*1K, which 
comprised CYP1A2*1F (-163C>A, rs762551), CYP1A2*1E (-739T>G, rs2069526) 
and -729C>T (rs12720461) was associated with 40% lower enzymatic activity 
compared with the reference CYP1A2*1A haplotype. There were no significant 
differences in the activity of CYP1A2 among individuals harboring the haplotypes 
CYP1A2*1A, CYP1A2*1F (-163C>A, rs762551) and CYP1A2*1J [CYP1A2*1F (-
163C>A, rs762551) and CYP1A2*1E (-739T>G, rs2069526)]. It has been 
suggested that the differences in results reported by Sachse et al. (220) and 
Aklillu et al. (223) may be due to the incomplete screening of SNPs in the 
CYP1A2 gene (222). 
Recent reports suggest that the 5′ transcriptional region is more polymorphic in 
Asian than in Caucasian populations (221, 224). One of the SNPs in the 5′ 
transcriptional region, CYP1A2*1C (-3860G>A, rs2069514) was initially detected 
in the Japanese population with a frequency of 0.23 and was shown to be 
associated with decreased enzyme inducibility as indicated by the lower 
metabolic ratio of caffeine in subjects harbouring this polymorphism (218). 
However, this finding was not replicated when the probe substrate was 
substituted with theophylline (225), possibly due to small number of the study 
population and presence of linkage disequilibrium between CYP1A2*1C (-
3860G>A, rs2069514) and other SNPs. On the other hand, Chen et al (224) 
demonstrated that CYP1A2*1C (-3860G>A, rs2069514) and -3113A>G 
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(rs2069521), occurred at minor allele frequencies of 0.22 and 0.09, respectively, 
in the Chinese population. These two alleles were found to be in linkage with 
other SNPs. A total of nine haplotypes was discerned and the haplotypes 
comprising CYP1A2*1C (-3860G>A, rs2069514) or -3113A>G (rs2069521) were 
associated with lower CYP1A2 enzymatic activity when caffeine was utilized as 
the probe substrate. Although the CYP1A2*1D (-2467delT, rs35694136) variant 
was present at higher frequency in the Chinese population, no association with 
the metabolic ratio of caffeine was described until recently. Pavanello et al (219) 
reported an association between CYP1A2*1D (-2467delT, rs35694136) allele 
and higher caffeine metabolic ratio. This allele was also linked to a higher risk of 
developing lung cancer (226). Interestingly, CYP1A2*1D (-2467delT, rs35694136) 
was observed to be more prevalent in the Asians (MAF: 0.42 − 0.71) compared 
to the Africans and Caucasians (MAF: 0.05 − 0.24) (221). 
Owing to the presence of strong linkage disequilibrium between CYP1A2 
polymorphisms among the different study populations (222, 224, 227, 228), 
haplotypes, consisting of clusters of closely associated SNPs, rather than 
candidate SNPs has been shown to provide better explanation for the individual 
variations in phenotypic effects (213). It has also been suggested that the 
contrasting results reported by different investigators could have resulted from 
the incomplete screening of SNPs in the CYP1A2 gene (222). The studies 
carried out thus far have focused on selected CYP1A2 SNPs and comprehensive 
screening for polymorphisms across the whole gene is lacking. Furthermore, no 
studies have been conducted to evaluate the effect of CYP1A2 polymorphisms 
on the metabolism of tamoxifen or treatment response to tamoxifen. 
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1.3.1.2 Cytochrome P450, family 2, subfamily C (CYP2C) 
The CYP2C gene cluster is located on the long arm of chromosome 10 (10q24) 
(214) and consists of four genes organized in the order of CYP2C18, CYP2C19, 
CYP2C9 and CYP2C8 (229). Three of these genes, CYP2C8, CYP2C9 and 
CYP2C19, code for enzymes which are primarily expressed in the hepatic tissue 
while CYP2C18 is a pseudogene that does not produce any functional protein 
(230). There is significant sequence homology of between 77% and 93% 
observed across the four CYP2C genes which explains the substantial substrate 
overlap between the enzymes (231). Together, the CYP2C enzymes constitute 
approximately 20% of the total hepatic CYP content (202) and are involved in the 
metabolism of more than 20% of clinically used drugs (196).  
1.3.1.2.1  Cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) 
Within the CYP2C family, CYP2C9 exhibits the highest expression in the liver 
tissue and mediates the metabolism of approximately 15% of all drugs (196, 200). 
The substrates of CYP2C9 include NSAIDs (ibuprofen, diclofenac), 
sulphonylureas (tolbutamide, glipizide), anti-epileptics (phenytoin, phenobarbital), 
angiotensin II receptor inhibitors (losartan, irbesartan) and anti-coagulants 
(warfarin, S-acenocumarol) (196). Large inter-individual variations in the activity 
of CYP2C9 have been observed leading to disparity in drug response and 
adverse effects (207). Numerous factors have been suggested to account for this 
observation including environmental factors that induce nuclear transcription 
factors regulating CYP2C9 gene expression and inhibition of CYP2C9 activity 
due to concomitant administration of drugs (232). Administration of oral 
contraceptives has been found to reduce CYP2C9 activity (233). In addition, 
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genetic variants present along the CYP2C9 gene have been demonstrated to 
exert functional impact on the expression and activity of CYP2C9 in both in vitro 
experiments and in vivo pharmacological studies (234-236).  
Spanning 50 734 base pairs (bp) in length along chromosome 10 (214), 
CYP2C9 consists of nine exons with approximately 520 polymorphisms reported 
in various populations (237, 238). Among these SNPs, two functional non-
synonymous polymorphisms have been widely investigated, CYP2C9*2 (430T>C, 
rs1799853) and CYP2C9*3 (1075A>C, rs1057910) (236). CYP2C9*2 (430T>C, 
rs1799853) leads to amino acid substitution R144C (239), which has been 
suggested to interfere with the interaction between the enzyme and P450 
reductase thereby leading to a 20% to 30% decrease in enzymatic activity 
towards S-naproxen (235). Likewise, CYP2C9*3 (1075A>C, rs1057910) located 
at exon 7 and causes I359L substitution, leads to reduction in enzymatic activity 
(240). The phenotypic effect of CYP2C9*3 (1075A>C, rs1057910) is more drastic 
than that of CYP2C9*2 (430T>C, rs1799853) variant (241). This is probably due 
to the fact that the variant is located at the substrate recognition domain of the 
active site of the enzyme. In vitro, CYP2C9*3 (1075A>C, rs1057910) has been 
found to reduce the Vmax of CYP2C9 by as much as 70% compared to the wild-
type enzyme (241). The variant allelic frequencies of these two SNPs display 
broad differences across different ethnic groups with a higher prevalence rate in 
the Caucasian population (238). CYP2C9*2 (430T>C, rs1799853) is absent in 
the Asians but has been reported in Caucasians (MAF: 0.10 – 0.15) and African 
Americans (MAF: 0.025). In contrast, CYP2C9*3 (1075A>C, rs1057910) is 
observed in Asians albeit at low frequencies of 0.04 – 0.07. The allelic 
frequencies of CYP2C9*3 (1075A>C, rs1057910) allele in Caucasians and 
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African Americans are 0.04 – 0.10 and 0.01 – 0.02, respectively. Although other 
non-synonymous polymorphisms exist, the frequencies are too low to account for 
the wide inter-individual variation in CYP2C9 activity observed (238, 242).  
Although the impact of both polymorphisms on the metabolism of tamoxifen has 
been investigated, the results have been controversial. In a pilot study involving 
80 breast cancer patients, both CYP2C9*2 (430T>C, rs1799853) and CYP2C9*3 
(1075A>C, rs1057910) were not shown to influence the plasma levels of 
tamoxifen, 4-OHT and endoxifen (140). However, in a more recent study 
comprising more than 200 German patients, CYP2C9 polymorphic variants were 
demonstrated to have a modest impact on the disposition of tamoxifen (118). 
Furthermore, these studies involved Caucasian subjects where the frequencies 
of the CYP2C9 polymorphisms and patterns of linkage disequilibium (LD) 
between polymorphisms differ significantly from the Asian populations. Hence, 
the impact of CYP2C9 polymorphisms on the plasma levels of tamoxifen and its 
metabolites remained to be determined in Asian subjects. 
1.3.1.2.2  Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) 
The CYP2C19 gene is located on chromosome 10q24, consists of nine exons 
and spans approximately 90 kilobases (kb) (214, 229). It is expressed mainly in 
the liver, although significant amounts are also found in the duodenum and other 
parts of the intestinal tract (196, 200). CYP2C19 is responsible for the 
metabolism of approximately 10% of all clinically utilized drugs such as the 
tricyclic anti-depressants (imipramine, amitriptyline), benzodiazepine (diazepam), 
proton pump inhibitors (omeprazole, pantoprazole), mephenytoin and clopidogrel 
(196, 243). The activity of CYP2C19 exhibits a bimodal distribution based on an 
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individual’s metabolic capacity for S-mephenytoin hydroxylation (244), the probe 
drug for CYP2C19, and displays a wide degree of inter-individual and inter-ethnic 
variation (245). Approximately 20% of Asian subjects are CYP2C19 poor 
metabolizers (PM) compared with 5% in the Caucasian and African populations 
(246). This differential CYP2C19 metabolic activity is mainly due to the presence 
of reduced activity genetic variants such as CYP2C19*2 (681G>A, rs4244285) 
and CYP2C19*3 (636G>A, rs4986893).  
Approximately 21 genetic variants and more subvariants have been discovered 
along the CYP2C19 gene (215). The CYP2C19*2 (681G>A, rs4244285) 
polymorphism is located on exon 5 and results in a splicing defect (247). The 
CYP2C19*3 (636G>A, rs4986893) polymorphism positioned on exon 4 is a 
nonsense polymorphism which leads to the generation of a premature stop 
codon 20 bp downstream of the SNP (248). Both variant alleles are null alleles 
leading to the total absence of enzyme activity. These polymorphisms have been 
found to be highly prevalent in the Asian populations with CYP2C19*2 (681G>A, 
rs4244285) allele present in 30% of the Chinese compared to 15% and 17% of 
the Caucasian and African populations respectively (246). Compared to the 
CYP2C19*2 (681G>A, rs4244285) allele, CYP2C19*3 (636G>A, rs4986893) is 
less frequent. The allelic frequencies of CYP2C19*3 (636G>A, rs4986893) in 
Chinese, Caucasian and African populations have been reported as 0.05, 0.0004 
and 0.004 respectively (246). These two genetic variants have been found to 
account for more than 90% of all PM phenotype observed in the Asian and 
Caucasian populations (249). However, significant variations in the CYP2C19 
activity still exists among subjects with the EM phenotype after accounting for 
possible confounding factors suggesting the presence of yet undiscovered 
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functional variants along the CYP2C19 gene (250). This observation prompted 
the search for novel polymorphisms which could possibly explain this variability.  
Two polymorphisms defining CYP2C19*17 (-3402C>T, rs11188072 and -806C>T, 
rs12248560) have been recently reported to be in complete LD in the 5′ 
transcriptional regulatory region in Caucasian populations (250). These 
polymorphisms have been associated with an increase in CYP2C19 
transcriptional activity in vitro. The -806T variant allele was shown to bind to 
hepatic nuclear proteins in subsequent electrophoretic mobility shift assay 
(EMSA), an observation absent from the -806C wild-type allele. Although the 
specific transcription factor mediating this effect could not be isolated, the data 
suggested the creation of a binding site for transcription factor which promotes 
transcription of CYP2C19 gene (250). In in vivo studies, CYP2C19*17 (-3402C>T, 
rs11188072 and -806C>T, rs12248560) was associated with 2-fold increase in 
the MR of omeprazole and 4-fold increase in the MR of mephenytoin in 
homozygous variant subjects compared to subjects who were wild-type (250). 
These studies indicate an association between CYP2C19*17 (-3402C>T, 
rs11188072 and -806C>T, rs12248560) and greater CYP2C19 activity. The 
variant allele has been reported to be present in approximately 18% of 
Caucasians and Ethiopians (250). However, the frequencies of CYP2C19*17 (-
3402C>T, rs11188072 and -806C>T, rs12248560) alleles are low in the Chinese 
(MAF: 0.04) as well as other Asian populations such as Japanese and Koreans 
(243). 
Of interest, CYP2C19*17 [-3402C>T and -806C>T (rs12248560)] but not 
CYP2C19*2 (681G>A, rs4244285) and CYP2C19*3 (636G>A, rs4986893) was 
recently shown to be associated with longer relapse-free interval in a subgroup of 
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German patients receiving tamoxifen who were homozygous for the CYP2D6*4 
(1846G>A, rs3892097) (251). In other populations, both CYP2C19*2 (681G>A, 
rs4244285) and CYP2C19*3 (636G>A, rs4986893) have also not been found to 
influence the response to as well as the incidence of adverse effects of tamoxifen 
in other study populations (252). However, the effect of CYP2C19*17 (-3402C>T, 
rs11188072 and -806C>T, rs12248560) was not investigated in this study. More 
recently, all three polymorphisms have not been found to impact the plasma 
concentrations of tamoxifen and its metabolites as well as the corresponding 
MRs (118). 
1.3.1.3 Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) 
CYP2D6 is one of the most important CYP enzyme involved in the metabolism of 
xenobiotics (203). The enzyme is predominantly expressed in the liver (202, 253) 
with extrahepatic expression in the duodenum and brain. Despite contributing 
only 2% to the overall hepatic CYP content (200, 202, 253), it is responsible for 
the metabolism of 25% of all clinically important drugs (254). The substrates of 
CYP2D6 include antidepressants (amitriptyline, imipramine, desipramine, 
paroxetine, fluoxetine), antipsychotics (haloperidol, thioridazine, risperidone), 
antiarrhythmics (flecainide, encainide), analgesics (tramadol, oxycodone, 
codeine) and β-adrenergic receptor antagonists (carvedilol, S-metoprolol, 
bufuralol, propafenone) (255-257). It is the only non-inducible CYP enzyme but 
can be inhibited by several compounds such as fluoxetine and paroxetine (258) 
(Table 1.2). 
The enzymatic activity of CYP2D6 has been found to display multi-modal profile 
and is highly varied among individuals (259). Phenotyping with the probe drugs 
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of CYP2D6, sparteine, debrisoquine, dextromethorphan and metoprolol, has led 
to the characterization of the enzymatic activity into four major metabolic classes 
(257, 260) in descending order of metabolizing capacity: ultrarapid metabolizer 
(UM), extensive metabolizer (EM), intermediate metabolizer (IM) and poor 
metabolizer (PM). Among these four categories, EM is the reference phenotype 
whereby individuals who are EM are considered to exhibit normal enzymatic 
activity. Phenotyping is usually performed by determining the MR of the substrate 
in the plasma or urine. Using debrisoquine as the probe substrate, the frequency 
of PM in the Caucasian population has been estimated to be 5% to 10% (259) 
while the range varied widely from 0% to 19% in African populations (261). PMs 
are rare in most Asian populations, with the exception of Indians for which the 
frequency has been reported as 1.8% to 4.8% (262). Instead, majority of the 
Asian populations is anticipated to be IM due to high prevalence of the reduced 
function allele, CYP2D6*10 (100C>T, rs1065852) (263, 264). In addition, almost 
one-third of Ethiopian population has been classified as UM (261). Variations in 
the metabolizing capacity have been established to be largely due to presence of 
genetic variations in the CYP2D6 gene. However, other factors such as 


















or could potentially 
have some in vivo 
effect 
Compounds 
expected to have 
little in vivo 
inhibition 
SSRI/ SNRI Paroxetine Sertraline Venlafaxine 
 Fluoxetine Citalopram Desvenlafaxine 
 Bupropion Fluvoxamine Escitalopram 
 Duloxetine  Mirtazapine 
TCA  Clomipramine  
  Doxepin  
  Desipramine  
  Imipramine  
  Amitriptyline  
   Nortriptyline  
Anti-psychotics Thioridazine Chlorpromazine Thiothixene 
 Perphenazine Fluphenazine Clozapine 
 Pimozide Haloperidol Risperidone 
   Clozapine 
   Olanzapine 
   Ziprasidone 
      Quetiapine 
Cardiovascular agent Quinidine Amiodarone Diltiazem 
 Ticlopidine Nicardipine  
  Verapamil  
  Amlodipine  
  Felodipine  
  Nifedipine  
Anti-infectives Terbinafine Ritonavir Indinavir 
  Halofantrine Saquinavir 
  Chloroquine Nelfinavir 
   Nevirapine 
      Efavirenz 
H2 receptor antagonists  Cimetidine Ranitidine 
H1 receptor antagonists   Clemastine Chlorpheniramine 
  Tripelennamine Cetirizine 
  Promethazine Loratadine 
    Hydroxyzine   
Adapted from Sideras et al. 
§Selective serotonin reuptake inhibitor, SSRI; Selective noradrenergic reuptake 
inhibitor, SNRI; Tricyclic antidepressants, TCA. 
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Although CYP2D6 is non-inducible, it can be inhibited by a diverse range of 
clinically used drugs (258, 260). Quinidine is by far the most potent inhibitor of 
CYP2D6 and has been shown to decrease the metabolizing capacity of CYP2D6 
in EM subjects to the level of a PM status. This phenomenon is known as 
phenocopying (265, 266). Other potent to moderate inhibitors of CYP2D6 include 
the fluoxetine, paroxetine, bupropion, duloxetine, thioridazine, perphenazine, and 
pimozide (267). Co-administration of these inhibitors with CYP2D6 substrates 
can lead to clinically significant drug interactions (260). As the majority of the 
inhibitors stated above are also known substrates of CYP2D6, chronic 
administration of these drugs could possibly lead to autoinhibition of CYP2D6 
and influence its metabolism (260).  
CYP2D6 is encoded by a 4.4 kb gene comprising of nine exons and is mapped 
onto chromosome 22q13.1 (268, 269). The gene is located 3′ downstream of two 
highly homologous pseudogenes, CYP2D7P and CYP2D8P within the same 
CYP2D subfamily (269, 270). The CYP2D6 gene has been reported to be highly 
polymorphic with over 100 different genetic variants (215). The commonly 
occurring alleles are listed in Table 1.3. Based on the functional consequences of 
the alleles, the polymorphisms are generally classified as null (no functional 
enzymatic activity), reduced (decrease in the enzymatic activity), normal and 
increased function alleles (260, 271).  
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Table 1.3 Common CYP2D6 polymorphic variants. 








Variant Allelic Frequencies 
Asians Caucasians Africans 
*2 2850C>T rs16947 Exon 6 R296C Normal allele 0.092 – 0.20 0.22 – 0.37 0.109 – 0.78 
*3 2549delA rs4986774 Exon 5 259fx Null allele 0.00 – 0.008 0.01 – 0.039 0.00 – 0.006 
*4 1846G>A rs3892097 Exon 4 Splicing 
defect 
Null allele 0.00 – 0.028 0.113 – 0.23 0.009 – 0.085 
*6 1707delT rs5030655 Exon 3 118fx Null allele 0.00 0.00 – 0.014 0.00 – 0.005 
*7 2935A>C rs5030867 Exon 6 H324P Null allele NA 0.015 NA 
*8 1758G>T  Exon 3 G169X Null allele 0.00 <0.01 NA 
*9 2615_2617 
delAAG 
rs5030656 Exon 5 K281del Reduced 
function allele 
0.033 0.00 – 0.029 0.00 – 0.003 
*10 100C>T rs1065852 Exon 1 P34S Reduced 
function allele 
0.381 – 0.70 0.014 – 0.08 0.025 – 0.086 
*14 1758G>A  Exon 3 G169R Null allele 0.015 – 0.02 NA NA 
*17 1023C>T rs28371706 Exon 2 T107I Reduced 
function allele 
0.005 0.00 – 0.016 0.09 – 0.34 
*29 1659G>A rs61736512 Exon 7 V136I Reduced 
function allele 
NA NA 0.2 




0.04 0.084 NA 
*xN multiple 
CYP2D6 
 – – Increased 
function allele 
0.01 0.008 – 0.07 0.014 – 0.136 
*5 CYP2D6 
deletion 
  – – Null allele 0.045 – 0.062 0.008 – 0.073 .006 – 0.069 
†NA, Not Available. 
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The frequencies of these alleles have been found to vary extensively across 
populations from different ethnic background (272). In the Caucasian ethnic group, 
CYP2D6*4 (1846G>A, rs3892097) is the most frequently occurring allele (MAF: 0.20) 
(272) and has been estimated to be responsible for up to 90% of all Caucasian PMs 
(260). CYP2D6*4 (1846G>A, rs3892097) causes the relocation of the splice site 
from intron 3 to exon 4 and subsequent production of a non-functional protein (273-
275). Despite the high frequency of this allele in the Caucasian population, it has 
been reported to be present in only 1% to 9% of the Africans and rare (MAF: 0.01 – 
0.02) in Asians (272). In contrast, CYP2D6*10 (100C>T, rs1065852) which leads to 
amino acid substitution P34S is the more prevalent allele in Asian subjects (264, 
276). The substitution located at the proline-rich region near the NH2-terminal, 
hindered the protein folding resulting in 97.5% reduction in the activity of the variant 
enzyme compared to the wild-type protein (277). Although CYP2D6*10 (100C>T, 
rs1065852) allele is present in almost half of the Japanese and Chinese populations 
(264, 277), it has been found to be almost absent in subjects of European descent 
(278). The frequencies of CYP2D6*10 (100C>T, rs1065852) have been found to be 
at least five-fold lower in the Africans and Caucasians (MAF: 0.025 – 0.086) 
compared to the Asians (257). 
The most prevalent alleles observed in the African populations are CYP2D6*17 
(1023C>T, rs28371706 and 2850C>T, rs16947) and CYP2D6*29 (1659G>A, 
rs61736512 and 3183G>A, rs59421388) which lead to reduced enzyme activity (266, 
272). The polymorphisms defining CYP2D6*17 (1023C>T, rs28371706 and 
2850C>T, rs16947), 1023C>T (rs28371706) and 2850C>T (rs16947) lead to amino 
acid substitutions T107I and R296C respectively (266, 279). Presence of 2850C>T 
(rs16947) alone has been described as CYP2D6*2 (2850C>T, rs16947) which do not 
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significantly influence the enzyme activity (280). However, when these two 
polymorphisms were transfected together in COS-1 cells, the activity of the variant 
enzyme was only 20% of that observed in the wild-type protein (281). The frequency 
of CYP2D6*17 (1023C>T, rs28371706 and 2850C>T, rs16947) varies greatly across 
different African populations with frequencies ranging between 9% and 34% (272, 
281). Another variant, CYP2D6*29 (1659G>A, rs61736512 and 3183G>A, 
rs59421388) has been reported to decrease bufuralol hydroxylation compared to the 
wild-type enzyme (282). The two SNPs defining CYP2D6*29 (1659G>A, rs61736512 
and 3183G>A, rs59421388) cause the amino acid substitutions of valine for 
isoleucine and methionine at codon 136 and 338 respectively (282). Although 
CYP2D6*29 (1659G>A, rs61736512 and 3183G>A, rs59421388) polymorphism was 
originally identified in the European subjects (283), it has only been detected at high 
frequency of 20% in the African Tanzanian population (282). Both CYP2D6*17 
(1023C>T, rs28371706 and 2850C>T, rs16947) and CYP2D6*29 (1659G>A, 
rs61736512 and 3183G>A, rs59421388) have been often described as African-
specific due to the rare occurrence in non-African populations (272). 
CYP2D6*41 (2988G>A, rs28371706) is a more recently identified polymorphism 
which leads to reduced CYP2D6 functionality (284). This intronic polymorphism 
interferes with the splicing mechanism leading to omission of exon 6 from the mature 
mRNA and subsequent production of a variant protein with reduced activity (285). 
This allele is commonly accepted for causing the IM phenotype in Caucasians (266).  
In addition to SNPs, copy number variation or CNV is also fairly common in CYP2D6. 
The deletion of the entire 12.1 kb region inclusive of the CYP2D6 gene, denoted as 
CYP2D6*5 (CYP2D6del), results in the complete loss of CYP2D6 expression and 
catalytic activity (286) and has been found at similar frequencies of 4% to 7% across 
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various ethnicities (272). CYP2D6*5 (CYP2D6del) is believed to arise due to unequal 
crossover of the sister chromatids (257). Repeated unequal crossover of the 
chromatids, on the other hand, is the underlying cause of CYP2D6*xN (CYP2D6dup) 
or CYP2D6 gene multiplication which has been found to be more prevalent in the 
Ethiopians (MAF: 0.29) (261), Saudi Arabians (MAF: 0.21) (287), Africans (MAF: 
0.049) (288), Italians (MAF: 0.10), Spaniards (MAF: 0.07 – 0.10) (289-291) and 
Turkish (MAF: 0.087) (292). As many as 13 gene copies have been detected in 
individuals and the UM phenotype has been attributed to the presence of multiple 
copies of CYP2D6 (261, 293).  
1.3.1.3.1  Effect of CYP2D6 on Disposition of Tamoxifen  
CYP2D6 was initially reported to influence the plasma levels of tamoxifen and its 
metabolites in a pilot study involving twelve female breast cancer patients receiving a 
chronic daily dose of 20 mg tamoxifen (122). In this prospective study, patients were 
prescribed 10 mg daily of paroxetine, a CYP2D6 inhibitor. The baseline plasma 
levels of tamoxifen and its primary metabolites (NDM, 4-OHT and endoxifen) were 
compared with their corresponding concentrations after four weeks of paroxetine 
treatment. Plasma endoxifen level was found to display the most significant decrease 
in response to paroxetine with reduction in mean plasma concentration from the pre-
treatment level of 12.4 ng/ml to 5.5ng/ml four weeks after paroxetine treatment. 
Similar trend has not been reported with other metabolites. When the CYP2D6 
genotype status [CYP2D6*4 (1846G>A, rs3892097), CYP2D6*6 (1707delT, 
rs5030655) and CYP2D6*8 (1758G>T)] was considered, a lower baseline endoxifen 
level was reported in patients carrying the variant alleles compared to wild-type. In 
addition, a lower extent of decrease in endoxifen concentration following paroxetine 
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administration was observed in patients carrying the variant alleles (24% reduction) 
compared to the wild-type allele (64% reduction).   
Likewise, in a subsequent larger cohort of 80 patients (140), a gene-dose dependent 
decrease in the mean plasma endoxifen concentration was observed as the number 
of copies of variant CYP2D6 alleles [CYP2D6*3 (2549delA, rs4986774), *4 
(1846G>A, rs3892097), *5 (CYP2D6del) and *6 (1707delT, rs5030655)] increased. 
The mean plasma endoxifen level of patients carrying two variant alleles was found 
to be similar to that observed in patients who were wild-type for CYP2D6 alleles and 
receiving a potent CYP2D6 inhibitor such as paroxetine. Besides, the study 
investigated the effect of functional SNPs in other candidate genes, CYP2C9, 
CYP3A5 and SULT1A1 though the associations were found to be negative. An 
expanded cohort consisting 158 Caucasian patients and screening of a total of 33 
CYP2D6 alleles lead to similar findings (294). Both CYP2D6 genotypes and 
inhibitors of CYP2D6 were found to influence the plasma levels of endoxifen. The 
study additionally demonstrated that the ratio of endoxifen/NDM was a better 
indicator of CYP2D6 activity with a higher discriminating power for CYP2D6 
phenotypic subgroups. This observation has been subsequently replicated by Gjerde 
et al (133) in 151 Norwegian patients. In addition, decreased 4-OHT and increased 
NDM plasma concentrations in the presence of CYP2D6 variants were reported. The 
relationship between the MR of endoxifen/NDM was found to be similar to that 
observed by Borges et al (294). Similar significant trend with the MR of 4-
OHT/tamoxifen and inverse relationship with the MR of NDM/tamoxifen were 
observed. The observation with the ratio of NDM/tamoxifen is likely due to the 
carryover effect from the pathway involving the conversion of NDM to endoxifen. 
Impaired CYP2D6 catalytic capacity due to the presence of CYP2D6 decreased 
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function or null alleles led to the decreased formation of endoxifen and accumulation 
of NDM with respect to tamoxifen. This is reflected as an increase in the ratio of 
NDM/tamoxifen. Surprisingly, an increase in the ratio of N-
didesmethyltamoxifen/NDM with increasing number of CYP2D6 variant alleles was 
also observed in the same study (133). 
In the East Asian populations namely the Koreans (142) and Japanese (295), 
plasma levels of endoxifen and 4-OHT have been correlated with CYP2D6 variant 
genotypes, consistent with the studies involving Caucasian patients (133, 294). 
Unlike the Caucasian cohort, the CYP2D6 alleles implicated were mainly CYP2D6*5 
(CYP2D6del) and CYP2D6*10 (100C>T, rs1065852) although CYP2D6*4 (1846G>A, 
rs3892097), CYP2D6*14 (1758G>A), CYP2D6*21 (2573_2574insC), CYP2D6*36 
and CYP2D6*41 (2988G>A, rs28371725) were screened in the Japanese cohort and 
found to be present at low frequencies (295). Plasma levels of tamoxifen and NDM 
were not found to be associated with CYP2D6 variants in these populations. In the 
Chinese population, CYP2D6*10 (100C>T, rs1065852) has also been linked to 
reduced plasma 4-OHT concentration (296). However, the plasma levels of 
endoxifen were not measured and the investigators only genotyped CYP2D6*10 
(100C>T, rs1065852) without consideration of other alleles such as *5 (CYP2D6del) 
and *14 (1758G>A) which were present in the Chinese population. 
Recently, nine variants prevalent in the Caucasian populations were genotyped in 
236 German patients: CYP2D6*3 (2549delA, rs4986774), *4 (1846G>A, rs3892097), 
*5 (CYP2D6del), *6 (1707delT, rs5030655), *7 (2935A>C, rs5030867), *8 (1758G>T), 
*9 (2615_2617 delAAG, rs5030656), *10 (100C>T, rs1065852) and *41 (2988G>A, 
rs28371725) (118). In line with previous studies, reduced function and null alleles of 
CYP2D6 were found to correlate with lower plasma levels of endoxifen and 4-OHT 
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as well as the MRs of NDM/endoxifen and tamoxifen/4-OHT. Furthermore, CYP2D6 
genetic variants were reported to account for 68.7% and 38.6% of the variance 
observed in NDM/endoxifen and endoxifen plasma concentration respectively. 
Compared to endoxifen, the contribution of CYP2D6 genetic variants to the formation 
of 4-OHT was lower. The investigators estimated that approximately 27.6% and 9% 
of the deviation in MR of tamoxifen/4-OHT and plasma concentration of 4-OHT 
respectively were being attributed to CYP2D6 variants. Currently, all the studies 
indicate that CYP2D6 play a major role in determining the formation of 4-OHT and 
endoxifen, the active metabolites of tamoxifen. However, much variability in the 
plasma concentrations of these metabolites remained unexplained. It was postulated 
that genetic variants in other candidate genes along the biochemical pathway of 
tamoxifen might provide the explanation.  
1.3.1.3.2  Effect of CYP2D6 on Treatment Outcome of Tamoxifen 
Soon after the discovery of the activity of endoxifen and the impact of CYP2D6 
pharmacogenetics on the inter-individual variability of plasma endoxifen 
concentration (122), Goetz et al (297) reported a trend of worse relapse-free time 
and disease-free survival in Caucasian patients (n=223) carrying the CYP2D6*4/*4 
genotype from the prospective, randomized, phase III clinical trial conducted by the 
North Central Cancer Treatment Group. Although univariate analyses indicated 
significant phenotypic-genotypic associations, the results upon adjusting for nodal 
status and tumor size became non-significant and no effect on overall survival was 
established. Interestingly, none of the CYP2D6*4/*4 carriers experienced moderate 
to severe hot flashes in contrast to the 20% reported in patients who were wild-type 
or heterozygous. However, there were several limitations that confounded the 
findings of this study leading to subsequent investigations carried out in different 
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patient cohorts. These limitations included small sample size, genotyping of only two 
SNPs in CYP2D6, lack of information on concomitant medications, inclusion of ER-
negative patients and absence of plasma levels of tamoxifen and its active 
metabolites. 
In the follow-up study, Goetz et al (298) demonstrated the importance of co-
administration of CYP2D6 inhibitors. Based on the CYP2D6 genotypes and the 
concomitant use of CYP2D6 inhibitors, the patients were classified as EM or PM. 
Patients with poor CYP2D6 metabolizing capacity were associated with shorter time 
to breast cancer recurrence, relapse-free survival and disease-free survival 
compared to CYP2D6 EM. Although a trend towards inferior overall survival was 
reported in CYP2D6 PM, the effect was not significant. The association was 
replicated in a subsequent study involving German and American Caucasian patients 
(251, 299). In additional, Schroth et al (300) reported improvement in the prediction 
of risk of disease recurrence with expanded coverage of 33 CYP2D6 alleles. In 
patients classified as PM due to presence of variant alleles, the hazards ratio was 
increased from 1.33 to 2.87 after extensive genotyping of CYP2D6 alleles. These 
data suggest a greater accuracy in the prediction of CYP2D6 phenotype status with 
the genotyping of greater number of functional alleles. In the Asian populations, 
CYP2D6 genotypes were found to similarly influence the risk of disease recurrence 
or disease free survival in Japanese (301) and Chinese (296) patients receiving 
adjuvant tamoxifen monotherapy. However, only CYP2D6*10 (100C>T, rs1065852) 
was genotyped in these patient cohorts. 
The relationship described in the adjuvant indication of tamoxifen therapy has also 
been observed in metastatic breast cancer patients. The time to progression and 
overall survival in metastatic Caucasian patients were found to be significantly 
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shorter in patients with CYP2D6 poor metabolizing capacity as defined by the 
presence of CYP2D6 genetic variants and use of CYP2D6 inhibitors (302). This 
effect was similarly observed in the Korean population albeit with a much smaller 
sample size of 21 subjects (142).  
However, the current evidence supporting the clinical use of CYP2D6 genotyping 
has been controversial as many investigators have failed to observe the relationship 
between CYP2D6 activity and treatment outcome of tamoxifen. Among the first to 
report such disparate observations were Wegman et al (303) and Nowell et al (304). 
While Nowell and colleagues did not find an association between progression-free 
survival or overall survival  and CYP2D6*4 (1846G>A, rs3892097) genotype status 
(304), Wegman et al (303) reported a more favorable response for tamoxifen in 
terms of disease-free survival among patients who were homozygous for CYP2D6*4 
(1846G>A, rs3892097). Other investigators also noted null associations between 
CYP2D6 variant alleles and survival outcomes in the Caucasian, Japanese and 
Korean patient populations receiving tamoxifen as adjuvant therapy (305-307). In 
recent times, the functional impact of CYP2D6 has once again been examined 
retrospectively in large number of breast cancer patients previously recruited for 
Breast International Group (BIG) 1-98 trial (n=4393) (308) and Arimidex, Tamoxifen, 
Alone or in Combination (ATAC) (n=588) (309). Both studies did not observe any 
association between CYP2D6 PM phenotype and disease free survival. In contrary 
to previous observations, patients classified as CYP2D6 IM or PM in the BIG 1-98 
trial were found to have heightened risk of hot flashes (308). Previously, the use of 
CYP2D6 inhibitor and CYP2D6 genotype status were suggested to affect the 
incidences of tamoxifen-induced hot flashes, treatment adherence to tamoxifen or 
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discontinuation of tamoxifen treatment (297). However, these findings were not 
replicated by other groups (310). 
Lately, Madlensky and colleagues suggested that patients with steady state plasma 
endoxifen concentrations less than 5.97 ng/ml were associated with 30% higher risk 
of additional breast cancer events (174). No associations with plasma concentrations 
of tamoxifen, NDM and 4-OHT were observed. This report indicated that instead of a 
linear dose-response relationship, a minimum level of endoxifen is required for the 
therapeutic efficacy of tamoxifen. The investigators also noted that patients classified 
as CYP2D6 PMs were found to have endoxifen concentration below the threshold. 
Interestingly, 24% of the CYP2D6 PMs were able to achieve plasma levels of 
endoxifen above this therapeutic threshold, suggesting the presence of in vivo 
compensatory mechanisms for the metabolisms in these patients. This finding also 
partially explained the contradictory observations with regard to CYP2D6 genetic 
variants and tamoxifen treatment response. 
1.3.1.4 Cytochrome P450, family 3, subfamily A (CYP3A) 
The CYP3A family of enzymes is considered the most important class of CYP 
enzymes due to its broad substrate specificities and involvement in the metabolism 
of approximately 50% of all clinically used drugs (204, 205, 311). There are 4 
isoforms of CYP3A enzymes, namely CYP3A4, CYP3A5, CYP3A7 and the newly 
discovered CYP3A43 (312, 313). Among these enzymes, CYP3A4 and to a lesser 
extent CYP3A5 are among the most important in terms of adult metabolism (203, 
314). The most abundant CYP enzyme is CYP3A4 which accounts for 50% to 60% 
of the overall hepatic content of CYP (202). It can be found expressed ubiquitously in 
the liver and intestinal tissues although the intestinal content has been estimated to 
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be only about 1% of that in the liver (315, 316). The differential expression pattern 
suggested that a tissue-specific regulation in the expression of CYP3A enzymes. In 
comparison, CYP3A5 only accounts for 2% to 3% of the total hepatic CYP3A content 
(196, 205, 317) and is more frequently found in extrahepatic tissues such as lung, 
kidney, colon and esophagus (255). Significant overlap in the substrate specificities 
has been observed due to considerable sequence homology in the genes encoding 
these enzymes though the catalytic rate differs between the two isozymes (318). 
Thus, most of the probe drugs were not able to differentiate between the activity of 
CYP3A4 and CYP3A5 (205). The substrates of CYP3A differ widely in terms of 
molecular weight and therapeutic activity including the macrolide antibiotics 
(erythromycin), nifedipine, cyclosporine, taxanes (docetaxel, paclitaxel) and statins 
(simvastatin, atorvastatin) (196, 204). 
Wide variabilities in the expression levels and enzymatic activities of CYP3A4/5 
between individuals and ethnic groups have been observed (255). It has been 
estimated that protein expression and metabolic activity of CYP3A4 can vary 
approximately 40- and 10-fold, respectively, with approximately 90% of the deviation 
in CYP3A activity can be attributed to genetic factors (319, 320). The CYP3A 
enzymes are encoded by genes clustered on chromosome 7q21 – 22. This gene 
cluster comprised of four functional genes (CYP3A4, CYP3A5, CYP3A7, CYP3A43) 
and three pseudogenes (CYP3AP1, CYP3AP2, CYP3AP3) (312, 313). High 
sequence homology has been observed among the various genes in this sub-family 
explaining the relatedness in the substrate affinities.  
1.3.1.4.1  Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) 
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The CYP3A4 gene consists of 13 exons spanning 27 kb (312). Although more than 
19 variants and numerous sub-variants have been discovered (215), the frequencies 
of these variants are generally rare especially in the Asian populations (321). Hence, 
polymorphisms in CYP3A4 did not appear to fully explain the variability in CYP3A4 
activity (322). Nevertheless, the most widely investigated CYP3A4 polymorphism is 
CYP3A4*1B (-392A>G, rs2740574) (323) which was found to be located in the 
nifedipine-specific response element of the 5′ transcriptional regulatory region and 
has been associated with lower CYP3A activity (324). Studies in African American 
and Caucasian showed that the clearance of midazolam was 30% lower in subjects 
carrying 2 copies of the variant allele compared to individuals who were homozygous 
wild-type. The allelic frequency is reported to be highest in the Africans at 0.53 to 
0.69 followed by the Caucasian and Hispanics (MAF: 0.036 – 0.11) (305,. Hitherto, 
this allele has not been detected in the Asian populations including Japanese, 
Chinese, Malays and Indians (325, 326). Due to its low frequency, the effect of 
CYP3A4 polymorphisms on the disposition and treatment outcome of tamoxifen is 
unknown. 
1.3.1.4.2  Cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5) 
Unlike CYP3A4, CYP3A5 has been found to be highly polymorphic with respect to its 
CYP3A5*3 (6986A>G, rs776746) allele. CYP3A5*3 (6986A>G, rs776746) is located 
at intron 3 and leads to the incorporation of the intronic region into the mRNA, 
premature termination of protein synthesis and production of a non-functional protein 
(317). Hence, subjects carrying two copies of the variant allele are known as 
CYP3A5 non-expressors (322). This polymorphism is most commonly observed in 
the Caucasian population followed by Asians and Africans with allelic frequencies of 
0.90, 0.75 and 0.20 respectively (321, 327). This observation correlates well with the 
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observed variation in hepatic expression of CYP3A5 reported previously. CYP3A5 
expression is only detectable in 10% to 20% of the Caucasian (317) population 
compared to 33% of the Japanese (328) and 55% of the African American subjects 
(317). The frequencies observed in our local populations are similar to that in other 
Asian populations (329). Thus far, CYP3A5*3 (6986A>G, rs776746) has been 
associated with lower tacrolimus dose requirement in heart transplant patients (330). 
Besides CYP3A5*3 (6986A>G, rs776746), CYP3A5*6 (14690G>A, rs10264272) is 
another commonly investigated polymorphism (317). Although this polymorphic 
variant has been reported at moderate frequency of approximately 0.06 in the African 
population, it is absent in both Caucasian and Asian patients (317, 321). Thus, 
CYP3A5*3 (6986A>G, rs776746) polymorphism appears to be the predominant 
polymorphic variant of CYP3A5. Several studies had evaluated the impact of 
CYP3A5*3 (6986A>G, rs776746) on plasma concentrations of the metabolites, MRs 
and treatment outcome of tamoxifen (118, 140, 297, 331, 332). However, none of 
these studies reported significant relationships.  
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1.3.2 Phase II Drug Metabolizing Enzymes 
1.3.2.1 Uridine 5′-diphosphate glucuronosyltransferase (UDP 
glucuronosyltransferase, UGT) 
Glucuronidation is the most common phase II drug conjugative reaction accounting 
for approximately one-third to 45% (314) of all phase II drug metabolism. It refers to 
the conjugation of the glucuronic acid to a substrate of exogenous or endogenous 
origin. The resultant substrates are usually inactive compounds with higher water 
solubility and greater polarity enabling greater ease of excretion (333). Hence, this 
reaction which is exclusively mediated by a class of enzymes known as UGT or 
uridine-diphosphate-glucuronosyltransferase, is generally considered a detoxification 
mechanism  (334). 
UGT is a superfamily of enzymes which catalyze the conjugation of glucuronic acid 
to a wide variety of xenobiotics and endobiotics using uridine-diphosphate-glucuronic 
acid (UDPGA) as a co-substrate (335). The substrates of UGTs include carcinogens, 
drugs, components of natural products and steroidal hormones (333). Like CYP 
enzymes, various UGT isoforms has been found to exhibit disparity in enzymatic 
expression across different tissue (336, 337). However, the liver is the main site of 
expression while the level of expression in other extra-hepatic sites including 
intestine and breast tissue varies (337). These enzymes are membrane-bound and 
localized in the endoplasmic reticulum of the mammalian cells with their catalytic 
sites facing the lumen (334, 338). The structure of UGTs is highly conserved across 
different isoforms and consists of an N-terminal signal sequence which targets the 
enzyme to the endoplasmic membrane, variable substrate binding domain, 
conserved UDPGA binding site, transmembrane domain and C-terminus cytosolic 
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tail (Fig 1.5) (333). Based on gene sequence homology, the UGTs are divided into 
four families, UGT1, UGT2, UGT3 and UGT8 (339). Amongst these four classes of 
UGTs, UGT1 and UGT2 enzymes are the most efficient in employing UDPGA as the 
co-substrate and are further subdivided into UGT1A/B and UGT2A/B respectively. 
However, only enzymes belonging to the UGT1A and UGT2B are of particular 
therapeutic relevance (339).  
The UGT1A subfamily consists of nine enzymatic isoforms (UGT1A1, UGT1A3, 
UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10) which are 
encoded by the UGT1A gene locus spanning approximately 200 kb on chromosome 
2q37 (Fig 1.5A) (340, 341). All UGT1A genes share common exons 2 to 5 which 
encode the UDPGA binding site and the C-terminal domains. The variable exon 1 
which is unique for each UGT1A isoform codes for the N-terminal region and the 
variable substrate binding site. The expression of the various UGT1A isoforms are 
regulated by the proximal promoter region located 5′ upstream of the various exons 1 
and the corresponding 3′ donor RNA splice site. During transcription, exon 1 would 
be spliced to the exons 2 to 5 (333, 336, 342). The relative locations of the exons 1 
of different UGT1A isoforms are depicted in Fig 1.5A (343). Other than the nine 
functional genes, the UGT1A gene locus also consists of four pseudogenes 
(UGT1A2P, UGT1A11P, UGT1A12P and UGT1A13P). Relative high sequence 
homology ranging from 50% to 92% has been observed across the various exons 1 
of UGT1A genes (339).  
Unlike UGT1A, UGT2B subfamily is encoded by distinct genes which are clustered 
on chromosome 4 (4q13 – q21, Fig 1.5B). A total of seven genes including UGT2B4, 
UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17 and UGT2B28 as well as five 
pseudogenes (UGT2B24P, UGT2B25P, UGT2B26P, UGT2B27P, and UGT2B29P) 
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have been reported (344). The UGT2B genes are highly related to each other with at 
least 70% similarity in gene sequences (339). Each UGT2B gene consists of six 
exons of which exons 1 and 2 translate to the substrate binding domain of the 
enzyme while exons 3 to 6 code for the UDPGA binding domain till the C-terminus 
tail (333, 339). 
 




Both UGT1A and UGT2B genes have been found to be highly polymorphic and 
genetic variants in these genes have been shown to alter the expression and activity 
of these enzymes (345). Inter-ethnic variability in pharmacogenetic profile of various 
UGTs has been widely reported (258, 335, 346). As UGTs play central roles in the 
detoxification of a broad range of substrates, variation in its enzymatic activity is 
likely to have important implications in the therapeutic outcome and adverse effects 
of drug treatment. 
Several UGTs have been shown to be greatly involved in the biochemical pathway of 
tamoxifen. In addition to tamoxifen, the two active metabolites, 4-OHT and endoxifen 
have also been demonstrated to be the substrates of various UGT isoforms in 
human liver microsomes (129). In vitro experiments have showed that tamoxifen is 
glucuronidated to form TAM-N-glucuronide and both metabolites have been found to 
exhibit similar binding affinity for ER (128). Zheng et al showed that tamoxifen-N-
glucuronides, N- and O-glucuronides of 4-OHT as well as the O-glucuronides of 
endoxifen were not able to inhibit E2-mediated induction of the progesterone receptor 
gene in contrary to the observations with 4-OHT and endoxifen (127). The 
glucuronides of 4-OHT and endoxifen exhibited 57- to 130-fold reduction in the 
estrogen receptor binding activities compared to the corresponding unconjugated 
metabolites (127). These observations illustrated the inactivity of the glucuronidated 
compounds and confirm the role of glucuronidation as a detoxification mechanism in 
the metabolic pathway of tamoxifen. 
1.3.2.1.1 UDP glucuronosyltransferase 1 family, polypeptide A4 (UGT1A4) 
UGT1A4 is primarily expressed in the liver although it is also detected along the 
gastrointestinal and biliary tracts (333, 337). The enzyme is mainly involved in the N-
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glucuronidation of primary and secondary amines in various drugs which include 
imipramine, amitriptyline, trifluoperazine, clozapine, lamotrigine, nicotine as well as 
carcinogenic substances [NNAL or 4-(methyl-nitrosoamino)-1-(3-pyridyl)-1-butanol, 
N-OH-PhIP or N-hydroxyl-2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine] (128, 
347-350). The UGT1A4 gene encoding the protein (534 amino acids) spans 54 508 
bp along chromosome 2q37 and is subsequently transcribed to a 2374 bp mRNA 
(341, 351). As with other UGT1A genes, UGT1A4 is highly polymorphic across 
different ethnic populations and high LD between the polymorphisms in promoter 
region and exon 1 are consistently reported (352-356). However, little is known about 
the function of these polymorphisms with the exception of two missense 
polymorphisms, UGT1A4*2 (70C>A, rs6755571) and UGT1A4*3 (142T>G, 
rs2011425), located in exon 1 of the gene (134, 349, 357-359).  
UGT1A4*2 (70C>A, rs6755571) is a Caucasian-specific polymorphism leading to 
amino acid substitution P24T (349). This SNP has been reported to be present in 6% 
to 11% of the Caucasian subjects but absent in the East Asian populations (349, 
353). In contrast, the UGT1A4*3 (142T>G, rs2011425) which results in the 
substitution of amino acid at codon 48 (L48V) (360) has been observed at allelic 
frequency of 0.12 to 0.13 in the Koreans and Japanese and 0.18 in the Chinese. In 
the Caucasians, however, the allelic frequency of UGT1A4*3 (142T>G, rs2011425) 
has been found to be similar to its UGT1A4*2 (70C>A, rs6755571) counterpart (352-
356). The impact of these two non-synonymous SNPs on the glucuronidating 
capacities of UGT1A4 for various substrates has been previously compared against 
the wild-type UGT1A4 enzyme in HEK293 cells expressing both types of proteins 
(360). The glucuronidation activity of enzymes UGT1A4.2 and UGT1A4.3 for β-
napthylamine was found to be 30.5% and 57.2% of that observed in UGT1A4.1 
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protein respectively. Similarly, undetectable and 31.5% reduction in benzidine 
glucuronidation was noted with UGT1A4*2 (70C>A, rs6755571) and UGT1A4*3 
(142T>G, rs2011425) expressing UGT1A4 enzyme respectively (349). However, 
nearly no enzymatic activity was detected against steroidal compounds (trans-
androsterone, dihydrotestoerone) with UGT1A4*3 (142T>G, rs2011425) variant 
while approximately one-third reduction in the activity was observed with the 
UGT1A4*2 (70C>A, rs6755571) variant (359). In vivo, Turkish patients carrying 
UGT1A4*3 (142T>G, rs2011425) was associated with a 52% reduction in the plasma 
levels of lamotrigine compared to patients who were wild-type (361). Collectively, 
these observations suggest that these alleles may exhibit substrate-specific effects. 
In addition to these two polymorphisms, other rare genetic variants in the coding 
regions have been described to alter the protein function (358).  
Besides the coding variants, polymorphisms present in the proximal promoter region 
of the UGT1A4 gene have been investigated for its functional impact (362). Of note, -
163G>A (rs3732218) and -219T>C (rs3732219) were suggested to be in complete 
LD with UGT1A4*3 (142T>G, rs2011425) in German healthy subjects (362) and 
presence of these two regulatory variants have been found to reduce both 
constitutive and inducible genetic expression of UGT1A4 (352). However, similar 
result was not obtained when these two polymorphisms were examined in a 
haplotypic construct containing additional two polymorphisms present in the 5′ 
upstream region, -419G>A (rs3732220) and -457C>T (rs3732221) (352). No 
functional changes in the gene expression of UGT1A4 as well as the glucuronidating 
capacity for N-OH-PhIP or trifuoperazine were observed (352). 
With regards to glucuronidation of tamoxifen and 4-OHT, only the impact of 
UGT1A4*2 (70C>A, rs6755571) and UGT1A4*3 (142T>G, rs2011425) were 
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previously investigated and the effects of these variants differ widely (118, 134). 
While the catalytic activity of both variant proteins do not differ significantly from the 
wild-type protein with respect to glucuronidation of 4-OHT, the UGT1A4.3 variant 
isoform displayed a 105% increase in the Vmax/Km for tamoxifen compared to the 
wild-type protein (134). In contrast, no differential glucuronidation capacity for 
tamoxifen was observed for UGT1A4.2 variant protein. More recently, UGT1A4*3 
(142T>G, rs2011425) has been associated with a lower MR of tamoxifen/tamoxifen-
N-glucuronide, indicating a higher rate of tamoxifen N-glucuronidation, than the wild-
type allele in German breast cancer patients (118, 134). Nevertheless, the effects of 
other polymorphisms remained unknown.  
1.3.2.1.2 UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7) 
UGT2B7 is considered the most widely investigated isoform from the UGT2B 
subfamily and plays an important role in the metabolism of xenobiotics. The 
exogenous substrates of UGT2B7 include codeine, morphine, ketoprofen, naproxen, 
ibuprofen, carvedilol, propranolol, zidovudine, dihydroartemisinin, clofibrate, valproic 
acid and epirubicin (363). Endogenous substrates such as steroid hormone (catechol 
estrogens, androsterone), retinoids and bile acids are also glucuronidated by 
UGT2B7 (364, 365). Tamoxifen and its metabolites represent one of the more 
recently identified substrates of this enzyme (129). Like UGT1A4, it is highly 
expressed in the liver (333). Concurrently, the enzyme is found at lower levels in 
gastrointestinal tract, pancreas, kidney, lung, CNS, testis and prostate. By virtue of 
its location and broad range of substrates, variability in the UGT2B7 activity is likely 
to have functional impact.  
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UGT2B7 is encoded by six exons spanning 16kb on chromosome 4 (344, 365), 
along which a missense mutation in exon 2 is the most widely investigated (366). 
The allele, named as UGT2B7*2 (802C>T, rs7439366) is a non-synonymous 
polymorphism leading to the substitution of amino acid, H286Y (366). It is highly 
prevalent in the Caucasian population with variant frequency of 0.49 to 0.54 while the 
frequencies in the Africans, Japanese and Korean populations are lower but similar 
at 0.21 to 0.39 (367-370). Although some studies have shown that the allele is 
associated with reduced catalytic capacity (371), others have not been able to 
replicate this finding. Hence, the functional consequence of this polymorphic variant 
remains controversial (372). In the Caucasian patients, Sawyer et al (371) reported 
complete LD between the polymorphism, -161C>T (rs7668258), and UGT2B7*2 
(802C>T, rs7439366) and the SNPs were associated with slower glucuronidation of 
morphine to form morphine-6-glucuronide. Subsequently, Duguay et al (373) noted a 
2.5- to 7- fold reduction in the transcription of UGT2B7 with -138A>G (rs73823859) 
which was in LD with UGT2B7*2 (802C>T, rs7439366) in Caucasian subjects. In fact, 
genetic analyses of UGT2B7 in healthy Koreans and Japanese individuals revealed 
high LD between UGT2B7*2 (802C>T, rs7439366) and other SNPs along the gene, 
particularly those in the promoter region (367, 370, 374). This is consistent with the 
observation of a small gene with minimal crossing-over events. Recently, it has been 
found that haplotypic combinations of 10 tag-SNPs (-45597G>T, -6682_-
6683insGCAAAT, 372A>G, IVS1+9_IVS1+10insT, IVS1+829T>C, IVS1+985A>G, 
IVS1+999C>A, IVS1+1250A>G, 801A>T, IVS4+185C>A) were associated with 
increase in the gene expression and glucuronidating capacity of UGT2B7 on 
morphine in the Caucasian population (375). Diplotypes containing the variant 
haplotype (-45597G, -6682_-6683wt, 372A, IVS1+9_IVS1+10wt, IVS1+829T, 
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IVS1+985G, IVS1+999C, IVS1+1250G, 801T, IVS4+185C) were reportedly 
associated with 45% increase in the average plasma level of morphine-3-glucuronide. 
Previous kinetic analyses in human liver microsomes demonstrated significant 
reduction in the glucuronidation rate of 4-OHT and endoxifen as the number of 
UGT2B7*2 (802C>T, rs7439366) allele (286Y) increased (195). Compared to 
microsomes with the UGT2B7*1/*1 genotype, significant decreases of 13% and 28% 
in the O-glucuronidation of 4-OHT were observed in microsomes with the 
UGT2B7*1/*2 and UGT2B7*2/*2 genotypes respectively. Similarly, O-glucuronidation 
of (Z)-endoxifen was considerably lower in microsomes with either one or two copies 
of the UGT2B7*2 (802C>T, rs7439366) allele compared to wild-type microsomes. 
However, this was not observed in Caucasian patients when the impact of 
UGT2B7*2 (802C>T, rs7439366) on plasma levels of tamoxifen and its metabolites 
or the corresponding metabolic ratios were investigated (118). As UGT2B7 has been 
shown to be highly polymorphic, the impact of UGT2B7 polymorphisms may be more 
accurately examined in haplotypes instead of individual SNPs. 
1.3.2.1.3 UDP glucuronosyltransferase 2 family, polypeptide B15 (UGT2B15) 
In common with UGT2B7, UGT2B15 also catalyzes the glucuronidation of 
xenobiotics as well as endogenous steroidal compounds such as estrogens and 
androgens. Substrates of UGT2B15 are usually simple phenolic compounds or 
aliphatic alcohol including eugenol, 7-hydroxylated coumarins, flavonoids, 
anthraquinones, hydroxycotinine, oxazepam, lorazepam, 5-hydroxylrofecoxib, 8-
hydroxyquinoline, 4′-hydroxyphenytoin and nandrolone (376, 377). In addition to its 
high hepatic expression, UGT2B15 is also located in the esophagus, colon, kidney, 
lung, adipose tissue, skin, breast, ovary, uterus, prostate and testis (333, 337).  
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The UGT2B15 gene is approximately 24 kb (377) and has been found to be highly 
polymorphic (378). Polymorphic variants in UGT2B15 have been widely investigated 
for its impact on pharmacokinetics of lorazepam and oxazepam as well as steroid 
metabolism and risk of prostate cancer (379-382). Thus far, UGT2B15*2 (253G>T, 
rs1902023) remained the most frequently investigated polymorphism of UGT2B15. 
The allelic frequency of the variant allele has been found to be higher in Caucasian 
(MAF: 0.55) compared to Asians (MAF: 0.37). The change in amino acid at codon 85 
(D85Y) due to this transversion has been demonstrated to exhibit higher Vmax for 
androstane-3α, 17α-diol and dihydrotestosterone in vitro. Subsequently, Court et al 
(380) also observed a 5-fold lower glucuronidation rate of S-oxazepam and a 10-fold 
difference in narigenin glucuronidation for UGT2B15*2 (253G>T, rs1902023) as 
compared to UGT2B15*1. However, variations in the magnitude of the allelic impact 
between various substrates suggest substrate dependency in the functional effect of 
the allele. 
Recently, Sun et al (383) reported excess allelic expression of UGT2B15*1 over the 
UGT2B15*2 (253G>T, rs1902023) allele in the liver but not in the breast tissue. 
Screening of the promoter and exon 1 identified seven polymorphisms which were in 
perfect LD with UGT2B15*2 (253G>T, rs1902023) in the Caucasian and Asian 
subjects while near perfect LD (r2 = 0.92) was observed in the Africans. Subsequent 
reporter gene assay revealed a 20% higher transcriptional activity in the wild-type 
haplotype relative to the UGT2B15*2 (253G>T, rs1902023) haplotype (383). Detailed 
examination of the 5′ upstream region identified the polymorphisms, -1137C>T 
(rs35513228) and -818G>T (rs34010522), to be possible causative variants. 
Thereafter, the same investigators investigated the functional impact of another non-
synonymous SNP, UGT2B15*4 (1568C>A, rs4148269, T523K) in exon 6 (384). 
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UGT2B15*4 (1568C>A, rs4148269) which results in the change in amino acid, 
T523K, has previously been shown to have no effect on the glucuronidation of S-
oxazepam (380). Similar to UGT2B15*2 (253G>T, rs1902023), the UGT2B15*4 
(1568C>A, rs4148269) allele was associated with a lower mRNA expression 
compared to UGT2B15*1. However, the differential expression was observed in both 
the liver and breast tissue and independent of the impact of UGT2B15*2 (253G>T, 
rs1902023) polymorphism. Resequencing of UGT2B15 exon 6 and the 3′ 
downstream region revealed 10 additional SNPs, of which 1761T>C (rs3100) was in 
almost complete LD (r2 = 0.81) with UGT2B15*4 (1568C>A, rs4148269) in the 
Caucasian study subjects (384). Significantly higher genetic expression was 
observed with the 1761T (rs3100) allele compared to the 1761C (rs3100) allele 
across hepatic, prostate, breast and colon cell lines. This observation has been 
attributed to the presence of a miRNA binding site at the 3′ UTR of the gene although 
no causative miRNA was identified (384).  
Thus far, only UGT2B15*2 (253G>T, rs1902023) has been investigated for its impact 
on variations in plasma concentrations of tamoxifen and the metabolites and no 
significant association was observed (118). In the earlier study involving 162 
Caucasian and African-American patients, UGT2B15*2 (253G>T, rs1902023) 
together with SULT1A1*2 (638G>A, rs9282861) was associated with poorer disease-
free survival and overall survival in tamoxifen-treated patients (304). It was 
suggested that the amino acid substitution due to the UGT2B15*2 (253G>T, 
rs1902023) allele results in an increase Vmax with similar Km compared to 
UGT2B15*1 allele. Hence, the increase in the elimination of tamoxifen active 
metabolites due to the presence of the variant alleles could be the causative factor 
for the poorer response to tamoxifen. However, this observation was not consistently 
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observed as evident by the non-reproducibility in the larger cohort of 677 Swedish 
breast cancer patients (332).  
1.3.2.2 Sulfotransferase (SULT) 
Sulfotransferases or SULTs are the second major contributors, after UGTs, to the 
overall phase II drug metabolism (314). Almost one-quarter of all phase II 
conjugative reactions are catalyzed by SULT which transfer the sulfonate group from 
the co-substrate (or donor group), 3′-phosphoadenosine-5′-phosphosulphate (PAPS), 
to the nucleophilic acceptor group of the substrate (385, 386). Sulfonation of these 
substrates increases the hydrophilicity and decreases the capacity of the substrates 
to diffuse across membranes thereby facilitating the excretion of the drug by biliary or 
renal route. The sulfonating reaction mediated by SULT is one with high affinity and 
low capacity (387-389). Thus, SULTs and UGTs complement each other during the 
catalysis of overlapping substrates. When the substrate concentration is low, 
sulfonation dominates while glucuronidation prevails at high substrate concentration. 
The summation of these two reactions display linear kinetics until saturation of the 
UGTs takes place.  
SULTs are broadly classified into two major groups, the membrane-bound and 
cytosolic SULTs (389). The membrane-bound SULTs are mainly concerned with the 
metabolism of endogenous substrates such as peptides, proteins, lipids and 
glycosaminoglycans (390). On the contrary, cytosolic or soluble SULTs mediate the 
sulfonation of various xenobiotics including therapeutic drugs, toxic chemicals, 
chemical carcinogens, as well as physiological compounds such as bile acids, 
peptides, lipids, hormones (390-392). Cytosolic SULTs are further categorized into 
four families based on the similarities in the amino acid sequences and catalytic 
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profiles of various isoforms: SULT1, SULT2, SULT4 and SULT6 (390, 393, 394). 
Between each family, at least 45% similarity in the amino acid sequence identity has 
been observed while enzymes within each family exhibit more than 60% similarity 
(393, 395). Among the various SULT families, SULT1 and SULT2 are the largest and 
possibly the most important in the metabolism of xenobiotics. SULT1 consists of 
three member isoforms (SULT1A1, SULT1A2 and SULT1A3) while SULT2 is made 
up of SULT2A1 and SULT2B1 (387). Different SULT isoforms display distinctive 
profiles in their tissue distributions, sensitivities toward inhibitors and thermal 
sensitivities although significant overlaps in the substrate specificities have been 
observed (387). 
1.3.2.2.1  Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 
(SULT1A1) 
SULT1A1 is the most extensively investigated cytosolic SULT due to its tissue 
distribution and substrate specificity (387). Also known as the thermostable phenol 
SULT, it catalyzes the metabolism of a broad range of xenobiotics which include 
paracetamol, minoxidil, diethylstilbestrol, 4-OHT and naringenin (389, 396). It is also 
involved in the activation of several carcinogens in the environmental and dietary 
sources. The activity of SULT1A1 has frequently been studied with the use of 4-
nitrophenol as a probe substrate (397). The main site of SULT1A1 expression is the 
liver while other extrahepatic sites expressing SULT1A1 comprised of 
gastrointestinal tract, platelets and placenta (389, 398). Previous studies have 
reported a strong correlation between the expression and activity of the enzyme in 
most tissues (399, 400). Concurrently, a genetic basis for the variation in SULT1A1 
activity and regulation of the thermal stability of the enzyme has been indicated (401-
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403). These observations have been confirmed by subsequent studies conducted by 
Raftogianis et al (404).  
Raftogianis et al (404) discovered a total of 15 genetic variants across the 3.7 kb 
SULT1A1 gene which is mapped onto chromosome 16q12 (405, 406). SULT1A1 
consists of seven coding and one non-coding exons (407). Among the 15 alleles, 
SULT1A1*2 (638G>A, rs9282861) and SULT1A1*3 (667A>G, rs1801030) displayed 
relatively high allelic frequencies (404, 408). SULT1A1*2 (638G>A, rs9282861) 
located in exon 6 causes an amino acid substitution of R213H (408). It has been 
found to be highly prevalent in the Caucasian (MAF: 0.31 − 0.37) and African (MAF: 
0.26 − 0.29) populations (409, 410). In comparison, only 8% of the Chinese and 
16.8% of the Japanese carry this allele. Located 29 bases downstream of the 
SULT1A1*2 (638G>A, rs9282861) allele is the SULT1A1*3 (667A>G, rs1801030) 
allele which results in the amino acid change of V223M (404). SULT1A1*3 (667A>G, 
rs1801030) has been found to be prevalent only in the African American at 22.9%. 
The allelic frequency has been observed to be less than 3% in the Caucasians, less 
than 1% in the Chinese and absent in the Japanese (409, 410).  
In the same study, Raftogianis et al (404) demonstrated an 85% reduction in the 
platelet SULT activity in subjects homozygous for SULT1A1*2 (638G>A, rs9282861) 
variant compared to subjects who were homozygous wild-type or heterozygous. A 
subsequent study (411) showed similar observations with a lower magnitude of 
difference in SULT1A1 activity was observed between the variant and wild-type 
allozymes. In addition to SULT1A1*2 (638G>A, rs9282861), the functional impact of 
SULT1A1*3 (667A>G, rs1801030) polymorphism has been investigated 
simultaneously in MCF-7 cells stably expressing recombinant forms of SULT1A1.1, 
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SULT1A1.2 and SULT1A1.3 proteins. The activities of these allozymes was 
examined against a broad range of substrates: p-nitrophenol, 17β-estradiol, 2-
methoxyestradiol, catecholestrogens, 4-OHT and dietary flavonoids (411). The 
activity of SULT1A1.1 allozyme was generally higher than that of SULT1A1.3 which 
was comparatively higher than SULT1A1.2 though substrate dependent variations 
were present. In particular, the half-life of SULT1A1.2 protein was shorter and the 
anti-proliferative effect of 4-OHT was reported to be higher in cells expressing the 
SULT1A1.2 allozyme. Further investigations revealed a greater extent of 
ubiquitination of SULT1A1.2 protein indicating greater degradation of the variant 
protein and decreased elimination of 4-OHT via the sulfonation pathway. 
Although the impact of SULT1A1*2 (638G>A, rs9282861) has been verified in vitro, 
the in vivo effect of this polymorphism on the pharmacokinetics and 
pharmacodynamics of tamoxifen remained controversial. Two groups of investigators 
have independently showed that SULT1A1*2 (638G>A, rs9282861) do not 
significantly influence the steady state plasma concentrations of tamoxifen and the 
metabolites in the Caucasian populations (133, 140). In contrast, the MRs of 
NDM/tamoxifen and N-didesmethyltamoxifen/NDM have been found to vary 
significantly with the SULT1A1*2 (638G>A, rs9282861) genotypes (133). With 
reference to the effect on tamoxifen treatment outcome, a counterintuitive effect of 
poorer treatment outcome was associated with SULT1A1*2 (638G>A, rs9282861) 
allele (412). Almost 3-fold higher adjusted hazards ratio has been observed in 
patients homozygous for the SULT1A1*2 (638G>A, rs9282861) allele compared to 
patients who were homozygous wild-type or heterozygous. When combined with 
UGT2B15*2 (253G>T, rs1902023), both alleles have been associated with greater 
risk of recurrence and inferior survival in Caucasian breast cancer patients (304). 
 77
However, comparable results have not been observed in successive studies by 
Wegman et al (303, 332) and Serrano et al (413).  
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1.4 Hypothesis 
Tamoxifen is a prodrug that undergoes complex metabolism to form multiple 
metabolites of which 4-OHT and endoxifen display the greatest ER antagonistic 
activity (101-103). Along the tamoxifen biochemical pathway, various CYP isoforms 
(CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5) have been 
reported to be involved in the formation of several metabolites including 4-OHT and 
endoxifen (119). CYP3A4/5 and CYP2D6 have been demonstrated to be the major 
isozymes involved in the metabolic pathway in both in vitro and in vivo studies (119, 
122). Genes encoding these CYP enzymes are highly polymorphic with wide 
interethnic variability (196).  
Previously, it has been shown that CYP2D6*4 (1846G>A; rs3892097) polymorphism 
which is a null allele, influence the pharmacokinetics and treatment outcome of 
tamoxifen in Caucasian patients (140, 297).  However, the frequency of this variant 
allele is low in our Asian population. Instead, CYP2D6*5 (CYP2D6del) and 
CYP2D6*10 (100C>T; rs1065852) polymorphisms which are associated with 
decreased enzymatic activity, are present at higher frequencies in the Asian Chinese, 
Japanese and Korean populations (272). Besides CYP2D6, the polymorphic genetic 
profiles of other CYP genes remained largely unknown in Asian populations.  
In addition, several phase II conjugating enzymes (UGT1A4, UGT2B7, UGT2B15 
and SULT1A1) have been implicated in the elimination of the activity of tamoxifen 
and its metabolites (128, 129, 389). The catalytic activities of these enzymes 
influence the relative plasma levels of tamoxifen and its metabolites at the target 
sites. Like the CYP genes, the phase II pharmacogenes are highly polymorphic and 
several functional SNPs leading to differential enzymatic capacity have been 
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reported with ethnic differences (333, 396). However, little is known about the 
pharmacogenetic profiles of these phase II pharmacogenes in the Asian populations. 
Despite strong in vitro evidence illustrating the participation of multiple UGTs and 
SULTs enzymes and the impact of functional polymorphisms on tamoxifen 
metabolism, in vivo studies investigating the contributions of these phase II 
candidate genes are generally lacking especially in the Asian populations.  
Since the disposition of tamoxifen involves multiple phase I and II enzymes, the 
current study hypothesize that functional polymorphisms present in candidate genes 
along the tamoxifen biochemical pathway is likely to influence tamoxifen disposition 
and subsequently treatment outcome of tamoxifen. Due to the interethnic variability 
observed in the distribution frequency of several functional polymorphisms in the 
candidate genes, it is hypothesized that functional polymorphisms which are uniquely 
present in the Asian populations may be important in affecting the pharmacokinetics 
of tamoxifen in Asian pre-menopausal breast cancer patients receiving adjuvant 
tamoxifen therapy. 
1.5 Aims  
(1) To profile the genetic polymorphisms of genes encoding the Phase I metabolic 
enzymes (CYP1A2, CYP2C9/19, and CYP2D6) in our local Asian healthy 
populations, namely Chinese, Malays and Indians. 
(2) To profile the genetic polymorphisms of genes encoding the Phase II metabolic 
enzymes which include UGT1A4, UGT2B15, UGT2B7, and SULT1A1 in our local 
Asian healthy populations, namely Chinese, Malays and Indians. 
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(3) To study the influence of functional polymorphisms and tag-SNPs present in the 
candidate genes encoding the phase I (CYP1A2, CYP2C9/19, CYP2D6 and 
CYP3A5) and phase II (UGT1A4, UGT2B15, UGT2B7, and SULT1A1) drug 
metabolizing enzymes on the biochemical pathway of tamoxifen in Asian breast 
cancer patients receiving tamoxifen therapy. 
 
 81
Chapter 2: Materials and Methods 
2.1 Study Design 
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2.2 Study Populations 
2.2.1 Healthy Subjects 
The healthy subject population comprised of three ethnic groups predominant in the 
Asian population of Singapore, namely Chinese, Malays, and Indians (N=80 in each 
group). The ethnicities of all subjects were determined by self-declaration by the 
healthy volunteers through three generations. Informed consent was obtained from 
all subjects. The study was approved by the ethics review committees of the National 
Cancer Centre, Singapore, and National University Hospital, Singapore. 
2.2.2 Breast Cancer Patients 
A total of 202 breast cancer patients of Asian ethnic origin were recruited 
prospectively in National Cancer Centre, Singapore. All patients were histologically 
diagnosed with ER and/or PR positive breast tumors and received 20mg of 
tamoxifen daily. The study was approved by the ethics review committee of the 
National Cancer Centre, Singapore. The risk and benefit of participation in the study 
were explained to the patient in the presence of a third-party witness and written 
consent was obtained from all patients for participation in this study. 
2.2.2.1 Inclusion criteria 
• Histologically or cytologically confirmed breast cancer;  
• age greater than 21 years; 
• estrogen- or progesterone-receptor positive tumours; 
• patients receiving tamoxifen 20mg daily as monotherapy or a 
combination of tamoxifen with other anti-cancer related therapy; 
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• patients who are scheduled to commence on adjuvant tamoxifen 
therapy (stage I to III); 
• patients already receiving adjuvant tamoxifen for greater than or equal 
to 8 weeks;  
• written and informed consent obtained from participating patients. 
2.2.2.2 Exclusion criteria 
• Expected survival of less than 6 months; 
• inability to understand and sign informed consent; 
• patients receiving CYP2D6 inhibitors or inducers within the past four 
weeks from the time of study enrollment. However, patients started on 
CYP2D6 inhibitors or inducers after commencing on tamoxifen 
therapy will not be excluded from the study; 
• pregnancy; 
• patients with prior malignancies other than those who have received 
curative treatment for basal cell carcinoma of the skin or carcinoma in-
situ of the uterine cervix; 
• uncontrolled intercurrent illness including, but not limited to, ongoing 
or active infection, symptomatic congestive heart failure, unstable 
angina pectoris, cardiac arrhythmia, or psychiatric illness/social 
situations that would limit compliance with study requirements; 
• allergy to tamoxifen. 
2.2.2.3 Baseline Evaluations 
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At the time of study enrolment, the following information was collected from eligible 
patients:  
• Demographics; 
• height;  
• weight;  
• medical history; 
• radiological or clinical tumor evaluation; 
• liver function test (total protein, albumin, total bilirubin, alkaline 
phosphatase, alanine transaminase and aspartate transaminase);  
• adverse events; 
• concomitant medications. 
2.2.2.4 Tamoxifen Administration and Monitoring of Treatment Compliance 
All patients were administered tamoxifen at a daily dose of 20 mg. Three milliliters of 
blood was obtained from each patient after treatment with tamoxifen for eight weeks 
or more when steady state level of tamoxifen was reached. A pill diary was issued to 
each patient to monitor compliance to therapy. 
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2.3 Chemicals and Reagents 
Table 2.1 lists all chemicals employed in the experiments. 
Table 2.1 List of chemicals, reagents and suppliers. 
Reagents and Chemicals Company 
RNase A Qiagen, Germany 
Gentra® Puregene® DNA Hydration 
Solution 
Qiagen, Germany 
Isopropanol, HPLC Grade Tedia Company Inc, OH, USA 
Taq Polymerase Genotech Pte Ltd, Singapore 
10× PCR Buffer  Fermentas International Inc, Canada  
Magnesium Chloride (25mM) Fermentas International Inc, Canada  
dNTP Mix (10mM) Genotech Pte Ltd, Singapore 
Desalted Purified Oligonucleotides 
(100µM) 
AITbiotech Pte Ltd, Singapore 
SeaKem® LE Agarose Lonza Rockland, Inc., ME, USA 
Tris Hydrochloride Life Technologies Corporation, CA, USA 
Acetic Acid, Glacial, Analytical Grade Thermo Fisher Scientific Inc., MA, USA 
Ethidium Bromide Sigma Aldrich Co. LLC, Singapore 
DNA Ladder Fermentas International Inc, Canada  
6x Loading Dye Fermentas International Inc, Canada  
Exonuclease I Genotech Pte Ltd, Singapore 
Shrimp Alkaline Phosphatase Promega Corporation, WI, USA 
Big Dye® Terminator v3.1 Cycle 
Sequencing Kit 
Life Technologies Corporation, CA, USA 
Ethanol, Analytical grade Thermo Fisher Scientific Inc., MA, USA 
Sodium Acetate VWR International LLC, PA, USA 
Ethylenediamine-tetraacetic Acid 
(EDTA) 
Life Technologies Corporation, CA, USA 
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Table 2.1 List of chemicals, reagents and suppliers (Continued). 
Reagents and Chemicals Company 
Formamide, Genetic Analysis Grade Life Technologies Corporation, CA, USA 
CYP450 2D6I Intellipac® Reagent 
Module 
AutoGenomics, CA, USA 
INFINITI™ Wash Buffer AutoGenomics, CA, USA 
CYP450 2D6I BioFilmChip Microarray 
Magazine 
AutoGenomics, CA, USA 
Propranolol (99%) Sigma-Aldrich Co. LLC, Singapore 
Tamoxifen (≥99%) Sigma-Aldrich Co. LLC, Singapore 
N-desmethyltamoxifen (NDM) Dr D. A. Flockhart, Indiana University 
School of Medicine, Indianapolis, IN, USA 
(Z)-4-hydroxytamoxifen (≥98%) Sigma-Aldrich Co. LLC, Singapore 
Endoxifen Dr D. A. Flockhart, Indiana University 
School of Medicine, Indianapolis, IN, USA 
(Z)-Endoxifen Dr P. Lazarus, Pennsylvania State 
University College of Medicine, PA, USA 
(E)-Endoxifen Dr P. Lazarus, Pennsylvania State 
University College of Medicine, PA, USA 
Methanol, HPLC Grade Tedia Company Inc, OH, USA 
Sodium Hydroxide Merck, NJ, USA 
Sodium Dodecyl Sulphate VWR International LLC, England 
n-hexane, Analytical Grade Tedia Company Inc, OH, USA 
n-butanol, Analytical Grade VWR International LLC, England 
Acetonitrile, HPLC Grade Tedia Company Inc, OH, USA 
Ammonium Chloride Sigma-Aldrich Co. LLC, St Louis, MO, USA 
Sodium Bicarbonate Sigma-Aldrich Co. LLC, St Louis, MO, USA 
Ammonium Acetate Sigma-Aldrich Co. LLC, St Louis, MO, USA 
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2.4 Pharmacogenetic Analysis 
Genetic analysis of the candidate genes were performed for all healthy subjects and 
patients. With reference to CYP2C9, CYP2D6, CYP3A5 and SULT1A1, the 
functional polymorphisms have been well characterized and screening for selected 
functional SNPs was done. The pharmacogenetic profiles of CYP2C19, UGT1A4, 
UGT2B7 and UGT2B15 in Asians remained less commonly studied. Hence, the 5′ 
upstream and untranslated region (UTR), exons, exon-intron boundaries as well as 
3′ UTR and downstream regions of these genes were screened in our healthy 
subjects to identify novel SNPs. -The polymorphic profiles of these genes in our local 
healthy populations (Chinese, Malays and Indians) were established. The tag-SNPs 
were derived from the healthy subjects and genotyped in our Asian patient 
population. Genetic screening of all genes with the exception of CYP2D6 was 
performed by in vitro amplification of the genomic region of interest using polymerase 
chain reaction (PCR) followed by direct sequencing as detailed in the following 
sections. With regard to CYP2D6, genotyping of the polymorphic variants were 
performed using the BioFilmChip™ and the INFINITI™ analyzer (AutoGenomics, CA, 
USA). 
2.4.1 DNA extraction (from whole blood) 
Three milliliters of blood was collected from each healthy subject as well as patient in 
BD Vacutainer® EDTA-coated blood collection tubes (Becton, Dickinson U.K. Limited, 
England). Samples were stored at 4°C until extraction of DNA was carried out using 
ethanol precipitation method.  
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RBC lysis solution (9 mL) was added to 3 mL of whole blood which had been 
transferred to a 15mL-centrifuge tube. The mixture was inverted 10 times to mix the 
components well and incubated at room temperature for 20 minutes. This process 
allowed for the lysis of the red blood cells. The sample was centrifuged at 2000 g for 
10 mins. After which, the supernatant was discarded and the white blood cells were 
collected as the pellet. Cell lysis solution (3 mL) was subsequently added to the 
pellet and pipetted repeatedly to lyse the cells and suspend the contents in the 
solution. To ensure that the extracted DNA was free from RNA, 15 µL of RNase 
solution (4 mg/mL) was added and the specimen was incubated at 37°C for one hour 
in a orbital shaker (Thermo Fisher Scientific Inc, MA, USA) at 250 rpm. After 
removing from the shaker, the sample was quickly cooled by incubating the sample 
in ice for three minutes. Protein precipitation solution (1 mL) was added to the 
sample and vortexed vigorously for 20 seconds. After centrifugation at 2000 g for 10 
mins, the precipitated protein formed a tight, dark brown pellet and the supernatant 
containing the DNA was poured into another centrifuge tube containing 3 mL of 
isopropanol. Subsequent to gentle mixing of the solution by 50 times inversion, the 
DNA was precipitated and was visible as white strands. The DNA was pelleted by 
centrifuging the specimen at 2000 g for three minutes. The supernatant was 
discarded and the pellet was washed with 2 mL of ethanol (70%). The specimen was 
centrifuged at 2000 g for 1 minute and the supernatant was removed. The pellet was 
air-dried for 5 to 10 minutes before suspending in 250 µL of DNA hydration solution. 
The sample was then incubated at 65°C for 1 hour to facilitate the dissolution of DNA. 
One hour later, the sample was briefly centrifuged and transferred to the 1.5-mL 
microcentrifuge tube for storage at 4°C till further analysis. The concentration of the 
DNA was quantified using Nanodrop 1000 spectrophotometer v3.7 (Thermo Fisher 
Scientific, DE, USA).  
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2.4.2 Polymerase Chain Reaction (PCR) 
The genomic regions of interest in CYP1A2, CYP2C9, CYP2C19, CYP3A5, UGT1A4, 
UGT2B7, UGT2B15 and SULT1A1 were amplified using polymerase chain reaction 
(PCR). Each PCR reaction consists of the components list in Table 2.2.  
Table 2.2 PCR components and its final concentration in each PCR reaction used 






Water, Nuclease-free – 6.7 
10× Taq Buffer [750 mM Tris-HCl (pH 8.8 at 25°C), 
200 mM (NH4)2SO4, 0.1% (v/v) Tween 20] 
1× 1.0 
Magnesium Chloride, 25mM 2.0 mM 0.8 
dNTPs, 10 mM 0.3 mM 0.3 
Forward Primer, 10 µM 0.2 µM 0.2 
Reverse Primer, 10 µM 0.2 µM 0.2 
Taq, 5 Units/µL 0.15 Units/µL 0.3 
DNA, 20 ng/µL 1 ng/µL 0.5 
Total – 10.0 
After setting up the PCR reactions in 200-µL thin-walled microcentrifuge tubes, 
consisting of 10 µL each, the reactions were placed in BIO-RAD DNAEngine Peltier 
Thermal Cycler (Biorad Laboratories, CA, USA) and subjected to the respective 
thermal cycling conditions. The cycling conditions differ with various primers and are 
illustrated in the respective sections describing the pharmacogenetics of the different 
candidate genes.  
The presence of the PCR amplicons was confirmed by agarose gel electrophoresis. 
A volume of 2.0 µL of each PCR product was mixed with 0.5 µL of 6× gel loading dye 
 90
and loaded onto a 1% agarose gel stained with ethidium bromide. Simultaneously, 
2.0 µL of DNA ladder was beside the samples in the same agarose gel. Gel 
electrophoresis was carried out at 120 V for 25 to 30 minutes. Under ultraviolet 
transillumination, bright bands the correct sizes indicate the presence of the desired 
PCR amplicons. 
2.4.3 Purification of PCR Amplicons 
The PCR amplicons or products were purified via enzymatic treatmentwith addition 
of 1.0 µL of exonuclease I (Exo; 20 units/µL) and 1.0 µL of shrimp alkaline 
phosphate (SAP; 1 unit/µL) to 10 µL of each PCR reaction volume. The PCR 
amplicons with the added enzymes were subjected to the following thermal cycling 
conditions: 37 °C for 45 minutes followed by 80 °C for 15 minutes. At the active 
temperature of 37 °C, excess single stranded nuclei acids such as primers were 
removed from the aliquot in a 3′ to 5′ direction by Exo while excess nucleotides were 
eliminated by 5' dephosphorylation mediated by SAP. Both enzymes were denatured 
during the 15 minutes incubation at 80 °C. All samples were stored at 4 °C until 
subsequent analyses. 
2.4.4 DNA Sequencing 
Direct, dye terminating sequencing reaction was carried out for the screening of the 
eight candidate genes (CYP1A2, CYP2C9, CYP2C19, CYP3A5, UGT1A4, UGT2B7, 
UGT2B15 and SULT1A1). The reaction was performed using the Applied Biosystem 
(ABI) Big Dye Terminator v3.1 Cycle Sequencing kit (Life Technologies Corporation, 
CA, USA) with modification of the manufacturer's protocol on the ABI 3730 DNA 
 91
analyzer (Life Technologies Corporation, CA, USA). The kit consists of the ready 
reaction mix and 5× reaction buffer.  
The components present in each sequencing reaction volume of 5 µL are listed in 
Table 2.3. 





Water, Nuclease-free – 0.6 
5× Sequencing Buffer 0.5× 0.5 
Primer, 10 µM 0.8 µM 0.4 
Big Dye Terminator v3.1 Ready Reaction Mix – 1.0 
PCR amplicon – 2.5 
Total – 5.0 
The reactions were prepared in the 96-well plate and briefly centrifuged to mix and 
bring the contents to the bottom of the well. The dye-terminating reactions were 
subjected to the following thermal cycling conditions in the BIO-RAD DNAEngine 
Peltier Thermal Cycler (Biorad Laboratories, CA, USA): initial denaturation of 
amplicons at 96 °C for 1 minute followed by 25 cycles of denaturation at 96 °C for 10 
seconds, annealing at 50 °C for 5 seconds and 60 °C for 4 minutes.  
At the end of the thermal cycling reaction, the reaction plate was pulsed centrifuge 
and 2.0 µL of stop solution consisting of 1.0 µL of 3M sodium acetate and 1 µL of 
125mM EDTA (pH 8.0) was added to each sample to stop the dye terminating 
reaction. Subsequently, 25 µL of ethanol (100%) was added to each sample and the 
reaction plate was incubated at room temperature, protected from light, for 15 
minutes before centrifugation at 3000 g for 30 mins at 4°C. 
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After 30 minutes, ethanol was drained from each sample well by plate inversion on a 
2-ply square paper towel and pulse-centrifugation at 200g for 20 secs at 4°C. The 
sample pellets were cleaned by addition of 70 µL of ethanol (70%) and centrifugation 
at 1700 g for 15 mins at 4°C. Similarly, ethanol (70%) was drained after 15 minutes 
by inverting the plate on a 2-ply square paper towel and pulse-centrifuged at 200g for 
20 secs at 4°C for two times. The samples were vacuum-dried for 5 mins and heated 
at 95°C on a dry block for 5 mins to remove any residual ethanol. Twenty microliter 
of formamide was added to each sample well to re-suspend the pellet before loading 
the sample plate into the ABI 3730 DNA analyzer (Life Technologies Corporation, CA, 
USA). The electropherograms were analyzed using Sequence Analysis v5.2 
software (Life Technologies Corporation, CA, USA). Polymorphic variants were 
identified by alignment of the electropherograms from various samples against the 
reference sequences in the SeqScape v2.5 software.  
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2.4.5 Pharmacogenetics of Phase I Drug Metabolizing Enzymes  
2.4.5.1 Cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) 
Comprehensive screening of the entire CYP1A2 gene (UCSC RefSeq: NM_000761) 
spanning 7.8 kb on chromosome 15 was undertaken. CYP1A2 consists of seven 
exons as well as one non-coding exon. In addition to the exonic and intronic regions, 
screening of the 5′ upstream and 3′ downstream regions (about 2.5 kb each) were 
also performed. The region of interest was segregated into 12 fragments of 
approximately 1kb each. A total 12 pair of primers were designed using the Primer 3 
software (414) (http://frodo.wi.mit.edu/) to amplify the gene fragments (Table 2.4). 
The PCR amplification conditions are listed in Tables 2.4 and 2.5. 
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1 5' upstream F: 5'-aacctcaaaccttgacctttttc-3' 1245 59 30 
R: 5'-aacctccttttgaatggttctgt-3' 
2 5' upstream F: 5'-caagttcaagccattctcctg-3' 612 59 30 
R: 5'-caggagaatggcttgaacttg-3' 
3 5' upstream F: 5'-gcctctctttaggatgcaaaatc-3' 627 59 30 
R: 5'-gggatcccagagattgtaaattggtcccaaga-3' 
4 5' upstream F: 5'-attcatatcaggtgatcaggacaa-3' 1051 59 30 
R: 5'-cagaataccaggcagaagatgg-3' 
5 Exon 2 F: 5'-tgactgaggaaatgaatgaatga-3' 1103 59 30 
R: 5'-gcttcaaggatgaggaaactga-3' 
6 Exon 3 F: 5'-tatcaggactttgacaaggtgag-3' 1183 63 30 
R: 5'-aggaagacagaaacaaggaaacc-3' 
7 Exon 4 – 5 F: 5'-cagtttccccatctgaacaataa-3' 1106 65 30 
R: 5'-gactttgagcaagggtaggattc-3' 
8 Exon 6 F: 5'-aaagttccacttgtgatctcagc-3' 1173 59 30 
R: 5'-gtccggctaatttttgttttgta-3' 
9 Intron 6 F: 5'-ggggacctcaattgctatagtct-3' 1189 59 30 
R: 5'-ctcagctcactgcactctctct-3' 
10 Exon 7 F: 5'-aggctggtcattttagagagagc-3' 1025 59 28 
R: 5'-tgtagagacagggtcccactatg-3' 
11 3' UTR § F: 5'-gcccttgtttctcttcctttct-3' 1127 65 35 
R: 5'-ggtggtgtgtgcctgtagtct-3' 
12 3' UTR § F: 5'-ttcctctgtctcctaagctgga-3' 1034 59 30 
R: 5'-ctgaggctagccactacattca-3' 





Table 2.5 Thermal cycling conditions employed in the PCR 






1 95 180 – 
2 94 45 
28 – 35 ‡ 3 59 – 65 † 45 
4 72 45 
5 72 420 – 
6 4 ∞ – 
† The annealing temperature varies with the gene fragments 
amplified. Table 2.4 lists the annealing temperature of each 
fragment. 
‡ The number of cycles repeating steps 2 to 4 differed with the 
gene fragments amplified. Table 2.4 lists the information 
specific to each fragment. 
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2.4.5.2 Cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9)  
Genotyping of CYP2C9*2 (430T>C; rs1799853) and CYP2C9*3 (1075A>C; 
rs1057910) was achieved by PCR amplification of the region of interest using two 
sets of primers reported previously (415) followed by direct sequencing. The primers 
used are listed in Table 2.6. The thermal cycling conditions used in amplification of 
CYP2C9 (UCSC RefSeq: NM_000771) are listed in Table 2.7. 
Table 2.6 Primer sequences and PCR conditions for genotyping of CYP2C9 
polymorphisms (UCSC RefSeq: NM_000771). 








430C>T (*2) F: 5′-gcaaatggacaaaatagtaa-3′ 652 57 30 
[Exon 3] R: 5′-ctaacaaccaggactcata-3′ 
1075A>C (*3) F: 5′-ctccttttccatcagttttt-3′ 327 51 35 
[Exon 7] R: 5′-ttatgcacttctctcaccc-3′ 
§Ta, annealing temperature; Amp. Cycles, number of amplification cycles. 
 
Table 2.7 Thermal cycling conditions employed in the PCR 






1 95 180 – 
2 94 45 
30 or 35 ‡ 3 51 or 57 † 45 
4 72 45 
5 72 420 – 
6 4 ∞ – 
† The annealing temperature varies with the gene fragments 
amplified. Table 2.6 lists the annealing temperature of each 
fragment. 
‡ The number of cycles repeating steps 2 to 4 differed with the 
gene fragments amplified. Table 2.6 lists the information 
specific to each fragment. 
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2.4.5.3 Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) 
CYP2C19 consists of nine coding exons and spans more than 90 kb on chromosome 
10q24 beside CYP2C9. The coding regions (including exon-intron boundaries) as 
well as the upstream and downstream regions (13.5 kilobases in total) of CYP2C19 
gene (UCSC RefSeq: NM_000769.1) were screened by dividing the gene region into 
15 fragments (Table 2.8). The primers were designed with Primer 3 software (414) 
(http://frodo.wi.mit.edu/) and submitted to NCBI Primer-BLAST (416) 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to ensure binding specificities. PCR 
conditions for amplification of CYP2C19 (UCSC RefSeq: NM_000769.1) are listed in 
Tables 2.8 and Tables 2.9. 
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Table 2.8 Primer sequences and PCR conditions for amplification of CYP2C19 










1 5′ Upstream F: 5′-actatgaaactctggtaatataagg-3′ 748 55.5 
R: 5′-tataggtttaccatgttgtctattc-3′ 
2 5′ Upstream F: 5′-tagtagttgtgctccttggcatt-3′ 1058 55.5 
R: 5′-ttgagagctaggtgttccagttc-3′ 
3 5′ Upstream F: 5′-gaactgggagttgaaaaactgtg-3′ 1003 55.5 
R: 5′-gagctgacatttgagttgaaggt-3′ 
4 5′ Upstream F: 5′-aatgaccagtgaaacattgtgc-3′ 1060 63.5 
R: 5′-tcgaagattaggagactttgtcc-3′ 
5 Exon 1 F: 5′-tagggggttaaatggtaaaggtg-3′ 1276 63.5 
R: 5′-cttatctgcttttgctggtccta-3′ 
6 Exon 2 – 3 F: 5′-ggattccatagagaggtgctttt-3′ 1468 59 
R: 5′-agtgaggctgaccatacaaacat-3′ 
7 Exon 4 F: 5′-gatgtgattccctctgaaacttg-3′ 747 63.5 
R: 5′-gaaacagggctttggagtttagt-3′ 
8 Exon 5 F: 5′-tcagaggctgcttgatagaaatc-3′ 962 63.5 
R: 5′-ccttcactcactttttgatggag-3′ 
9 Exon 6 F: 5′-atagatgcagaaaaagcccttg-3′ 989 65 
R: 5′-cctctactgtgcaaagatgtcct-3′ 
10 Exon 7 F: 5′-aatgctgaagtgggttgttg-3′ 1272 63.5 
R: 5′-accctgacagaaattctagccc-3′ 
11 Exon 8 F: 5′-cccacaacagtccccgaa-3′ 580 55.5 
R: 5′-gaggatgtatcaccagcggag-3′ 
12 Exon 9 F: 5′-ggtgaagagtaagcatgtccatt-3′ 1034 59 
R: 5′-atatccattcctcccaatacctg-3′ 
13 3′ Downstream F: 5′-attagaccttccttcctttgtgc-3′ 1063 65 
R: 5′-agaaattttgttcagccaggtg-3′ 
14 3′ Downstream F: 5′-gaaatggagtcccacttttgttc-3′ 1096 59 
R: 5′-gaagcaagtgtttggagtgaaag-3′ 
15 3′ Downstream F: 5′-gaagagaaagtggaaatgggta-3′ 759 55.5 
R: 5′-aaattcacgtgctcctttatgc-3′ 




Table 2.9 Thermal cycling conditions employed in the PCR 






1 95 180 – 
2 94 45 
30 3 55 – 65 † 45 
4 72 45 
5 72 420 – 
6 4 ∞ – 
† The annealing temperature varies with the gene fragments 
amplified. Table 2.8 lists the annealing temperature of each 
fragment. 
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2.4.5.4 Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) 
A total of 14 functional CYP2D6 polymorphisms [*2 (2850C>T; rs16947), *2A (–
1584C>G), *3 (2549delA; rs35742686), *4 (1846G>A; rs3892097), *6 (1707delT; 
rs5030655), *7 (2935A>C; rs5030867), *8 (1758G>T), *9 (2615-2617delAAG; 
rs5030656), *10 (100C>T; rs1065852), *12 (124G>A; rs5030862), *14 (1758G>A), 
*17 (1023C>T; rs28371706), *29 (1659G>A; rs61736512), and *41 (2988G>A; 
rs28371725)], gene deletion [*5 (CYP2D6del)] and duplication [*xN (CYP2D6dup)] 
were genotyped. CYP2D6 (UCSC RefSeq: NM_000106.4) genotyping was 
performed using the INFINITI® CYP450 2D6I assay (AutoGenomics, CA, USA) and 
INFINITI® analyzer (AutoGenomics, CA, USA). The genotyping assay was preceded 
by the amplification step comprising of two multiplex PCR reactions, A and B, for 
each sample. Each 20 µL PCR reaction volume comprised of 16.70 µL of 
amplification mix A or B, 0.3 µL of Taq polymerase (5 Units/µL) and 3.0 µL of sample 
DNA (100 ng/µL). The PCR reaction was subjected to the thermal cycling conditions 
stipulated in Table 2.7. 
Table 2.10 Thermal cycling conditions for 








1 94 120 – 
2 94 15 
20 3 66 – 60  (–0.3 °C/ cycle) 30 
4 68 240 
5 94 15 
15 6 58 30 
7 68 240 
8 68 60 – 
9 4 ∞ – 
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After the PCR amplification, 10 µL of each reaction A and B was added and mixed 
well in a 24-well plate. A mixture consisting of 3.00 µL of SAP, 0.75 µL of Exo and 
0.25 µL of Taq were added to each mixed PCR reaction. The samples were pulsed 
centrifuged to bring the contents to the bottom of each well and loaded into the 
INFINITI® analyzer. Simultaneously, the INFINITI® CYP450 2D6I BioFilmChip 
microarray magazines, Intellipac® reagent modules, tips and wash buffers were 
loaded into the analyzer. 
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2.4.5.5 Cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5) 
The intronic SNP, CYP3A5*3 (6986A>G; rs776746), was genotyped using PCR 
amplification using primers previously reported previously (417, 418) followed by 
direct sequencing. The forward and reverse primers used were 5′-
catgacttagtagacagatga-3′ and 5′-ggtccaaacagggaagaggt-3′ respectively. The PCR 
conditions are stated in Table 2.11. 
Table 2.11 Thermal cycling conditions employed in the PCR 






1 95 180 – 
2 95 60 
35 3 59 60 
4 72 60 
5 72 420 – 
6 4 ∞ – 
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2.4.6 Pharmacogenetics of Phase II Drug Metabolizing Enzymes 
2.4.6.1 UDP glucuronosyltransferase 1 family, polypeptide A4 (UGT1A4) 
The UGT1A4 (UCSC RefSeq: NM_007120) gene is mapped onto chromosome 2q37 
within the UGT1A gene cluster. The gene spans 54.5 kb and consists of a variable 
exon 1 and four common exons 2 to 5. Nine sets of primers (Table 2.12), each 
amplifying approximately one to two kb gene region, were designed to screen for 
polymorphic variants in the coding regions, exon-intron junctions as well as the 5′ 
and 3′ downstream regions (2.5 kb each). Primers were designed with Primer 3 
software (414) (http://frodo.wi.mit.edu/) and blasted against the NCBI database (416) 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to ensure specificity of primers. The 
gene was amplified by PCR followed by direct sequencing. PCR conditions for 
amplification of UGT1A4 are stipulated in Tables 2.12 and 2.13.  
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Table 2.12  Primers and PCR conditions used in amplification of UGT1A4 gene 










1 5’ Upstream F: 5’-gcattctgattctgtccattctt-3’ 1345 60 
R: 5’-gtctgtaagggcttgagaactcc-3’ 
2 5’ Upstream F: 5’-aggagggttcttaagatgcagac-3’ 1554 60 
R: 5’-ctacatttgtttccttcgcctta-3’ 
3 Exon 1 – Intron 1 F: 5’-gtgttgggaattgaatgagaaag-3’ 1904 60 
R: 5’-cacggtcttatctcctccctagt-3’ 
4 Exon 2 – Intron 2 F: 5’-aattctgtaagcaggaacccttc-3’ 1084 60 
R: 5’-agtatcgtgttgttcgcaagatt-3’ 
5 Exon 3 – Intron 4 F: 5’-cacagttactgatcctcccactc-3’ 1016 65 
R: 5’-gacacctgtaatcccagctacac-3’ 
6 Exon 5 – 3’ UTR F: 5’-ggtgcatgactaattccagctac-3’ 1100 65 
R: 5’-aagccattcattcatttcaccta-3’ 
7 3’ downstream F: 5’-ctctggtgtctttgatcaggatg-3’ 1058 65 
R: 5’-gtctcaaactcccgatcttaggt-3’ 
8 3’ downstream F: 5’-gcatgattatgacagaaagtttgg-3’ 1010 63 
R: 5’-tgttcctcattgggataagtctg-3’ 
9 3’ downstream F: 5’-gaagattctcccaaggtgttttt-3’ 1045 62 
R: 5’-tccctcacacgctgatagtaagt-3’ 
§Ta, annealing Temperature; UTR, untranslated region; Amp. Cycles, number of 
amplification cycles. 
 
Table 2.13 Thermal cycling conditions employed in the PCR amplification 
UGT1A4 gene region. 
Steps Temperature(°C) Time (seconds) Number of Cycles 
1 95 180 – 
2 94 45 
30 3 60 – 65 † 45 
4 72 45 ‡ 
5 72 420 – 
6 4 ∞ – 
† The annealing temperature varies with the gene fragments amplified. 
Table 2.12 lists the annealing temperature of each fragment. 
‡ The extension temperature of each cycle was increased to 2 minutes for 
primer set 3 in Table 2.12. 
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2.4.6.2 UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7) 
UGT2B7 is a 16 kb gene localized on chromosome 4 and consists of six exons. To 
characterize the genetic profile of UGT2B7 (UCSC RefSeq: NM_001074.2), the 
region of interest which includes approximately 2.5 kb 5′ upstream and 3′ 
downstream of the gene as well as the exons and exon-intron junctions was 
segregated into ten genetic fragments. The ten pairs of primers (Table 2.14) were 
designed using Primer 3 software (414) (Rozen et al, 2000; http://frodo.wi.mit.edu/) 
and blasted against the NCBI database (416) 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR conditions employed in the 
amplification of UGT2B7 gene region are noted in Table 2.15. However, the 
amplification of primer sets number seven and nine in Table 2.14, the denaturation, 
annealing and extension times in each cycle was altered. Detailed information is 
listed in Table 2.14. 
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1 5’ Upstream F: 5′-tctgtggatcaagttgtttcctt-3′ 909 65 30 
R: 5′-gaaagggtgggttaatgtatgtg-3′ 
2 5’ Upstream F: 5′-ctcatatcaatgttgatggttgc-3′ 1052 55 35 
R: 5′-ccaagcttgtagtacattcagca-3′ 
3 5’ Upstream – 
Exon 1 
F: 5′-gaactatagtcttgtaacagggtctgc-3′ 1268 58 30 
R: 5′-ggtctgaccatctcttaatctgttg-3′ 
4 Exon 1 F: 5′-tacattttaacttcttggctaa-3′ 1043 55 35 
R: 5′-atttcctggggtgttctgt-3′ 
5 Exon 2 F: 5′-tgaaactatgtctctttattag-3′ 1243 55 35 
R: 5′-tttttatataatttttattacttgc-3′ 
6 Exon 3 F: 5′-agaacctatattagtaactttag-3′ 773 53 35 
R: 5′-ttatggacaggaggtgagaa-3′ 
7 Exon 4 – Exon 5 F: 5′-tttttgaggaatcgccagtcttc-3′ 2261 59 35 † 
R: 5′-ggctaagcggtcataggaagt-3′ 
8 Exon 6 – 3′ 
UTR§ 
F: 5′-gcagacccccttagagtt-3′ 1016 55 35 
R: 5′-gccaagcaatactactcatc-3′ 
9 3′ downstream F: 5′-tgttgttctaattcacagtatactc-3′ 1258 60 30 ‡ 
R: 5′-cctgcaagaatggcctaattt-3′ 
10 3′ downstream F: 5′-gtactagtttgcattcccacagc-3′ 969 55 35 
R: 5′-ggggacgtggagagtctttat-3′ 
§Ta, annealing Temperature; UTR, untranslated region; Amp. Cycles, number of 
amplification cycles. 
† The denaturation, annealing and elongation temperature for each cycle were 30 seconds, 
45 seconds and 150 seconds respectively. 
‡ The denaturation, annealing and elongation temperature for each cycle were 45 seconds, 




Table 2.15 Thermal cycling conditions employed in the PCR amplification 
UGT2B7 gene region. 
Steps Temperature(°C) Time (seconds) Number of Cycles 
1 95 180 – 
2 94 45 § 
30 – 35 ‡ 3 55 – 65 † 45 § 
4 72 45 § 
5 72 420 – 
6 4 ∞ – 
† The annealing temperature varies with the gene fragments amplified. Table 
2.14 lists the annealing temperature of each fragment. 
‡ The number of cycles repeating steps 2 to 4 differed with the gene 
fragments amplified. Table 2.14 lists the information specific to each 
fragment. 
§ The denaturation (step 2), annealing (step 3) and extension (step 4) 
temperatures of each cycle were altered for primer sets 7 and 9 in Table 
2.14. Detailed information for each fragment is listed in Table 2.14. 
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2.4.6.3 UDP glucuronosyltransferase 2 family, polypeptide B15 (UGT2B15) 
The entire UGT2B15 (UCSC RefSeq: NM_001076) gene spans about 24 kb on 
chromosome 4. Ten sets of primers amplifying ten genetic fragments were designed 
to identify polymorphisms present in the 5′ upstream (2.5 kb), 3′ downstream (2.5 kb), 
six exons and the exonic-intronic boundaries (Table 2.16). The primers were 
designed using Primer 3 software (414) (http://frodo.wi.mit.edu/) and NCBI database 
(416) (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Amplification of UGT2B15 
involved the thermal cycling steps which are listed in Tables 2.16 and 2.17. 
Table 2.16 Primer Sequences and PCR Conditions used in amplification of UGT2B15 gene 












1 Promoter F: 5′-ttgagagagatcagtgagggaga-3′ 1098 58 30 
R: 5′-caaaatctacatggcctctcttg-3′ 
2 Promoter F: 5′-gagagaacagggaaaaaggagac-3′ 1095 58 30 
R: 5′-gagacatcccaaacactgtgagt-3′ 
3 Promoter F: 5′-gcctttctgctacttcctctacc-3′ 1031 58 30 
R: 5′-tggtcttatgcaatgcttctttt-3′ 
4 5′ UTR – 
Exon 1 
F: 5′-tcaatcttttgttggtctccttg-3′ 1085 58 30 
R: 5′-ccccagggttctaactgattcta-3′ 
5 Exon 2 F: 5′-acatggggattatggggatta-3′ 1004 58 30 
R: 5′-caatgagtttgggatctcttctg-3′ 
6 Exon 3 F: 5′-tggctccaatgactcctaactaa-3′ 1092 58 30 
R: 5′-agtaaaaacagccagattgcttg-3′ 
7 Exon 4 F: 5′-gggatacatgagacatcaatcaa-3′ 1029 58 30 
R: 5′-aaagtgtccgctatttttcagtg-3′ 
8 Exon 5 F: 5′-cctactccctgctgcctttta-3′ 1069 58 30 
R: 5′-ttagggctgtggctttgtaacta-3′ 
9 Intron 5 – 
Exon 6 
F: 5′-ctaggacaagtaggtgcctgtgt-3′ 1068 58 30 
R: 5′-aggaatgctatcacatccaaaga-3′ 
10 Exon 6 – 
3′ UTR §  
F: 5′-gcagtcttctggattgagtttgt-3′ 1998 60  32 † 
R: 5′-tccagtttttctgctctgttttc-3′ 
§Ta, annealing Temperature; UTR, untranslated region; Amp. Cycles, number of amplification 
cycles. 
† The denaturation, annealing and elongation temperature for each cycle were 30 seconds, 
45 seconds and 150 seconds respectively. 
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Table 2.17 Thermal cycling conditions employed in the PCR 








1 95 180 – 
2 94 45 § 
30 – 32 ‡ 3 58 – 60 † 45 § 
4 72 45 § 
5 72 420 – 
6 4 ∞ – 
† The annealing temperature varies with the gene fragments 
amplified. Table 2.16 lists the annealing temperature of each 
fragment. 
‡ The number of cycles repeating steps 2 to 4 differed with the 
gene fragments amplified. Table 2.16 lists the information 
specific to each fragment. 
§ The denaturation (step 2), annealing (step 3) and extension 
(step 4) temperatures of each cycle were altered for primer set 
10 in Table 2.16. Detailed information for each fragment is 
listed in Table 2.16. 
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2.4.6.4 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 
(SULT1A1) 
The polymorphisms, SULT1A1*2 (638G>A; rs9282861) and SULT1A1*3 (667A>G; 
rs1801030) are found in exon 6 of the SULT1A1 gene (UCSC RefSeq: NM_001055). 
Genotyping of these two SNPs was achieved by PCR amplification of the region of 
interest using the primers (F: 5′-gttgaggagttggctctgcaggg-3′ and R: 5′-
tagttggtcatagggttcttcttcatctcc-3′) designed using Primer 3 (414) 
(http://frodo.wi.mit.edu/) and NCBI database (416) 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), followed by direct sequencing. The 
PCR conditions employed are noted in Table 2.18. 
Table 2.18 Thermal cycling conditions employed in the PCR 







1 95 180 – 
2 94 45 
30 3 56 45 
4 72 45 
5 72 420 – 
6 4 ∞ – 
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2.5 Pharmacokinetic Analysis 
Peripheral blood samples (3 mL) were collected from recruited patients who had 
received 20 mg of tamoxifen daily for 8 weeks or more when steady state levels of 
the metabolites would have been achieved. The blood samples were collected, 
protected from light, and immediately centrifuged at 2000 g for ten minutes. Plasma 
was extracted from each sample and stored at –80 °C till pharmacokinetic analysis 
of tamoxifen and its metabolites (NDM, 4-OHT and endoxifen). 
Quantification of tamoxifen and its primary metabolites for the analysis of 
pharmacogenetic effects of phase I drug metabolizing enzymes was performed using 
HPLC-fluorescence assay in Laboratory of Clinical Pharmacology, National Cancer 
Centre, Singapore. However, with regard to the impact of phase II drug metabolizing 
enzymes, quantification assay used was HPLC tandem MS or LC-MS, performed in 
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. 
In this subsequent LC-MS assay, a total of 29 metabolites including tamoxifen, NDM, 
4-OHT and endoxifen was quantified. 
2.5.1 HPLC-fluorescence Assay 
The pure compounds, propranolol (99%), (Z)-tamoxifen (≥99%) and (Z)-4-OHT 
(≥98%), were purchased from Sigma-Aldrich Co. LLC, Singapore. The metabolites, 
NDM, (E)- and (Z)-endoxifen were kind gifts from Dr D. A. Flockhart (Indiana 
University School of Medicine, Indianapolis, IN, USA) and Dr P. Lazarus 
(Pennsylvania State University College of Medicine, PA, USA). Ammonium acetate 
and sodium hydroxide were obtained from Sigma-Aldrich Co. LLC, Singapore, and 
Merck, NJ, USA, respectively. Analytical grade, glacial, acetic acid was bought from 
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Thermo Fisher Scientific Inc., MA, USA while n-hexane (analytical grade) and n-
butanol (analytical grade) were purchased from Tedia Company Inc, OH, USA and 
VWR International LLC, England respectively. The mobile phase, acetonitrile (HPLC 
grade), was acquired from Tedia Company Inc, OH, USA.  
2.5.1.1 Instrumentation and chromatographic conditions 
The analyses of plasma levels of tamoxifen and its metabolites, NDM, 4-OHT and 
endoxifen, were performed using reverse-phase high performance liquid 
chromatography (HPLC) on the Waters Alliance HPLC® system (Waters Assoc. 
Milford, MA). The HPLC system consists of the Waters 2690 separation module 
(Waters Assoc. Milford, MA) coupled with the post-column reactor photochemical 
reactor (MicroSolv Technology Corporation, New Jersey), and Waters 474 scanning 
fluorescence detector (Waters Assoc.). The photochemical reactor is fitted with a 
254-nm ultraviolet lamp which converts the analytes to the fluorescent phenanthrene 
derivatives. Chromatographic separation of the sample was performed on the Agilent 
Zorbax Eclipse XDB C8 chromatography column (150mm×4.6 mm, 5µm, Agilent, 
USA) with the same guard column (12.5mm×4.6 mm, 5µm, Agilent, USA) attached to 
the preceding part of the column. The mobile phase comprised of acetonitrile and 
100 mM ammonium acetate (pH 5.5) with a gradient elution profile stated in Table 
2.19. The excitation and emission wavelength of the fluorescence detector was set at 
260 nm and 375 nm respectively. The chromatograms of all samples were acquired, 
stored and analyzed using the Millenium software (version 3.20, Waters Assoc.).  
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100 mM Ammonium 
acetate (pH 5.5) (%) 
1 0.01 1.0 30.0 70.0 
2 25.00 1.0 38.3 61.7 
3 28.00 1.0 47.0 53.0 
4 36.00 1.0 55.0 45.0 
5 38.00 1.0 80.0 20.0 
6 41.00 1.0 30.0 70.0 
2.5.1.2 Standard Stock Solutions, Calibration and Quality Control (QC) Samples 
Standard stock solutions of concentrations 1.0, 0.5, 10.0 and 10.0 µg/mL were 
prepared for (Z)-endoxifen, 4-OHT, NDM and tamoxifen respectively. These stock 
solutions were prepared by dissolving weighed amount of each pure compound in 
methanol. Working solutions were prepared by serial dilutions from the primary stock 
solution using methanol as diluent. A standard solution of internal standard, 
propranolol, with the concentration of 5 µg/mL was prepared by dissolving the pure 
compound in methanol. All solutions were stored at −20 °C until analysis. 
2.5.1.3 Sample Preparation and Analysis of Plasma Concentrations of Analytes 
using HPLC-fluorescence 
The plasma concentrations of tamoxifen, NDM, 4-OHT and endoxifen were 
determined by modification of the methods developed by Lee et al (419) and Zhu et 
al (420). Twenty microlitre of the internal standard, propranolol (5 µg/mL), was added 
to a 2-mL polypropylene microfuge tube and evaporated to dryness. Subsequently, 
200 µL of each plasma sample was added to the dried tube with 10 µL of sodium 
hydroxide (4 mM). The components were mixed at 1400 rpm using Eppendorf 
Thermomixer Comfort (Eppendorf AG, Hamburg, Germany) for 5 minutes. After 
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which, 1.6 mL of n-hexane:n-butanol (98:2, v:v) was added and the mixture was 
vigorously vortexed for 20 seconds followed by mixing at 1400 rpm for 15 minutes. 
The specimen was then centrifuged at 4000 g for ten minutes at ambient 
temperature. The top, organic layer was dispensed into a fresh microfuge tube and 
evaporated to dryness using centrifugal concentrator at room temperature. To the 
dried residue, 50 µL of methanol was added and vigorous mixing at 1400 rpm for 5 
minutes performed. Finally, the specimen was centrifuged at 13000 g for 5 minutes 
and 40 µL of the supernatant was injected into the analytical column, Agilent Zorbax 
Eclipse XDB C8 chromatography column (150mm×4.6 mm, 5µm, Agilent, USA).  
The analytical conditions employed were the gradient elution comprising of 
acetonitrile and 100 mM ammonium acetate (pH 5.5) as described in Table 2.11. 
Eluted analytes were converted to its phenanthrene derivatives with fluorescent 
properties via a post-column photoreaction. The detection parameter of the 
fluorescence detector was set at an excitation wavelength of 260 nm and emission 
wavelength of 375 nm. The gain was set at 100 for endoxifen and 4-OHT but one for 
tamoxifen and NDM. The retention times of propranolol (internal standard), endoxifen, 
4-OHT, NDM and tamoxifen were 5.1 minutes, 20.4 minutes, 23.5 minutes, 33.4 
minutes, and 35.8 minutes, respectively. The limits of quantification (LOQ) were 10.0 
ng/mL for both tamoxifen and NDM, 0.5 ng/mL and 1.0 ng/mL for 4-OHT and 
endoxifen respectively. The calibration curves were linear over the concentration 
ranges of 10.0 – 800.0 ng/mL for tamoxifen (r2 = 0.9977) and NDM (r2 = 0.9974), 0.5 
– 40.0 ng/mL for 4-OHT (r2 = 0.9993) and 1.0 – 80.0 ng/mL for endoxifen (r2 = 
0.9973). The intra-day and inter-day coefficients of variation were less than 7.0% and 
14.0%, respectively. 
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2.5.2 LC-MS Assay  
The LC-MS analytical method was as described by Murdter et al (118) and 
performed by our collaborators in Dr Margarete Fischer-Bosch-Institute of Clinical 
Pharmacology, Stuttgart, Germany.  
The pure compounds, (Z)-tamoxifen (≥99%) and (Z)-4-OHT (≥98%), were purchased 
from Sigma, Deisenhofen, Germany. Other metabolites, including (Z)-α-
hydroxytamoxifen, [2H5]-NDM, (E)- and (Z)- [2H5]-endoxifen, and 3-hydroxytamoxifen 
were purchased from Toronto Research Chemicals, Toronto, Ontario, Canada. 
Lastly, NDM and N,N-didesmethyltamoxifen were kind gifts from Klinge Pharma 
GmbH, Munich, Germany. In addition, (Z)-endoxifen (>98%), (Z)-4′-hydroxytamoxifen, 
(Z)-4′-N-hydroxy-desmethyltamoxifen, tamoxifen-N+-glucuronide, 4-
hydroxytamoxifen-N+-glucuronide,  (E)- and (Z)- tamoxifen-4-O-glucuronide, (E)- and 
(Z)- N-desmethyltamoxifen-4-O-glucuronide, [2H3]-tamoxifen, (E)- and (Z)- [2H5]-4-
OHT, and (E)- and (Z)- [2H5]-tamoxifen-4-O-glucuronide, were synthesized in 
accordance to previous published methods (128, 421).  
2.5.2.1 Instrumentation and chromatographic conditions 
The quantitative analysis of 29 metabolites including tamoxifen was performed on 
Agilent 1200 Series Rapid Resolution LC System coupled to a 6460 triple 
quadrapole mass spectrometer with a Jet Stream electrospray source (Agilent, USA). 
Chromatographic separation of the sample was performed on the Agilent Zorbax 
Eclipse plus C18 chromatography column (100mm×2.0 m m, 1.8µm, Agilent 
Technologies, Waldbronn, Germany). The sample was eluted using a gradient profile 
of acetonitrile in 0.1% acetic acid in water.  
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2.5.2.2 Standard Stock Solutions, Calibration and Quality Control (QC) Samples 
A total of seven calibration samples were prepared. Calibration samples of 
concentrations similar to the expected plasma concentrations of steady state levels 
observed in patients were obtained by addition of relevant amounts of all reference 
compounds in acetonitrile to blank plasma. Concentrations of analytes without pure 
reference compounds were calculated using calibration data of compounds with 
similar structures.  
2.5.2.3 Sample Preparation and Analysis of Plasma Concentrations of Analytes 
using LC-MS 
A volume of 50 µL of sample plasma was added to 100 µL of 1% acetic acid in 
acetonitrile containing the internal standards before centrifugation. This process 
removed the proteins from the sample. Subsequently, the clear supernatant was 
removed and diluted with 150 µL of 0.1% acetic acid in water. 
2.5.3 Calculation of Metabolic Ratios (MRs) 
The relative conversion of one metabolite to another was examined with the use of 
plasma concentration ratios or metabolic ratios (MRs). Similar, the relative 
contributions of 4-OHT and NDM as intermediate metabolites in the formation of 
endoxifen were studied using total plasma concentration ratios or total metabolic 
ratios (TMRs). The derivations of MRs and TMRs were described in Table 2.20. 
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Table 2.20 Calculation of metabolic ratios (MRs) and total 
metabolic ratios (TMRs). 
Metabolic ratios (MRs)  
MRNDM/TAM CNDM/CTAM 
MRZ-END/NDM
 L CZ-END/CNDM (×100) 
MRZ-4-OHT/TAM 
L CZ-4-OHT/CTAM (×100) 
MRZ-END/Z-4-OHT CZ-END/CZ-4-OHT 
MRTAM-N-Gluc/TAM 








Total metabolic ratios (TMRs)  
TMR4-OHT CEND/CTAM + C4-OHT (×102) 
TMRNDM CEND/ CTAM + CNDM (×102) 
‡ The metabolic ratios were multiplied by 100 to reduce 
the number of decimal points for ease of analysis as the 
original ratios were much lower than one. 
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2.6 Statistical Analysis 
2.6.1 Genetic Analysis 
Chi-square test was employed to assess Hardy-Weinberg equilibrium between 
genotype frequencies. Pairwise linkage disequilibrium (LD) between polymorphisms 
in candidate genes (CYP1A2, CYP2C19, UGT1A4, UGT2B7 and UGT2B15) was 
described using coefficient of LD (|D′|) and rho square (r2) values in the Haploview 
version 4.0 software (Daly Lab, Broad Institute, MA, USA). The |D′| value quantifies 
the non-random association of polymorphisms at two or more loci while r2 value 
measures the correlation of different pairs of alleles. Tag-SNPs in phase I (CYP1A2 
and CYP2C19) and phase II pharmacogenes (UGT1A4, UGT2B7 and UGT2B15) 
were identified using TAGGER (Haploview version 4.0 software, Daly Lab, Broad 
Institute, MA, USA) (422) and TAGster (National Institute of Environmental Health 
Sciences, NC, USA) (423) respectively . Haplotypes were inferred using the 
maximum likelihood estimation based on expectation-maximization (EM) algorithm in 
Haploview version 4.0 software (Daly Lab, Broad Institute, MA, USA) (424). These 
analyses were conducted for each healthy ethnic group and the inter-ethnic 
differences were examined by Chi-square test. Haplotype pairs of individual patients 
were phased using PLINK version 1.07 software (425) 
(http://pngu.mgh.harvard.edu/purcell/plink/) . The significance level was set at a P 
value of less than or equal to 0.05 for all pairwise comparisons. All statistical tests 
were performed using SPSS version 14.0 (IBM Corp, NY, USA) 
2.6.2 Pharmacokinetics-Pharmacogenetics Correlations 
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Summary statistics for the steady state concentrations of tamoxifen, NDM, 4-OHT 
and endoxifen were for each ethnic group, and the ethnic differences were examined 
by non-parametric analyses. The distribution profiles of all phenotypic parameters 
were examined using histograms and conformation to normality was assessed using 
Kolmogorov-Smirnov test. Spearman correlation analysis was employed to examine 
the relationships between the plasma concentrations of analytes and baseline 
characteristics of the study population. Associations between polymorphic variants 
present along the candidate genes and steady state plasma concentrations of the 
analytes were examined using non-parametric Kruskal-Wallis and Mann-Whitney U-
tests in PASW version 18.0 (IBM Corp, NY, USA) as the phenotypic parameters 
were found to deviate from Normal distribution. Hodges-Lehmann estimates and the 
corresponding 95% confidence intervals for all non-parametric pairwise comparisons 
were analysed using PASW version 18.0 (IBM Corp, NY, USA) to represent the 
difference in median between two populations. Post-hoc power analysis was 
performed to estimate the effect sizes that can be detected with a study power of 
80% at different variant allelic frequencies using G*Power version 3.1.7 (Heinrich-
Heine-Universität Düsseldorf, Düsseldorf, Germany). The tabulated form of the 
power detecting differences of various effect sizes across the range of variant allelic 
frequencies is included Appendix C. The haplotypic effects of UGT1A4 tag-SNPs 
were examined using haplotype-specific regression analysis in Haplostats (R version 
2.15.0; http://www.r-project.org). Before the application of the regression analysis, 
the phenotypic parameters were ln-transformed to ensure conformity to normal 
distribution. The significance level was set at a P value of less than or equal to 0.05 
for all pairwise comparisons.  
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Chapter 3: Results and Discussions 
3.1 Patient Demographics and Characteristics 
Pharmacogenetic analyses of the effects of the phase I pharmacogenes were 
performed when the sample size of the study reached 163. The plasma 
concentrations of the primary metabolites (tamoxifen, NDM, 4-OHT and endoxifen) 
were analysed using HPLC methods (426). As study recruitment was ongoing, 
subsequent analyses of the phase II pharmacogenes included patients recruited 
after analyses phase I pharmacogenes were performed. Thus, the sample size 
included in the phase II analyses was 202. However, in this subsequent analysis, 
plasma levels of the primary analytes as well as the corresponding phase II 
conjugates were quantified using LC-MS methods (118). Hence, the baseline 
characteristics of the patients included in these two batches of analyses are listed in 
Table 3.1. The baseline characteristics of the patient cohort were not found to differ 
when the sample size of the study was increased from 163 to 203. The median age 
of the breast cancer patients was 49 years (range: 30 – 74 years) with approximately 
four-fifth of the patients being premenopausal. The median height and weight were 
156.0 cm (range: 134.0 – 172.0 cm) and 58.0 kg (range: 39.0 – 91.7 kg). The ethnic 




Table 3.1 Characteristics and demographics of Asian breast cancer patients included in phase I 
and II analyses. 
  Phase I Analyses (N=163) Phase II Analyses (N=202) 
  Median (Range) Mean ± SD Median (Range) Mean ± SD 
Age 49 (30 – 74) 49.7 ± 7.8 49 (30 – 74) 49.6 ± 7.7 
Height 156 (134 – 172) 156.0 ± 6.4 156 (134 – 172) 156.2 ± 6.2 
Weight 58.0 (39.0 – 91.7) 58.9 ± 10.2 58.0 (39.0 – 91.7) 58.7 ± 9.9 
BMI 23.3 (14.3 – 38.2) 24.3 ± 4.2 23.2 (14.3 – 38.2) 24.1 ± 4.1 
              
  N (%)   N (%)   
Ethnicities       
Chinese 137 (84.0)  168 (83.2)  
Malays 12 (7.4)  15 (7.4)  
Indians 14 (8.6)  19 (9.4)  
       
       
Menopausal Status       
Pre-menopause 134 (82.2)  162 (80.2)  
Post-menopause 29 (17.8)  40 (19.8)  
       
Prior Radiotherapy 116 (71.2)  134 (66.3)  
       
Prior Chemotherapy 139 (85.3)  168 (83.2)  
Anthracycline based 49 (30.1)  51 (25.2)  
Anthracycline/Taxane 
based 
77 (47.2)  64 (31.7)  
No Chemotherapy 24 (14.7)  34 (16.8)  
       
ER Status       
Positive 142 (87.1)  180 (89.1)  
Negative 21 (12.9)  22 (10.9)  
       
PR Status       
Positive 152 (93.3)  184 (91.1)  
Negative 10 (6.1)  17 (8.4)  
Unknown 2 (1.2)  1 (0.5)  
       
HER-2 Status       
Positive 42 (25.8)  48 (23.8)  
Negative 113 (69.3)  144 (71.3)  
Unknown 8 (4.9)  10 (5.0)  
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3.2 Plasma Concentrations of Tamoxifen and its Metabolites 
The steady state plasma concentrations of the metabolites were initially quantified 
using HPLC coupled with fluorescence detection in 163 patients. Using HPLC 
method, the plasma concentrations of tamoxifen and its three primary metabolites 
(NDM, 4-OHT and endoxifen) were analysed (426). Subsequently, using LC-MS 
method, a total of 29 analytes (Table 3.2), including tamoxifen, NDM, 4-OHT and 
endoxifen, were quantified in 203 patients (118). The latter method allowed for the 
separation of (E)- and (Z)-isomers of the various metabolites. Previously, only the 
(Z)-isomers of 4-OHT and endoxifen were quantified using HPLC assay.  
The plasma concentrations of the four analytes quantified via the two methods were 
found to be highly correlated (Spearman’s r, tamoxifen vs NDM vs (Z)-endoxifen vs 
(Z)-4-OHT: 0.96 vs 0.97 vs 0.94 vs 0.90, P < 0.001). Variations between individuals’ 
plasma concentrations between the two methods were found to be lowest with 
tamoxifen and highest with (Z)-4-OHT with median percentage deviations of 2.86% 
and 27.7% respectively. The median percentage deviations of NDM and (Z)-
endoxifen were 16.2% and 15.8% respectively (Table 3.3). This was likely due to the 
low concentrations of (Z)-4-OHT compared to other metabolites and that the 
concentrations were toward the lower limit of quantification. It has been suggested 
that wide discrepancies in the steady state plasma concentrations of tamoxifen and 
its metabolites reported by various groups were due to methodological differences in 
assay methods for which certain reported methods were not able to separate the (E)- 
and (Z)-isomers of the metabolites (427). However, the plasma concentrations of 




Table 3.2 Plasma Concentrations of Analytes (ng/ml) in Asians (N=202) and Caucasians (N=236). 




Asians (N=202) Caucasians (N=236) 
L 
 
Tamoxifen TAM 199.19 (39.18 – 463.20) 150.50 (24.63 – 328.20) 
N-desmethyltamoxifen NDM 355.19 (50.68 – 896.21) 251.42 (79.61 – 719.98) 
(Z)-Endoxifen (Z)-END 15.75 (2.06 – 52.84) 10.35 (1.16 – 30.40) 
(E)-Endoxifen (E)-END 0.19 (0.03 – 6.64) 0.13 (0.04 – 13.17) 
(Z)-4-hydroxytamoxifen (Z)-4-OHT 2.67 (0.47 – 7.17) 2.22 (0.28 – 4.95) 
(E)-4-hydroxytamoxifen (E)-4-OHT 0.03 (0.02 – 1.00) 0.09 (0.04 – 2.78) 
Tamoxifen-N-Glucuronide Tam-N-Gluc 1.01 (0.15 – 11.09) 0.88 (0.19 – 14.30) 
(E)-N-desmethyltamoxifen-4-O-
glucuronide 
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 0.76 (0.10 – 4.66) 
(Z)-N-desmethyltamoxifen-4-O-
glucuronide 
(Z)-NDM-4-O-Gluc 0.26 (0.02 – 1.81) 0.24 (0.04 – 1.67) 
(E)-Tamoxifen-4-O-glucuronide (E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.28 (0.04 – 2.26) 
(Z)-Tamoxifen-4-O-glucuronide (Z)-Tam-4-O-Gluc 0.03 (0.03 – 0.24) 0.08 (0.04 – 1.54) 
(Z)-4-hydroxytamoxifen-N-
glucuronide 
(Z)-4-OHT-N-Gluc 0.05 (0.04 – 0.14)  NA 
Tamoxifen-N-Oxide Tam-NO 11.25 (1.93 – 34.87) 11.20 (2.98 – 42.78) 
3-hydroxytamoxifen 3-OHT 0.36 (0.03 – 1.05) 0.26 (0.07 – 1.10) 
3′-hydroxytamoxifen 3'-OHT 0.41 (0.16 – 1.32)  NA 
(Z)-4′-hydroxytamoxifen (Z)-4′-OHT 4.33 (0.80 – 10.54) 3.31 (0.52 – 10.07) 
(E)-4′-hydroxytamoxifen (E)-4′-OHT 0.03 (0.03 – 1.04) 0.14 (0.05 – 1.94) 
α-hydroxytamoxifen α-OHT 0.52 (0.09 – 3.80) 0.36 (0.05 – 1.99) 
N,N-didesmethyltamoxifen NDDM 55.92 (7.06 – 169.55) 31.70 (9.62 – 103.73) 
3-hydroxy-N-desmethyltamoxifen 3-OH-NDM 1.63 (0.80 – 4.93) 1.11 (0.16 – 4.30) 
3′-hydroxy-N-desmethyltamoxifen 3'-OH-NDM 0.88 (0.34 – 2.65)  NA 
(Z)-4′-hydroxy-N-
desmethyltamoxifen 
(Z)-4′-OH-NDM 9.56 (1.17 – 22.13) 7.69 (1.57 – 19.46) 
(E)-4′-hydroxy-N-
desmethyltamoxifen 
(E)-4′-OH-NDM 0.14 (0.02 – 2.59) 0.19 (0.08 – 5.93) 
α-hydroxy-N-desmethyltamoxifen α-OH-NDM 1.09 (0.19 – 6.70) 1.11 (0.15 – 5.84) 
(Z)-4-hydroxy-N,N-
didesmethyltamoxifen 
(Z)-4-OH-NDDM 1.33 (0.26 – 3.36)  NA 
N-desmethyltamoxifen-3-O-
glucuronide 
NDM-3-O-Gluc 2.92 (0.31 – 25.88) 2.16 (0.35 – 15.64) 
N-desmethyltamoxifen-3′-O-
glucuronide 
NDM-3'-O-Gluc 2.14 (0.22 – 20.06)  NA 
Tamoxifen-3-O-glucuronide Tam-3-O-Gluc 0.97 (0.11 – 11.77) 0.65 (0.06 – 5.11) 
Tamoxifen-3′-O-glucuronide Tam-3'-O-Gluc 2.67 (0.23 – 20.82)  NA 
† UK, Unknown; NA, Not available; LLOQ, Lower limit of quantification 
‡ Data taken from Murdter et al (118) 
§ Plasma concentrations of analytes reflected were quantified using LC-MS method 
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Table 3.2 Plasma Concentrations of Analytes (ng/ml) in Asians (N=202) and Caucasians (N=236) (continued). 















Tamoxifen TAM 205.36 ± 78.29 159.12 ± 58.44 38.12 36.73 
N-desmethyltamoxifen NDM 385.72 ± 148.24 272.69 ± 106.35 38.43 39.00 
(Z)-Endoxifen (Z)-END 17.95 ± 10.60 10.87 ± 5.38 59.06 49.49 
(E)-Endoxifen (E)-END 0.26 ± 0.61 0.44 ± 1.33 238.47 302.27 
(Z)-4-hydroxytamoxifen (Z)-4-OHT 2.98 ± 1.29 2.25 ± 0.84 43.24 37.33 
(E)-4-hydroxytamoxifen (E)-4-OHT 0.04 ± 0.09 0.22 ± 0.41 219.21 186.36 
Tamoxifen-N-Glucuronide Tam-N-Gluc 1.36 ± 1.36 1.37 ± 1.72 99.66 125.55 
(E)-N-desmethyltamoxifen-4-
O-glucuronide 
(E)-NDM-4-O-Gluc 1.55 ± 2.84 0.97 ± 0.78 183.33 80.41 
(Z)-N-desmethyltamoxifen-4-
O-glucuronide 
(Z)-NDM-4-O-Gluc 0.35 ± 0.30 0.29 ± 0.20 83.85 68.97 
(E)-Tamoxifen-4-O-
glucuronide 
(E)-Tam-4-O-Gluc 0.45 ± 0.78 0.34 ± 0.26 171.63 76.47 
(Z)-Tamoxifen-4-O-
glucuronide 
(Z)-Tam-4-O-Gluc 0.04 ± 0.03 0.32 ± 0.44 71.28 137.50 
(Z)-4-hydroxytamoxifen-N-
glucuronide 
(Z)-4-OHT-N-Gluc 0.07 ± 0.03 NA 48.40 NA 
Tamoxifen-N-Oxide Tam-NO 12.38 ± 6.12 12.09 ± 6.24 49.43 51.61 
3-hydroxytamoxifen 3-OHT 0.39 ± 0.18 0.28 ± 0.13 47.18 46.43 
3′-hydroxytamoxifen 3'-OHT 0.45 ± 0.20 NA 43.35 NA 
(Z)-4′-hydroxytamoxifen (Z)-4′-OHT 4.49 ± 1.67 3.53 ± 1.37 37.18 38.81 
(E)-4′-hydroxytamoxifen (E)-4′-OHT 0.04 ± 0.08 0.24 ± 0.28 238.62 116.67 
α-hydroxytamoxifen α-OHT 0.61 ± 0.41 0.40 ± 0.23 66.87 57.50 
N,N-didesmethyltamoxifen NDDM 60.94 ± 24.53 33.66 ± 14.46 40.25 42.96 
3-hydroxy-N-
desmethyltamoxifen 
3-OH-NDM 1.81 ± 0.82 1.18 ± 0.62 45.22 52.54 
3′-hydroxy-N-
desmethyltamoxifen 
3'-OH-NDM 0.94 ± 0.37 NA 38.65 NA 
(Z)-4′-hydroxy-N-
desmethyltamoxifen 
(Z)-4′-OH-NDM 10.23 ± 3.73 7.96 ± 2.99 36.46 37.56 
(E)-4′-hydroxy-N-
desmethyltamoxifen 
(E)-4′-OH-NDM 0.19 ± 0.28 0.37 ± 0.57 145.28 154.05 
α-hydroxy-N-
desmethyltamoxifen 
α-OH-NDM 1.16 ± 0.61 1.25 ± 0.65 52.58 52.00 
(Z)-4-hydroxy-N,N-
didesmethyltamoxifen 
(Z)-4-OH-NDDM 1.45 ± 0.59 NA 41.08 NA 
N-desmethyltamoxifen-3-O-
glucuronide 
NDM-3-O-Gluc 4.00 ± 3.65 2.66 ± 1.96 91.32 73.68 
N-desmethyltamoxifen-3′-O-
glucuronide 
NDM-3'-O-Gluc 2.72 ± 2.00 NA 73.65 NA 
Tamoxifen-3-O-glucuronide Tam-3-O-Gluc 1.28 ± 1.19 0.75 ± 0.52 93.06 69.33 
Tamoxifen-3′-O-glucuronide Tam-3'-O-Gluc 3.36 ± 2.65 NA 79.02 NA 
† UK, Unknown; NA, Not available; LLOQ, Lower limit of quantification 
‡ Data taken from Murdter et al (118) 
§ Plasma concentrations of analytes reflected were quantified using LC-MS method 
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Table 3.2 Plasma Concentrations of Analytes (ng/ml) in Asians (N=202) and Caucasians (N=236) (continued). 
























Tamoxifen TAM 0.50 0 0.0 0 
N-desmethyltamoxifen NDM 1.00 0 0.0 0 
(Z)-Endoxifen (Z)-END 0.10 0 0.0 0 
(E)-Endoxifen (E)-END 0.05 46 22.8 9.7 
(Z)-4-hydroxytamoxifen (Z)-4-OHT 0.05 0 0.0 0 
(E)-4-hydroxytamoxifen (E)-4-OHT 0.05 51 25.3 69.3 
Tamoxifen-N-Glucuronide Tam-N-Gluc 0.05 0 0.0 2.9 
(E)-N-desmethyltamoxifen-4-O-
glucuronide 
(E)-NDM-4-O-Gluc 0.05 0 0.0 0 
(Z)-N-desmethyltamoxifen-4-O-
glucuronide 
(Z)-NDM-4-O-Gluc 0.05 1 0.5 3.8 
(E)-Tamoxifen-4-O-glucuronide (E)-Tam-4-O-Gluc 0.05 0 0.0 9.2 
(Z)-Tamoxifen-4-O-glucuronide (Z)-Tam-4-O-Gluc 0.05 129 63.9 77.3 
(Z)-4-hydroxytamoxifen-N-
glucuronide 
(Z)-4-OHT-N-Gluc UK 189 93.6 NA 
Tamoxifen-N-Oxide Tam-NO 0.20 0 0.0 0 
3-hydroxytamoxifen 3-OHT 0.05 3 1.5 0.4 
3′-hydroxytamoxifen 3'-OHT UK 13 6.4 NA 
(Z)-4′-hydroxytamoxifen (Z)-4′-OHT 0.05 0 0.0 0 
(E)-4′-hydroxytamoxifen (E)-4′-OHT 0.05 198 98.0 57.6 
α-hydroxytamoxifen α-OHT 0.02 0 0.0 0 
N,N-didesmethyltamoxifen NDDM 0.20 0 0.0 0 
3-hydroxy-N-desmethyltamoxifen 3-OH-NDM UK 25 12.4 0 
3′-hydroxy-N-desmethyltamoxifen 3'-OH-NDM UK 6 3.0 NA 
(Z)-4′-hydroxy-N-
desmethyltamoxifen 
(Z)-4′-OH-NDM 0.05 0 0.0 0 
(E)-4′-hydroxy-N-
desmethyltamoxifen 
(E)-4′-OH-NDM 0.05 32 15.8 19.3 
α-hydroxy-N-desmethyltamoxifen α-OH-NDM UK 0 0.0 0 
(Z)-4-hydroxy-N,N-
didesmethyltamoxifen 
(Z)-4-OH-NDDM UK 0 0.0 NA 
N-desmethyltamoxifen-3-O-
glucuronide 
NDM-3-O-Gluc UK 0 0.0 0 
N-desmethyltamoxifen-3′-O-
glucuronide 
NDM-3'-O-Gluc UK 0 0.0 NA 
Tamoxifen-3-O-glucuronide Tam-3-O-Gluc UK 0 0.0 2.1 
Tamoxifen-3′-O-glucuronide Tam-3'-O-Gluc UK 0 0.0 NA 
† UK, Unknown; NA, Not available; LLOQ, Lower limit of quantification 
‡ Data taken from Murdter et al (118) 
§ Plasma concentrations of analytes reflected were quantified using LC-MS method 
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Table 3.3 Comparison of parameters derived from HPLC-fluorescence and LC-MS methods (N=163). 






  LC-MS 
L














   
Tamoxifen TAM 204.94 (39.26 – 599.91) 200.33 (39.18 – 463.20) 222.55 ± 95.11 210.17 ± 81.14 42.74 38.61 
N-
desmethyltamoxifen 
NDM 302.95 (40.82 – 802.98) 362.81 (50.68 – 896.21) 331.48 ± 130.96 393.81 ± 152.16 39.51 38.64 
(Z)-Endoxifen (Z)-END 13.69 (1.74 – 42.80) 16.45 (2.06 – 52.84) 15.50 ± 8.75 18.23 ± 10.50 56.45 57.59 
(Z)-4-
hydroxytamoxifen 
(Z)-4-OHT 1.96 (0.47 – 5.33) 2.76 (0.47 – 7.17) 2.21 ± 0.94 3.03 ± 1.28 42.33 42.36 
Phase I Metabolic Ratios Median (Range) Mean ± SD CV (%) 
Metabolic Ratios 
(MRs) 
Formula  HPLC-fluorescence 
†
  LC-MS 
L














   
MRNDM/TAM CNDM/CTAM 1.56 (0.62 – 2.76) 1.94 (0.82 – 3.17) 1.55 ± 0.36 1.92 ± 0.41 23.32 21.10 
MRZ-END/NDM 
§
 CEND/CNDM (×100) 4.97 (0.92 – 27.81) 4.56 (1.03 – 29.09) 5.27 ± 3.53 5.15 ± 3.46 66.97 67.15 
MRZ-4-OHT/TAM 
§
 CZ-4-OHT/CTAM (×100) 1.01 (0.19 – 2.35) 1.43 (0.41 – 3.13) 1.07 ± 0.40 1.51 ± 0.52 37.73 34.44 
MRZ-END/Z-4-OHT CZ-END/CZ-4-OHT 
6.90 (1.99 – 13.18) 5.97 (1.85 – 12.63) 6.88 ± 2.30 5.87 ± 1.85 33.43 31.47 
† Plasma concentrations of analytes determined using HPLC-fluoresence method in Asian breast cancer patients (N=163). 
‡ Plasma concentrations of analytes determined using LC-MS method in Asian breast cancer patients (N=163). 
§ The metabolic ratios were multiplied by 100 to reduce  the number of decimal points for ease of analysis as the original ratios were much lower than one. 
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Table 3.4 Comparison of plasma concentrations of analytes between different Asian ethnic groups. 




Overall (n=202) Chinese (n=168) Malays (n=15) Indians (n=19) 
Tamoxifen TAM 199.19 (39.18 – 463.20) 200.28 (39.87 – 463.20) 213.75 (39.18 – 310.56) 169.53 (113.26 – 347.01) 
N-desmethyltamoxifen NDM 355.19 (50.68 – 896.21) 362.66 (50.68 – 896.21) 389.07 (98.59 – 652.24) 337.59 (142.51 – 676.10) 
(Z)-Endoxifen (Z)-END 15.75 (2.06 – 52.84) 15.85 (2.06 – 52.84) 11.81 (2.18 – 34.92) 22.80 (9.05 – 42.23) 
(E)-Endoxifen (E)-END 0.19 (0.03 – 6.64) 0.18 (0.03 – 6.64) 0.18 (0.03 – 4.88) 0.21 (0.03 – 0.38) 
(Z)-4-hydroxytamoxifen (Z)-4-OHT 2.67 (0.47 – 7.17) 2.69 (0.70 – 7.17) 2.43 (0.47 – 4.41) 3.26 (1.52 – 5.87) 
(E)-4-hydroxytamoxifen (E)-4-OHT 0.03 (0.02 – 1.00) 0.03 (0.02 – 0.81) 0.03 (0.02 – 1.00) 0.03 (0.02 – 0.05) 
Tamoxifen-N-Glucuronide Tam-N-Gluc 1.01 (0.15 – 11.09) 1.03 (0.15 – 11.09) 1.03 (0.23 – 2.23) 0.94 (0.28 – 3.53) 
(E)-N-desmethyltamoxifen-4-
O-glucuronide 
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 0.90 (0.07 – 29.78) 0.91 (0.22 – 5.64) 1.47 (0.40 – 3.83) 
(Z)-N-desmethyltamoxifen-4-
O-glucuronide 
(Z)-NDM-4-O-Gluc 0.26 (0.02 – 1.81) 0.26 (0.02 – 1.81) 0.22 (0.05 – 1.46) 0.33 (0.10 – 0.93) 
(E)-Tamoxifen-4-O-
glucuronide 
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.28 (0.05 – 8.14) 0.26 (0.07 – 1.28) 0.39 (0.12 – 0.99) 
Tamoxifen-N-Oxide Tam-NO 11.25 (1.93 – 34.87) 11.34 (1.93 – 34.87) 9.87 (1.93 – 25.33) 10.70 (4.57 – 21.18) 
3-hydroxytamoxifen 3-OHT 0.36 (0.03 – 1.05) 0.36 (0.03 – 1.05) 0.31 (0.03 – 0.62) 0.36 (0.09 – 0.80) 
3′-hydroxytamoxifen 3'-OHT 0.41 (0.16 – 1.32) 0.42 (0.17 – 1.32) 0.36 (0.21 – 0.73) 0.38 (0.16 – 0.75) 
(Z)-4′-hydroxytamoxifen (Z)-4′-OHT 4.33 (0.80 – 10.54) 4.37 (0.80 – 10.54) 3.55 (1.52 – 7.32) 4.33 (1.99 – 9.84) 
α-hydroxytamoxifen α-OHT 0.52 (0.09 – 3.80) 0.53 (0.10 – 3.80) 0.57 (0.09 – 0.91) 0.46 (0.28 – 0.88) 
N,N-didesmethyltamoxifen NDDM 55.92 (7.06 – 169.55) 55.93 (7.06 – 169.55) 55.60 (10.03 – 105.49) 65.97 (27.78 – 130.51) 
3-hydroxy-N-
desmethyltamoxifen 
3-OH-NDM 1.63 (0.80 – 4.93) 1.62 (0.80 – 4.93) 1.46 (0.80 – 3.18) 1.79 (0.98 – 3.90) 
3′-hydroxy-N-
desmethyltamoxifen 
3'-OH-NDM 0.88 (0.34 – 2.65) 0.88 (0.34 – 2.65) 0.85 (0.48 – 1.60) 0.88 (0.50 – 1.63) 
(Z)-4′-hydroxy-N-
desmethyltamoxifen 
(Z)-4′-OH-NDM 9.56 (1.17 – 22.13) 9.66 (1.17 – 22.13) 8.87 (3.04 – 16.60) 8.04 (3.21 – 17.89) 
(E)-4′-hydroxy-N-
desmethyltamoxifen 
(E)-4′-OH-NDM 0.14 (0.02 – 2.59) 0.13 (0.02 – 2.59) 0.16 (0.02 – 1.86) 0.11 (0.02 – 0.25) 
α-hydroxy-N-
desmethyltamoxifen 
α-OH-NDM 1.09 (0.19 – 6.70) 1.10 (0.19 – 6.70) 1.16 (0.19 – 1.58) 0.97 (0.41 – 1.86) 
(Z)-4-hydroxy-N,N-
didesmethyltamoxifen 
(Z)-4-OH-NDDM 1.33 (0.26 – 3.36) 1.36 (0.26 – 3.36) 1.27 (0.30 – 2.21) 1.14 (0.57 – 3.11) 
† Plasma concentrations of analytes reflected were quantified using LC-MS method 
‡ The metabolic ratios were multiplied by 100 to reduce  the number of decimal points for ease of analysis as the original ratios were much lower than one. 
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Table 3.4. Comparison of plasma concentrations of analytes between different Asian ethnic groups (continued). 




Overall (n=202) Chinese (n=168) Malays (n=15) Indians (n=19) 
N-desmethyltamoxifen-3-O-
glucuronide 
NDM-3-O-Gluc 2.92 (0.31 – 25.88) 2.91 (0.31 – 25.88) 2.73 (0.58 – 13.70) 3.50 (1.45 – 8.90) 
N-desmethyltamoxifen-3′-O-
glucuronide 
NDM-3'-O-Gluc 2.14 (0.22 – 20.06) 2.14 (0.22 – 20.06) 1.93 (0.6 – 5.10) 2.18 (1.05 – 7.28) 
Tamoxifen-3-O-glucuronide Tam-3-O-Gluc 0.97 (0.11 – 11.77) 0.97 (0.11 – 11.77) 0.84 (0.16 – 2.81) 1.01 (0.51 – 3.45) 
Tamoxifen-3′-O-glucuronide Tam-3'-O-Gluc 2.67 (0.23 – 20.82) 2.73 (0.23 – 20.82) 2.23 (0.45 – 8.37) 2.70 (0.72 – 13.27) 
Metabolic Ratios (MRs)                 
MRs Formula                 
MRNDM/TAM CNDM/CTAM 1.95 (0.82 – 4.27) 1.96 (0.82 – 4.27) 1.96 (1.44 – 2.58) 1.72 (1.24 – 2.40) 
MRZ-END/NDM
 L
 CEND/CNDM (×100) 4.54 (1.03 – 39.05) 4.51 (1.03 – 39.05) 2.39 (1.25 – 10.4) 6.11 (1.41 – 11.84) 
MRZ-4-OHT/TAM 
L
 CZ-4-OHT/CTAM (×100) 1.44 (0.41 – 4.03) 1.44 (0.41 – 4.03) 1.14 (0.74 – 2.71) 1.59 (0.54 – 3.12) 










6.15 (2.20 – 80.56) 5.92 (2.20 – 80.56) 7.95 (2.99 – 23.68) 6.60 (3.90 – 16.96) 





10.52 (4.05 – 174.19) 10.15 (4.05 – 174.19) 14.25 (5.86 – 36.24) 12.06 (6.67 – 30.65) 
† Plasma concentrations of analytes reflected were quantified using LC-MS method 
‡ The metabolic ratios were multiplied by 100 to reduce  the number of decimal points for ease of analysis as the original ratios were much lower than one. 
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The median and ranges of variations in the plasma concentrations of the four 
analytes were also similar between the two methods as shown in Table 3.3. Using 
either analytical methods, the inter-individual variations in plasma concentrations of 
tamoxifen, NDM and (Z)-4-OHT were found to vary between 11- to 20-fold while that 
for endoxifen varied by more than 24-fold. Variations in the steady state plasma 
concentrations of tamoxifen and its three metabolites were consistent with that 
reported by other investigators (118, 141). The median plasma concentrations of 
tamoxifen, NDM, 4-OHT and endoxifen in the breast cancer patients are listed in 
Tables 3.3 and 3.4. High degree of interindividual variations was also observed for 
the MR (5- to 46-fold) and the TMR (25- to 35- fold). None of the patients were 
prescribed CYP2D6 inhibitors while they were receiving tamoxifen.  
Correlations between the plasma concentrations and the baseline characteristics of 
subjects were examined by means of Spearman’s correlation coefficients. Age 
significantly correlated with several of the metabolites, including tamoxifen, NDM, 
(Z)-endoxifen and their glucuronides but not with (E)- or (Z)-isomers of 4-OHT. 
Associations were also observed between indicators of body mass with inverse 
correlations observed between height or weight and plasma levels of the various 
metabolites were observed. In addition, menopausal status was also associated with 
plasma concentration of (Z)-Tam-4-O-Gluc. This might indicate an influence of 
hormonal status on individuals’ metabolic capacity for tamoxifen. 
 As plasma concentrations of various metabolites are influenced by multiple enzymes 
and can be metabolized to several secondary metabolites, metabolic ratios which are 
ratios of the steady state plasma concentrations of any two metabolites involved in 
specific pathway were examined in this study. The metabolic ratios were found to be 
associated with changes in height, weight and menopausal status of patients. Other 
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baseline characteristics such as prior radiotherapy, prior chemotherapy, cancer 
stage, hormone receptor status were not found to be strongly associated with the 
plasma concentrations of the analytes and the metabolic ratios.  
Among the 29 metabolites assayed by LC-MS method, 11 metabolites were found to 
be present at concentrations below the lower limit of quantification in varying 
numbers of patients (Table 3.2). Concentrations which were lower than the lower 
limit of quantification were taken as half the concentration of the limit of 
quantification. However, the plasma concentrations of two of these 11 metabolites, 
(E)-4′-hydroxytamoxifen [(E)-4′-OHT] and (Z)-4-hydroxytamoxifen-N-glucuronide [(Z)-
4-OHT-N-Gluc] were found to be lower than the limit of quantification in more than 
90% of all Asian patients. Plasma concentrations of (Z)-Tam-4-O-Gluc [(Z)-Tam-4-O-
Gluc] were also lower than the limit of quantification in 63.9% of the study population. 
Hence, these three metabolites were removed from subsequent analyses.  
The phase II metabolite, (Z)-4-OHT-N-Gluc, is an N-glucuronide of the active 
metabolite, (Z)-4-OHT, as previously reported by Ogura et al (130). Although the 
investigators observed the formation of both O- and N-glucuronides from (E)- and 
(Z)-4-OHT in human liver microsomes, the rate of N-glucuronidation of (Z)-4-OHT 
was found to be higher than that of O-glucuronidation. In contrast, the rate of N-
glucuronidation for (E)-4-OHT was found to be negligible at a rate of 2% of that 
observed for O-glucuronidation of (E)-4-OHT (130). This led to the postulation that 
the N-glucuronidation pathway of (Z)-4-OHT might be more important than O-
glucuronidation (130). However, majority of Asian patients in the current study was 
found to have extremely low levels of (Z)-4-OHT-N-Gluc compared to the O-
glucuronides. This indicates that O-glucuronidation pathway in particular that of the 
(Z)-4-OHT might be a more prevalent phase II mechanism mediating the elimination 
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of 4-OHT in human subjects in constrast to findings from in vitro findings. The higher 
in vivo levels of (E)-Tam-4-O-Gluc, the O-glucuronide of (Z)-4-OHT, might also imply 
significant contributions from extrahepatic UGT isoforms to the O-glucuronidation of 
(Z)-4-OHT. Consistently, Sun et al (129) has previously reported the involvement of 
UGT1A8 and UGT1A10 in the O-glucuronidation of both 4-OHT and endoxifen as 
opposed to N-glucuronidation of (Z)-4-OHT for which only UGT1A4 was involved.  
Another metabolite, (E)-endoxifen, was also found to be present at low concentration 
among Asian patients [median (range): 0.19 (0.03 − 6.64) ng/ml] with 22.3% of the 
study population exhibiting concentrations below the limit of quantification (Table 
3.2). This level was much higher compared to the 9.7% reported in German patients 
(118) suggesting that the E/Z isomerization of endoxifen might be more prevalent in 
Caucasian than in Asian subjects. Although the plasma concentrations of (E)-
endoxifen were low, the median plasma level of its O-glucuronide, (Z)-NDM-4-O-
Gluc, was present at 1.4-fold higher with only one patient having level below the 
quantification limit. The median MR indicating the relative glucuronidation of (E)-
endoxifen, MRZ-NDM-4-O-Gluc/E-END, was found to be 27.5-fold higher than the 
corresponding MR for (Z)-endoxifen, MRE-NDM-4-O-Gluc/Z-END. Similar trends were 
observed in relation to the O-glucuronidation of 4-OHT where the MR indicating the 
O-glucuronidation of (E)-4-OHT, MRZ-Tam-4-O-Gluc/E-4-OHT, was much higher (9.7-fold) 
than that of (Z)-4-OHT, MRE-Tam-4-O-Gluc/Z-4-OHT (Table 3.4). Taken together, these 
observations indicated greater extent of glucuronidations of the (E)-isomers of the 
active metabolites, 4-OHT and endoxifen. This was in concordance with previous 
enzymatic assays performed by Nishiyama et al (428) who highlighted the geometric 
selectivity with regard to glucuronidation and sulfation of the metabolites. UGTs were 
 132
found to preferentially glucuronidate (E)-4-OHT while SULTs selectively sulfonate 
(Z)-4-OHT.  
Besides differences observed among analytes with low concentrations, much higher 
plasma concentrations of tamoxifen, (Z)-endoxifen and (E)-NDM-4-O-Gluc of 
approximately 1.3- to 1.5-fold difference were observed in the Asian population 
compared to the Caucasian subjects. However, intra-ethnic variations in the plasma 
concentrations of these metabolites in the Asian ethnic group were found to be 
similar with reports from the Caucasians. The Asian breast cancer patient cohort also 
exhibit 1.4-fold higher plasma NDM concentration with greater inter-individual 
variations compared to the Caucasian population.  
Previous studies have highlighted that differences in plasma levels of tamoxifen 
metabolites reported in various studies may not be entirely due to ethnic variations 
Firstly, different assay methods for the measurement of the metabolite 
concentrations were employed in these two studies (427, 429). Difference in the 
sensitivities of the analytical instruments might contribute to the variations in the 
results. Moreover, in a recent comparison of two LC-MS/MS analytical methods for 
tamoxifen and its metabolites, Jager et al (427) highlighted the importance of 
selective analytical methods for the accurate quantification of the analytes and that 
difference in analytical methodology may contribute to the difference as well as 
variations in analyte plasma concentration reported in the literature. The 
investigators observed discrepancies between the plasma concentrations measured 
via two different methods using the same instruments with one of the LC-MS/MS-
based methods reporting a 2– to 3– fold overestimation of the endoxifen and 4-OHT 
levels due to lower selectivity for analytes of similar masses and fragmentation 
patterns (427). However, the comparison of analyte plasma concentrations between 
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the Asians and Caucasians was based on LC-MS quantification using the same 
analytical method, instrument and location (118). Hence, the inter-ethnic variations 
observed could not be due to technical issues. 
Secondly, therapeutic compliance or adherence to treatment regimen in patients may 
partially account for the disparity in the results. Monitoring of treatment compliance 
was not routinely reported in reported studies (133) and it has been previously 
reported that non-compliance can be as higher as 80% among tamoxifen treated 
patients (430). With respect to the data derived from Caucasian patients included in 
the Table 3.2, monitoring of treatment compliance was not mentioned (118). 
However, serial blood sampling at six months and one year following 
commencement of therapy showed high concordance between the plasma levels of 
the metabolites, indicating compliance to treatment. Co-medications received by 
patients were also noted down by Murdter el al (118) in this study. In this study 
involving Asian subjects, adherence to treatment regimen was monitored by means 
of pill diary where patients were asked record any incident of missing doses and 
information on the concomitant medications received by recruited patients during the 
course of treatment with tamoxifen was also tracked. In addition, all Asian patients 
included in the current prospective study were not receiving any inhibitors of 
CYP2D6 which could affect the plasma levels of the analytes concurrently. Thus, the 
disparities observed in the plasma concentrations of the analytes among the Asians 
and Caucasians were likely generic inter-ethnic variations.  
Among the 202 Asian patients included in the second phase of the study, 168 
subjects were Chinese, 15 were Malays and 19 were Indians. The median and 
ranges of the plasma concentrations of the metabolites at steady state within each 
ethnic group are listed in Table 3.4. Differences in the median levels of the analytes 
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were examined via pairwise non-parametric statistics. The plasma concentration of 
(E)-NDM-4-O-Gluc was found to differ between subjects from different ethnic 
background. The median level of (E)-NDM-4-O-Gluc was found to be similar 
between Chinese and Malay subjects but 1.6-fold higher in the Indians (P = 0.12). 
Correspondingly, Indian subjects were observed to have median plasma (Z)-
endoxifen levels of 1.4- and 1.9-fold higher than the Chinese subjects. The higher 
plasma concentration of (E)-NDM-4-O-Gluc appeared to be due to elimination of 
increased amount of (Z)-endoxifen in the Indian subjects. This might suggest greater 
activity of the phase I enzymes in Indian patients.  
Recently, Lu et al (160, 161)reported aromatase inhibitory activity with several 
metabolites of tamoxifen of which the greatest inhibition was observed with 
norendoxifen or (Z)-4-hydroxy-N,N-didesmethyltamoxifen with IC50 of 30 nM or 10.78 
ng/ml. The compound was found to selectively inhibit aromatase but not other CYP 
enzymes. Interestingly, this metabolite was present at detectable levels with median 
concentration of 1.33 ng/ml (range: 0.26 − 3.36 ng/ml) (161). Although the plasma 
concentration of this metabolite was much lower than the reported IC50, the 
concentration at the target tissue is currently unknown. It has been previously 
reported that tamoxifen and its metabolites accumulate in tissues at concentrations 
10- to 60-fold higher than the plasma concentrations (110-114). Hence, the clinical 
relevance of this metabolite remains to be determined.  
It has been recently reported by Madlensky et al (174)that a minimum endoxifen 
concentration of 5.97 ng/ml is required for the patient to experience clinical efficacy. 
However, given the complex metabolism of tamoxifen to form a wide range of 
metabolites with varying activities, the therapeutic effects of tamoxifen is unlikely to 
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be due to any single metabolite. Hence, future studies investigating the PK-PD 
relationship of tamoxifen therapy should examined the combined action of all 
metabolites.  
In summary, the metabolism of tamoxifen was found to be highly complex. Thus far, 
29 metabolites were quantified in the Asian patient cohort and steady state plasma 
concentrations of these metabolites were found to vary widely between patients. 
Ethnic differences in the plasma concentrations of the analytes were noted between 
Asian and Caucasians. Various causative factors, genetic and non-genetic, 
contributing to these variations have been suggested and the effects of various 
genetic factors remain to be elucidated. 
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3.3 Pharmacogenetics of Phase I Drug Metabolizing Enzymes 
3.3.1 Cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) 
3.3.1.1 Genetic Analysis of CYP1A2 
A total of 25 polymorphisms were detected during the screening of CYP1A2 in 126 
healthy individuals belonging to three distinct Asian populations (431). There were 11 
polymorphisms detected in the 5’ transcriptional regulatory region, four in the exonic 
regions, nine in the intronic regions and one in the 3’ untranslated region (Fig 3.1). 
Nine of the 25 polymorphisms (-2602insA, -202C>A, -114G>A, IVS4+92G>A, 
1049T>G, IVS5+199C>T, IVS6+418C>T, 1459G>A and 1503C>T) were novel SNPs 
with minor allele frequencies of 5% or less in each of the three ethnic groups (Table 
3.5). With regards to the four exonic SNPs, two were synonymous polymorphisms 
[1503C>T and 1548C>T (*1B, rs2470890)] while the other two were non-
synonymous polymorphisms (1049T>G, V350G; and 1459G>A, V487M).  
There were wide interethnic differences in the allelic frequencies of the CYP1A2 
polymorphic variants in the Asian population. Among the 25 SNPs, 8 SNPs were 
polymorphic in only specific Asian ethnic groups with minor allelic frequencies 
ranging between 0.01 and 0.05 (Table 3.5): -2602insA, -202C>A, -114G>A and 
1503C>T in the Chinese population; 1049T>G and IVS5+199C>T in the Malay 
population and IVS2-99G>A (rs34264399) and IVS4+92G>A in the Indian population. 
The -2808A>C (rs12592480) and -733G>C (rs28399417) SNPs were present in both 
the Chinese and Malay populations but monomorphic in the Indian population. The -
2467delT (*1D, rs35694136) and -163C>A (*1F, rs762551) SNPs were detected at 
high frequencies in the Asian ethnic groups with similar frequencies in the Chinese 
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and Malay populations but different from those observed in the Indian healthy 
population (Table 3.5). Significant interethnic differences were observed with regards 
to the genotypic distribution of IVS2-99G>A (rs34264399) (P < 0.01) and 1548C>T 
(*1B, rs2470890) (P = 0.05) SNPs across all three Asian populations (Table 3.5).  
 
 
Fig 3.1 Polymorphisms present in CYP1A2 Gene (UCSC RefSeq: NM_000761) 
(431). 
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Table 3.5 Genotypic and allelic frequencies of polymorphisms in CYP1A2 (UCSC RefSeq: NM_000761). 
SN SNPs Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies (95% Confidence Interval) 




Healthy Subjects (N=42) 






Allele Chinese (N=42) Malays (N=42) Indians (N=42) 
1 -2847T>C TT 38 (90.5) 33 (82.5) 32 (82.1)   T 0.95 (0.91 – 1.00) 0.91 (0.85 – 0.97) 0.91 (0.85 – 0.97)  
 (rs2069522) TC 4 (9.5) 7 (17.5) 7 (17.9)   C 0.05 (0.00 – 0.09) 0.09 (0.03 – 0.15) 0.09 (0.03 – 0.15)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
2 -2808A>C AA 41 (97.6) 36 (90) 40 (100.0)   A 0.99 (0.97 – 1.01) 0.94 (0.88 – 0.99) 1.00 (1.00 – 1.00)  
 (rs12592480) AC 1 (2.4) 3 (7.5) 0 0.0   C 0.01 (-0.01 – 0.04) 0.06 (0.01 – 0.12) 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 1 (2.5) 0 (0.0)        
3 -2602InsA
#
 wt/wt 40 (95.2) 42 (100.0) 41 (100.0)   wt 0.98 (0.94 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  wt/InsA 2 (4.8) 0 (0.0) 0 (0.0)   InsA 0.02 (-0.01 – 0.06) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  InsA/InsA 0 (0.0) 0 (0.0) 0 (0.0)        
4 -2467delT wt/wt 4 (10.5) 7 (16.7) 12 (29.3) 32 (19.6) wt 0.34 (0.24 – 0.45) 0.39 (0.29 – 0.50) 0.54 (0.43 – 0.65) 0.47 (0.42 – 0.53) 
 (rs35694136, *1D) wt/delT 18 (47.4) 19 (45.2) 20 (48.8) 90 (55.2) delT 0.66 (0.55 – 0.77) 0.61 (0.50 – 0.71) 0.46 (0.36 – 0.57) 0.53 (0.47 – 0.58) 
  delT/delT 16 (42.1) 16 (38.1) 9 (22.0) 41 (25.2)      
5 -1804A>C/G AA 33 (91.7) 31 (91.2) 31 (81.6)   A 0.96 (0.91 – 1.00) 0.96 (0.91 – 1.01) 0.90 (0.83 – 0.96)  
 (rs2069524) AC 0 (0.0) 0 (0.0) 1 (2.6)   C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.04)  
  AG 3 (8.3) 3 (8.8) 5 (13.2)   G 0.04 (-0.00 – 0.09) 0.04 (-0.01 – 0.09) 0.09 (0.03 – 0.16)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
  CG 0 (0.0) 0 (0.0) 1 (2.6)        
  GG 0 (0.0) 0 (0.0) 0 (0.0)        
6 -1708T>C TT 33 (84.6) 30 (85.7) 33 (80.5)   T 0.91 (0.85 – 0.97) 0.91 (0.85 – 0.98) 0.90 (0.84 – 0.97)  
 (rs2069525) TC 5 (12.8) 4 (11.4) 8 (19.5)   C 0.09 (0.03 – 0.15) 0.09 (0.02 – 0.15) 0.10 (0.03 – 0.16)  
  CC 1 (2.6) 1 (2.9) 0 (0.0)        
7 -739T>G TT 39 (92.9) 36 (85.7) 33 (80.5) 129 (79.1) T 0.96 (0.93 – 1.00) 0.93 (0.87 – 0.98) 0.90 (0.84 – 0.97) 0.89 (0.86 – 0.93) 
 (rs2069526, *1E) TG 3 (7.1) 6 (14.3) 8 (19.5) 33 (20.2) G 0.04 (0.00 – 0.08) 0.07 (0.02 – 0.13) 0.10 (0.03 – 0.16) 0.11 (0.07 – 0.14) 
  GG 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)      
8 -733G>C GG 38 (90.5) 37 (88.1) 42 (100.0) 149 (91.4) G 0.94 (0.89 – 0.99) 0.93 (0.87 – 0.98) 1.00 (1.00 – 1.00) 0.95 (0.93 – 0.98) 
 (rs28399417) GC 3 (7.1) 4 (9.5) 0 (0.0) 13 (8.0) C 0.06 (0.01 – 0.11) 0.07 (0.02 – 0.13) 0.00 (0.00 – 0.00) 0.05 (0.02 – 0.07) 
  CC 1 (2.4) 1 (2.4) 0 (0.0) 1 (0.6)      
9 -202C>A
#
 CC 37 (94.9) 41 (100.0) 42 (100.0)   C 0.95 (0.90 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  CA 0 (0.0) 0 (0.0) 0 (0.0)   A 0.05 (0.00 – 0.10) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  AA 2 (5.1) 0 (0.0) 0 (0.0)        
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=42) vs Malays (N=42). 
‡ denotes P < 0.05, Malays (N=42) vs Indians (N=42). 
§ denotes P < 0.05, Chinese (N=42) vs Indians (N=42). 
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Table 3.5 Genotypic and allelic frequencies of polymorphisms in CYP1A2 (UCSC RefSeq: NM_000761) (Continued). 
SN SNPs Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies (95% Confidence Interval) 
Healthy Subjects (N=42) 
Patients 
(N=163) 
 Healthy Subjects (N=42) 






Allele Chinese (N=42) Malays (N=42) Indians (N=42) 
10 -163C>A CC 4 (10.5) 1 (2.6) 6 (14.3) 17 (10.4) C 0.29 (0.19 – 0.39) 0.22 (0.13 – 0.31) 0.42 (0.31 – 0.52) 0.34 (0.29 – 0.39) 
 (rs762551, *1F) CA 14 (36.8) 15 (38.5) 23 (54.8) 77 (47.2) A 0.71 (0.61 – 0.81) 0.78 (0.69 – 0.87) 0.58 (0.48 – 0.69) 0.66 (0.61 – 0.71) 
  AA 20 (52.6) 23 (59.0) 13 (31.0) 69 (42.3)      
11 -114G>A
#
 GG 40 (97.6) 41 (100.0) 42 (100.0)   G 0.98 (0.94 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  GA 0 (0.0) 0 (0.0) 0 (0.0)   A 0.02 (-0.01 – 0.06) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  AA 1 (2.4) 0 (0.0) 0 (0.0)        
12 IVS2-249C>T CC 38 (90.5) 35 (85.4) 34 (81.0)   C 0.95 (0.91 – 1.00) 0.93 (0.87 – 0.98) 0.91 (0.84 – 0.97)  
 (rs4646425) CT 4 (9.5) 6 (14.6) 8 (19.0)   T 0.05 (0.00 – 0.09) 0.07 (0.02 – 0.13) 0.10 (0.03 – 0.16)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)        
13 IVS2-99G>A GG 41 (100.0) 40 (100.0) 35 (85.4)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.93 (0.87 – 0.98)  
 (rs34264399) GA 0 (0.0) 0 (0.0) 6 (14.6)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.07 (0.02 – 0.13)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
14 IVS4+43G>A GG 33 (91.7) 28 (77.8) 34 (81.0) 123 (75.5) G 0.94 (0.89 – 1.00) 0.81 (0.71 – 0.90) 0.85 (0.77 – 0.92) 0.87 (0.83 – 0.90) 
 (rs2472304) GA 2 (5.6) 2 (5.6) 3 (7.1) 36 (22.1) A 0.06 (0.00 – 0.11) 0.19 (0.10 – 0.29) 0.16 (0.08 – 0.23) 0.13 (0.10 – 0.17) 
  AA 1 (2.8) 6 (16.7) 5 (11.9) 4 (2.5)      
15 IVS4+92G>A
#
 GG 41 (100.0) 40 (100.0) 39 (97.5)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.96 – 1.01)  
  GA 0 (0.0) 0 (0.0) 1 (2.5)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.04)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
16 IVS4-65G>C GG 23 (69.7) 22 (59.5) 22 (55)   G 0.83 (0.74 – 0.92) 0.77 (0.67 – 0.87) 0.71 (0.61 – 0.81)  
 (rs3743484) GC 9 (27.3) 13 (35.1) 13 (32.5)   C 0.17 (0.08 – 0.26) 0.23 (0.13 – 0.33) 0.29 (0.19 – 0.39)  
  CC 1 (3.0) 2 (5.4) 5 (12.5)        
17 1049T>G
#
 TT 38 (100.0) 37 (94.9) 40 (100.0)   T 1.00 (1.00 – 1.00) 0.95 (0.90 – 1.00) 1.00 (1.00 – 1.00)  
  TG 0 (0.0) 0 (0.0) 0 (0.0)   G 0.00 (0.00 – 0.00) 0.05 (0.00 – 0.10) 0.00 (0.00 – 0.00)  
  GG 0 (0.0) 2 (5.1) 0 (0.0)        
18 IVS5+199C>T
#
 CC 42 (100.0) 41 (97.6) 41 (100.0)   C 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.01) 1.00 (1.00 – 1.00)  
  CT 0 (0.0) 1 (2.4) 0 (0.0)   T 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.04) 0.00 (0.00 – 0.00)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)        
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=42) vs Malays (N=42). 
‡ denotes P < 0.05, Malays (N=42) vs Indians (N=42). 
§ denotes P < 0.05, Chinese (N=42) vs Indians (N=42). 
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Table 3.5 Genotypic and allelic frequencies of polymorphisms in CYP1A2 (UCSC RefSeq: NM_000761) (Continued). 
SN SNPs Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies (95% Confidence Interval) 
Healthy Subjects (N=42) 
Patients 
(N=163) 
 Healthy Subjects (N=42) 






Allele Chinese (N=42) Malays (N=42) Indians (N=42) 
19 IVS5-318G>C CC 24 (60.0) 26 (61.9) 21 (50.0)   C 0.79 (0.70 – 0.88) 0.76 (0.67 – 0.85) 0.66 (0.55 – 0.76)  
 (rs55711332) CT 15 (37.5) 12 (28.6) 13 (31.0)   T 0.21 (0.12 – 0.30) 0.24 (0.15 – 0.33) 0.35 (0.24 – 0.45)  
  TT 1 (2.5) 4 (9.5) 8 (19.0)        
20 IVS6+81T>C TT 31 (88.6) 31 (88.6) 33 (80.5)   T 0.94 (0.89 – 1.00) 0.94 (0.89 – 1.00) 0.90 (0.84 – 0.97)  
 (rs4646427) TC 4 (11.4) 4 (11.4) 8 (19.5)   C 0.06 (0.00 – 0.11) 0.06 (0.00 – 0.11) 0.10 (0.03 – 0.16)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
21 IVS6+418C>T
#
 CC 36 (97.3) 38 (95.0) 38 (90.5)   C 0.99 (0.96 – 1.01) 0.98 (0.94 – 1.01) 0.95 (0.91 – 1.00)  
  CT 1 (2.7) 2 (5.0) 4 (9.5)   T 0.01 (-0.01 – 0.04) 0.03 (-0.01 – 0.06) 0.05 (0.00 – 0.09)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)        
22 1459G>A
#
 GG 39 (97.5) 37 (97.4) 39 (92.9)   G 0.99 (0.96 – 1.01) 0.99 (0.96 – 1.01) 0.96 (0.93 – 1.00)  
  GA 1 (2.5) 1 (2.6) 3 (7.1)   A 0.01 (-0.01 – 0.04) 0.01 (-0.01 – 0.04) 0.04 (0.00 – 0.08)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
23 1503C>T
#
 CC 39 (97.5) 38 (100.0) 42 (100.0)   C 0.99 (0.96 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  CT 1 (2.5) 0 (0.0) 0 (0.0)   T 0.01 (-0.01 – 0.04) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)        
24 1548C>T CC 30 (75.0) 28 (73.7) 32 (76.2)   C 0.88 (0.80 – 0.95) 0.82 (0.73 – 0.90) 0.88 (0.81 – 0.95)  
 (rs2470890, *1E) CT 10 (25) 6 (15.8) 10 (23.8)   T 0.13 (0.05 – 0.20) 0.18 (0.10 – 0.27) 0.12 (0.05 – 0.19)  
  TT 0 (0.0) 4 (10.5) 0 (0.0)        
25 *1324C>G CC 20 (52.6) 19 (51.4) 17 (41.5) 84 (51.5) C 0.74 (0.64 – 0.84) 0.68 (0.57 – 0.78) 0.62 (0.52 – 0.73) 0.71 (0.66 – 0.76) 
 (rs17861162) CG 16 (42.1) 12 (32.4) 17 (41.5) 63 (38.7) G 0.26 (0.16 – 0.36) 0.32 (0.22 – 0.43) 0.38 (0.27 – 0.48) 0.29 (0.24 – 0.34) 
    GG 2 (5.3) 6 (16.2) 7 (17.1) 16 (9.8)           
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=42) vs Malays (N=42). 
‡ denotes P < 0.05, Malays (N=42) vs Indians (N=42). 




3.3.1.2 Linkage Disequilibrium (LD) Analysis of CYP1A2 Polymorphisms 
Pairwise LD analysis for the identified CYP1A2 polymorphisms was performed 
among Chinese, Malay and Indian populations (Figs 3.2A – C, respectively). There 
was strong LD observed between the following polymorphisms across all three 
ethnic groups: -2847T>C (rs2069522), -1804A>C/G (rs2069524), -1708T>C 
(rs2069525), -739T>G (*1E, rs2069526), IVS2-249C>T (rs4646425) and 
IVS6+81T>C (rs4646427) with each other (|D′| = 1.00; R2 > 0.60) except 
IVS6+81T>C (rs4646427) with -1804A>C/G (rs2069524) and -739T>G (*1E, 
rs2069526) in Malays. The polymorphism IVS6+81T>C (rs4646427) was found to be 
in moderate linkage with -1804A>C/G (rs2069524) (|D′| = 0.63; R2 = 0.54) and -
739T>G (*1E, rs2069526) (|D′| = 0.77; R2 = 0.75) in the Malay population. Close 
associations were observed among *1324C>G (rs17861162), IVS4-65G>C 
(rs2472304) and IVS5-318G>C (rs55711332) (|D′|  0.89; R2  0.67) in Chinese 
and Malays.  
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Fig 3.2 LD matrix for CYP1A2 polymorphisms 
in (A) Chinese, (B) Malays, and (C) Indians. 
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3.3.1.3 Haplotypes, Network and tag-SNP Analysis of CYP1A2 Polymorphisms 
A total of 16 haplotypes were determined in the Chinese population and four high 
frequency haplotypes (H1-C, H2-C, H3-C & H4-C) accounted for a cumulative 
frequency of 66.7%. There were 22 haplotypes identified in the Malay population with 
six high frequency haplotypes (H1-M, H2-M, H3-M, H4-M, H5-M & H6-M) occurring 
with a cumulative frequency of 66.9%. The haplotype structure diversity was greatest 
in the Indian population with five high frequency haplotypes (H1-I, H2-I, H3-I, H4-I & 
H5-I) constituting 61.6% of all haplotypes. The cumulative frequencies of minor 
haplotypes were observed to be 9.4%, 4.0% and 1.5 % in Chinese, Malay and Indian 
populations, respectively. 
The high frequency haplotypes in each of the three Asian populations were further 
aligned to identify the common haplotypes across all three ethnic groups. A total of 
eight common haplotypes were derived for all ethnicities (H1–H8, Table 3.6). 
Haplotypes H1 and H3 were common in all three ethnic groups while other 
haplotypes were only detected in selected populations: H2 and H8 in Malays and 
Chinese, H6 in Malays and Indians, H4 and H5 in Indians and H7 in Malay. The 
haplotype H2 [-2467delT (*1D, rs35694136) and –163C>A (*1F, rs762551)] 
displayed the highest average frequency at 28.4% while the reference haplotype H1 
was observed in 17.5% of the populations. 
The median joining algorithm was employed to calculate the haplotype network 
between the common haplotypes (Fig 3.3) (22) and six polymorphisms were 
identified as tag-SNPs which distinguished between the common haplotypes [-
739T>G (*1E, rs2069526), *1324C>G (rs17861162), -2467delT (*1D, rs35694136), -
163C>A (*1F, rs762551), IVS4+43G>A (rs2472304) and -733G>C (rs28399417)]. 
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The haplotypes H6 and H7 as well as H1 and H5 were closely related and both pair 
of haplotypes could be distinguished by IVS4+43G>A (rs2472304), while haplotypes 
H3 and H8 could be differentiated by -733G>C (rs28399417). The haplotype H4 was 
observed to display the greatest diversity from other common haplotypes. H4 was 
connected to the other haplotypes by a median vector (mv2) that was tagged by 6 
polymorphic variants (Fig 3.3).  
 
 
Fig 3.3 Network diagram illustrating the relationship between CYP1A2 common 
haplotypes in healthy Asian populations. 
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H1 0.18 0.20 0.11 0.21 T W A T T G C C G G G T C C 
H2 0.28 0.31 0.26 − T D A T T G A C G G G T C C 
H3 0.15 0.11 0.13 0.21 T D A T T G A C G C C T C G 
H4 0.07 − − 0.07 C D G C G G A T G G G C C G 
H5 0.07 − − 0.07 T W A T T G C C A G G T C C 
H6 0.06 − 0.06 0.06 T W A T T G A C G G G T T C 
H7 0.05 − 0.05 − T W A T T G A C A G G T T C 
H8 0.05 0.05 0.05 − T D A T T C A C G C C T C G 
a. The polymorphisms selected as htTAG SNPs are bolded.  
b. Abbreviations: W- wild type, D- deletion and I- insertion. 
c. Average Frequency refers to average of the observed frequencies in each ethnic group.  
d. ‘–‘ refers to an absence of the haplotype in the ethnic group. 
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3.3.1.4 Pharmacogenetic-pharmacokinetic Associations of CYP1A2 Polymorphisms  
The tag-SNPs in CYP1A2 were investigated for its impact on steady state plasma 
levels of tamoxifen and its metabolites as well as its metabolic ratios. No significant 
associations between the genotypes of the tag-SNPs and the various parameters 
were observed (Table 3.7). 
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Table 3.7 Effect of CYP1A2 polymorphisms on steady state plasma levels and metabolic ratios of tamoxifen and its metabolites (N=163). 





wt/wt (N=32) wt/delT (N=90) delT/delT (N=41) wt/wt vs wt/delT wt/wt vs delT/delT wt/delT vs delT/delT 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 196.12 (50.06 – 452.29) 198.58 (39.26 – 599.91) 216.07 (92.26 – 476.75) 0.749 0.484 0.655 0.795 
       [-5.48 (-39.63 – 27.39)] [-15.08 (-55.24 – 26.75)] [-7.89 (-41.63 – 26.08)]  
NDM 298.59 (40.82 – 757.13) 302.17 (78.46 – 802.98) 337.13 (153.41 – 556.45) 0.866 0.556 0.575 0.806 
       [-2.53 (-52.62 – 47.57)] [-15.54 (-71.73 – 34.92)] [-12.94 (-57.20 – 32.32)]  
4-OHT 1.83 (0.97 – 5.33) 2.08 (0.47 – 5.09) 1.93 (0.75 – 4.57) 0.749 0.633 0.758 0.880 
       [-0.06 (-0.42 – 0.28)] [-0.08 (-0.48 – 0.25)] [-0.05 (-0.40 – 0.29)]  
Endoxifen 12.92 (4.18 – 42.56) 13.56 (1.74 – 36.82) 14.38 (4.74 – 42.8) 0.641 0.404 0.558 0.687 
       [-0.65 (-3.72 – 2.38)] [-1.27 (-5.13 – 1.91)] [-0.91 (-3.87 – 1.96)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.65) 1.50 (0.88 – 2.76) 1.63 (0.77 – 2.28) 0.621 0.903 0.472 0.738 
       [0.05 (-0.11 – 0.19)] [-0.01 (-0.18 – 0.18)] [-0.05 (-0.18 – 0.08)]  
MR4-OHT/TAM (×100) 1.02 (0.46 – 1.93) 1.01 (0.19 – 2.26) 0.99 (0.43 – 2.35) 0.866 0.689 0.847 0.941 
       [0.01 (-0.13 – 0.19)] [0.03 (-0.15 – 0.23)] [0.01 (-0.13 – 0.16)]  
MREND/NDM (×100) 4.46 (1.06 – 27.81) 4.49 (0.92 – 14.86) 5.14 (1.26 – 13.58) 0.958 0.903 0.929 0.992 
       [-0.04 (-1.07 – 1.01)] [-0.06 (-1.70 – 1.00)] [-0.05 (-1.20 – 0.88)]  
MREND/4-OHT 6.41 (3.48 – 13.18) 6.67 (1.99 – 12.34) 7.56 (3.46 – 12.74) 0.740 0.248 0.321 0.478 
              [-0.15 (-1.06 – 0.80)] [-0.58 (-1.53 – 0.34)] [-0.36 (-1.23 – 0.40)]   
-739T>G (*1E, 
rs2069526) 
TT (N=129) TG (N=34) 
  
TT vs TG + GG 
      
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 197.35 (39.26 – 599.91) 233.87 (95.6 – 380.1)   0.171    
       [-23.90 (-58.06 – 11.40)]    
NDM 301.79 (40.82 – 802.98) 313.85 (105.23 – 606.01)   0.677    
       [-9.93 (-55.99 – 37.06)]    
4-OHT 1.93 (0.47 – 5.33) 2.38 (0.87 – 4.51)   0.178    
       [-0.22 (-0.59 – 0.10)]    
Endoxifen 12.86 (1.74 – 42.8) 15.81 (6.41 – 31.05)   0.099    
       [-2.48 (-5.42 – 0.45)]    




Table 3.7 Effect of CYP1A2 polymorphisms on steady state plasma levels and metabolic ratios of tamoxifen and its metabolites (N=163) (Continued). 





TT (N=129) TG (N=34)     TT vs TG + GG 
      
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.59 (0.62 – 2.76) 1.45 (0.77 – 2.16)   0.120    
       [0.12 (-0.02 – 0.24)]    
MR4-OHT/TAM (×100) 1.01 (0.19 – 2.26) 1.04 (0.39 – 2.35)   0.703    
       [-0.03 (-0.19 – 0.12)]    
MREND/NDM (×100) 4.35 (0.92 – 27.81) 5.60 (1.47 – 14.86)   0.256    
       [-0.66 (-2.16 – 0.39)]    
MREND/4-OHT 6.66 (1.99 – 13.18) 7.25 (4.1 – 10.82)   0.365    
       [-0.38 (-1.20 – 0.44)]    
-733G>C 
(rs28399417) 







Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 202.53 (39.26 – 599.91) 210.33 (146.38 – 476.75)   0.427    
       [-16.08 (-56.43 – 26.53)]    
NDM 302.51 (40.82 – 802.98) 325.90 (239.27 – 474.29)   0.722    
       [-8.33 (-66.64 – 50.47)]    
4-OHT 1.94 (0.47 – 5.33) 2.62 (1.52 – 4.57)   0.137    
       [-0.36 (-0.92 – 0.10)]    
Endoxifen 13.39 (1.74 – 42.56) 21.45 (7.22 – 42.8)   0.058    
       [-5.13 (-12.01 – 0.13)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.57 (0.62 – 2.76) 1.44 (0.83 – 2.07)   0.434    
       [0.07 (-0.13 – 0.29)]    
MR4-OHT/TAM (×100) 1.01 (0.19 – 2.35) 1.08 (0.6 – 1.92)   0.496    
       [-0.08 (-0.34 – 0.16)]    
MREND/NDM (×100) 4.50 (0.92 – 27.81) 6.62 (1.79 – 11.18)   0.131    
       [-1.56 (-3.71 – 0.30)]    
MREND/4-OHT 6.69 (1.99 – 13.18) 7.98 (4.22 – 10.85)   0.195    
       [-0.93 (-2.39 – 0.36)]    




Table 3.7 Effect of CYP1A2 polymorphisms on steady state plasma levels and metabolic ratios of tamoxifen and its metabolites (N=163) (Continued). 





CC (N=17) CA (N=77) AA (N=69) CC vs CA CC vs AA CA vs AA 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 197.35 (50.06 – 452.29) 191.32 (39.26 – 578.17) 228.99 (79.82 – 599.91) 0.840 0.377 0.129 0.288 
       [-3.80 (-48.57 – 44.29)] [-24.51 (-77.63 – 30.74)] [-22.06 (-52.64 – 7.67)]  
NDM 304.05 (40.82 – 757.13) 300.42 (78.46 – 666.26) 337.13 (105.23 – 802.98) 0.464 0.824 0.099 0.250 
       [21.76 (-41.35 – 93.39)] [-6.75 (-84.32 – 64.78)] [-32.30 (-74.89 – 6.36)]  
4-OHT 1.92 (0.97 – 3.77) 2.08 (0.47 – 5.33) 1.93 (0.7 – 4.57) 0.641 0.445 0.659 0.737 
       [-0.12 (-0.62 – 0.31)] [-0.17 (-0.65 – 0.24)] [-0.08 (-0.38 – 0.22)]  
Endoxifen 8.61 (4.18 – 39.47) 13.39 (1.74 – 42.56) 14.38 (3.48 – 42.8) 0.225 0.092 0.465 0.242 
       [-2.07 (-6.42 – 1.50)] [-2.62 (-7.49 – 0.42)] [-0.93 (-3.54 – 1.49)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.57 (0.82 – 2.65) 1.48 (0.62 – 2.76) 1.62 (0.77 – 2.28) 0.177 0.471 0.537 0.436 
       [0.13 (-0.06 – 0.31)] [0.09 (-0.12 – 0.30)] [-0.04 (-0.16 – 0.08)]  
MR4-OHT/TAM (×100) 1.05 (0.46 – 1.93) 1.01 (0.19 – 2.1) 0.99 (0.43 – 2.35) 0.691 0.498 0.208 0.420 
       [-0.04 (-0.24 – 0.20)] [0.07 (-0.13 – 0.27)] [0.09 (-0.04 – 0.24)]  
MREND/NDM (×100) 3.87 (1.06 – 10.25) 5.24 (0.92 – 27.81) 5.03 (1.26 – 14.86) 0.252 0.498 0.519 0.503 
       [-0.59 (-2.24 – 0.62)] [-0.42 (-2.26 – 0.71)] [0.27 (-0.67 – 1.03)]  
MREND/4-OHT 5.39 (3.48 – 13.18) 6.90 (1.99 – 12.34) 7.17 (3.46 – 12.74) 0.183 0.064 0.334 0.159 
       [-0.74 (-2.14 – 0.40)] [-1.13 (-2.31 – 0.07)] [-0.34 (-1.05 – 0.38)]  
IVS4+43G>A 
(rs2472304) 
GG (N=123) GA (N=36) AA (N=4) GG vs GA GG vs AA GA vs AA 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 202.53 (39.26 – 578.17) 221.18 (79.82 – 599.91) 227.05 (147.72 – 281.43) 0.215 0.730 0.778 0.448 
       [-20.58 (-55.00 – 13.32)] [-10.39 (-95.15 – 74.35)] [11.54 (-86.55 – 103.42)]  
NDM 302.95 (40.82 – 757.13) 300.44 (105.23 – 802.98) 364.80 (233.35 – 438.48) 0.758 0.590 0.744 0.839 
       [-7.47 (-56.37 – 41.33)] [-32.87 (-139.74 – 79.95)] [-38.12 (-146.99 – 141.32)]  
4-OHT 1.96 (0.47 – 5.09) 2.21 (0.7 – 5.33) 1.72 (1.5 – 3.2) 0.374 0.751 0.528 0.618 
       [-0.16 (-0.54 – 0.17)] [0.11 (-0.67 – 1.09)] [0.19 (-0.57 – 1.33)]  
Endoxifen 12.86 (1.74 – 42.8) 15.77 (3.48 – 42.56) 11.97 (9.47 – 22.78) 0.203 0.879 0.617 0.436 
       [-1.84 (-5.30 – 0.89)] [-0.36 (-7.00 – 9.74)] [1.55 (-6.17 – 11.90)]  





Table 3.7 Effect of CYP1A2 polymorphisms on steady state plasma levels and metabolic ratios of tamoxifen and its metabolites (N=163) (Continued). 





GG (N=123) GA (N=36) AA (N=4) GG vs GA GG vs AA GA vs AA 
Overall 
P values 
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.57 (0.77 – 2.76) 1.44 (0.62 – 2.26) 1.63 (1.28 – 1.92) 0.199 0.679 0.472 0.389 
       [0.09 (-0.05 – 0.23)] [-0.05 (-0.39 – 0.29)] [-0.16 (-0.52 – 0.24)]  
MR4-OHT/TAM (×100) 1.01 (0.19 – 2.35) 0.97 (0.55 – 2.26) 0.95 (0.68 – 1.14) 0.564 0.481 0.845 0.700 
       [0.04 (-0.10 – 0.20)] [0.14 (-0.21 – 0.51)] [0.08 (-0.24 – 0.52)]  
MREND/NDM (×100) 4.97 (0.92 – 13.58) 4.78 (1.51 – 27.81) 4.33 (2.21 – 6.34) 0.642 0.740 0.712 0.842 
       [-0.26 (-1.44 – 0.72)] [0.25 (-2.47 – 3.83)] [0.51 (-2.22 – 4.48)]  
MREND/4-OHT 6.90 (1.99 – 13.18) 7.02 (4.07 – 11.96) 6.72 (5.46 – 8.53) 0.344 0.793 0.913 0.628 
       [-0.37 (-1.20 – 0.41)] [-0.22 (-2.23 – 2.12)] [0.20 (-2.05 – 2.54)]  
*1324C>G 
(rs17861162) 
CC (N=84) CG (N=63) GG (N=16) CC vs CG CC vs GG CG vs GG 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 196.12 (39.26 – 599.91) 202.53 (79.82 – 476.75) 224.62 (114.68 – 419.41) 0.541 0.106 0.257 0.276 
       [-8.54 (-36.95 – 18.51)] [-36.88 (-78.32 – 10.10)] [-28.10 (-69.63 – 24.95)]  
NDM 301.14 (40.82 – 802.98) 309.48 (105.23 – 666.26) 305.24 (208.32 – 512.35) 0.521 0.756 0.903 0.803 
       [-12.90 (-53.77 – 27.04)] [-8.11 (-73.62 – 51.36)] [3.21 (-54.47 – 60.93)]  
4-OHT 1.94 (0.47 – 5.33) 2.08 (0.7 – 5.09) 2.06 (1.49 – 3.44) 0.616 0.275 0.400 0.521 
       [-0.08 (-0.39 – 0.21)] [-0.21 (-0.72 – 0.17)] [-0.18 (-0.57 – 0.28)]  
Endoxifen 11.69 (1.74 – 42.56) 15.64 (3.48 – 42.8) 15.13 (7.29 – 28.77) 0.106 0.132 0.714 0.149 
       [-2.12 (-4.93 – 0.40)] [-3.16 (-6.94 – 1.06)] [-0.86 (-5.20 – 4.47)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.58 (0.62 – 2.76) 1.57 (0.83 – 2.28) 1.34 (0.77 – 1.82) 0.978 0.096 0.100 0.220 
       [0.00 (-0.12 – 0.13)] [0.15 (-0.03 – 0.36)] [0.15 (-0.04 – 0.34)]  
MR4-OHT/TAM (×100) 1.02 (0.19 – 2.26) 1.00 (0.39 – 2.35) 0.93 (0.55 – 1.82) 0.787 0.625 0.803 0.886 
       [0.02 (-0.11 – 0.15)] [0.05 (-0.17 – 0.28)] [0.03 (-0.21 – 0.26)]  
MREND/NDM (×100) 3.97 (0.92 – 27.81) 5.24 (1.26 – 14.86) 5.44 (1.73 – 11.18) 0.350 0.397 0.990 0.546 
       [-0.41 (-1.43 – 0.39)] [-0.70 (-2.58 – 0.73)] [0.01 (-2.25 – 1.40)]  
MREND/4-OHT 6.30 (1.99 – 13.18) 7.33 (4.1 – 12.74) 7.36 (4.22 – 9.82) 0.037 0.333 0.733 0.102 
       [-0.74 (-1.53 – -0.04)] [-0.57 (-1.71 – 0.59)] [0.19 (-0.98 – 1.31)]  




CYP1A2 is a phase I enzyme involved in the catalysis of NDM from tamoxifen. The 
gene encoding this enzyme is highly polymorphic with a total of 25 SNPs being 
detected in the screening of CYP1A2 gene in 126 healthy individuals from the three 
Asian ethnic groups (Chinese, Malay and Indians) in the current study (431). Nine of 
the 25 polymorphisms were novel (Table 3.5). The polymorphisms located in the 
exons were rare and present at frequencies of 5.0% or less with the exception of 
1548C>T (*1B, rs2470890) which was present in 12.0% to 18.0% of the healthy 
populations (Table 3.5), consistent with previous reports (228, 432). High frequency 
polymorphic variants included -163C>A (*1F, rs762551) and -2467delT (*1D, 
rs35694136). The allelic frequency of -163C>A (*1F, rs762551) in our study 
population was similar to that of other Asian, Caucasian and African populations 
which ranged from 0.60 to 0.71 (218, 222, 223, 227). However, the allelic frequency 
of -163C>A (*1F, rs762551) was significantly higher in the Malay population (MAF: 
0.78) compared to the Indian population (MAF: 0.58) (P = 0.02). The allelic 
frequency of -2467delT (*1D, rs35694136) in the Indian population (MAF: 0.46) was 
similar to the Japanese (MAF: 0.42) (228) while the Chinese (MAF: 0.66) and Malay 
(MAF: 0.61) populations were similar to the Korean population (MAF: 0.71) (222). 
These observed frequencies were consistently higher than that in the Caucasian 
populations (MAF: 0.19 – 0.24) (219). These results suggest that -163C>A (*1F, 
rs762551) and -2467delT (*1D, rs35694136) alleles may exert a greater influence on 
CYP1A2 activity in the Chinese and Malay populations compared to the Indian 
populations. 
Two of the 9 novel polymorphisms, 1049T>G and 1459G>A were non-synonymous 
variants resulting in V350G and V487M amino acid changes, respectively. The 
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residue V350 is located two amino acids from D348 in the N-terminal of helix J 
positioned on the surface of the CYP1A2 protein (210, 433). The polymorphism 
1042G>A (*3, rs56276455) leads to the amino acid substitution D348N and has been 
previously reported to be associated with decreased expression of CYP1A2 in E. coli 
(432). In addition, helix J has been found to be conserved within the cytochrome 
P450 proteins (433, 434). Hence, it is postulated that V350G may possibly exert an 
influence on the expression of CYP1A2. On the other hand, V487 is located between 
2 beta sheets near the N-terminal of the CYP1A2 polypeptide and is four amino 
acids upstream of substrate binding site 6 (435). Future studies will be required to 
determine the functional and phenotypic effect of these polymorphisms.  
The -163C>A (*1F, rs762551) polymorphism has previously been shown to be 
associated with increased inducibility of CYP1A2, leading to higher in vivo enzyme 
activity (220, 436). It was first described to be associated with higher caffeine 
metabolic ratio (220) and had been implicated in alterations of the plasma metabolic 
ratio of clozapine and olanzapine (437, 438) in subsequent studies. On the other 
hand, recent studies have reported conflicting findings with regards to the -163C>A 
(*1F, rs762551) allele being a cancer susceptibility allele (439-441).  This could 
probably be attributed to differences in allelic frequencies of the -163C>A (*1F, 
rs762551) polymorphism in various ethnic groups resulting in varying linkage and 
haplotype patterns of the -163C>A (*1F, rs762551) polymorphism with other 
CYP1A2 polymorphic variants (223, 227). The frequency of -163C>A (*1F, rs762551) 
polymorphism occurring independently of other SNPs is reportedly higher in the 
Swedish and Ethiopian populations (0.57 and 0.50 respectively) compared to 
Japanese and Korean populations (<0.01 and 0.08, respectively) (223, 227, 228). 
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The polymorphism, -163C>A (*1F, rs762551) was not found to be present 
independently in all of our healthy and patient study populations (Table 3.5). 
The -2467delT (*1D, rs35694136) allele was noted to occur at a higher frequency in 
Chinese and Malay populations (MAF: 0.66 and 0.61, respectively) compared to the 
Indian population (MAF: 0.46) (Table 3.5). In a recent study, Pavanello et al (219) 
reported a significant association between the variant allele and an increase in the 
metabolic ratio of caffeine and urinary mutagenicity (indicator of genotoxic effect) in 
the Tunisian population (219). The current evidence (219, 226) thus seem to suggest 
that -2467delT (*1D, rs35694136) may be associated with greater CYP1A2 activity. 
In the current study, the effects of the six CYP1A2 tag-SNPs, namely -2467delT (*1D, 
rs35694136), -739T>G (*1E, rs2069526), -733G>C (rs28399417), -163C>A (*1F, 
rs762551), IVS4+43G>A (rs2472304) and *1324C>G (rs17861162) on the steady 
state plasma concentrations were investigated. The plasma concentrations of 
tamoxifen and its metabolites were not found to vary in any discernible trend 
between the genotypes of CYP1A2 tag-SNPs. As the plasma concentrations of the 
metabolites are substrates for multiple phase I and II enzymes and can be influenced 
by the activity of these enzymes, metabolic ratios were employed for the comparison. 
Metabolic ratios which are the ratios of the steady state concentrations of the 
metabolites are more accurate indicators of the relative conversion of one metabolite 
to another. Similar to the observations with the plasma concentrations of the analytes, 
no distinct trends in the variations of the metabolic ratios were observed between 
different genotypes of CYP1A2 polymorphisms under investigation (Table 3.7).  
Although CYP1A2 has been found to be active in the in vitro metabolism of 
tamoxifen to 4-OHT and NDM, no effect on these two metabolic pathways was 
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observed (119). However, it was also noted that among the panel of CYP enzymatic 
isoforms screened in the previous study, CYP1A2 exhibited the slowest rate of 
catalysis of tamoxifen into the respective metabolites in comparison to CYP2C9/19, 
CYP2D6 and CYP3A4/5 (119). The catalytic rates of CYP1A2 for tamoxifen to NDM 
and 4-OHT were found to be lower than and equal to CYP2B6 respectively. Hence, 
the effect of CYP1A2 activity on the metabolism of tamoxifen might be minimal in the 
in vivo system where the metabolic capacities of other phase I enzymes involved in 
the metabolism of tamoxifen were not impaired either due to presence of interacting 
substrates or genetic variations. 
In addition, the effects of CYP1A2 polymorphisms on the expression and activity of 
CYP1A2 have been controversial (210). Although previous study comparing the 
metabolism of caffeine between monozygotic and dizygotic twins has suggested that 
genetic factors account for a high proportion of the variability in CYP1A2 activity 
(212), none of the CYP1A2 polymorphisms has been found to account for a 
significant proportion of the variability. In search of the genetic factors which can 
potentially influence the activity of CYP1A2, Klein et al (442) adopted a pathway-
targeted approach which comprehensively investigated the effects of polymorphisms 
present in the candidate genes regulating the expression of CYP1A2 mRNA and 
protein as well as CYP1A2 activity, indicated by O-deethylation of phenacetin. The 
investigators also studied the impact of CYP1A2 polymorphisms (442). In contrary to 
previous findings (213, 220, 223), no association with variations in CYP1A2 mRNA 
levels, protein expression and activity was observed with CYP1A2 SNPs. However, 
ten polymorphic variants located in the upstream regulatory genes (ARNT, AhRR, 
HNF1α, IL1β, SRC1 and VDR) were associated with phenotypic changes in 
expression levels and activity of CYP1A2. These observations suggest that trans-
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acting instead of cis-acting factors may play a more important role in affecting 
CYP1A2 activity.  
Furthermore, the activity of CYP1A2 is also influenced by other non-genetic factors 
(221, 227). Recently, Perera et al (443) investigated the effects of genetic variants in 
CYP1A2 and genes regulating the expression of CYP1A2 (VDR, RXRα, HNF1α, 
AhRR, ARNT, SRC-1, IL-1β) as well as diet and lifestyle factors among South Asian 
and European subjects on CYP1A2 activity which is indicated by the metabolic ratio 
of caffeine. Similar variations in the activity of CYP1A2 were observed between the 
two ethnicities with lower overall CYP1A2 activity observed among the South Asians. 
Compared to the genetic factors which only accounted for 1.9% of the variability in 
caffeine metabolic ratio, diet and lifestyle factors including CYP1A2-inhibitory 
medications, caffeine intake, cigarette smoking, ethnicity, gender and alcohol intake 
were reported to account for greater proportion (39%) of the variability in CYP1A2 
activity (443). Interestingly, the study also showed that the consumption of food 
which induce CYP1A2 (cabbages, cauliflower and broccoli) could influence the 
activity of CYP1A2. It should be noted that these dietary components are common in 
Asian diet. It was also highlighted by the authors that spices present in curry 
(turmeric, cumin and coriander), a common dietary component among Asians might 
inhibit the activity of CYP1A2 (443). The information on dietary habits as well as 
smoking status of the study subjects were not available for the current study and 
could be possible confounding factors. 
In summary, the pharmacogenetic profile of CYP1A2 in three healthy Asian 
populations in Singapore was found to display great inter-ethnic diversity but was 
similar to other Asian populations (Koreans and Japanese) (222, 228). Six tag-SNPs 
were identified but genotyping of these six tag-SNPs in the Asian breast cancer 
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patients did not reveal any significant impact on the plasma concentrations of 
tamoxifen and its metabolites or the metabolic ratios. However, the activity of 
CYP1A2 may be affected by other genetic (polymorphisms in other upstream 
regulatory genes) and non-genetic factors such as diet and lifestyle. Information 
regarding many these factors which could possibly confound the observations was 
not available for the current study. Hence, future studies controlling for these non-
genetic factors with consideration for the trans regulatory factors may help to further 
elucidate the role of CYP1A2 the in vivo metabolism of tamoxifen.
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3.3.2 Cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) 
3.3.2.1 Genetic Analysis of CYP2C9 
The polymorphisms in CYP2C9 [*2 (430C>T, rs1799853) and *3 (1075A>C, 
rs1057910)] were noted to display significant inter-ethnic variations and are depicted 
in Table 3.8. Among the Asian breast cancer patients, allelic and genotypic profiles 
of both CYP2C9 polymorphisms were similar to those of the healthy Chinese 
population (Table 3.8).  
3.3.2.2 Influence of CYP2C9 Polymorphisms on the Plasma Levels of Tamoxifen and 
its Metabolites 
As the CYP2C9*2 (430C>T, rs1799853) allele was absent in our study population, 
the effect of CYP2C9*2 (430C>T, rs1799853) could not be evaluated. The 
CYP2C9*3 (1075A>C, rs1057910) variant was not found to significantly influence the 
plasma concentrations of the analytes (Table 3.9). Similarly, the plasma metabolic 
ratios were not found to vary considerably between patients carrying different 
CYP2C9*3 (1075A>C, rs1057910) genotypes (Table 3.9). 
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Table 3.8 Genotypic and allelic frequencies of CYP2C9*2 (430T>C, rs1799853) and *3 (1075A>C, rs1057910). 
Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=163) 
CYP2C9*2 *1/*1 80 (100.0) 79 (100.0) 73 (94.8) 163 (100.0) *1 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.97 (0.95 – 1.00) 1.00 (1.00 – 1.00) 
(430C>T, rs1799853) *1/*2 0 (0.0) 0 (0.0) 4 (5.2) 0 (0.0) *2 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)‡ 0.03 (0.00 – 0.05)§ 0.00 (0.00 – 0.00) 
 *2/*2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
CYP2C9*3 *1/*1 78 (97.5) 72 (90.0) 66 (82.5) 150 (92.0) *1 0.99 (0.97 – 1.00) 0.95 (0.92 – 0.98) 0.90 (0.85 – 0.95) 0.96 (0.94 – 0.98) 
(1075A>C, rs1057910) *1/*3 2 (2.5) 8 (10.0) 12 (15.0) 12 (7.4) *3 0.01  (0.00 – 0.03)† 0.05 (0.02 – 0.08) 0.10 (0.05 – 0.15)§ 0.04 (0.02 – 0.06) 
  *3/*3 0 (0.0) 0 (0.0) 1 (1.3) 1 (0.6)           
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.9 Effects of CYP2C9*3 (1075A>C, rs1057910) polymorphism on median (range) plasma 








*1/*1 (N=150) *1/*3 (N=13) *1/*1 vs *1/*3 + *3/*3 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 207.39 (50.06 – 599.91) 185.67 (39.26 – 364.69) 0.247 
     [28.15 (-21.4 – 81.67)] 
NDM 304.64 (40.82 – 802.98) 296.72 (78.46 – 536.83) 0.429 
     [28.76 (-43.1 – 112.57)] 
4-OHT 2.02 (0.7 – 5.33) 1.67 (0.47 – 3.42) 0.089 
     [0.45 (-0.08 – 1.01)] 
Endoxifen 13.40 (1.74 – 42.8) 15.64 (1.79 – 39.47) 0.709 
     [-0.98 (-7.55 – 4.3)] 
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.58 (1 – 2.28) 0.759 
     [-0.03 (-0.24 – 0.18)] 
MR4-OHT/TAM (×100) 1.01 (0.19 – 2.35) 0.99 (0.39 – 1.64) 0.571 
     [0.05 (-0.16 – 0.30)] 
MREND/NDM (×100) 4.54 (0.92 – 27.81) 6.11 (1.47 – 14.86) 0.301 
     [-0.89 (-3.30 – 0.66)] 
Total Metabolic Ratios (TMRs) 
TMRNDM 2.70 (0.51 – 10.69) 3.79 (0.88 – 7.45) 0.194 
     [-0.63 (-2.00 – 0.35)] 
TMR4-OHT 6.56 (1.14 – 19.5) 9.54 (2.16 – 17.48) 0.126 
          [-1.92 (-4.74 – 0.64)] 
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 




Two functional polymorphisms of CYP2C9 [*2 (430C>T, rs1799853) and *3 
(1075A>C, rs1057910)] were investigated for associations with tamoxifen disposition 
in Asian breast cancer patients in the present study. Both CYP2C9*2 (430T>C, 
rs1799853) and *3 (1075A>C, rs1057910) are nonsynonymous polymorphisms 
which mapped to different domains of the enzyme and lead to significant reductions 
in CYP2C9 catalytic capability (236). In the healthy Asian populations, the genotypic 
and allelic distributions of these two functional polymorphisms were found to differ 
between ethnicities. The polymorphic variant CYP2C9*2 (430T>C, rs1799853) which 
is highly prevalent in 10% to 15% of the Caucasians (239, 444) was absent in both 
the Chinese and Malay populations and only present in 4% of the Indian subjects. 
Consistently, the variant CYP2C9*2 (430C>T, rs1799853) allele was not observed in 
our patient cohort. Thus, no further genotypic-phenotypic correlation was performed 
with regard to this polymorphism. On the contrary, CYP2C9*3 (1075A>C, 
rs1057910) was found in the Chinese and Malay populations at allelic frequencies of 
9- and 1.8- fold lower than the Indian population respectively. The frequency of the 
CYP2C9*3 (1075A>C, rs1057910) allele in our Indian subjects was comparable to 
that reported in the Caucasians (MAF, Indian vs Caucasian: 0.09 vs 0.10) (238, 444). 
In the breast cancer patient cohort, the polymorphic variant was observed at a 
frequency of 4%. 
CYP2C9*2 (430T>C, rs1799853) is a transition located on exon 3 resulting in the 
substitution of arginine for cysteine at codon 144 of the polypeptide (239). Although 
this polymorphism is not localized at the substrate recognition site, it interferes with 
the interaction between CYP2C9 enzyme and NADPH-P450 reductase during the 
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oxidative metabolism cascade (236, 445). Interaction between CYP enzyme and 
P450 reductase is vital as P450 reductase supplies the electrons required for the 
oxidative reaction catalyzed by the CYP enzyme (446). Thus, the CYP2C9*2 
(430T>C, rs1799853) allele is frequently associated with significant reductions in 
Vmax and with 20% to 30% lower enzymatic activity compared to the wild-type protein 
(241).  
In contrast, CYP2C9*3 (1075A>C, rs1057910) results in the amino acid substitution 
I359L which is located within the substrate recognition site (240, 447). It affects the 
interaction between the enzyme and substrate resulting in alteration in the binding 
affinity and intrinsic clearance of CYP2C9 substrates (447, 448). Compared with 
CYP2C9*2 (430T>C, rs1799853), greater reductions in Vmax and intrinsic clearance 
have been observed. In addition, alterations in Km indicative of changes in substrate 
binding affinity across various substrates have also been reported (241).  
Consistent to the observations with other substrates, Coller et al (194) reported 
significant reductions in the 4-hydroxylation of tamoxifen by CYP2C9 variant proteins 
compared with the wild-type enzyme in baculovirus insect cells expressing 
recombinant forms of CYP2C9. The intrinsic clearance of tamoxifen to 4-OHT 
mediated by the CYP2C9.2 and CYP2C9.3 variant was only 52% and 11%, 
respectively, of that observed with the CYP2C9.1 protein though the effect is not 
significant. Hence, the authors suggested that the functional impact of CYP2C9*3 
(1075A>C, rs1057910) is much larger than CYP2C9*2 (430T>C, rs1799853). Coller 
et al (194) postulated that approximately 46% of the overall formation of 4-OHT can 
be attributed to the activity of CYP2C9 which is similar to the contribution of CYP2D6 
(about 45%). Consistently, this in vitro observation was verified in 236 Caucasian 
subjects (118). Both CYP2C9*2 (430T>C, rs1799853) and *3 (1075A>C, rs1057910) 
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carriers were associated with lower plasma concentrations of endoxifen and 4-OHT, 
and higher MR Tam/(Z)-4-OHT. The authors suggested that a substantial amount of 
4-OHT is formed via the activity of CYP2C9 and 20% to 30% of endoxifen is 
contributed by 4-OHT (118).  
However, in our study population, only 1 homozygous variant and 12 heterozygous 
carriers of the CYP2C9*3 (1075A>C, rs1057910) genotype were observed. Steady 
state plasma concentrations of tamoxifen, 4-OHT and NDM as well as the 
corresponding metabolic ratios did not differ significantly between the different 
genotype groups. The parameters were also not found to display any particular 
trend. This was similar to observations by Jin et al (140) where the effects of both 
CYP2C9*2 (430T>C, rs1799853) and *3 (1075A>C, rs1057910) were examined in 
80 breast cancer patients of Caucasian ethnic origins.  
One possible reason for the disparity in the observations between the various studies 
might be due to difference in allelic frequencies of the two patient populations. 
Though the frequency of CYP2C9*3 (1075A>C, rs1057910) was similar between the 
current Asian and German populations (MAF: 0.04 vs 0.05 respectively), CYP2C9*2 
(430T>C, rs1799853) which was absent in the Asian populations, is present in 
12.5% of the German subjects as reported by Murdter et al (118) (Table 3.8). Hence, 
the small sample size of our Asian population carrying the CYP2C9*3 (1075A>C, 
rs1057910) polymorphism might not be able to provide an accurate estimate of the 
impact of CYP2C9 polymorphisms.  
Another causative factor might be the relative contributions of CYP2C9 and CYP2D6 
activities to the metabolism of tamoxifen. In addition to the observation of lower rate 
of 4-OHT formation in liver microsomes carrying the variant CYP2C9 [*2 (430C>T, 
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rs1799853) and *3 (1075A>C, rs1057910)] which was not statistically significant, 
Coller et al reported a greater reduction in the formation rate of 4-OHT among 
carriers of CYP2D6 and CYP2C9 defective alleles compared with microsomes which 
were defective for CYP2D6 but wild-type for CYP2C9 (194). This indicates that 
CYP2C9 plays a greater role in the absence of functional CYP2D6 activity. However, 
we were not able to verify this finding in our study population as there were only 4 
subjects who were homozygous for CYP2D6 defective alleles [CYP2D6*5 
(CYP2D6del), *10 (100C>T, rs1065852) and *41 (2988G>A, rs28371725)] and 
carried the CYP2C9*3 (1075A>C, rs1057910) polymorphism. 
Futhermore, it is reported that CYP2D6 PMs are approximately present in 5% to 10% 
of the Caucasian population while it is rare in Asian populations with the exception of 
Indian subjects (1.8% − 4.8%) (270, 272). Since the contribution of CYP2C9 
increases in the absence of CYP2D6 activity, the effect of CYP2C9 functional 
polymorphisms might be more apparent in the Caucasian populations in which a 
larger proportion of the subjects are defective for CYP2D6 compared to the Asian 
population (194). This might partially explain the absence of an association between 
the CYP2C9 polymorphisms and plasma concentrations of endoxifen and 4-OHT in 
the Asian populations. 
Taken together, these findings indicate that CYP2C9 polymorphisms is important in 
the formation of 4-OHT especially in the absence of functional CYP2D6 activity. 
However, in the Asian populations where CYP2D6 PM is rare and the frequencies of 
CYP2C9 polymorphisms are low, the effect of CYP2C9 may not be apparent. It 
would be interesting to re-examine the impact of CYP2C9 polymorphisms in a cohort 
of Indian breast cancer patients in which the frequencies of CYP2C9 variant alleles 
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3.3.3 Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) 
3.3.3.1 Genetic Profile of CYP2C19 Polymorphisms 
A total of 66 polymorphisms were identified from the comprehensive screening of all 
nine exons (including exon-intron boundaries) as well as the upstream and 
downstream regions (13.5 kilobases in total) in 80 healthy subjects from each of the 
three healthy ethnic groups (Chinese, Malays and Indians). A total of twenty-four and 
five SNPs were located in the 5′ upstream and 3′ downstream regions, respectively, 
while 14 exonic and 23 intronic variants were found. Among the 66 polymorphisms, 
18 were present at allelic frequencies of less than 1% and 10 were present in 
approximately 1% – 5% of all ethnic populations (Fig 3.4). The functional effects of 
these polymorphisms were predicted using FastSNP and tabulated in Table 3.10 
(449). 
The frequencies of exonic polymorphisms were generally low (<10%) except for 
99C>T (rs17885098; Chinese vs Malays vs Indians: 0.90 vs 0.84 vs 0.88), 681G>A 
(*2; rs4244285; Chinese vs Malays vs Indians: 0.31 vs 0.22 vs 0.37) and 990C>T 
(rs3758580; nearly 33% across all ethnic groups). The frequencies of 636G>A (*3; 
rs4986893) and 1251A>C (rs17886522) were also relatively high at the respective 
allelic frequencies of about 6% in the healthy Chinese and Malay subjects (Table 
3.11). However, both polymorphisms were found to be significantly lower at 1% in 
the Indians (P ≤ 0.020). In general, the coding regions were generally well conserved.  
The two polymorphisms which define CYP2C19*17, -3402C>T (*17; rs11188072) 
and -806C>T (*17; rs12248560), and has been reported to be in complete LD, were 
found to be present at significantly different frequencies across different ethnic 
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populations (P < 0.001, Table 3.11). Likewise, the prevalence of three other 
polymorphisms found in the current study, IVS1+359A>T (rs7918461), IVS8-119C>T 
(rs12268020) and *+1189_*+1191DelCCA were significantly between the three 
ethnic groups (P < 0.001, Table 3.11). More than 2.8-fold difference in allelic 
frequencies of these polymorphisms was observed between the ethnicities with 
highest frequencies observed in the Indians followed by Malays and Chinese (P < 
0.001, Table 3.11). Both -3595T>C and 518C>T (rs61311738) were present in 1% 
and 5% of the healthy Indian population respectively but absent in Chinese and 
Malays. In contrast, *+1264C>G was absent in the Indian subjects although it was 
observed in 7% of the Chinese and Malay populations. In addition, the following 
SNPs were found to display highly diverse variant allelic frequencies in the Indians 
but similar frequencies in Chinese and Malays: -3332A>C (rs7101258), IVS1-
231G>A (rs7916649) and IVS7-106T>C (rs4917623) (P ≤ 0.014, Table 3.11). 
 





Table 3.10 Functional effects of CYP2C19 polymorphisms.  
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
-3595G>A  5′ Upstream Promoter/regulatory region Creates binding site for RORalp 
-3592T>C  5′ Upstream Promoter/regulatory region Disrupts binding site for CdxA 
-3402C>T (*17) rs11188072 5′ Upstream Promoter/regulatory region Disrupts binding site for AML-1a 
-3331C>T  5′ Upstream Promoter/regulatory region Creates binding site for CHOP-C 
-3266G>T  5′ Upstream Promoter/regulatory region Creates binding site for Nkx-2 and CdxA 
-3219T>G  5′ Upstream Promoter/regulatory region Disrupts binding site for AP-1 and CdxA 
-2720T>C  5′ Upstream Promoter/regulatory region Disrupts binding site for TATA and CdxA 
-2306G>A  5′ Upstream Promoter/regulatory region Creates binding site for Ik-2 
-2040C>T  5′ Upstream Promoter/regulatory region Creates binding site for Pbx-1, Nkx-2 and GATA-1 
-1418C>T rs3814637 5′ Upstream Promoter/regulatory region Creates CdxA binding site 
-889T>G rs11568732 5′ Upstream Promoter/regulatory region Creates CdxA binding site 
-806C>T (*17) rs12248560 5′ Upstream Promoter/regulatory region  
-559T>C  5′ Upstream Promoter/regulatory region Disrupts binding site for CdxA 
-363C>A  5′ Upstream Promoter/regulatory region Creates binding site for Nkx-2 
-13G>A  5′ Upstream Promoter/regulatory region Disrupts binding site for SRY 
7C>T  Exon 1 Missense (non-conservative); Splicing regulation P3S predicted to have benign effect with PSIC score of 0.058; 
Disrupts binding site for splicing factor SC35 
10T>C  Exon 1 Missense (conservative); Splicing regulation F4L predicted to have benign effect with PSIC score of 0.061; 
Disrupts binding site for splicing factor Srp40 
99C>T rs17885098 Exon 1 Sense/synonymous; Splicing regulation P33P; Disrupts binding site for splicing protein SC35; Creates 
binding sites hsa-miR-4516 and hsa-miR-3192 
IVS1+359A>T rs7918461 Intron 1 Intronic enhancer Creates binding sites for Brn-2, CdxA, Oct-1 
IVS1-340T>G rs17884832 Intron 1 Intronic enhancer Creates binding site for E2F 
IVS1-231G>A rs7916649 Intron 1 Intronic enhancer Creates CdxA binding site 
IVS1-47G>A rs17878649 Intron 1 Intronic enhancer Disrupt binding site for YY1 (Tin and Yang 1) 
276G>C rs17878459 Exon 2 Missense (conservative); Splicing regulation E92D predicted to have benign effect with PSIC score of 0.001; 
Affects binding of exonic splicing enhancer 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions 
‡ No miRNA was predicted to bind to CYP2C19 when the analysis was performed using miRecords software. 
§




Table 3.10 Functional effects of CYP2C19 polymorphisms. (continued) 
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
IVS2-23A>G rs12769205 Intron 2 Intronic enhancer Disrupt binding site for SRY (sex-determining region Y gene product) 
431G>A## rs17884712 Exon 3 Missense (non-conservative) R144H; Predicted to have probably damaging effect with PSIC score 
of 0.999; Disrupts binding site for hsa-miR-3615 
IVS3+332 T>C rs17879992 Intron 3 Intronic enhancer Affects binding site for transcription factors (GATA-1/3, CdxA > Oct-1) 
518C>T# rs61311738 Exon 4 Missense (conservative) A173V predicted to have possibly damaging effect with PSIC score of 
0.954 
636G>A (*3) rs4986893 Exon 4 Nonsense Generation of a premature stop codon 
IVS4-152A>G##  Intron 4 Intronic enhancer Disrupts binding site for CdxA 
681G>A rs4244285 Exon 5 Sense/synonymous; Splicing regulation Affects binding site for splice proteins; Disrupts binding site for hsa-
miR-1268 and hsa-miR-4281 
784G>A##  Exon 5 Missense; Splicing regulation D262N predicted to have possibly damaging effect with PSIC score 
0.545; Disrupts binding site for splicing factor SC35 
IVS5+228A>G rs12571421 Intron 5 Intronic enhancer Disrupts GATA-2 binding site 
IVS5-203G>C##  Intron 5 Intronic enhancer Creates binding site for GATA-1 
IVS5-123T>C##  Intron 5 Intronic enhancer Disrupts binding site for CdxA and HFH-2 
IVS5-113T>G rs28399511 Intron 5 Intronic enhancer Creates GATA-2 binding site 
IVS6-196T>A rs28399513 Intron 6 Intronic enhancer Disrupts C/EBPb binding site 
990C>T rs3758580 Exon 7 Sense/synonymous; Splicing regulation V330V; Disrupts binding site for splicing protein SRp55; Disrupts 
binding sites for has-miR-4697-5p 
991A>G rs3758581 Exon 7 Missense (conservative); Splicing regulation I331V predicted to have predicted benign effect with PSIC score of 
0.011; Disrupts binding site for splicing protein Srp40; Disrupts 
binding sites for has-miR-2861 
1119C>T##   Exon 7 Sense/synonymous; Splicing regulation D373D; Disrupts binding site for splicing factor SF2/ASF 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions 
‡ No miRNA was predicted to bind to CYP2C19 when the analysis was performed using miRecords software. 
§




Table 3.10 Functional effects of CYP2C19 polymorphisms. (continued) 
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
1127T>A##  Exon 7 Missense; Splicing regulation F376Y predicted to have probably damaging effect with PSIC score of 
0.993; Creates binding site for splicing factor SRp55 
IVS7+206T>C##  Intron 7 Intronic enhancer Disrupts binding site for CdxA 
IVS7-106T>C rs4917623 Intron 7 Intronic enhancer Disrupts SRY binding site 
1251A>C rs17886522 Exon 8 Sense/synonymous; Splicing regulation G417G; Affects binding site for splice proteins 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions 
‡ No miRNA was predicted to bind to CYP2C19 when the analysis was performed using miRecords software. 
§
 Analyses using MicroInspector software was restricted to SNPs in the exonic sites.  
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Table 3.11Genotypic and allelic frequencies of polymorphisms in CYP2C19 (UCSC RefSeq: NM_000769). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies (95% Confidence Interval) 
Healthy Subjects (N=80) 
Patients 
(N=163) 
 Healthy Subjects (N=80) 






Alleles Chinese (N=80) Malays (N=80) Indians (N=80) 
1 -3619A>G AA 68 (85.0) 63 (78.8) 65 (81.3) 137 (84.0) A 0.92 (0.88 – 0.96) 0.89 (0.84 – 0.94) 0.89 (0.85 – 0.94) 0.91 (0.88 – 0.94) 
 (rs78721914) AG 11 (13.8) 16 (20.0) 13 (16.3) 23 (14.1) G 0.08 (0.04 – 0.12) 0.11 (0.06 – 0.16) 0.11 (0.06 – 0.15) 0.09 (0.06 – 0.12) 
  GG 1 (1.3) 1 (1.3) 2 (2.5) 3 (1.8)      
2 -3595G>A GG 80 (100.0) 80 (100.0) 79 (98.8)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  GA 0 (0.0) 0 (0.0) 1 (1.3)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
3 -3592T>C TT 80 (100.0) 79 (98.8) 73 (91.3)   T 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.96 (0.92 – 0.99)  
  TC 0 (0.0) 1 (1.3) 7 (8.8)   C 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)‡ 0.04 (0.01 – 0.08)§  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
4 -3402C>T CC 78 (98.7) 72 (90.0) 52 (65.0)   C 0.99 (0.98 – 1.01) 0.95 (0.92 – 0.98) 0.81 (0.75 – 0.87)  
 (*17, rs11188072) CT 1 (1.3) 8 (10.0) 25 (31.3)   T 0.01 (-0.01 – 0.02)† 0.05 (0.02 – 0.08)‡ 0.19 (0.13 – 0.25)§  
  TT 0 (0.0) 0 (0.0) 3 (3.8)        
5 -3332A>C AA 69 (87.3) 70 (87.5) 79 (98.8) 148 (90.8) A 0.94 (0.9 – 0.97) 0.94 (0.9 – 0.98) 0.99 (0.98 – 1.01) 0.95 (0.93 – 0.98) 
 (rs7101258) AC 10 (12.7) 10 (12.5) 1 (1.3) 15 (9.2) C 0.06 (0.03 – 0.10) 0.06 (0.02 – 0.10)‡ 0.01 (-0.01 – 0.02)§ 0.05 (0.02 – 0.07) 
  CC 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
6 -3331C>T CC 77 (97.5) 73 (91.3) 66 (83.5)   C 0.99 (0.97 – 1.00) 0.96 (0.92 – 0.99) 0.91 (0.86 – 0.95)  
  CT 2 (2.5) 7 (8.8) 11 (13.9)   T 0.01 (0.00 – 0.03) 0.04 (0.01 – 0.08) 0.09 (0.05 – 0.14)§  
  TT 0 (0.0) 0 (0.0) 2 (2.5)        
7 -3329G>T GG 77 (97.5) 72 (90.0) 66 (83.5)   G 0.99 (0.97 – 1.00) 0.95 (0.92 – 0.98) 0.91 (0.86 – 0.95)  
  GT 2 (2.5) 8 (10.0) 11 (13.9)   T 0.01 (0.00 – 0.03) 0.05 (0.02 – 0.08) 0.09 (0.05 – 0.14)§  
  TT 0 (0.0) 0 (0.0) 2 (2.5)        
8 -3266G>T GG 40 (50.6) 47 (58.8) 32 (40.5)   G 0.69 (0.62 – 0.76) 0.78 (0.71 – 0.84) 0.64 (0.56 – 0.71)  
 (rs4532967) GT 29 (36.7) 30 (37.5) 37 (46.8)   T 0.31 (0.24 – 0.38) 0.23 (0.16 – 0.29)‡ 0.36 (0.29 – 0.44)  
  TT 10 (12.7) 3 (3.8) 10 (12.7)        
9 -3248C>T CC 79 (100.0) 80 (100.0) 78 (98.7)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  CT 0 (0.0) 0 (0.0) 1 (1.3)   T 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)        
10 -3219T>G  TT 77 (97.5) 72 (90.0) 66 (83.5) 150 (92.0) T 0.99 (0.97 – 1.00) 0.95 (0.92 – 0.98) 0.91 (0.86 – 0.95) 0.96 (0.94 – 0.98) 
  TG 2 (2.5) 8 (10.0) 11 (13.9) 12 (7.4) G 0.01 (0.00 – 0.03) 0.05 (0.02 – 0.08) 0.09 (0.05 – 0.14)§ 0.04 (0.02 – 0.06) 
    GG 0 (0.0) 0 (0.0) 2 (2.5) 1 (0.6)           
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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Table 3.11 Genotypic and allelic frequencies of polymorphisms in CYP2C19 (UCSC RefSeq: NM_000769) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies (95% Confidence Interval) 
Healthy Subjects (N=80) 
Patients 
(N=163) 
 Healthy Subjects (N=80) 






Alleles Chinese (N=80) Malays (N=80) Indians (N=80) 
11 -2772G>A GG 77 (97.5) 74 (92.5) 66 (83.5)   G 0.99 (0.97 – 1.00) 0.96 (0.93 – 0.99) 0.91 (0.86 – 0.95)  
  GA 2 (2.5) 6 (7.5) 11 (13.9)   A 0.01 (0.00 – 0.03) 0.04 (0.01 – 0.07) 0.09 (0.05 – 0.14)§  
  AA 0 (0.0) 0 (0.0) 2 (2.5)        
12 -2720T>C TT 77 (97.5) 71 (89.9) 66 (83.5)   T 0.99 (0.97 – 1.00) 0.94 (0.91 – 0.98) 0.91 (0.86 – 0.95)  
  TC 2 (2.5) 7 (8.9) 11 (13.9)   C 0.01 (0.00 – 0.03) 0.06 (0.02 – 0.09) 0.09 (0.05 – 0.14)§  
  CC 0 (0.0) 1 (1.3) 2 (2.5)        
13 -2306G>A GG 71 (89.9) 78 (98.7) 78 (100.0)   G 0.95 (0.92 – 0.98) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
  GA 8 (10.1) 1 (1.3) 0 (0.0)   A 0.05 (0.02 – 0.08)† 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)§  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
14 -2040C>T CC 73 (92.4) 73 (92.4) 74 (92.5) 157 (96.3) C 0.96 (0.93 – 0.99) 0.96 (0.93 – 0.99) 0.96 (0.93 – 0.99) 0.98 (0.97 – 1.00) 
  CT 6 (7.6) 6 (7.6) 6 (7.5) 6 (3.7) T 0.04 (0.01 – 0.07) 0.04 (0.01 – 0.07) 0.04 (0.01 – 0.07) 0.02 (0.00 – 0.03) 
  TT 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
15 -1504A>G AA 78 (98.7) 80 (100.0) 80 (100.0)   A 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  AG 1 (1.3) 0 (0.0) 0 (0.0)   G 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  GG 0 (0.0) 0 (0.0) 0 (0.0)        
16 -1418C>T CC 67 (84.8) 60 (76.9) 65 (81.3) 136 (83.4) C 0.92 (0.87 – 0.96) 0.88 (0.83 – 0.93) 0.89 (0.85 – 0.94) 0.90 (0.87 – 0.94) 
 (rs3814637) CT 11 (13.9) 17 (21.8) 13 (16.3) 23 (14.1) T 0.08 (0.04 – 0.13) 0.12 (0.07 – 0.17) 0.11 (0.06 – 0.15) 0.10 (0.06 – 0.13) 
  TT 1 (1.3) 1 (1.3) 2 (2.5) 4 (2.5)      
17 -1030G>T GG 79 (100.0) 78 (98.7) 77 (100.0)   G 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
 (rs17882329) GT 0 (0.0) 1 (1.3) 0 (0.0)   T 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)        
18 -889T>G  TT 68 (86.1) 61 (76.3) 64 (82.1)   T 0.93 (0.89 – 0.97) 0.88 (0.82 – 0.93) 0.9 (0.85 – 0.95)  
 (rs11568732) TG 11 (13.9) 18 (22.5) 12 (15.4)   G 0.07 (0.03 – 0.11) 0.13 (0.07 – 0.18) 0.1 (0.05 – 0.15)  
  GG 0 (0.0) 1 (1.3) 2 (2.6)        
19 -843_-842InsT wt/wt 79 (100.0) 79 (98.8) 75 (96.2)   wt 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.98 (0.96 – 1.00)  
 (rs76163838) wt/insT 0 (0.0) 1 (1.3) 3 (3.8)   insT 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.02 (0.00 – 0.04)  
  insT/insT 0 (0.0) 0 (0.0) 0 (0.0)        
20 -806C>T  CC 78 (98.7) 72 (90.0) 52 (65.8) 153 (93.9) C 0.99 (0.98 – 1.01) 0.95 (0.92 – 0.98) 0.81 (0.75 – 0.87) 0.97 (0.95 – 0.99) 
 (*17, rs12248560) CT 1 (1.3) 8 (10.0) 24 (30.4) 10 (6.1) T 0.01 (-0.01 – 0.02)† 0.05 (0.02 – 0.08)‡ 0.19 (0.13 – 0.25)§ 0.03 (0.01 – 0.05) 
    TT 0 (0.0) 0 (0.0) 3 (3.8) 0 (0.0)           
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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Table 3.11 Genotypic and allelic frequencies of polymorphisms in CYP2C19 (UCSC RefSeq: NM_000769) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies (95% Confidence Interval) 
Healthy Subjects (N=80) 
Patients 
(N=163) 







Alleles Chinese (N=80) Malays (N=80) Indians (N=80) 
21 -559T>C TT 77 (97.5) 80 (100.0) 77 (100.0)   T 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  TC 2 (2.5) 0 (0.0) 0 (0.0)   C 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
22 -529G>C GG 74 (98.7) 80 (100.0) 78 (100.0)   G 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  GC 1 (1.3) 0 (0.0) 0 (0.0)   C 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
23 -363C>A CC 78 (100.0) 80 (100.0) 78 (98.7)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00)  
  CA 0 (0.0) 0 (0.0) 0 (0.0)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03)  
  AA 0 (0.0) 0 (0.0) 1 (1.3)        
24 -13G>A GG 74 (100.0) 79 (100.0) 76 (98.7)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  GA 0 (0.0) 0 (0.0) 1 (1.3)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
25 7C>T CC 74 (100.0) 79 (100.0) 78 (98.7)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  CT 0 (0.0) 0 (0.0) 1 (1.3)   T 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)        
26 10T>C TT 74 (100.0) 79 (100.0) 78 (98.7)   T 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  TC 0 (0.0) 0 (0.0) 1 (1.3)   C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
27 99C>T  CC 4 (5.0) 7 (8.9) 5 (6.3)   C 0.1 (0.05 – 0.15) 0.16 (0.1 – 0.22) 0.13 (0.07 – 0.18)  
 (rs17885098) CT 8 (10.0) 11 (13.9) 10 (12.5)   T 0.9 (0.85 – 0.95) 0.84 (0.78 – 0.9) 0.88 (0.82 – 0.93)  
  TT 68 (85.0) 61 (77.2) 65 (81.3)        
28 IVS1+359A>T AA 78 (100.0) 74 (93.7) 60 (75.0)   A 1.00 (1.00 – 1.00) 0.97 (0.94 – 1.00) 0.83 (0.77 – 0.89)  
 (rs7918461) AT 0 (0.0) 5 (6.3) 13 (16.3)   T 0.00 (0.00 – 0.00)† 0.03 (0.00 – 0.06)‡ 0.17 (0.11 – 0.23)§  
  TT 0 (0.0) 0 (0.0) 7 (8.8)        
29 IVS1-340T>G TT 67 (83.8) 62 (77.5) 65 (82.3)   T 0.91 (0.86 – 0.95) 0.88 (0.83 – 0.93) 0.9 (0.85 – 0.95)  
 (rs17884832) TG 11 (13.8) 17 (21.3) 12 (15.2)   G 0.09 (0.05 – 0.14) 0.12 (0.07 – 0.17) 0.1 (0.05 – 0.15)  
  GG 2 (2.5) 1 (1.3) 2 (2.5)        
30 IVS1-231G>A GG 31 (39.2) 31 (38.8) 6 (7.6)   G 0.52 (0.44 – 0.6) 0.57 (0.49 – 0.65) 0.28 (0.21 – 0.35)  
 (rs7916649) GA 20 (25.3) 29 (36.3) 32 (40.5)   A 0.48 (0.4 – 0.56) 0.43 (0.35 – 0.51)‡ 0.72 (0.65 – 0.79)§  
    AA 28 (35.4) 20 (25.0) 41 (51.9)               
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 




Table 3.11 Genotypic and allelic frequencies of polymorphisms in CYP2C19 (UCSC RefSeq: NM_000769) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies (95% Confidence Interval) 
Healthy Subjects (N=80) 
Patients 
(N=163) 
 Healthy Subjects (N=80) 






Alleles Chinese (N=80) Malays (N=80) Indians (N=80) 
31 IVS1-47G>A GG 64 (83.1) 69 (86.3) 77 (96.3)   G 0.91 (0.86 – 0.95) 0.93 (0.88 – 0.97) 0.98 (0.96 – 1.00)  
 (rs17878649) GA 12 (15.6) 10 (12.5) 3 (3.8)   A 0.09 (0.05 – 0.14) 0.08 (0.03 – 0.12) 0.02 (0.00 – 0.04)  
  AA 1 (1.3) 1 (1.3) 0 (0.0)        
32 276G>C GG 80 (100.0) 79 (98.8) 80 (100.0)   G 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
 (rs17878459) GC 0 (0.0) 1 (1.3) 0 (0.0)   C 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
33 IVS2-23A>G AA 42 (53.2) 48 (60.0) 31 (38.8)   A 0.7 (0.63 – 0.77) 0.79 (0.72 – 0.85) 0.63 (0.56 – 0.71)  
 (rs12769205) AG 27 (34.2) 30 (37.5) 39 (48.8)   G 0.3 (0.23 – 0.37) 0.21 (0.15 – 0.28)‡ 0.37 (0.29 – 0.44)  
  GG 10 (12.7) 2 (2.5) 10 (12.5)        
34 431G>A  GG 78 (100.0) 78 (100.0) 79 (98.8)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
 (*9, rs17884712) GA 0 (0.0) 0 (0.0) 1 (1.3)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
35 IVS3+332 T>C TT 66 (84.6) 62 (77.5) 69 (86.3)   T 0.92 (0.87 – 0.96) 0.87 (0.82 – 0.92) 0.93 (0.89 – 0.97)  
 (rs17879992) TC 11 (14.1) 15 (18.8) 11 (13.8)   C 0.08 (0.04 – 0.13) 0.13 (0.08 – 0.18) 0.07 (0.03 – 0.11)  
  CC 1 (1.3) 3 (3.8) 0 (0.0)        
36 IVS3-270_-269DelTT wt/wt 77 (97.5) 71 (91.0) 66 (83.5)   wt 0.99 (0.97 – 1.00) 0.96 (0.92 – 0.99) 0.91 (0.86 – 0.95)  
 (rs17885417) wt/delTT 2 (2.5) 7 (9.0) 11 (13.9)   delTT 0.01 (0.00 – 0.03) 0.04 (0.01 – 0.08) 0.09 (0.05 – 0.14)§  
  delTT/delTT 0 (0.0) 0 (0.0) 2 (2.5)        
37 518C>T CC 77 (100.0) 79 (100.0) 72 (90.0) 161 (98.8) C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.95 (0.92 – 0.98) 0.99 (0.99 – 1.00) 
 (rs61311738) CT 0 (0.0) 0 (0.0) 8 (10.0) 2 (1.2) T 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)‡ 0.05 (0.02 – 0.08)§ 0.01 (0.00 – 0.01) 
  TT 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
38 636G>A  GG 68 (89.5) 69 (87.3) 79 (98.8) 147 (90.2) G 0.95 (0.91 – 0.98) 0.94 (0.9 – 0.97) 0.99 (0.98 – 1.01) 0.95 (0.92 – 0.97) 
 (*3, rs4986893) GA 8 (10.5) 10 (12.7) 1 (1.3) 15 (9.2) A 0.05 (0.02 – 0.09) 0.06 (0.03 – 0.10)‡ 0.01 (-0.01 – 0.02)§ 0.05 (0.03 – 0.08) 
  AA 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)      
39 IVS4-205A>G AA 67 (84.8) 61 (77.2) 64 (82.1)   A 0.92 (0.87 – 0.96) 0.88 (0.83 – 0.93) 0.9 (0.85 – 0.95)  
 (rs7088784) AG 11 (13.9) 17 (21.5) 12 (15.4)   G 0.08 (0.04 – 0.13) 0.12 (0.07 – 0.17) 0.1 (0.05 – 0.15)  
  GG 1 (1.3) 1 (1.3) 2 (2.6)        
40 IVS4-152A>G AA 79 (100.0) 78 (98.7) 78 (100.0)   A 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
  AG 0 (0.0) 1 (1.3) 0 (0.0)   G 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
    GG 0 (0.0) 0 (0.0) 0 (0.0)               
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 




Table 3.11 Genotypic and allelic frequencies of polymorphisms in CYP2C19 (UCSC RefSeq: NM_000769) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies 
Healthy Subjects (N=80) 
Patients 
(N=163) 
 Healthy Subjects (N=80) 






Alleles Chinese (N=80) Malays (N=80) Indians (N=80) 
41 681G>A  GG 39 (50.6) 47 (59.5) 31 (39.2) 72 (44.2) G 0.69 (0.62 – 0.76) 0.78 (0.71 – 0.84) 0.63 (0.56 – 0.71) 0.65 (0.60 – 0.70) 
 (*2, rs4244285) GA 28 (36.4) 29 (36.7) 38 (48.1) 67 (41.1) A 0.31 (0.24 – 0.38) 0.22 (0.16 – 0.29)‡ 0.37 (0.29 – 0.44) 0.35 (0.30 – 0.40) 
  AA 10 (13.0) 3 (3.8) 10 (12.7) 24 (14.7)      
42 784G>A GG 78 (100.0) 78 (98.7) 79 (100.0)   G 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
  GA 0 (0.0) 1 (1.3) 0 (0.0)   A 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
43 IVS5+228A>G AA 38 (51.4) 45 (57.0) 31 (39.2)   A 0.69 (0.61 – 0.76) 0.76 (0.69 – 0.83) 0.63 (0.56 – 0.71)  
 (rs12571421) AG 26 (35.1) 30 (38.0) 38 (48.1)   G 0.31 (0.24 – 0.39) 0.24 (0.17 – 0.31)‡ 0.37 (0.29 – 0.44)  
  GG 10 (13.5) 4 (5.1) 10 (12.7)        
44 IVS5-203G>C GG 79 (98.8) 79 (100.0) 80 (100.0)   G 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  GC 1 (1.3) 0 (0.0) 0 (0.0)   C 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
45 IVS5-189A>T AA 78 (97.5) 71 (89.9) 67 (83.8)   A 0.99 (0.97 – 1.00) 0.95 (0.92 – 0.98) 0.91 (0.86 – 0.95)  
 (rs55732648) AT 2 (2.5) 8 (10.1) 11 (13.8)   T 0.01 (0.00 – 0.03) 0.05 (0.02 – 0.08) 0.09 (0.05 – 0.14)§  
  TT 0 (0.0) 0 (0.0) 2 (2.5)        
46 IVS5-154DelG wt/wt 69 (86.3) 69 (86.3) 79 (98.8)   wt 0.93 (0.89 – 0.97) 0.93 (0.89 – 0.97) 0.99 (0.98 – 1.01)  
 (rs56007608) wt/delG 11 (13.8) 11 (13.8) 1 (1.3)   T 0.07 (0.03 – 0.11) 0.07 (0.03 – 0.11) 0.01 (-0.01 – 0.02)§  
  delG/delG 0 (0.0) 0 (0.0) 0 (0.0)        
47 IVS5-123T>C TT 77 (98.7) 78 (100.0) 80 (100.0)   T 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  TC 1 (1.3) 0 (0.0) 0 (0.0)   C 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
48 IVS5-113T>G TT 77 (98.7) 70 (89.7) 67 (83.8)   T 0.99 (0.98 – 1.01) 0.95 (0.91 – 0.98) 0.91 (0.86 – 0.95)  
 (rs28399511) TG 1 (1.3) 8 (10.3) 11 (13.8)   G 0.01 (-0.01 – 0.02)† 0.05 (0.02 – 0.09) 0.09 (0.05 – 0.14)§  
  GG 0 (0.0) 0 (0.0) 2 (2.5)        
49 IVS5-51C>G  CC 40 (50.6) 45 (58.4) 31 (38.8)   C 0.69 (0.62 – 0.76) 0.77 (0.71 – 0.84) 0.63 (0.56 – 0.71)  
 (rs4417205) CG 29 (36.7) 29 (37.7) 39 (48.8)   G 0.31 (0.24 – 0.38) 0.23 (0.16 – 0.29)‡ 0.37 (0.29 – 0.44)  
  GG 10 (12.7) 3 (3.9) 10 (12.5)        
50 IVS6+259C>G CC 78 (98.7) 79 (100.0) 74 (92.5)   C 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 0.96 (0.93 – 0.99)  
 (rs17882345) CG 1 (1.3) 0 (0.0) 6 (7.5)   G 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)‡ 0.04 (0.01 – 0.07)  
    GG 0 (0.0) 0 (0.0) 0 (0.0)               
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 




Table 3.11 Genotypic and allelic frequencies of polymorphisms in CYP2C19 (UCSC RefSeq: NM_000769) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%)   Allelic Frequencies 




Healthy Subjects (N=80) 






Alleles Chinese (N=80) Malays (N=80) Indians (N=80) 
61 IVS8-119C>T CC 77 (98.7) 70 (88.6) 52 (65.8)   C 0.99 (0.98 – 1.01) 0.94 (0.91 – 0.98) 0.81 (0.75 – 0.87)  
 (rs12268020) CT 1 (1.3) 9 (11.4) 24 (30.4)   T 0.01 (-0.01 – 0.02)† 0.06 (0.02 – 0.09)‡ 0.19 (0.13 – 0.25)§  
  TT 0 (0.0) 0 (0.0) 3 (3.8)        
62 *1168G>A GG 79 (100.0) 75 (100.0) 79 (98.8)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  GA 0 (0.0) 0 (0.0) 1 (1.3)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
63 *1189_*1191DelCCA wt/wt 78 (98.7) 72 (90.0) 58 (72.5)   wt 0.99 (0.98 – 1.01) 0.95 (0.92 – 0.98) 0.86 (0.81 – 0.92)  
  wt/delCCA 1 (1.3) 8 (10.0) 22 (27.5)   delCCA 0.01 (-0.01 – 0.02)† 0.05 (0.02 – 0.08)‡ 0.14 (0.08 – 0.19)§  
  delCCA/delCCA 0 (0.0) 0 (0.0) 0 (0.0)        
64 *1264C>G CC 68 (86.1) 69 (86.3) 80 (100.0) 148 (90.8) C 0.93 (0.89 – 0.97) 0.93 (0.89 – 0.97) 1.00 (1.00 – 1.00) 0.95 (0.93 – 0.98) 
  CG 11 (13.9) 11 (13.8) 0 (0.0) 15 (9.2) G 0.07 (0.03 – 0.11) 0.07 (0.03 – 0.11)‡ 0.00 (0.00 – 0.00)§ 0.05 (0.02 – 0.07) 
  GG 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
65 *2054G>T GG 40 (50.6) 46 (58.2) 32 (40.5) 73 (44.8) G 0.69 (0.62 – 0.76) 0.77 (0.71 – 0.84) 0.65 (0.57 – 0.72) 0.65 (0.60 – 0.71) 
  GT 29 (36.7) 30 (38.0) 38 (48.1) 67 (41.1) T 0.31 (0.24 – 0.38) 0.23 (0.16 – 0.29)‡ 0.35 (0.28 – 0.43) 0.35 (0.29 – 0.40) 
  TT 10 (12.7) 3 (3.8) 9 (11.4) 23 (14.1)      
66 *2438T>C TT 79 (100.0) 79 (100.0) 76 (96.2)   T 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.98 (0.96 – 1.00)  
  TC 0 (0.0) 0 (0.0) 3 (3.8)   C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.02 (0.00 – 0.04)  
    CC 0 (0.0) 0 (0.0) 0 (0.0)               
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 




3.3.3.2 LD Analysis of CYP2C19 Polymorphisms 
Pairwise LD analyses performed in each of the three ethnic groups (Figs 3.5A – C) 
showed that polymorphisms in the 5′ upstream region were found to be in strong 
linkage with specific polymorphisms in the exonic, intronic or 3′ downstream regions 
across all three ethnicities. Of note, the functional polymorphism 636G>A (*3; 
rs4986893) was in high LD with 1251A>C (rs17886522), -3332A>C (rs7101258) and 
IVS5-154DelG (rs56007608) (│D'│=1, R2 >0.88). Similarly, 681G>A (*2; rs4244285) 
was found to be in tight linkage with five other polymorphic variants [-3266G>T, 
IVS2-23A>G (rs12769205), IVS5+228A>G (rs12571421), IVS5-51C>G (rs4417205) 
and *+2054G>T (│D'│>0.95, R2 >0.89)]. Similar to previous reports, -806C>T (*17; 
rs12248560) was in complete LD with -3402C>T (*17; rs11188072). Both 
polymorphisms were also strongly linked to IVS8-119C>T (rs12268020) (│D'│=1, 
R2 >0.88). 
Additionally, strong linkage patterns were observed between the following 
polymorphic variants across the three Asian populations: -3219T>G with -3331C>T, -
3329G>T, -2720T>C, IVS5-189A>T (rs55732648) and IVS5-113T>G (rs28399511) 
(│D'│=1, R2 >0.86); -1418C>T (rs3814637) with -3619A>G (rs78721914) and IVS4-
205A>G (rs7088784) (│D'│=1, R2 >0.93); IVS7-201G>A (rs17882222) with -
2040C>T (│D'│=1, R2 =1); IVS6-196T>A (rs28399513) with 990C>T (rs3758580) 
(│D'│>0.97, R2 >0.88).  
3.3.3.3 Selection of CYP2C19 tag-SNPs 
Tag-SNPs representative of the entire CYP2C19 gene region were selected by 
application of pairwise tagging to all SNPs in TAGGER (Haploview 4.2, Broad 
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institute USA). A total of 14 common tag-SNPs were identified in the three Asian 
populations [-3619A>G, -3332A>C (rs7101258), -3219T>G, -2040C>T, -1418C>T 
(rs3814637), -806C>T (*17; rs12248560), 518C>T (rs61311738), 636G>A (*3, 
rs4986893), 681G>A (*2; rs4244285), 990C>T (rs3758580), IVS7-106T>C 
(rs4917623), 1251A>C (rs17886522), *+1264C>G and *+2054G>T] and genotyped 
in 164 Asian breast cancer patients. The genotypic and allelic frequencies of tag-




Fig 3.5 LD matrix for CYP2C19 polymorphisms in (A) Chinese, 
(B) Malays, and (C) Indians. 
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3.3.3.4 Influence of CYP2C19 Polymorphisms on the Plasma Levels of Tamoxifen 
and its Metabolites 
A total of 14 tag-SNPs were investigated for their phenotypic effect on disposition of 
tamoxifen. The median plasma levels of tamoxifen and the three metabolites 
observed in patients within each genotypic group of the 14 SNPs are depicted in 
Table 3.12. The effect of the exonic polymorphism 518C>T (rs61311738) was not 
further analysed as there were only two heterozygote carriers. Modest increases in 
the plasma concentrations of tamoxifen and NDM were found to be associated with 
1251A>C (rs17886522). Patients carrying one or two copies of the variant allele of 
1251A>C (rs17886522) were found to have 1.3-fold higher median (range) plasma 
tamoxifen [AA vs AC+CC: 197.48 (39.26 – 599.91) vs 254.76 (184.28 – 364.69), P = 
0.042] and NDM [AA vs AC+CC: 300.49 (40.82 – 802.98) vs 377.26 (215.01 – 
590.65), P = 0.043] concentrations. 
3.3.3.5 Influence of CYP2C19 Polymorphisms on the Metabolic Ratios of Tamoxifen 
and its Metabolites 
Among the 14 SNPs included in the study, six polymorphic variants were found to 
significantly affect the metabolic ratios (MRs) of tamoxifen: -3332A>C (rs7101258), -
3219T>G, -1418C>T (rs3814637), 636G>A (*3; rs4986893), 1251A>C (rs17886522) 
and *+1264C>G in the exploratory analyses (P < 0.05). For specific polymorphisms 
[-3219T>G, 636G>A (*3; rs4986893) and 1251A>C (rs17886522)] which had only 
one patient carrying the homozygous variant genotype, the patient harbouring the 
variant genotype was grouped with the heterozygous carriers during analyses. The 
median MR4-OHT-TAM observed in patients who were heterozygous or homozygous 
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variant for -3332A>C (rs7101258), 636G>A (*3; rs4986893), 1251A>C (rs17886522) 
or *+1264C>G was 9.6% to 12.5% lower than the reference genotype group (P < 
0.05, Table 3.12). Similarly, the -1418C>T (rs3814637) polymorphism was linked to 
a gene-dose dependent decrease in median (range) MR4-OHT-TAM [CC vs CT vs TT: 
1.05 (0.19 – 2.35) vs 0.96 (0.43 – 1.64) vs 0.56 (0.39 – 0.99), P = 0.019] (Table 
3.12). Furthermore, 1251A>C (rs17886522) was also associated with a 2.3-fold 
reduction in the median (range) MREND-NDM [AA vs AC+CC: 5.14 (0.92 – 27.81) vs 
2.25 (1.26 – 10.72), P = 0.026] (Table 3.12).  
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Table 3.12 Effect of CYP2C19 polymorphisms on steady state plasma levels and metabolic ratios of tamoxifen and its metabolites (N=163). 





AA (N=137) AG (N=23) GG (N=3) AA vs AG AA vs GG AG vs GG 
Overall P 
values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 204.38 (50.06 – 599.91) 211.17 (39.26 – 362.76) 191.32 (147.73 – 364.69) 0.685 0.925 0.904 0.920 
       [-8.45 (-44.40 – 31.79)] [-6.29 (-159.75 – 112.06)] [-1.93 (-154.00 – 110.16)]  
NDM 301.79 (40.82 – 802.98) 317.19 (78.46 – 590.65) 337.13 (302.51 – 536.83) 0.765 0.310 0.446 0.586 
       [-8.17 (-65.53 – 53.53)] [-62.54 (-236.34 – 95.11)] [-62.32 (-240.11 – 111.52)]  
4-OHT 2.05 (0.7 – 5.33) 1.92 (0.47 – 3.82) 1.42 (0.75 – 1.89) 0.558 0.097 0.138 0.215 
       [0.10 (-0.24 – 0.54)] [0.82 (-0.12 – 1.93)] [0.70 (-0.22 – 1.68)]  
Endoxifen 13.39 (1.74 – 42.8) 14.57 (1.79 – 39.47) 7.91 (6.56 – 15.85) 0.765 0.259 0.316 0.510 
       [-0.57 (-4.75 – 2.99)] [3.92 (-3.56 – 15.20)] [5.78 (-3.89 – 16.18)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.53 (1 – 2) 1.58 (1.47 – 2.28) 0.761 0.392 0.356 0.650 
       [0.02 (-0.13 – 0.18)] [-0.21 (-0.75 – 0.26)] [-0.23 (-0.79 – 0.16)]  
MR4-OHT/TAM (×100) 1.04 (0.19 – 2.35) 0.97 (0.43 – 1.64) 0.51 (0.39 – 0.99) 0.285 0.048 0.118 0.087 
       [0.08 (-0.07 – 0.25)] [0.45 (0.00 – 0.93)] [0.42 (-0.04 – 0.70)]  
MREND/NDM (×100) 4.78 (0.92 – 27.81) 6.07 (1.26 – 14.86) 1.95 (1.47 – 5.24) 0.754 0.109 0.118 0.258 
       [-0.19 (-1.68 – 0.90)] [1.58 (-0.74 – 5.62)] [2.03 (-0.69 – 6.33)]  
-3332A>C 
(rs7101258) 
AA (N=148) AC (N=15)     AA vs AC       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 197.42 (39.26 – 599.91) 254.76 (164.79 – 364.69)   0.053    
       [-41.78 (-81.28 – 0.97)]    
NDM 300.98 (40.82 – 802.98) 377.26 (215.01 – 590.65)   0.057    
       [-61.13 (-128.23 – 3.46)]    
4-OHT 1.98 (0.47 – 5.33) 1.92 (1.10 – 3.82)   0.936    
       [0.02 (-0.38 – 0.48)]    
Endoxifen 13.55 (1.74 – 42.8) 13.69 (4.74 – 23.04)   0.550    
       [0.97 (-2.64 – 5.47)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.53 (1.06 – 1.95)   0.730    
       [0.03 (-0.16 – 0.19)]    
MR4-OHT/TAM (×100) 1.04 (0.19 – 2.35) 0.94 (0.39 – 1.40)   0.044    
       [0.19 (0.01 – 0.38)]    
MREND/NDM (×100) 5.08 (0.92 – 27.81) 3.50 (1.26 – 10.72)   0.103    
       [0.86 (-0.21 – 2.71)]    
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.12 Effect of CYP2C19 polymorphisms on steady state plasma levels and metabolic ratios of tamoxifen and its metabolites (N=163) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence IntervalI)] 
†
 
-3219T>G TT (N=150) TG + GG (N=13) 
    TT vs TG + GG       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 207.39 (50.06 – 599.91) 185.67 (39.26 – 364.69)   0.247    
       [28.15 (-21.40 – 81.67)]    
NDM 304.64 (40.82 – 802.98) 296.72 (78.46 – 536.83)   0.429    
       [28.76 (-43.10 – 112.57)]    
4-OHT 2.02 (0.7 – 5.33) 1.67 (0.47 – 3.42)   0.089    
       [0.45 (-0.08 – 1.01)]    
Endoxifen 13.40 (1.74 – 42.8) 15.64 (1.79 – 39.47)   0.709    
       [-0.98 (-7.55 – 4.30)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.58 (1 – 2.28)   0.759    
       [-0.03 (-0.24 – 0.18)]    
MR4-OHT/TAM (×100) 1.01 (0.19 – 2.35) 0.99 (0.39 – 1.64)   0.571    
       [0.05 (-0.16 – 0.30)]    
MREND/NDM (×100) 4.54 (0.92 – 27.81) 6.11 (1.47 – 14.86)   0.301    
       [-0.89 (-3.30 – 0.66)]    
-2040C>T CC (N=157) CT (N=6)     CC vs CT       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 205.16 (39.26 – 599.91) 193.69 (156.87 – 307.42)   0.764    
       [7.09 (-46.84 – 76.29)]    
NDM 302.95 (40.82 – 802.98) 327.38 (273.94 – 446.3)   0.672    
       [-12.97 (-94.62 – 80.52)]    
4-OHT 1.93 (0.47 – 5.33) 2.34 (1.92 – 2.48)   0.454    
       [-0.29 (-0.75 – 0.55)]    
Endoxifen 13.42 (1.74 – 42.8) 19.35 (8.85 – 23.78)   0.319    
       [-2.48 (-9.70 – 4.27)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.57 (0.62 – 2.76) 1.49 (1.28 – 2.31)   0.475    
       [-0.14 (-0.51 – 0.21)]    
MR4-OHT/TAM (×100) 1.00 (0.19 – 2.35) 1.12 (0.81 – 1.5)   0.378    
       [-0.12 (-0.42 – 0.19)]    
MREND/NDM (×100) 4.78 (0.92 – 27.81) 5.58 (2.45 – 8.27)   0.543    
       [-0.53 (-3.08 – 2.09)]    
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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CC (N=136) CT (N=23) TT (N=4) CC vs CT CC vs TT CT vs TT 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 202.10 (50.06 – 599.91) 214.57 (39.26 – 362.76) 190.61 (147.73 –  364.69) 0.391 1.000 0.785 0.695 
       [-17.27 (-52.31 – 24.84)] [0.11 (-95.72 – 89.80)] [19.61 (-106.80 – 106.57)]  
NDM 300.98 (40.82 – 802.98) 323.23 (78.46 – 590.65) 319.82 (301.83 –  536.83) 0.472 0.361 0.733 0.539 
       [-18.53 (-76.1 – 42.9)] [-44.75 (-162.16 – 79.68)] [-21.20 (-196.60 – 105.33)]  
4-OHT 2.06 (0.7 – 5.33) 1.92 (0.47 – 3.82) 1.29 (0.75 –  1.89) 0.560 0.030 0.076 0.087 
       [0.11 (-0.24 – 0.55)] [0.83 (0.11 – 1.74)] [0.70 (-0.11 – 1.66)]  
Endoxifen 13.55 (1.74 – 42.8) 14.57 (1.79 – 39.47) 7.23 (6.55 –  15.85) 0.992 0.087 0.172 0.242 
       [0.02 (-3.98 – 3.55)] [4.83 (-0.65 – 14.31)] [5.60 (-1.51 – 16.18)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.49 (1 – 2) 1.59 (1.47 –  2.28) 0.667 0.431 0.339 0.647 
       [0.03 (-0.12 – 0.19)] [-0.16 (-0.56 – 0.21)] [-0.17 (-0.62 – 0.13)]  
MR4-OHT/TAM (×100) 1.05 (0.19 – 2.35) 0.96 (0.43 – 1.64) 0.56 (0.39 –  0.99) 0.133 0.017 0.065 0.022 
       [0.12 (-0.03 – 0.29)] [0.45 (0.08 – 0.83)] [0.38 (-0.02 – 0.60)]  
MREND/NDM (×100) 5.00 (0.92 – 27.81) 4.97 (1.26 – 14.86) 2.06 (1.47 –  5.24) 0.875 0.047 0.101 0.144 
       [0.08 (-1.33 – 1.21)] [1.99 (0.04 – 5.04)] [1.91 (-0.22 – 5.90)]  
-806C>T (*17, 
rs12248560) 
CC (N=153) CT (N=10)     CC vs CT       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 205.16 (39.26 – 599.91) 166.42 (100.24 – 
369.89) 
  0.232    
       [30.40 (-20.19 – 81.47)]    
NDM 304.05 (40.82 – 802.98) 279.42 (159.67 – 
403.52) 
  0.198    
       [47.34 (-25.19 – 118.13)]    
4-OHT 1.93 (0.47 – 5.33) 2.49 (0.96 – 3.75)   0.638    
       [-0.18 (-0.82 – 0.46)]    
Endoxifen 13.69 (1.74 – 42.8) 15.60 (6.37 – 31.05)   0.511    
       [-2.10 (-8.21 – 3.27)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.67 (0.92 – 1.93)   0.983    
       [0.00 (-0.22 – 0.24)]    
MR4-OHT/TAM (×100) 1.00 (0.19 – 2.26) 1.15 (0.55 – 2.35)   0.182    
       [-0.18 (-0.51 – 0.10)]    
MREND/NDM (×100) 4.78 (0.92 – 27.81) 5.92 (2.66 – 11.85)   0.141    
       [-1.26 (-3.24 – 0.71)]    
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CC (N=161) CT (N=2)     CC vs CT       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 204.94 (39.26 – 599.91) 224.94 (186.28 – 263.6)   0.775    
       [-15.20 (-122.16 – 133.78)]    
NDM 302.95 (40.82 – 802.98) 258.73 (206.96 – 310.51)   0.390    
       [59.37 (-91.55 – 262.89)]    
4-OHT 1.94 (0.47 – 5.33) 2.83 (2.23 – 3.43)   0.234    
       [-0.62 (-2.08 – 0.92)]    
Endoxifen 13.69 (1.74 – 42.8) 15.52 (11.43 – 19.61)   0.809    
       [-1.78 (-12.26 – 13.80)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.57 (0.62 – 2.76) 1.14 (1.11 – 1.18)   0.066    
       [0.42 (-0.04 – 0.85)]    
MR4-OHT/TAM (×100) 1.00 (0.19 – 2.35) 1.25 (1.2 – 1.3)   0.335    
       [-0.23 (-0.69 – 0.44)]    
MREND/NDM (×100) 4.78 (0.92 – 27.81) 5.92 (5.52 – 6.31)   0.557    
       [-1.16 (-4.23 – 3.94)]    
636G>A (*3, 
rs4986893) 
GG (N=147) GA (N=16)     GG vs GA + AA       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 197.48 (39.26 – 599.91) 246.92 (164.79 – 364.69)   0.070    
       [-37.02 (-75.19 – 2.82)]    
NDM 300.49 (40.82 – 802.98) 350.25 (215.01 – 590.65)   0.066    
       [-54.58 (-116.19 – 6.75)]    
4-OHT 2.00 (0.47 – 5.33) 1.91 (1.1 – 3.82)   0.659    
       [0.08 (-0.30 – 0.55)]    
Endoxifen 13.69 (1.74 – 42.8) 12.83 (4.74 – 23.04)   0.343    
       [1.59 (-1.80 – 5.84)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.56 (1.06 – 1.95)   0.763    
       [0.02 (-0.15 – 0.18)]    
MR4-OHT/TAM (×100) 1.04 (0.19 – 2.35) 0.92 (0.39 – 1.4)   0.022    
       [0.21 (0.03 – 0.39)]    
MREND/NDM (×100) 5.14 (0.92 – 27.81) 2.88 (1.26 – 10.72)   0.061    
       [0.97 (-0.04 – 2.81)]    
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GG (N=72) GA (N=67) AA (N=24) GG vs GA GG vs AA GA vs AA 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 203.84 (50.06 – 578.17) 204.94 (39.26 – 599.91) 212.39 (84.27 – 421.16) 0.919 0.800 0.815 0.962 
       [-1.60 (-28.87 – 28.02)] [-4.79 (-48.63 – 33.38)] [-6.47 (-48.16 – 35.06)]  
NDM 337.62 (40.82 – 734.94) 291.48 (78.46 – 802.98) 307.35 (84.77 – 757.13) 0.428 0.582 0.964 0.699 
       [15.28 (-27.97 – 58.97)] [16.54 (-44.48 – 73.26)] [-0.72 (-57.41 – 55.60)]  
4-OHT 1.90 (0.7 – 5.02) 1.97 (0.47 – 5.33) 2.32 (0.87 – 4.51) 0.575 0.412 0.540 0.648 
       [-0.08 (-0.37 – 0.21)] [-0.18 (-0.71 – 0.25)] [-0.13 (-0.58 – 0.28)]  
Endoxifen 11.47 (3.48 – 42.8) 14.38 (1.79 – 42.56) 16.37 (1.74 – 28.64) 0.538 0.253 0.349 0.456 
       [-0.70 (-3.18 – 1.83)] [-2.28 (-6.58 – 1.66)] [-1.62 (-5.61 – 2.08)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.60 (0.82 – 2.76) 1.54 (0.62 – 2.65) 1.44 (1.01 – 2.1) 0.481 0.134 0.377 0.336 
       [0.04 (-0.09 – 0.17)] [0.13 (-0.04 – 0.29)] [0.07 (-0.08 – 0.23)]  
MR4-OHT/TAM (×100) 0.99 (0.39 – 2.35) 1.02 (0.19 – 1.84) 1.01 (0.55 – 2.1) 0.495 0.594 0.921 0.752 
       [-0.04 (-0.19 – 0.09)] [-0.05 (-0.25 – 0.13)] [-0.01 (-0.20 – 0.19)]  
MREND/NDM (×100) 3.88 (1.06 – 14.86) 5.17 (0.92 – 27.81) 5.78 (1.73 – 10) 0.714 0.417 0.488 0.681 
       [-0.15 (-1.14 – 0.65)] [-0.56 (-2.26 – 0.61)] [-0.40 (-1.78 – 0.78)]  
990C>T 
(rs3758580) 
CC (N=73) CT (N=66) TT (N=24) CC vs CT CC vs TT CT vs TT 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 205.16 (50.06 – 578.17) 209.03 (39.26 – 599.91) 183.47 (84.27 – 421.16) 0.896 0.783 0.756 0.945 
       [-1.91 (-29.16 – 27.94)] [6.55 (-35.90 – 44.29)] [8.02 (-35.41 – 46.31)]  
NDM 338.11 (40.82 – 734.94) 292.38 (78.46 – 802.98) 296.62 (84.77 – 757.13) 0.430 0.270 0.622 0.498 
       [15.52 (-28.05 – 59.96)] [31.12 (-25.92 – 87.56)] [13.61 (-40.88 – 69.32)]  
4-OHT 1.89 (0.7 – 5.02) 1.98 (0.47 – 5.33) 2.32 (0.87 – 4.51) 0.481 0.447 0.609 0.638 
       [-0.09 (-0.38 – 0.20)] [-0.17 (-0.71 – 0.25)] [-0.12 (-0.57 – 0.32)]  
Endoxifen 10.97 (3.48 – 42.8) 14.43 (1.79 – 42.56) 16.37 (1.74 – 28.64) 0.521 0.165 0.290 0.347 
       [-0.71 (-3.21 – 1.71)] [-2.84 (-6.93 – 1.34)] [-1.95 (-5.81 – 1.81)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.60 (0.82 – 2.76) 1.53 (0.62 – 2.65) 1.44 (1.01 – 2.1) 0.406 0.160 0.465 0.357 
       [0.05 (-0.08 – 0.18)] [0.13 (-0.05 – 0.29)] [0.06 (-0.09 – 0.23)]  
MR4-OHT/TAM (×100) 0.99 (0.39 – 2.35) 1.02 (0.19 – 1.84) 1.09 (0.57 – 2.1) 0.468 0.312 0.590 0.543 
       [-0.04 (-0.19 – 0.09)] [-0.10 (-0.30 – 0.09)] [-0.05 (-0.24 – 0.13)]  
MREND/NDM (×100) 3.87 (1.06 – 14.86) 5.16 (0.92 – 27.81) 6.18 (1.82 – 10) 0.673 0.198 0.247 0.391 
       [-0.18 (-1.14 – 0.62)] [-0.99 (-2.54 – 0.38)] [-0.75 (-2.05 – 0.56)]  
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TT (N=39) TC (N=84) CC (N=40) TT vs TC TT vs CC TC vs CC 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 191.32 (39.26 – 421.16) 207.81 (51.8 – 599.91) 205.19 (50.06 – 578.17) 0.913 0.984 0.962 0.996 
       [-1.89 (-30.51 – 30.1)] [-0.75 (-41.00 – 36.66)] [-0.75 (-36.56 – 32.25)]  
NDM 302.51 (78.46 – 757.13) 298.57 (105.23 – 802.98) 346.62 (40.82 – 734.94) 0.991 0.468 0.532 0.761 
       [-0.29 (-48.99 – 42.43)] [-21.34 (-76.50 – 36.66)] [-14.69 (-67.54 – 30.73)]  
4-OHT 1.92 (0.47 – 4.51) 2.09 (0.72 – 5.33) 1.79 (0.7 – 5.02) 0.572 0.914 0.471 0.725 
       [-0.10 (-0.44 – 0.25)] [0.03 (-0.34 – 0.38)] [0.11 (-0.21 – 0.47)]  
Endoxifen 15.85 (1.74 – 28.64) 14.31 (3.83 – 42.56) 10.40 (3.48 – 42.8) 0.769 0.290 0.278 0.471 
       [0.30 (-2.83 – 3.56)] [2.28 (-1.57 – 6.21)] [1.44 (-1.19 – 4.63)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.47 (1.01 – 2.28) 1.56 (0.62 – 2.65) 1.64 (0.82 – 2.76) 0.672 0.232 0.339 0.465 
       [-0.03 (-0.16 – 0.11)] [-0.11 (-0.27 – 0.06)] [-0.07 (-0.22 – 0.08)]  
MR4-OHT/TAM (×100) 0.99 (0.39 – 2.1) 1.05 (0.19 – 2.35) 0.99 (0.46 – 2.26) 0.367 0.945 0.443 0.587 
       [-0.07 (-0.23 – 0.08)] [-0.01 (-0.18 – 0.16)] [0.05 (-0.09 – 0.22)]  
MREND/NDM (×100) 5.33 (1.47 – 10) 5.16 (0.92 – 27.81) 3.15 (1.06 – 13.58) 0.948 0.462 0.237 0.517 
       [-0.04 (-0.95 – 1.08)] [0.47 (-0.51 – 2.29)] [0.53 (-0.36 – 1.71)]  
1251A>C 
(rs17886522) 
AA (N=148) AC (N=15)     AA vs AC + CC       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 197.42 (39.26 – 599.91) 254.76 (184.28 – 364.69)   0.040    
       [-43.42 (-82.19 – -3.62)]    
NDM 300.48 (40.82 – 802.98) 377.26 (215.01 – 590.65)   0.042    
       [-64.45 (-128.79 – -2.59)]    
4-OHT 1.98 (0.47 – 5.33) 1.92 (1.1 – 3.82)   0.783    
       [0.05 (-0.35 – 0.54)]    
Endoxifen 13.73 (1.74 – 42.8) 11.96 (4.74 – 23.04)   0.256    
       [1.97 (-1.41 – 6.48)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.53 (1.06 – 1.95)   0.709    
       [0.03 (-0.15 – 0.2)]    
MR4-OHT/TAM (×100) 1.04 (0.19 – 2.35) 0.91 (0.39 – 1.4)   0.018    
       [0.23 (0.04 – 0.41)]    
MREND/NDM (×100) 5.14 (0.92 – 27.81) 2.25 (1.26 – 10.72)   0.028    
       [1.17 (0.12 – 3.12)]    
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence IntervalI)] 
†
 
*1264C>G CC (N=148) CG (N=15)     CC vs CG       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 197.42 (39.26 – 599.91) 254.76 (164.79 – 
364.69) 
  0.053    
       [-41.78 (-81.28 – 0.97)]    
NDM 300.98 (40.82 – 802.98) 377.26 (215.01 – 
590.65) 
  0.057    
       [-61.13 (-128.23 – 3.46)]    
4-OHT 1.98 (0.47 – 5.33) 1.92 (1.1 – 3.82)   0.936    
       [0.02 (-0.38 – 0.48)]    
Endoxifen 13.55 (1.74 – 42.8) 13.69 (4.74 – 23.04)   0.550    
       [0.97 (-2.64 – 5.47)]    
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.56 (0.62 – 2.76) 1.53 (1.06 – 1.95)   0.730    
       [0.03 (-0.16 – 0.19)]    
MR4-OHT/TAM (×100) 1.04 (0.19 – 2.35) 0.94 (0.39 – 1.4)   0.044    
       [0.19 (0.01 – 0.38)]    
MREND/NDM (×100) 5.08 (0.92 – 27.81) 3.50 (1.26 – 10.72)   0.103    
       [0.86 (-0.21 – 2.71)]    
*2054G>T GG (N=73) GT (N=67) TT (N=23) GG vs GT GG vs TT GT vs TT 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 205.16 (50.06 – 578.17) 204.94 (39.26 – 599.91) 186.28 (84.27 – 421.16) 0.998 0.983 0.982 1.000 
       [-0.09 (-27.68 – 29.45)] [0.87 (-41.73 – 38.95)] [-0.73 (-44.39 – 38.66)]  
NDM 338.11 (40.82 – 734.94) 291.48 (78.46 – 802.98) 305.23 (84.77 – 757.13) 0.371 0.370 0.842 0.553 
       [17.87 (-25.68 – 61.54)] [26.66 (-33.46 – 83.11)] [6.22 (-48.74 – 65.03)]  
4-OHT 1.89 (0.7 – 5.02) 1.97 (0.47 – 5.33) 2.41 (0.87 – 4.51) 0.541 0.339 0.451 0.559 
       [-0.08 (-0.37 – 0.20)] [-0.21 (-0.77 – 0.23)] [-0.17 (-0.65 – 0.28)]  
Endoxifen 10.97 (3.48 – 42.8) 14.38 (1.79 – 42.56) 16.40 (1.74 – 28.64) 0.501 0.179 0.269 0.346 
       [-0.74 (-3.24 – 1.66)] [-2.83 (-7.16 – 1.46)] [-1.98 (-6.11 – 1.89)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.60 (0.82 – 2.76) 1.54 (0.62 – 2.65) 1.44 (1.01 – 2.1) 0.462 0.106 0.320 0.278 
       [0.05 (-0.08 – 0.17)] [0.15 (-0.03 – 0.30)] [0.08 (-0.07 – 0.25)]  
MR4-OHT/TAM (×100) 0.99 (0.39 – 2.35) 1.02 (0.19 – 1.84) 1.04 (0.57 – 2.1) 0.424 0.384 0.708 0.584 
       [-0.05 (-0.2 – 0.08)] [-0.08 (-0.29 – 0.10)] [-0.03 (-0.23 – 0.16)]  
MREND/NDM (×100) 3.87 (1.06 – 14.86) 5.17 (0.92 – 27.81) 6.04 (1.82 – 10) 0.630 0.234 0.329 0.459 
       [-0.20 (-1.19 – 0.59)] [-0.90 (-2.49 – 0.42)] [-0.62 (-2.02 – 0.68)]  





The biochemical pathway of tamoxifen involves multiple cytochrome P450 enzymes. 
In particular, CYP2D6 and CYP3A4/5 are the major enzymes mediating the 
metabolism of tamoxifen and its metabolites (119, 121, 122). However, little is known 
about the impact of other CYP isozymes such as CYP2C19 on the pharmacokinetic 
disposition of tamoxifen. In this study, we studied the genetic variability of CYP2C19 
in three Asian ethnic groups present in Singapore and investigated the effects of 
these polymorphisms on the metabolism of tamoxifen and its metabolites in the local 
Asian breast cancer patients. 
The CYP2C19 gene was found to be highly polymorphic with 66 polymorphisms, 
identified in the exonic (including exon-intron boundaries), upstream and 
downstream regions (13.5 kilobases in total) in 80 healthy subjects from each of the 
three healthy ethnic groups (Chinese, Malays and Indians) (Fig 3.4, Table 3.11). A 
total of 24 novel variants were uncovered. Thus far, a total of 41 polymorphisms 
have been reported in the coding regions of CYP2C19 (196, 450). However, majority 
of these variants are present at low frequencies in specific ethnicities and were not 
observed in our study populations with the exception of 99C>T (rs17885098), 
518C>T (rs61311738), 636G>A (*3, rs4986893), 681G>A (*2, rs4244285), 990C>T 
(rs3758580), 991A>G (rs3758581) and 1251A>C (rs17886522). Among these 
polymorphisms, 681G>A (*2, rs4244285) and 990C>T (rs3758580) were the most 
prevalent. The variant allelic frequencies of 681G>A (*2, rs4244285) polymorphism 
in our Chinese and Indian populations were similar to previous reports in the South 
Indians and Mainland Chinese (0.38 and 0.32 respectively) (276, 451, 452). 
Surprisingly, the frequency of 681G>A (*2, rs4244285) in the Malay population was 
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more similar to the African and Caucasian populations (Malay vs Caucasian vs 
African: 0.22 vs 0.15 vs 0.17) than the other Asian populations (249). Besides 
681G>A (*2, rs4244285), another null allele which contributes to the PM phenotype, 
636G>A (*3, rs4986893), was also present in our Asian populations though the 
frequency was much lower than that observed with 681G>A (*2, rs4244285) at 0.06 
in both the healthy Chinese and Malay subjects, similar to previous reports in East 
Asians  (237, 452-455). Compared to the Chinese and Malays, the variant allelic 
frequency of 636G>A (*3, rs4986893) was found to be significantly lower at 0.01 in 
the Indians (P ≤ 0.020) which did not differ from the frequency of 0.03 and < 0.01 in 
the South Indians and Caucasians or Africans respectively (451, 453).  
Among the low frequency exonic polymorphisms detected in the current study, 
431G>A (*9, rs17884712) variant which has been previously identified in the Africans 
at a frequency of 0.06 was detected exclusively in our Indian subjects with an allelic 
frequency of 0.01 (456). This polymorphism was demonstrated by Wang et al (450) 
and Blaisdell et al (456) to cause reduction in the activity of 4′-hydroxylation of S-
mephenytoin. Additionally, Wang et al also observed a 56% reduction in the Vmax/Km 
for omeprazole 5′-hydroxylation with the CYP2C19.9 allozyme compared to the wild-
type protein (450). Hence, the in vivo effect of this variant should be further examined 
in the Indian patient cohort though this polymorphism was present in only 0.01 of our 
Indian subjects.  
Thirteen common tag-SNPs, representative of the entire CYP2C19 gene region, 
were selected and only 1251A>C (rs17886522) was found to exhibit a marginal 
effect on the steady state plasma levels of tamoxifen and NDM. To more accurately 
examine the effects of CYP2C19 on the disposition of tamoxifen, the effects of 
CYP2C19 polymorphisms on MRs were subsequently examined. Several 
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polymorphisms [-3332A>C (rs7101258), -1418C>T (rs3814637), 636G>A (*3, 
rs4986893), 1251A>C (rs17886522) and *+1264C>G] were found to be significantly 
associated with variations in MRs. Among these polymorphisms, -3332A>C 
(rs7101258), 636G>A (*3, rs4986893), 1251A>C (rs17886522) and *+1264C>G 
were found to exert similar effects on (Table 3.12) with carriers of the variant alleles 
exhibiting 0.9-fold lower MR4-OHT-TAM compared to the carriers of the wild-type alleles. 
It was also noted that these four polymorphisms were in high LD. Thus, the impact of 
these polymorphic variants on MR4-OHT-TAM might represent a combinatorial 
phenotypic effect of these SNPs or due to linkage of the SNPs with the functional 
polymorphism, 636G>A (*3, rs4986893).  The polymorphism, 636G>A (*3, 
rs4986893), is a widely reported functional variant leading to the creation of a 
premature stop codon and a non-functional protein (248). Consistently, the SNP was 
associated with lower MR4-OHT-TAM indicating a lower CYP2C19 catalytic capacity for 
the 4-hydroxylation of tamoxifen to form 4-OHT.  
In addition to 636G>A (*3, rs4986893), -1418C>T (rs3814637) which is residing in 
the 5′ upstream region of CYP2C19 was associated with lower MR4-OHT-TAM. The 
decrease in MR4-OHT-TAM corresponded to the number of variant alleles of -1418C>T 
(rs3814637). To elucidate the putative function of this polymorphism, transcription 
factor binding site analysis was performed using MatInspector (457). The analysis 
suggested the introduction of a putative binding site for the CCAAT-displacement 
protein (CDP) at -1418C>T (rs3814637). The protein CDP has been widely reported 
as a transcriptional repressor (458). Thus, the creation of the CDP binding site with 
the variant T allele may lead to a reduction in the expression of CYP2C19. 
Correspondingly, -1418C>T (rs3814637) was associated with lower MR4-OHT-TAM 
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which could be due to the abovementioned postulation. This putative mechanism 
would need to be verified in future study. 
In the previous study, Schroth et al (251), reported an association between 
CYP2C19*17 [-3402C>T and -806C>T (rs12248560)] and a more favourable 
relapse-free time compared to patients carrying the CYP2C19*1, *2 (681G>A, 
rs4244285) and *3 (636G>A, rs4986893) alleles. Both -3402C>T and -806C>T 
(rs12248560), which are located in the 5′ upstream region, is in complete LD. This 
variant allele was previously shown to be associated with increased transcription of 
CYP2C19 and 5-hydroxylation of omeprazole (250). The authors suggested that this 
was probably due to a higher expression of CYP2C19 in carriers of the *17 (-
3402C>T, rs11188072 and -806C>T, rs12248560) allele leading to increased 
production of the active metabolites of tamoxifen and better survival outcome (251). 
However, these two functional variants, CYP2C19*17 (-3402C>T, rs11188072 and -
806C>T, rs12248560) did not influence the plasma levels of the analytes and the 
metabolic ratios even though nearly 40% higher plasma endoxifen and 4-OHT levels 
were observed in CYP2C19*17 (-3402C>T, rs11188072 and -806C>T, rs12248560)  
carriers (Table 3.12). This was in line with reports by Murdter et al (118) where 
associations were not observed between CYP2C19*2 (681G>A, rs4244285), *3 
(636G>A, rs4986893) and *17 (-3402C>T, rs11188072 and -806C>T, rs12248560) 
with variations in plasma concentrations of tamoxifen and its metabolites. Taken 
together, these data seemed to suggest that the impact of CYP2C19 polymorphisms 
on treatment outcome of tamoxifen might not be solely attributed to the effect of the 
enzyme on the biochemical pathway of tamoxifen. CYP2C19 has been reported to 
be involved in the metabolism of estrogen the endogenous ligand of ER (459). 
Tamoxifen and its active metabolites compete with estrogen for the binding site of 
 193
ER to produce the therapeutic effect (84). Hence, relative amount of estrogen at the 
target site would influence the action and subsequent therapeutic effect of tamoxifen 
but not its dispositional profile.  
Interestingly, another functional polymorphism, 681G>A (*2; rs4244285), which was 
also a tag-SNP in the present study, was not found to be associated with variations 
of the plasma concentrations of the metabolites or MRs. The SNP, 681G>A (*2; 
rs4244285), is a defective allele which results in a splicing defect and subsequent 
loss of protein expression (247). However, the loss of expression of functional 
CYP2C19 predicted by this polymorphism did not correspond to lower levels or rates 
of formation of the metabolites. The catalytic role of CYP2C19 in the metabolic 
pathway of tamoxifen has been established in several in vitro experiments involving 
human liver microsomes and recombinant expression systems (119, 121). CYP2C19 
has been demonstrated to participate in the N-demethylation and 4-hydroxylation of 
tamoxifen as well as the 4-hydroxylation of NDM. However, these experiments 
characterising the metabolic profile of tamoxifen also indicate that CYP2C19 plays a 
minor role in the various catalytic pathways compared to CYP2D6 and CYP3A4/5. In 
particular, Desta et al showed that inhibition of CYP2C19 activity using omeprazole 
did not drastically inhibit the formation of NDM, 4-OHT and endoxifen (119). These 
results suggest that in the presence of other functional CYP enzymes, the 
contribution of CYP2C19 to the metabolism of tamoxifen is minimal, consistent with 
our observations in the Asian populations. 
In conclusion, observations from the present study suggest that CYP2C19 is likely to 
play a minor role in the pharmacokinetic disposition of tamoxifen which may not be 
apparent in the presence of functional forms of the main enzymes. However, in view 
of the modest effects observed with several polymorphisms, the effects of these 
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polymorphisms should be examined in an independent cohort and in the in vitro 
setting to elucidate the mechanistic basis of the observations. 
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3.3.4 Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) 
3.3.4.1 Genetic Profile of CYP2D6 
The allelic frequency distributions of CYP2D6 polymorphisms (Fig 3.6) in 228 healthy 
Asian subjects (Chinese, Malay and Indian, n=76 each) and 163 Asian breast cancer 
patients are indicated in Table 3.13.  
Wide inter-ethnic variations were observed in the allelic frequencies of CYP2D6 
polymorphisms in the healthy Asian populations (Table 3.13). Pairwise comparisons 
between the three Asian ethnic groups showed that the frequencies of the various 
CYP2D6 variants were similar between the Chinese and Malay ethnic groups but 
differed significantly from the Indians with regards to selected polymorphisms (Table 
3.13). The allelic frequency of CYP2D6*10 (100C>T, rs1065852) was approximately 
5-fold higher in the healthy Chinese and Malay populations compared to the Indian 
population (Chinese vs Malay vs Indians: 0.56 vs 0.57 vs 0.11, P < 0.001). Similarly, 
the allelic frequency of CYP2D6*5 (CYP2D6del) was approximately 2- to 3-fold 
higher in the Chinese compared to the Malays and Indians (Chinese vs Malay vs 
Indians: 0.09 vs 0.04 vs 0.03, P = 0.018) (Table 3.13). The Indian and Malay 
populations were also found to harbour significantly higher frequencies of 
CYP2D6*41 (2988G>A, rs28371725) compared with the Chinese population (Indians 
vs Malay vs Chinese: 0.15 vs 0.09 vs 0.01) (Table 3.13). 
The allelic and genotypic distribution profiles of the polymorphisms in the CYP2D6 
observed in the patient population were found to be similar to those of the healthy 
Chinese population (Table 3.13).  
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Fig 3.6 Polymorphisms in CYP2D6 gene (UCSC RefSeq: NM_000106). 
 
 197
Table 3.13 Genotypic and allelic frequencies of polymorphisms in CYP2D6 (N=76 each) and Asian breast cancer patient (N = 163) populations. 
Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=76) Malays (N=76) Indians (N=76) Patients (N=163) 
CYP2D6*2 *1/*1 37 (62.7) 47 (68.1) 23 (32.9) 91 (66.4) *1 0.81 (0.73 – 0.88) 0.83 (0.76 – 0.89) 0.56 (0.48 – 0.65) 0.80 (0.75 – 0.84) 
(2850C>T, rs16947) *1/*2 21 (35.6) 20 (29) 33 (47.1) 36 (26.2) *2 0.19 (0.12 – 0.27) 0.17 (0.11 – 0.24)‡ 0.44 (0.35 – 0.52)§ 0.20 (0.16 – 0.25) 
 *2/*2 1 (1.7) 2 (2.9) 14 (20.0) 10 (7.3)      
CYP2D6*2A *1/*1 41 (67.2) 57 (81.4) 38 (52.8) 104 (75.9) *1 0.83 (0.76 – 0.89) 0.90 (0.85 – 0.95) 0.72 (0.64 – 0.79) 0.86 (0.82 – 0.90) 
(-1584C>G) *1/*2A 19 (31.1) 12 (17.1) 27 (37.5) 27 (19.7) *2A 0.17 (0.11 – 0.24) 0.10 (0.05 – 0.15)‡ 0.28 (0.21 – 0.36)§ 0.14 (0.10 – 0.18) 
 *2A/*2A 1 (1.6) 1 (1.4) 7 (9.7) 6 (4.3)      
CYP2D6*4 *1/*1 50 (98) 50 (92.6) 57 (89.1) 133 (99.3) *1 0.99 (0.97 – 1.01) 0.96 (0.93 – 1.00) 0.91 (0.87 – 0.96) 1.00 (0.99 – 1.00) 
(1846G>A, rs3892097 ) *1/*4 1 (2.0) 4 (7.4) 3 (4.7) 1 (0.7) *4 0.01 (-0.01 – 0.03) 0.04 (0.00 – 0.07) 0.09 (0.04 – 0.13) <0.01 (0.00 – 0.01) 
 *4/*4 0 (0.0) 0 (0.0) 4 (6.3) 0 (0.0)      
CYP2D6*5 *1/*1 61 (81.3) 70 (92.1) 72 (94.7) 137 (84.0) *1 0.91 (0.86 – 0.95) 0.96 (0.93 – 0.99) 0.97 (0.95 – 1.00) 0.92 (0.89 – 0.95) 
(CYP2D6del) *1/*5 14 (18.7) 6 (7.9) 4 (5.3) 26 (16.0) *5 0.09 (0.05 – 0.14) 0.04 (0.01 – 0.07) 0.03 (0.00 – 0.05)§ 0.08 (0.05 – 0.11) 
 *5/*5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
CYP2D6*8/*14 *1/*1 50 (92.6) 61 (100 69 (100.0) 132 (97.0) *1 0.96 (0.91 – 0.99) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 
(1758G>T/A) *1/*8 1 (1.9) 0 (0.0) 0 (0.0) 0 (0.0) *8 0.02 (-0.01 – 0.04) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
 *1/*14 2 (3.7) 0 (0.0) 0 (0.0) 4 (3.0) *14 0.03 (0.00 – 0.06) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.02 (0.00 – 0.03) 
 *8/*8 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
 *14/*14 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
 *8/*14 1 (1.9) 0 (0.0) 0 (0.0) 0 (0.0)      
CYP2D6*9 *1/*1 59 (100.0) 65 (100 68 (98.6) 137 (100.0) *1 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 
(2615_2617delAAG, *1/*9 0 (0.0) 0 (0.0) 1 (1.4) 0 (0.0) *9 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 
rs5030656) *9/*9 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.13 Genotypic and allelic frequencies of polymorphisms in CYP2D6 (N=76 each) and Asian breast cancer patient (N = 163) populations (continued). 
Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=76) Malays (N=76) Indians (N=76) Patients (N=163) 
CYP2D6*10 *1/*1 14 (23.0) 12 (17.4) 56 (77.8) 42 (30.7) *1 0.47 (0.38 – 0.56) 0.43 (0.35 – 0.52) 0.88 (0.83 – 0.93) 0.50 (0.44 – 0.56) 
(100C>T, rs1065852) *1/*10 29 (47.5) 36 (52.2) 15 (20.8) 52 (38.0) *10 0.53 (0.44 – 0.62) 0.57 (0.48 – 0.65)‡ 0.12 (0.07 – 0.17)§ 0.50 (0.44 – 0.56) 
 *10/*10 18 (29.5) 21 (30.4) 1 (1.4) 43 (31.4)      
CYP2D6*12 *1/*1 61 (100.0) 68 (98.6) 72 (100.0) 137 (100.0) *1 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
(124G>A, rs5030862) *1/*12 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) *12 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
 *12/*12 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)      
CYP2D6*41 *1/*1 56 (96.6) 56 (82.4) 51 (73.9) 123 (89.8) *1 0.98 (0.96 – 1.01) 0.90 (0.85 – 0.95) 0.86 (0.80 – 0.92) 0.95 (0.92 – 0.97) 
(2988G>A, 
rs28371725) 
*1/*41 2 (3.4) 11 (16.2) 17 (24.6) 13 (9.5) *41 0.02 (-0.01 – 0.04)†  0.10 (0.05 – 0.15) 0.14 (0.08 – 0.20)§ 0.05 (0.03 – 0.08) 
 *41/*41 0 (0.0) 1 (1.5) 1 (1.4) 1 (0.7)      
CYP2D6*xN *1 61 (100.0) 69 (98.6) 71 (98.6) 131 (95.6) *1 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.99 (0.98 – 1.01) 0.98 (0.96 – 1.00) 
(CYP2D6dup) *1/*xN 0 (0.0) 1 (1.4) 1 (1.4) 6 (4.4) *xN 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.01 (-0.01 – 0.02) 0.02 (0.00 – 0.04) 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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3.3.4.2 Influence of CYP2D6 Polymorphisms on the Plasma Levels of Tamoxifen and 
its Metabolites 
The median (range) plasma levels of tamoxifen and the three metabolites observed 
in patients within each genotypic group are depicted in Table 3.14. Although 
CYP2D6*10 (100C>T, rs1065852) polymorphism was not found to be significantly 
associated with plasma concentrations of tamoxifen and 4-OHT, a stepwise 
decrease in median 4-OHT level was observed when comparing patients with zero, 
one or two copies of CYP2D6*10 (100C>T, rs1065852) allele (Figs 3.7A and C, 
Table 3.14). Significant gene-dose dependent effects were, however observed 
between the CYP2D6*10 (100C>T, rs1065852) allele and the plasma concentrations 
of NDM and endoxifen (Figs 3.7B and D, Table 3.14). The plasma level of NDM 
[median (range)] was approximately 1.6-fold and 2-fold higher in patients with *1/*10 
genotype [279.43 (115.41 - 502.13) ng/ml] and those with *10/*10 genotype [374.41 
(84.77 – 802.98) ng/ml] compared with patients harbouring reference *1/*1 genotype 
[174.59 (40.82 – 448.65) ng/ml] (P < 0.001) (Fig 3.7B, Table 3.14). Conversely, the 
median (range) plasma endoxifen levels were observed to be approximately 2.5-fold 
higher in patients carrying the *1/*1 [19.55 (4.18 - 39.47) ng/ml] or *1/*10 [19.74 
(7.26 – 33.24) ng/ml] genotypes compared to patients who were homozygous for *10 
allele [8.03 (1.74 – 34.68) ng/ml] (P < 0.001) (Fig 3.7D, Table 3.14).  
Although no significant associations were observed between CYP2D6*5 
(CYP2D6del) polymorphism and the plasma levels of tamoxifen and the three 
metabolites (Table 3.14), patients harbouring the *1/*5 genotype displayed 30% to 
50% higher median plasma concentrations of tamoxifen and NDM as well as 25% to 
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40% lower median plasma levels of 4-OHT and endoxifen compared with patients 
carrying the reference genotype (Table 3.14).  
There were 12 compound heterozygotes (*5/*10) and their endoxifen levels 
[median(range)] were similar to patients harbouring the *10/*10 genotype [8.03 (1.74 
– 34.68), P = 0.232] but significantly lower compared with patients homozygous 
[19.55 (4.18 – 39.47), P < 0.001] or heterozygous [*1/*5: 14.51 (10.73 – 26.04), P = 
0.001, *1/*10: 19.74 (7.26 – 33.24), P < 0.001] for the reference allele (Fig 3.7D) .  
With respect to the CYP2D6*41 (2988G>A, rs28371725) allele, no significant trend 
in the variations of plasma levels of analytes was observed. However, the six 
patients who carried one or two copies of the *41 (2988G>A, rs28371725) alleles 
were found to have 64.0% higher plasma NDM concentration (P = 0.136) and 13.4% 
lower plasma endoxifen concentration (P = 0.792) compared to patients who were 
homozygous wild type (Table 3.14).  
In addition to the six patients mentioned above, another seven patients were also 
found to carry CYP2D6*41 (2988G>A, rs28371725) allele. However, these seven 
patients were not included in the analysis as they were compound heterozygotes 
who harboured other functional alleles such as *10 (100C>T, rs1065852), *14 
(1758G>A), and *xN (CYP2D6dup) in addition to CYP2D6*41 (2988G>A, 
rs28371725). The presence of these variant alleles may confound the observation of 
the phenotypic effect of *41 (2988G>A, rs28371725) allele. Likewise, the effect of 
CYP2D6 gene amplifications could not be assessed in the present study population 
as there was only one patient with the *1/*xN genotype. Although five other patients 
also carried CYP2D6 gene amplifications, the effect of this variant could not be 
evaluated due to the concomitant presence of *10 (100C>T, rs1065852), *14 
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(1758G>A) and *41 (2988G>A, rs28371725) variant alleles. The number of patients 
carrying the same compound genotypes (such as *10/*41 or *14/*41) was also too 
low to be evaluable.  
Subsequent to pairwise comparison, the contributions of CYP2D6 to variations in the 
steady state plasma concentrations of the active metabolite, endoxifen were 
quantified using linear regression analysis (Table 3.14). CYP2D6 defective alleles 
remained highly associated with lower plasma levels of endoxifen even after 
adjustment for significant covariate, height. Approximately 41% of the variation in 
plasma levels of endoxifen was accounted by CYP2D6 genetics. 
3.3.4.3 Influence of CYP2D6 Polymorphisms on the Metabolic Ratios of Tamoxifen 
and its Metabolites 
The median (range) MR4-OHT-TAM of patients carrying the *10/*10 genotype [0.83 (0.19 
– 1.78)] was 1.25 to 1.5 times higher in patients harbouring the *1/*1 [1.34 (0.74 – 
1.93)] or *1/*10 [1.08 (0.50 – 2.26)] genotypes (Table 3.14). The MRZ-4-OHT-TAM was 
found to be comparable among patients harbouring the *1/*1 and *1/*10 genotypes 
(Fig 3.8B). Similarly, the median MREND-NDM was found to decrease as the number of 
*10 allele increased. Patients with the *1/*1 genotype [10.11 (5.63 – 14.86)] were 
observed to have approximately 1.5-fold higher MREND-NDM than patients carrying 
*1/*10 [6.62 (1.62 – 11.65)] which were in turn 2.9-fold higher than that in patients 
harbouring *10/*10 [2.31 (0.92 – 27.81)] (P < 0.001) (Fig 3.8A). Similar genotypic-
phenotypic trends were observed with regards to TMR4-OHT and TMRNDM.  The TMR4-
OHT median (range) was not found to differ significantly among patients who 
harboured *1/*1 [11.05 (6.09 – 14.73)] and *1/*10 [9.18 (2.39 – 18.70)] genotypes 
but were found to be 2.7-fold and 2.2-fold higher than patients who harboured 
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*10/*10 genotype [4.16 (1.14 – 17.05)] (P < 0.001) (Fig 3.8D). A gradual decrease in 
TMRNDM was observed across the different genotypes. Nearly 1.3-fold difference in 
TMRNDM was observed between *1/*1 and *1/*10 carriers while a 2.8-fold difference 
in TMRNDM was found between *1/*10 and *10/*10 carriers. 
A non-significant 20% decrease in MRZ-4-OHT-TAM [median (range)] was observed 
between patients carrying the *1/*1 [1.34 (0.74 – 1.93)] and *1/*5 [1.04 (0.62 – 1.72)] 
genotypes (Fig 3.8B). However, the MREND-NDM [median (range)] observed in patients 
who were heterozygous for the *5 allele [5.29 (4.48 – 8.00)] was found to be half of 
that observed in the homozygous wild type [10.11 (5.63 – 14.86)] patients (Fig 3.8A). 
Likewise, 1.3 to 1.5 times lower TMR4-OHT and TMRNDM were observed in *1/*5 
carriers compared to *1/*1 carriers (Figs 3.8C and D). 
The median MRs and TMRs were found to be similar between patients carrying 
*10/*10 and *5/*10 genotypes but significantly lower compared to patients who 
harboured *1/*1 genotypes (Figs 3.8A – D). The MREND-NDM [median (range)] in 
*5/*10 [2.15 (1.06 – 3.30)] carriers was found to be 4.7-fold, 2.5-fold and 3.1-fold 
lower than that observed in *1/*1 [10.11 (5.63 – 14.86)], *1/*5 [5.29 (4.48 – 8.00)] 
and *1/*10 [6.62 (1.65 – 11.65)] carriers, respectively (Table 2). The relationship 
between TMRNDM and genotypes was parallel to that observed with respect to MREND-
NDM (Figs 3.8A and C). 
A non-significant relationship between CYP2D6*41 (2988G>A, rs28371725) and 
median MRs was observed. The MREND-NDM and MRZ-4-OHT-TAM were found to be 1.6 
and 1.3 times lower in patients who were heterozygous or homozygous for *41 
(2988G>A, rs28371725) compared with patients who were homozygous for the 
reference allele, respectively (Table 3.14). Similarly, the plasma TMRs were 
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observed to be lower among *41 (2988G>A, rs28371725) carriers. The TMRNDM and 
TMR4-OHT [median (range)] were found to be 1.53-fold and 1.68-fold lower in patients 
who harboured *1/*41 or *41/*41 genotypes [TMRNDM: 3.27 (1.35-7.37), TMR4-OHT: 
6.59 (3.65-19.04)] compared with patients who were *1/*1 [TMRNDM: 5.03 (2.94-7.45), 




Table 3.14 Effects of CYP2D6 polymorphisms on median (range) plasma concentrations of analytes and plasma metabolic ratios (N = 111).     
Parameters 
Median (Range) 
*1/*1 *1/*5 *1/*10 *10/*10 *5/*10 *1/*41 + *41/*41 
(N=13) (N=9) (N=31) (N=40) (N=12) (N=6) 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 161.22 (50.06-369.89) 216.07 (93.56-325.56) 194.88 (51.8-421.16) 217.19 (84.27-599.91) 169.91 (39.26-452.29) 166.42 (147.72-578.17) 
NDM 174.59 (40.82-448.65) 261.07 (206.94-464.25) 279.43 (115.41-502.13) 374.41 (84.77-802.98) 330.67 (78.46-757.13) 286.3 (159.67-511.2) 
4-OHT 2.49 (0.97-3.36) 1.58 (1.25-3.25) 1.92 (0.86-4.51) 1.76 (0.72-3.82) 1.87 (0.47-3.17) 2.55 (0.75-5.02) 
Endoxifen 19.55 (4.18-39.47) 14.51 (10.73-26.04) 19.74 (7.26-33.24) 8.03 (1.74-34.68) 7.46 (1.79-13.77) 16.93 (6.37-33.99) 
Plasma Metabolic Ratios (MRs) 
MREND/NDM (×100) 10.11 (5.63-14.86) 5.29 (4.48-8.00) 6.62 (1.65-11.65) 2.31 (0.92-27.81) 2.15 (1.06-3.30) 6.21 (1.94-11.85) 
MR4-OHT/TAM (×100) 1.34 (0.74-1.93) 1.04 (0.62-1.72) 1.08 (0.50-2.26) 0.83 (0.19-1.78) 0.94 (0.46-1.80) 1.00 (0.51-2.35) 
Total Metabolic Ratios (TMRs) 
TMRNDM 5.03 (2.94-7.45) 3.3 (2.61-4.56) 3.91 (0.98-7.24) 1.5 (0.51-10.69) 1.41 (0.65-2.21) 3.27 (1.35-7.37) 
TMR4-OHT 11.05 (6.09-14.73) 8.49 (5.26-11.77) 9.18 (2.39-18.70) 4.16 (1.14-17.05) 4.29 (1.71-7.85) 6.59 (3.65-19.04) 




Table 3.14 Effects of CYP2D6 polymorphisms on median (range) plasma concentrations of analytes and plasma metabolic ratios (N = 111) 
(Continued). 
Parameters 
Pairwise P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
*1/*1 *1/*1  *1/*1 *1/*10 
vs vs vs vs 
*1/*5 *1/*10 *10/*10 *10/*10 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 0.404 0.177 0.079 0.578 
 [-24.13 (-94.13 – 46.46)] [-39.04 (-90.73 – 23.51)] [-49.51 (-101.92 – 5.00)] [-12.33 (-49.98 – 29.37)] 
NDM 0.077 0.006 0.001 0.011 
 [-70.38 (-141.87 – 3.93)] [-100.73 (-165.23 – -30.30)] [-157.7 (-233.32 – -98.37)] [-67.98 (-115.59 – -16.25)] 
4-OHT 0.616 0.709 0.176 0.041 
 [0.15 (-0.55 – 1.16)] [-0.10 (-0.69 – 0.64)] [0.43 (-0.16 – 0.99)] [0.42 (0.02 – 0.89)] 
Endoxifen 0.243 0.827 <0.001 <0.001 
 [3.34 (-2.94 – 9.69)] [0.49 (-5.05 – 6.16)] [10.46 (6.69 – 14.99)] [9.56 (7.30 – 13.06)] 
Plasma Metabolic Ratios (MRs) 
MREND/NDM (×100) 0.001 <0.001 <0.001 <0.001 
 [4.04 (2.14 – 5.65)] [3.38 (1.9 – 4.74)] [7.59 (6.36 – 8.41)] [4.16 (3.47 – 4.68)] 
MR4-OHT/TAM (×100) 0.141 0.146 <0.001 0.006 
 [0.23 (-0.08 – 0.60)] [0.17 (-0.07 – 0.43)] [0.46 (0.23 – 0.68)] [0.28 (0.09 – 0.47)] 
Total Metabolic Ratios (TMRs) 
TMRNDM 0.001 0.001 <0.001 <0.001 
 [1.74 (0.9 – 2.50)] [1.29 (0.57 – 2.07)] [3.57 (3.09 – 4.06)] [2.32 (1.90 – 2.73)] 
TMR4-OHT 0.030 0.108 <0.001 <0.001 
 [2.77 (0.33 – 4.89)] [1.79 (-0.57 – 3.54)] [6.96 (5.59 – 8.13)] [5.12 (4.04 – 6.37)] 
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 




Table 3.14 Effects of CYP2D6 polymorphisms on median (range) plasma concentrations of analytes and plasma metabolic ratios (N = 111) (Continued). 
Parameters 
Pairwise P values [Hodges-Lehmann Estimate (95% Confidence Interval)]   
*1/*1 *1/*5 *1/*10 *10/*10 *1/*1 
vs vs vs vs vs 
*5/*10 *5/*10 *5/*10 *5/*10 *1/*41 + *41/*41 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 0.957 0.477 0.316 0.171 0.430 
 [-4.12 (-92.59 – 79.41)] [28.82 (-103.79 – 108.70)] [33.60 (-42.82 – 104.33)] [47.85 (-25.96 – 114.82)] [-19.41 (-123.72 – 57.21)] 
NDM 0.057 0.434 0.685 0.409 0.136 
 [-121.54 (-284.10 – 17.51)] [-60.41 (-206.53 – 94.06)] [-24.99 (-139.73 – 91.07)] [45.72 (-84.42 – 155.75)] [-85.72 (-205.28 – 15.78)] 
4-OHT 0.174 0.434 0.136 0.745 0.759 
 [0.65 (-0.23 – 1.23)] [0.47 (-0.47 – 1.12)] [0.66 (-0.12 – 1.24)] [0.09 (-0.34 – 0.64)] [-0.32 (-2.03 – 1.41)] 
Endoxifen <0.001 0.001 <0.001 0.232 0.792 
 [12.00 (7.09 – 16.47)] [7.66 (4.25 – 12.58)] [11.8 (7.58 – 15.41)] [1.18 (-0.71 – 3.58)] [2.66 (-10.88 – 12.99)] 
Plasma Metabolic Ratios (MRs) 
MREND/NDM (×100) <0.001 <0.001 <0.001 0.587 0.054 
 [7.86 (6.32 – 8.98)] [3.30 (2.86 – 4.28)] [4.34 (3.32 – 5.01)] [0.13 (-0.27 – 0.50)] [3.86 (-0.04 – 7.11)] 
MR4-OHT/TAM (×100) 0.022 0.286 0.267 0.228 0.219 
 [0.35 (0.03 – 0.65)] [0.12 (-0.25 – 0.43)] [0.12 (-0.16 – 0.43)] [-0.13 (-0.35 – 0.09)] [0.35 (-0.29 – 0.79)] 
Total Metabolic Ratios (TMRs) 
TMRNDM <0.001 <0.001 <0.001 0.811 0.035 
 [3.62 (3.14 – 4.16)] [1.90 (1.42 – 2.35)] [2.37 (1.75 – 2.99)] [0.04 (-0.23 – 0.28)] [1.89 (0.08 – 3.52)] 
TMR4-OHT <0.001 <0.001 <0.001 0.905 0.054 
 [6.73 (4.99 – 8.27)] [4.17 (2.17 – 5.51)] [4.96 (3.25 – 6.69)] [-0.06 (-1.07 – 0.79)] [4.17 (-0.28 – 7.11)] 
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 




Fig 3.7 Association between CYP2D6*5 and *10 based genotypes and steady state plasma concentrations of (A) Tamoxifen, 
(B) NDM, (C) 4OHT and (D) Endoxifen. 
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Fig 3.8 Association between CYP2D6*5 and *10 based genotypes and plasma metabolic ratios: (A) MREND-NDM, (B) MR4OHT-
TAM, (C) TMRNDM and (D) TMR4OHT. 
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Table 3.15 Regression analysis of CYP2D6 genotypes on the plasma 
concentrations of endoxifen (A) before and (B) after adjustment of 
covariates. 




(A) Before adjustment of covariates (Adj. R2 = 0.386, P = <0.001) 
(Intercept) 2.39 0.08 <0.001 
CYP2D6*1/*10  0.01 0.10 0.939 
CYP2D6*1/*41  0.03 0.15 0.848 
CYP2D6*1/*5  -0.08 0.12 0.530 
CYP2D6*10/*10  -0.47 0.09 <0.001 
CYP2D6*10/*41  -0.48 0.15 0.002 
CYP2D6*41/*41  -0.63 0.30 0.041 
CYP2D6*5/*10  -0.52 0.11 <0.001 
          
(B) After adjustment of covariates (Adj. R2 = 0.412, P = <0.001) 
(Intercept) 3.93 0.64 <0.001 
CYP2D6*1/*10  0.00 0.09 0.964 
CYP2D6*1/*41  0.01 0.15 0.939 
CYP2D6*1/*5  -0.06 0.12 0.630 
CYP2D6*10/*10  -0.48 0.09 <0.001 
CYP2D6*10/*41  -0.51 0.15 0.001 
CYP2D6*41/*41  -0.65 0.30 0.032 
CYP2D6*5/*10   -0.53 0.11 <0.001 
Covariates:          
Height  -0.01 0.00 0.016 
† (Z)-Endoxifen concentration was transformed by raising to the power of  
0.3 before the application of the linear model. 
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3.3.4.4 Discussion 
CYP2D6 is a major enzyme involved in the 4-hydroxylations of tamoxifen and NDM 
(119, 122, 194). In this study, the effects of CYP2D6 functional polymorphisms on 
the steady state plasma concentrations of tamoxifen and its metabolites were 
investigated among Asian breast cancer patients receiving tamoxifen treatment.  
The CYP2D6 allelic distribution profiles were investigated in healthy Asian 
populations and found to be similar between the Chinese and Malay populations but 
differed from that of the Indian population (426). The CYP2D6*10 (100C>T, 
rs1065852) allele was the most prevalent polymorphism in our healthy population 
with more than half of our Chinese and Malay subjects carrying the allele. Similarly, 
CYP2D6*5 (CYP2D6del) was also present at a higher frequency in the Chinese 
population in line with previous reports (Table 3.13) (272, 286). Conversely, the 
allelic frequencies of *2 (2850C>T, rs16947), *2A (-1584C>G), *4 (1846G>A, 
rs3892097) and *41 (2988G>A, rs28371725) alleles in the Indians were 1.5- to 15-
fold higher than that of the Chinese and Malays but similar to that reported in the 
Caucasians (272). This suggests that the pharmacokinetic profile of tamoxifen and 
its metabolites in the Indians may be more alike to that observed in the Caucasian 
population while the pharmacokinetic profile in the Chinese and Malays would more 
likely be similar to the East Asian populations such as Koreans and Japanese. As 
Malay and Indian patients each constitute 8% of our study population, the impact of 
these ethnic-specific alleles could not be fully evaluated in the minority ethnic groups. 
In the present study, CYP2D6*10 (100C>T, rs1065852) allele was correlated to a 
higher NDM and a lower endoxifen levels in the plasma while associations with 
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tamoxifen and 4-OHT were not found to be significant (Figs 3.7A – D). Similar trend 
was observed when the phenotypic effect was examined in association with the 
compound genotypes CYP2D6*5/*10. This is suggestive of an accumulation of NDM 
in the plasma when the metabolic conversion of NDM to endoxifen is impaired. In 
contrast, the steady state concentrations of tamoxifen and NDM were not found to 
vary across different CYP3A5*3 (6986A>G, rs776746) genotypes and CYP3A4 has 
not been found to be polymorphic in the local Asian populations (325). This indicates 
that the formation of NDM from tamoxifen was not likely to be influenced by altered 
activity of CYP3A5 enzyme in our study population at the studied dose of tamoxifen. 
Taken together, this leads to the postulation that CYP2D6-mediated 4-hydroxylation 
of NDM is the rate-limiting step in the formation of endoxifen instead of the 
CYP3A4/5-catalysed N-demethylation of tamoxifen in patients receiving 20 mg 
tamoxifen daily. The plasma concentrations of NDM and endoxifen were comparable 
between patients with *1/*5 and *1/*10 as well as *5/*10 and *10/*10 genotypes, 
implying that the functional impact of the *5 (CYP2D6del) allele is comparable to that 
of the *10 (100C>T, rs1065852) allele. These observations differed slightly from 
those reported by Lim et al (142) in the Koreans and Xu et al (296) in the Chinese. 
Lim et al (142) demonstrated significant reductions in the steady state plasma 
concentrations of both active metabolites (4-OHT and endoxifen) in patients with 
either *10 (100C>T, rs1065852), *5 (CYP2D6del) or both alleles compared to 
patients who were homozygous wild type. No significant associations were observed 
between the CYP2D6 genotypes and plasma levels of tamoxifen and NDM among 
the Korean patients (142). Likewise, Xu et al (296) reported an association between 
the presence of two copies of the *10 (100C>T, rs1065852) allele and lower plasma 
concentration of 4-OHT in the Chinese population but not with plasma concentrations 
of tamoxifen. The effects of CYP2D6 polymorphisms on plasma levels of NDM and 
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endoxifen were not reported in this study (296). The discrepancy in the results 
obtained could be due to the difference in the CYP2D6 alleles screened in each 
study. The *5 (CYP2D6del), *10 (100C>T, rs1065852) and *2×N (CYP2D6*2dup) 
alleles were screened in the Koreans (142) while only the *10 (100C>T, rs1065852) 
allele was screened in the Chinese (296). In contrast, a comprehensive screening of 
16 functionally important polymorphisms was performed using the INFINITI™ 
CYP450 2D6I Assay in the present study. Recently, Schroth et al. (300) reported a 
discrepancy in the assigned phenotype status due to the difference in number of 
CYP2D6 polymorphisms screened. The investigators concluded that comprehensive 
screening of CYP2D6 polymorphisms provides more accurate prediction of CYP2D6 
phenotype status. 
The major active metabolite, endoxifen, can be formed from tamoxifen via two 
pathways involving either NDM or 4-OHT. CYP2D6 has been shown to play a major 
role in the 4-hydroxylation of NDM and tamoxifen to endoxifen and 4-OHT, 
respectively. To elucidate the influence of the CYP2D6*5 (CYP2D6del) and *10 
(100C>T, rs1065852) polymorphisms on the formation of the active metabolites, the 
associations between the two genetic variants and the MRs were examined. The 
metabolic ratios, MR4-OHT-TAM and MREND-NDM were found to decrease in a stepwise 
manner (Figs 3.4A and B) as the number of copies of variant alleles [CYP2D6*5 
(CYP2D6del) or *10 (100C>T, rs1065852)] increased. The effects were more 
apparent than those observed on the plasma concentrations of the analytes. These 
results suggest a correlation between the presence of *5 (CYP2D6del), *10 
(100C>T, rs1065852) or both alleles and a significantly lower rate of catalytic 
conversion of tamoxifen and NDM to 4-OHT and endoxifen, respectively.  
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To compare the relative impact of CYP2D6 polymorphisms on the formation of 
endoxifen via the NDM or 4-OHT pathways, the associations between CYP2D6*5 
(CYP2D6del) and *10 (100C>T, rs1065852) polymorphisms and the TMRs were 
studied. Consistent with the observations in MRs, both TMRs were observed to be 
lower in patients who were homozygous variant or compound heterozygotes with a 
more dominant effect being observed in TMRNDM. These observations further support 
that CYP2D6 play a critical role in the biosynthesis of endoxifen although other 
enzymes are involved. Furthermore, the data imply that CYP2D6 polymorphisms are 
more influential in the 4-hydroxylation of NDM to form endoxifen.  
Borges et al (294) and Gjerde et al (133) have previously examined the effects of 
CYP2D6 polymorphisms on metabolic ratios in two studies involving the Caucasian 
populations. In both studies, patients were classified as poor metabolizer (PM), 
intermediate metabolizer (IM), extensive metabolizer (EM) or ultrarapid metabolizer 
(UM) based on their CYP2D6 genotype status. Correlations between CYP2D6 
genotypes and metabolic ratios were investigated indirectly by studying the 
relationships between the CYP2D6 metabolizer status and the metabolic ratios. The 
patients who were EM or UM exhibited higher plasma concentration of endoxifen and 
MREND-NDM compared to patients who were IM or PM (133, 294). In addition, Gjerde 
et al (133) observed an association between the CYP2D6 metabolizer status and 
MR4-OHT-TAM in their study population though the effect was not as prominent 
compared with the association between the metabolizer status and MREND-NDM. The 
results of our study were consistent to that obtained by Borges et al (294) and Gjerde 
et al (133). Hence, regardless of the ethnicities, differential CYP2D6 activity as 
predicted by CYP2D6 genetic variations contributes to alterations in the conversion 
of tamoxifen and NDM to 4-OHT and endoxifen respectively. 
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Recently, the relative contributions of CYP2D6 polymorphisms to the plasma 
concentrations and MRs were quantified using linear modeling (118). Consistent with 
our findings, Murdter et al (118) also observed higher proportion of the variability in 
the 4-hydroxylation of NDM to endoxifen being explained by CYP2D6 genotypes 
compared to that of tamoxifen to form 4-OHT. Approximately 38.7% and 68.7% of 
the variabilities in the endoxifen levels and MREND-NDM were attributed to CYP2D6 
genotypes compared to 9% and 27.6% of 4-OHT levels and MR4-OHT-TAM (118). This 
further supports the previous in vitro findings where 4-hydroxylation of NDM to 
endoxifen was almost exclusively catalyzed by CYP2D6 while CYP2C9 was found to 
play a substantial role in the 4-hydroxylation of tamoxifen to 4-OHT. Coller et al (194) 
previously estimated that 45% and 46% of the overall formation of 4-OHT could be 
attributed to CYP2D6 and CYP2C9 respectively. Hence, CYP2D6 plays a more 
dominant role in the 4-hydroxylation of NDM which is the major pathway for the 
formation of endoxifen from tamoxifen. 
In addition, the present study evaluated the effect of CYP2D6*41 (2988G>A, 
rs28371725) on the disposition profile of tamoxifen which was not investigated 
previously. Our study showed that CYP2D6*41 (2988G>A, rs28371725) was 
associated with a non-significant increase in the plasma concentration of NDM and a 
corresponding decrease in plasma concentration of endoxifen. The metabolic ratios 
except TMRNDM were also found to be lower in CYP2D6*41 (2988G>A, rs28371725) 
carriers suggesting lower rates of endoxifen formation in patients carrying 
CYP2D6*41 (2988G>A, rs28371725) allele. However, the number of study subjects 
carrying CYP2D6*41 (2988G>A, rs28371725) allele was only six. Although additional 
CYP2D6*41 (2988G>A, rs28371725) carriers were present, these patients were 
compound heterozygotes who harboured other functional alleles that might confound 
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the observation of the functional phenotypic impact of CYP2D6*41 (2988G>A, 
rs28371725). Similarly, the effect of CYP2D6 gene amplifications in the present 
study population was not discernible due to its presence as compound heterozygotes 
in several patients. Hence the impact of *41 (2988G>A, rs28371725) as well as *xN 
(CYP2D6dup) should be further evaluated in a larger homogeneous patient 
population in which these two variants are more prevalent. 
In conclusion, the current study indicates that CYP2D6*5 (CYP2D6del) and *10 
(100C>T, rs1065852) are important factors that influence the plasma levels of 
tamoxifen and its metabolites, as well as metabolic ratios of tamoxifen, in a breast 
cancer population which consisted predominantly of Chinese subjects. A greater 
effect of CYP2D6 polymorphisms on the major catalytic pathway of tamoxifen 
involving NDM was observed. The impact of other CYP2D6 polymorphic variants 
needs to be further evaluated in our minor ethnic groups (Malays and Indians) owing 
to the high inter-ethnic variation observed.  
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3.3.5 Cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5) 
3.3.5.1 Genetic Profile of CYP3A5 
The pharmacogenetics of CYP3A5*3 (6986A>G; rs776746) has been previously 
reported in healthy Chinese, Malay and Indian populations by Balram et al. (460) and 
are reported in Table 3.16 for the purpose of comparison. The allelic and genotypic 
distributions of CYP3A5*3 (6986A>G; rs776746) observed in the patient population 
were found to be similar to those of the healthy Chinese population (Table 3.16).  
3.3.5.2 Influence of CYP3A5*3 (6986A>G; rs776746) on the Plasma Levels of 
Tamoxifen and its Metabolites as well as its Metabolic Ratios 
The relationships between the polymorphic variant, CYP3A5*3 (6986A>G; 
rs776746), and plasma concentrations of the analytes were not found to be 
statistically significant (Table 3.17). Likewise, the MRs were not found to differ 
between the different genotypes of CYP3A5*3 (6986A>G; rs776746). However, 
higher inter-individual variations in MRs and TMRs were observed as the number of 




Table 3.16 Genotypic and allelic frequencies of CYP3A5*3 (6986A>G, rs776746). 
Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 
Allelic Frequencies (95% Confidence Interval) 
Chinese Malays Indians 
Patients 
(N=163) 
Chinese Malays Indians Patients (N=163) 
CYP3A5*3
‡
 *1/*1  (8.3)  (10.2)  (12.2) 13 (8.0) *1 0.25 (0.18 – 0.31) 0.39 (0.33 – 0.45) 0.41 (0.34 – 0.47) 0.30 (0.25 – 0.35) 
(6986A>G, rs776746) *1/*3  (32.4)  (57.1)  (56.7) 71 (43.6) *3 0.76 (0.69 – 0.82) 0.61 (0.55 – 0.67) 0.59 (0.53 – 0.66) 0.70 (0.65 – 0.75) 
  *3/*3   (59.3)   (32.7)   (31.1) 79 (48.5)           
‡ Genotypic and allelic frequencies were from previous study by Balram et al  
 
 
Table 3.17 Effects of CYP3A5*3 (6986A>G, rs776746) polymorphism on median (range) plasma concentrations (ng/ml) and metabolic ratios of tamoxifen and its analytes (N = 163) 
Parameters 
Median (Range) P values [Hodges-Lehmann Estimate (95% CI)] † 
*1/*1 (N=13) *1/*3 (N=71) *3/*3 (N=79) *1/*1 vs *1/*3 *1/*1 vs *3/*3 *1/*3 vs *3/*3 
Overall 
P values 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 228.99 (51.8 – 369.89) 194.88 (39.26 – 578.17) 204.94 (50.06 – 599.91) 0.877 0.792 0.995 0.976 
       [5.20 (-52.66 – 61.55)] [7.31 (-47.53 – 59.77)] [0.01 (-25.99 – 28.26)]  
NDM 338.11 (115.41 – 464.25) 302.51 (78.46 – 757.13) 301.83 (40.82 – 802.98) 0.877 0.871 0.983 0.986 
       [3.76 (-76.56 – 74.16)] [3.48 (-62.26 – 65.84)] [0.56 (-40.76 – 39.55)]  
4-OHT 2.74 (0.86 – 3.61) 1.96 (0.47 – 5.09) 1.87 (0.72 – 5.33) 0.492 0.397 0.708 0.677 
       [0.17 (-0.38 – 0.81)] [0.23 (-0.28 – 0.85)] [0.05 (-0.24 – 0.32)]  
Endoxifen 21.26 (7.17 – 27.2) 15.56 (1.74 – 42.8) 12.15 (3.83 – 42.56) 0.540 0.305 0.365 0.462 
       [1.03 (-3.96 – 6.77)] [2.17 (-2.02 – 9.10)] [1.23 (-1.28 – 3.94)]  
Plasma Metabolic Ratios (MRs) 
MRNDM/TAM 1.46 (1.08 – 2.23) 1.58 (0.83 – 2.76) 1.56 (0.62 – 2.65) 0.926 0.889 0.989 0.993 
       [0.02 (-0.21 – 0.26)] [0.01 (-0.2 – 0.24)] [0.00 (-0.12 – 0.12)]  
MREND/4-OHT 7.54 (3.75 – 10.97) 7.04 (1.99 – 12.8) 6.08 (2.44 – 13.18) 0.946 0.367 0.193 0.365 
       [0.07 (-1.30 – 1.53)] [0.51 (-0.59 – 2.23)] [0.48 (-0.23 – 1.29)]  
Total Metabolic Ratios (TMRs) 
TMRNDM 3.30 (1.05 – 5.76) 2.89 (0.65 – 7.45) 2.54 (0.51 – 10.69) 0.447 0.279 0.494 0.499 
       [0.34 (-0.61 – 1.59)] [0.54 (-0.47 – 1.75)] [0.17 (-0.31 – 0.68)]  
TMR4-OHT 8.00 (2.51 – 18) 6.81 (1.71 – 19.5) 6.56 (1.14 – 19.04) 0.454 0.349 0.563 0.580 
              [0.83 (-1.57 – 3.96)] [1.35 (-1.19 – 4.22)] [0.36 (-0.89 – 1.57)]   
† Hodges-Lehmann Estimate (95% CI) available for pairwise comparisons only. 
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3.3.5.3 Discussion 
The CYP3A subfamily is a major group of phase I drug metabolizing enzymes 
involved in the metabolism of an estimated 50% of all clinically used drugs (196). 
Within the CYP3A subfamily, both CYP3A4 and CYP3A5 are the most prominent 
isoforms and have significant overlap in substrate specificity (322). With regards to 
the metabolism of tamoxifen, both CYP3A4 and CYP3A5 have been implicated in the 
N-demethylation of tamoxifen and 4-OHT to form NDM and endoxifen respectively 
(119, 120, 123).  
The pharmacogenetics of both CYP3A4 and CYP3A5 has been widely studied and 
most studies have employed a SNP-centric approach where the phenotypic 
association is conducted for specific functional polymorphisms (322). With regards to 
CYP3A4, -392A>G (*1B; rs2740574), is the most commonly investigated variant 
(323). Although this promoter variant is prevalent in the African population, it has 
been found to be rare in the Asian populations (325). Thus far, CYP3A4 
polymorphisms are reported at low frequencies in non-African populations (321). In 
contrast, CYP3A5 is more polymorphic than CYP3A4 (196). The intronic SNP, 
CYP3A5*3 (6986A>G; rs776746), is present at high frequency in non-African 
populations (317) and this transition leads to a splicing defect with premature 
termination of protein synthesis to form a non-functional protein (317). CYP3A5*3 
(6986A>G; rs776746) is consistently correlated with low hepatic expression of the 
enzyme and subjects carrying the homozygous variant genotypes are known as non-
expressors of CYP3A5 (317, 461). The functional impact of this variant has been 
frequently investigated (317, 462-464). Notably, heart transplant patients who 
expressed CYP3A5 required higher dose to maintain similar plasma concentration of 
 219
tacrolimus compared to CYP3A5 non-expressors (330). Correspondingly, a lower 
risk of acute rejection was associated with CYP3A5 non-expressors. However, this 
polymorphic variant is not consistently associated with the disposition of other 
substrates including midazolam, clopidogrel, cyclosporine and prednisone (322, 464, 
465). 
In the present study, CYP3A5*3 (6986A>G; rs776746) was not shown to significantly 
influence the disposition of tamoxifen, although CYP3A5 has been reported to 
mediate the metabolism of tamoxifen to its metabolites in vitro (119). Similarly, the 
plasma levels of endoxifen or other analytes were not found to vary considerably 
across different genotypes in our study population. This was consistent with previous 
studies which investigated the effect of the polymorphism on plasma disposition of 
tamoxifen and its metabolites. In an earlier study, Jin et al. (140) observed a non-
significant increase in endoxifen level in patients harbouring *1/*1 and *1/*3 
genotypes compared with patients carrying *3/*3 genotypes. Correspondingly, 
Tucker et al. (331) also did not find any significant association between CYP3A5*3 
(6986A>G; rs776746) and the plasma levels of tamoxifen and its metabolites. 
Likewise, subsequent studies were not able to show any demonstrable effects on the 
plasma levels or metabolic ratios of the metabolites as well as the treatment 
outcomes (118, 142). Several factors may contribute to these observations.  
Firstly, significant overlaps in the substrate specificities of CYP3A4 and CYP3A5 
have been reported (318, 322). A CYP3A5 selective probe drug has not been 
identified and the reported effect of CYP3A5 on the metabolism of its substrates is 
confounded by the presence of CYP3A4 activity on the same substrates. Although 
CYP3A5 activity is absent in patients carrying the CYP3A5*3/*3 genotype, these 
patients still express functional CYP3A4 which is present in much higher abundance 
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compared to CYP3A5 (197). At therapeutically relevant dose of tamoxifen, CYP3A4 
enzyme may be present in sufficient quantity to handle the metabolism of tamoxifen 
and the loss of CYP3A5 due to the polymorphism may not lead to differences in N-
demethylation of tamoxifen or 4-OHT. However, the effect of CYP3A5*3 (6986A>G; 
rs776746) might be apparent at high doses of tamoxifen which is not routinely 
prescribed in the clinical setting as higher doses of tamoxifen has not been shown to 
increase clinical efficacy. This dose dependency effect of CYP3A5*3 (6986A>G; 
rs776746) genotype has been demonstrated on the pharmacokinetics of ABT-773 
(466). 
Secondly, tamoxifen and its metabolites are found at higher concentrations in the 
liver compared to the plasma with up to 60-fold difference in concentrations being 
observed (110-114). Thus, liver is believed to be the predominant site of tamoxifen 
metabolism. Among the CYP3A enzymes, CYP3A4 is the major isoform expressed 
in the liver while expression of CYP3A5 has been reported to be sporadic. CYP3A5 
is more commonly expressed in extrahepatic tissues including lungs, kidney, colon, 
esophagus and anterior pituitary gland (255). It has been found that plasma 
concentrations of metabolites are mainly attributed to metabolic activities in the liver 
and gastrointestinal tract (135). Therefore, CYP3A5 may not be the dominant CYP3A 
isozyme catalyzing the metabolism of tamoxifen though it has been shown in in vitro 
experiments that the metabolic rate of tamoxifen by both CYP3A4 and CYP3A5 is 
similar (119). 
In conclusion, CYP3A isozymes (CYP3A4 and CYP3A5) have been shown to be 
important enzymes mediating the N-demethylation of tamoxifen and 4-OHT in both in 
vitro settings. However, at therapeutically relevant doses of tamoxifen, CYP3A5*3 
(6986A>G; rs776746) was not shown to be an important determinant of tamoxifen 
 221
disposition. To examine the genotypic impact of CYP3A5*3 (6986A>G; rs776746) 
polymorphism, administration of tamoxifen at higher dose levels is recommended. 
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3.4 Pharmacogenetics of Phase II Drug Metabolizing Enzymes  
3.4.1 UDP glucuronosyltransferase 1 family, polypeptide A4 (UGT1A4) 
3.4.1.1 Genetic Profile of UGT1A4 
Screening of the five exons, exonic-intronic junctions, 5′ upstream and 3′ 
downstream regions of UGT1A4 identified 61 polymorphisms across 10 kilobases 
among the healthy Asian subjects (Chinese, Malays and Indians, N=80 each). The 
putative effects of the uncovered polymorphisms were elucidated using FastSNP and 
tabulated in Table 3.18 (449). Approximately one-third of the polymorphic variants 
(N=18) were located in the 5′ upstream region and seven were found in the 3′ 
downstream sequence. Additionally, 14 exonic and 18 intronic SNPs were 
discovered (Fig 3.9). All exonic variants were present at frequencies of 4% or below 
with the exception of 142T>G (*3, rs2011425), 448T>C (rs12468274), 471T>C 
(rs2011404) and 804G>A (rs3732217) (Table 3.19). 
Among the 61 SNPs, 24 variants were present at frequencies of 4% or less. Of which, 
five SNPs were specific to the Chinese [30G>A (rs61764026), 31C>T (rs3892221), 
273C>T, 1094C>T and *+1292G>A], seven were exclusive to the Malays [-2070G>C, 
-206C>A, 174delG, 325A>G, IVS1+47T>C, IVS2+18C>T and *+1556C>T], four were 
only found in the Indians [-118C>A, 70C>A (*2, rs6755571), IVS1-145C>T and 
966A>G] (Table 3.19). All polymorphisms were in Hardy-Weinberg equilibrium 
except -163G>A (rs3732218) in the Chinese subjects. 
Significant differences in the genotypic distributions of 15 polymorphisms were 
observed across the three ethnic groups. The polymorphic variants, -2170C>T 
(rs6744284), -1846C>T (rs1875263), -1531C>T (rs3806592), -1180G>A (rs869283), 
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IVS1+196T>C (rs871514), IVS1+346T>G (rs13401281), IVS2-82T>C (rs2302538), 
IVS2-37T>C and 966A>G were present at higher frequencies in the Indian 
population compared to the Chinese and Malay healthy populations (P < 0.05, Table 
3.19). In contrast, 471T>C (rs2011404) was found to be 8- and 13- fold lower in the 
Chinese ethnic group compared to the Malay and Indian ethnicities respectively. The 
intronic polymorphism, IVS2+15T>C (rs4148327) was found to be four-fold higher in 
the Chinese compared to the Indians and absent in the Malay population. The 
frequency of healthy Chinese carrying the homozygous variant genotype of -163G>A 
(rs3732218) was two- and three-fold higher than that observed in the Malays and 
Indians respectively.  
 
Fig 3.9 Polymorphisms present in UGT1A4 gene (UCSC RefSeq: NM_007120).  
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Table 3.18 Functional effects of UGT1A4 polymorphisms.  
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
-2650A>G rs17868334 5′ Upstream Promoter/regulatory region Disrupts GATA-1 binding site 
-2583T>C rs17863791 5′ Upstream Upstream with no known function – 
-2484C>A rs17868335 5′ Upstream Promoter/regulatory region Disrupts C/EBPb binding site; Creates C/EBPa binding site 
-2341G>A rs17863792 5′ Upstream Upstream with no known function – 
-2273A>C rs17864696 5′ Upstream Promoter/regulatory region Creates binding site for GATA protein family and c-Ets 
transcription factor 
-2228A>G rs17874943 5′ Upstream Promoter/regulatory region Disrupts binding site for HNF-3a and CdxA 
-2170C>T rs6744284 5′ Upstream Upstream with no known function – 
-2070G>C  5′ Upstream Promoter/regulatory region Disrupts binding site for MZF1 
-1973A>G rs1875263 5′ Upstream Upstream with no known function – 
-1846C>T rs1875263 5′ Upstream Promoter/regulatory region Disrupts binding site for MZF1 
-1577T>C rs3806594 5′ Upstream Promoter/regulatory region Creates binding site for CdxA 
-1548A>G rs3806593 5′ Upstream Upstream with no known function – 
-1531C>T rs3806592 5′ Upstream Promoter/regulatory region Creates binding site for deltaE 
-1484A>G rs11676072 5′ Upstream Promoter/regulatory region Disrupts binding site for MZF-1 and CdxA; Creates binding site 
for STATx and c-Ets-1 
-1268T>C rs3806591 5′ Upstream Promoter/regulatory region Creates binding site for vMyb 
-1180G>A rs869283 5′ Upstream Upstream with no known function – 
-457C>T rs3732221 5′ Upstream Promoter/regulatory region Creates binding site for CdxA 
-419G>A rs3732220 5′ Upstream Promoter/regulatory region Disrupts binding site for HNF-3a and CRE-BP; Creates binding 
site for Oct-1 
-219C>T rs3732219 5′ Upstream Promoter/regulatory region Creates binding site for SRY 
-206C>A  5′ Upstream Upstream with no known function – 
-204G>A  5′ Upstream Promoter/regulatory region Creates binding site for CdxA 
-163G>A rs3732218 5′ Upstream Promoter/regulatory region Creates binding site for S8 and Nkx-2 
-118C>A  5′ Upstream Upstream with no known function – 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software was 
restricted to SNPs in the 3′ untranslated region. 
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Table 3.18 Functional effects of UGT1A4 polymorphisms. (continued) 
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
30G>A rs61764026 Exon 1 Exonic, synonymous polymorphism; 
Splicing regulation 
P10P; Creates binding site for Srp40. 
31C>T rs3892221 Exon 1 Exonic, nonsynonymous polymorphism R11W; Predicted to be benign with PSIC Score of 0.000 
70C>A rs6755571 Exon 1 Exonic, nonsynonymous polymorphism P24T; Substrate dependent effect; Predicted to be benign with 
PSIC Score of 0.158 
142T>G rs2011425 Exon 1 Exonic, nonsynonymous polymorphism L48V; Substrate dependent effect; Predicted to be benign with 
PSIC Score of 0.003 
173C>T  Exon 1 Exonic, nonsynonymous polymorphism A58V; Predicted to be benign with PSIC Score of 0.008 
174delG  Exon 1 Exonic, nonsynonymous polymorphism 59fsX6; Frameshift – early stop codon 
273C>T  Exon 1 Exonic, synonymous polymorphism; 
Splicing regulation 
R91R; Creates binding site for SRp55 
325A>G  Exon 1 Exonic, nonsynonymous polymorphism Predicted to be benign with PSIC Score of 0.063 
448T>C rs12468274 Exon 1 Exonic, synonymous polymorphism; 
Splicing regulation 
L150L; Creates binding site for SC35 
471T>C rs2011404 Exon 1 Exonic, synonymous polymorphism; 
Splicing regulation 
C157C; Creates binding site for AF2/ASF and SRp55 
804G>A rs3732217 Exon 1 Exonic, synonymous polymorphism; 
Splicing regulation 
P268P; Disrupts binding site for AF2/ASF; Creates binding site 
for SC35 
IVS1+43C>T rs2011219 Intron 1 Intronic with no known function – 
IVS1+47T>C  Intron 1 Intronic enhancer Creates binding site for TATA 
IVS1+101G>T  Intron 1 Intronic enhancer Creates binding site for Oct-1 
IVS1+196T>C rs871514 Intron 1 Intronic with no known function – 
IVS1+243G>C rs904855 Intron 1 Intronic with no known function – 
IVS1+314A>G rs904856 Intron 1 Intronic with no known function – 
IVS1+346T>G rs13401281 Intron 1 Intronic with no known function – 
IVS1+361C>T rs12466779 Intron 1 Intronic with no known function – 
IVS1+382G>C rs12463641 Intron 1 Intronic enhancer Disrupts binding site for S8 
IVS1+414A>G rs12468356 Intron 1 Intronic enhancer Disrupts binding site for GATA-1 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software was 




Table 3.18 Functional effects of UGT1A4 polymorphisms. (continued) 
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
IVS1-145C>T  Intron 1 Intronic enhancer Creates binding site for CdxA; Disrupts binding site for Oct-1 
966A>G  Exon 2 Exonic, synonymous 
polymorphism 
Q322Q 
IVS2+15T>C rs4148327 Intron 2 Intronic with no known function – 
IVS2+18C>T  Intron 2 Intronic enhancer Creates binding site for CdxA 
IVS2+307A>G rs1018124 Intron 2 Intronic enhancer Disrupts binding site for CdxA; Creates binding site for Brn-2 
IVS2-183C>G  Intron 2 Intronic with no known function – 
IVS2-86C>T  Intron 2 Intronic with no known function – 
IVS2-82T>C rs2302538 Intron 2 Intronic with no known function – 
IVS2-37T>C  Intron 2 Intronic enhancer Disrupts binding site for SRY 
1094C>T  Exon 4 Exonic, nonsynonymous 
polymorphism; Splicing 
regulation 
P365L; Predicted to be probably damaging with PSIC Score of 
1.000; Affects binding of splicing enhancer and Srp40 
*339G>C  3′ Untranslated Region Downstream with no known 
function 
– 
*440G>C rs8330 3′ Untranslated Region Downstream with no known 
function 
– 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software was 
restricted to SNPs in the 3′ untranslated region. 
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Table 3.19 Genotypic and allelic distribution profile of UGT1A4 (UCSC RefSeq: NM_007120). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
1 -2650A>G AA 46 (58.2) 43 (53.8) 45 (57.7)   A 0.75 (0.68 – 0.81) 0.74 (0.67 – 0.81) 0.77 (0.70 – 0.84)  
 (rs17868334) AG 26 (32.9) 32 (40) 30 (38.5)   G 0.25 (0.19 – 0.32) 0.26 (0.19 – 0.33) 0.23 (0.16 – 0.30)  
  GG 7 (8.9) 5 (6.3) 3 (3.8)        
2 -2583T>C TT 47 (58.8) 43 (53.8) 45 (58.4)   T 0.74 (0.67 – 0.81) 0.74 (0.67 – 0.81) 0.77 (0.71 – 0.84)  
 (rs17863791) TC 26 (32.5) 32 (40) 29 (37.7)   C 0.26 (0.19 – 0.33) 0.26 (0.19 – 0.33) 0.23 (0.16 – 0.29)  
  CC 7 (8.8) 5 (6.3) 3 (3.9)        
3 -2484C>A CC 46 (58.2) 43 (53.8) 44 (57.1)   C 0.74 (0.67 – 0.81) 0.74 (0.67 – 0.81) 0.77 (0.70 – 0.83)  
 (rs17868335) CA 25 (31.6) 32 (40) 30 (39)   A 0.26 (0.19 – 0.33) 0.26 (0.19 – 0.33) 0.23 (0.17 – 0.30)  
  AA 8 (10.1) 5 (6.3) 3 (3.9)        
4 -2341G>A GG 46 (59) 43 (53.8) 44 (57.9)   G 0.76 (0.69 – 0.82) 0.74 (0.67 – 0.81) 0.77 (0.70 – 0.84)  
 (rs17863792) GA 26 (33.3) 32 (40) 29 (38.2)   A 0.24 (0.18 – 0.31) 0.26 (0.19 – 0.33) 0.23 (0.16 – 0.30)  
  AA 6 (7.7) 5 (6.3) 3 (3.9)        
5 -2273A>C AA 47 (58.8) 43 (53.8) 45 (56.3)   A 0.75 (0.68 – 0.82) 0.74 (0.67 – 0.81) 0.76 (0.70 – 0.83)  
 (rs17864696) AC 26 (32.5) 32 (40) 32 (40)   C 0.25 (0.18 – 0.32) 0.26 (0.19 – 0.33) 0.24 (0.17 – 0.30)  
  CC 7 (8.8) 5 (6.3) 3 (3.8)        
6 -2228A>G AA 47 (58.8) 43 (53.8) 45 (56.3)   A 0.75 (0.68 – 0.82) 0.74 (0.67 – 0.81) 0.76 (0.69 – 0.82)  
 (rs17874943) AG 26 (32.5) 32 (40) 31 (38.8)   G 0.25 (0.18 – 0.32) 0.26 (0.19 – 0.33) 0.24 (0.18 – 0.31)  
  GG 7 (8.8) 5 (6.3) 4 (5)        
7 -2170C>T CC 65 (81.3) 55 (69.6) 27 (33.8) 151 (74.8) C 0.90 (0.85 – 0.95) 0.83 (0.77 – 0.89) 0.56 (0.49 – 0.64) 0.86 (0.82 – 0.89) 
 (rs6744284) CT 14 (17.5) 21 (26.6) 36 (45) 45 (22.3) T 0.10 (0.05 – 0.15) 0.17 (0.11 – 0.23)‡ 0.44 (0.36 – 0.51)§ 0.14 (0.11 – 0.18) 
  TT 1 (1.3) 3 (3.8) 17 (21.3) 6 (3.0)      
8 -2070G>C
#
 GG 80 (100) 76 (96.2) 80 (100)   G 1.00 (1.00 – 1.00) 0.98 (0.96 – 1.00) 1.00 (1.00 – 1.00)  
  GC 0 (0) 3 (3.8) 0 (0)   C 0.00 (0.00 – 0.00) 0.02 (0.00 – 0.04) 0.00 (0.00 – 0.00)  
  CC 0 (0) 0 (0) 0 (0)        
9 -1973A>G AA 48 (60.8) 43 (53.8) 45 (56.3) 126 (62.4) A 0.76 (0.69 – 0.83) 0.73 (0.66 – 0.80) 0.76 (0.70 – 0.83) 0.79 (0.75 – 0.83) 
 (rs1875263) AG 24 (30.4) 31 (38.8) 32 (40) 66 (32.7) G 0.24 (0.17 – 0.31) 0.27 (0.20 – 0.34) 0.24 (0.17 – 0.30) 0.21 (0.17 – 0.25) 
  GG 7 (8.9) 6 (7.5) 3 (3.8) 10 (5.0)      
10 -1846C>T CC 65 (81.3) 54 (67.5) 27 (33.8)   C 0.90 (0.85 – 0.95) 0.82 (0.76 – 0.88) 0.56 (0.49 – 0.64)  
 (rs1875263) CT 14 (17.5) 23 (28.8) 36 (45)   T 0.10 (0.05 – 0.15) 0.18 (0.12 – 0.24)‡ 0.44 (0.36 – 0.51)§  
    TT 1 (1.3) 3 (3.8) 17 (21.3)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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Table 3.19 Genotypic and allelic distribution profile of UGT1A4 (UCSC RefSeq: NM_007120) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
11 -1577T>C TT 48 (61.5) 43 (54.4) 49 (62)   T 0.78 (0.71 – 0.84) 0.74 (0.67 – 0.81) 0.79 (0.73 – 0.85)  
 (rs3806594) TC 25 (32.1) 31 (39.2) 27 (34.2)   C 0.22 (0.16 – 0.29) 0.26 (0.19 – 0.33) 0.21 (0.15 – 0.27)  
  CC 5 (6.4) 5 (6.3) 3 (3.8)        
12 -1548A>G AA 44 (56.4) 40 (51.3) 43 (55.1) 127 (62.9) A 0.71 (0.64 – 0.78) 0.72 (0.65 – 0.79) 0.75 (0.68 – 0.82) 0.79 (0.75 – 0.83) 
 (rs3806593) AG 23 (29.5) 32 (41) 31 (39.7) 64 (31.7) G 0.29 (0.22 – 0.36) 0.28 (0.21 – 0.35) 0.25 (0.18 – 0.32) 0.21 (0.17 – 0.25) 
  GG 11 (14.1) 6 (7.7) 4 (5.1) 11 (5.4)      
13 -1531C>T CC 65 (83.3) 55 (70.5) 49 (62) 154 (76.2) C 0.91 (0.87 – 0.96) 0.83 (0.77 – 0.89) 0.76 (0.69 – 0.83) 0.87 (0.84 – 0.90) 
 (rs3806592) CT 12 (15.4) 20 (25.6) 22 (27.8) 44 (21.8) T 0.09 (0.04 – 0.13) 0.17 (0.11 – 0.23) 0.24 (0.17 – 0.31)§ 0.13 (0.10 – 0.16) 
  TT 1 (1.3) 3 (3.8) 8 (10.1) 4 (2.0)      
14 -1484A>G AA 76 (100) 77 (100) 80 (100)   A 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
 (rs11676072) AG 0 (0) 0 (0) 0 (0)   G 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  GG 0 (0) 0 (0) 0 (0)        
15 -1268T>C TT 46 (58.2) 39 (53.4) 44 (56.4)   T 0.74 (0.67 – 0.81) 0.73 (0.65 – 0.80) 0.76 (0.69 – 0.82)  
 (rs3806591) TC 25 (31.6) 28 (38.4) 30 (38.5)   C 0.26 (0.19 – 0.33) 0.27 (0.20 – 0.35) 0.24 (0.18 – 0.31)  
  CC 8 (10.1) 6 (8.2) 4 (5.1)        
16 -1180G>A GG 63 (80.8) 46 (64.8) 25 (32.5)   G 0.90 (0.85 – 0.95) 0.80 (0.74 – 0.87) 0.55 (0.47 – 0.63)  
 (rs869283) GA 14 (17.9) 22 (31) 35 (45.5)   A 0.10 (0.05 – 0.15) 0.20 (0.13 – 0.26) 0.45 (0.37 – 0.53)§  
  AA 1 (1.3) 3 (4.2) 17 (22.1)        
17 -457C>T CC 47 (58.8) 42 (52.5) 44 (55.7)   C 0.75 (0.68 – 0.82) 0.73 (0.66 – 0.79) 0.76 (0.69 – 0.83)  
 (rs3732221) CT 26 (32.5) 32 (40) 32 (40.5)   T 0.25 (0.18 – 0.32) 0.28 (0.21 – 0.34) 0.24 (0.17 – 0.31)  
  TT 7 (8.8) 6 (7.5) 3 (3.8)        
18 -419G>A GG 47 (58.8) 42 (52.5) 44 (55.7) 126 (62.4) G 0.75 (0.68 – 0.82) 0.73 (0.66 – 0.79) 0.76 (0.69 – 0.83) 0.79 (0.75 – 0.83) 
 (rs3732220) GA 26 (32.5) 32 (40) 32 (40.5) 66 (32.7) A 0.25 (0.18 – 0.32) 0.28 (0.21 – 0.34) 0.24 (0.17 – 0.31) 0.21 (0.17 – 0.25) 
  AA 7 (8.8) 6 (7.5) 3 (3.8) 10 (5.0)      
19 -219C>T CC 47 (59.5) 42 (52.5) 43 (55.1) 126 (62.4) C 0.75 (0.68 – 0.81) 0.72 (0.65 – 0.79) 0.76 (0.69 – 0.82) 0.79 (0.75 – 0.83) 
 (rs3732219) CT 24 (30.4) 31 (38.8) 32 (41) 66 (32.7) T 0.25 (0.19 – 0.32) 0.28 (0.21 – 0.35) 0.24 (0.18 – 0.31) 0.21 (0.17 – 0.25) 
  TT 8 (10.1) 7 (8.8) 3 (3.8) 10 (5.0)      
20 -206C>A
#
 CC 79 (100) 79 (98.8) 78 (100)   C 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
  CA 0 (0) 1 (1.3) 0 (0)   A 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
  AA 0 (0) 0 (0) 0 (0)        
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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Table 3.19 Genotypic and allelic distribution profile of UGT1A4 (UCSC RefSeq: NM_007120) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
21 -204G>A GG 79 (100) 79 (98.8) 78 (98.7)   G 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.99 (0.98 – 1.01)  
  GA 0 (0) 1 (1.3) 1 (1.3)   A 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.01 (-0.01 – 0.02)  
  AA 0 (0) 0 (0) 0 (0)        
22 -163G>A GG 48 (61.5) 42 (52.5) 44 (55.7) 126 (62.4) G 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.79) 0.75 (0.69 – 0.82) 0.79 (0.75 – 0.83) 
 (rs3732218) GA 18 (23.1) 32 (40) 31 (39.2) 66 (32.7) A 0.27 (0.20 – 0.34)† 0.28 (0.21 – 0.34) 0.25 (0.18 – 0.31)§ 0.21 (0.17 – 0.25) 
  AA 12 (15.4) 6 (7.5) 4 (5.1) 10 (5.0)      
23 -118C>A
#
 CC 77 (100) 80 (100) 76 (97.4)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00)  
  CA 0 (0) 0 (0) 2 (2.6)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03)  
  AA 0 (0) 0 (0) 0 (0)        
24 30G>A GG 77 (96.3) 75 (100) 75 (100) 197 (97.5) G 0.98 (0.96 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.00) 
 (rs61764026) GA 3 (3.8) 0 (0) 0 (0) 5 (2.5) A 0.02 (0.00 – 0.04) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.02) 
  AA 0 (0) 0 (0) 0 (0) 0 (0.0)      
25 31C>T CC 79 (98.8) 76 (100) 75 (100) 202 (100.0) C 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
 (rs3892221) CT 1 (1.3) 0 (0) 0 (0) 0 (0.0) T 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  TT 0 (0) 0 (0) 0 (0) 0 (0.0)      
26 70C>A CC 80 (100) 78 (100) 75 (97.4) 201 (99.5) C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 1.00 (0.99 – 1.00) 
 (*2, rs6755571) CA 0 (0) 0 (0) 2 (2.6) 1 (0.5) A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03) <0.01 (0.00 – 0.01) 
  AA 0 (0) 0 (0) 0 (0) 0 (0.0)      
27 142T>G TT 51 (63.8) 52 (65.8) 47 (60.3) 129 (63.9) T 0.78 (0.71 – 0.84) 0.80 (0.73 – 0.86) 0.76 (0.69 – 0.82) 0.79 (0.75 – 0.83) 
 (*3, rs2011425) TG 22 (27.5) 22 (27.8) 24 (30.8) 61 (30.2) G 0.23 (0.16 – 0.29) 0.20 (0.14 – 0.27) 0.24 (0.18 – 0.31) 0.21 (0.17 – 0.25) 
  GG 7 (8.8) 5 (6.3) 7 (9) 12 (5.9)      
28 173C>T CC 80 (100) 75 (97.4) 75 (97.4) 200 (99.0) C 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 0.98 (0.96 – 1.00) 1.00 (0.99 – 1.00) 
  CT 0 (0) 2 (2.6) 1 (1.3) 2 (1.0) T 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03) 0.02 (0.00 – 0.04) <0.01 (0.00 – 0.01) 
  TT 0 (0) 0 (0) 1 (1.3) 0 (0.0)      
29 174delG
#
 wt/wt 80 (100) 75 (97.4) 77 (100) 202 (100.0) wt 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  wt/delG 0 (0) 2 (2.6) 0 (0) 0 (0.0) delG 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  delG/delG 0 (0) 0 (0) 0 (0) 0 (0.0)      
30 273C>T
#
 CC 79 (98.8) 79 (100) 78 (100) 202 (100.0) C 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  CT 1 (1.3) 0 (0) 0 (0) 0 (0.0) T 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  TT 0 (0) 0 (0) 0 (0) 0 (0.0)      
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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Table 3.19 Genotypic and allelic distribution profile of UGT1A4 (UCSC RefSeq: NM_007120) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
31 325A>G AA 78 (100) 76 (97.4) 76 (100) 202 (100.0) A 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  AG 0 (0) 2 (2.6) 0 (0) 0 (0.0) G 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  GG 0 (0) 0 (0) 0 (0) 0 (0.0)      
32 448T>C TT 44 (55.7) 44 (56.4) 46 (59.7) 124 (61.4) T 0.75 (0.68 – 0.81) 0.74 (0.68 – 0.81) 0.79 (0.72 – 0.85) 0.78 (0.74 – 0.82) 
 (rs12468274) TC 30 (38) 28 (35.9) 29 (37.7) 69 (34.2) C 0.25 (0.19 – 0.32) 0.26 (0.19 – 0.32) 0.21 (0.15 – 0.28) 0.22 (0.18 – 0.26) 
  CC 5 (6.3) 6 (7.7) 2 (2.6) 9 (4.5)      
33 471T>C TT 0 (0) 0 (0) 1 (1.3) 1 (0.5) T 0.01 (0.00 – 0.03) 0.08 (0.04 – 0.12) 0.13 (0.08 – 0.18) 0.04 (0.02 – 0.06) 
 (rs2011404) TC 2 (2.5) 12 (15.4) 18 (23.4) 13 (6.4) C 0.99 (0.97 – 1.00) 0.92 (0.88 – 0.96) 0.87 (0.82 – 0.92)§ 0.96 (0.94 – 0.98) 
  CC 77 (97.5) 66 (84.6) 58 (75.3) 188 (93.1)      
34 804G>A GG 44 (57.9) 38 (52.8) 45 (60.8) 123 (60.9) G 0.76 (0.70 – 0.83) 0.72 (0.64 – 0.79) 0.77 (0.70 – 0.84) 0.78 (0.74 – 0.82) 
 (rs3732217) GA 28 (36.8) 27 (37.5) 24 (32.4) 69 (34.2) A 0.24 (0.17 – 0.30) 0.28 (0.21 – 0.36) 0.23 (0.16 – 0.30) 0.22 (0.18 – 0.26) 
  AA 4 (5.3) 7 (9.7) 5 (6.8) 10 (5.0)      
35 IVS1+43C>T CC 44 (57.9) 42 (56.8) 46 (61.3)   C 0.77 (0.70 – 0.84) 0.75 (0.68 – 0.82) 0.79 (0.72 – 0.85)  
 (rs2011219) CT 29 (38.2) 27 (36.5) 26 (34.7)   T 0.23 (0.16 – 0.30) 0.25 (0.18 – 0.32) 0.21 (0.15 – 0.28)  
  TT 3 (3.9) 5 (6.8) 3 (4)        
36 IVS1+47T>C
#
 TT 75 (100) 72 (98.6) 75 (100)   T 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
  TC 0 (0) 1 (1.4) 0 (0)   C 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
  CC 0 (0) 0 (0) 0 (0)        
37 IVS1+101G>T
#
 GG 73 (97.3) 67 (97.1) 75 (100)   G 0.99 (0.97 – 1.01) 0.99 (0.97 – 1.01) 1.00 (1.00 – 1.00)  
  GT 2 (2.7) 2 (2.9) 0 (0)   T 0.01 (-0.01 – 0.03) 0.01 (-0.01 – 0.03) 0.00 (0.00 – 0.00)  
  TT 0 (0) 0 (0) 0 (0)        
38 IVS1+196T>C TT 31 (40.8) 24 (34.3) 7 (9.3) 79 (39.1) T 0.64 (0.57 – 0.72) 0.55 (0.47 – 0.63) 0.33 (0.26 – 0.41) 0.63 (0.58 – 0.68) 
 (rs871514) TC 36 (47.4) 29 (41.4) 36 (48) 96 (47.5) C 0.36 (0.28 – 0.43) 0.45 (0.37 – 0.53)‡ 0.67 (0.59 – 0.74)§ 0.37 (0.32 – 0.42) 
  CC 9 (11.8) 17 (24.3) 32 (42.7) 27 (13.4)      
39 IVS1+243G>C GG 44 (57.9) 37 (53.6) 45 (60.8)   G 0.76 (0.70 – 0.83) 0.72 (0.65 – 0.80) 0.78 (0.71 – 0.84)  
 (rs904855) GC 28 (36.8) 26 (37.7) 25 (33.8)   C 0.24 (0.17 – 0.30) 0.28 (0.20 – 0.35) 0.22 (0.16 – 0.29)  
  CC 4 (5.3) 6 (8.7) 4 (5.4)        
40 IVS1+314A>G AA 45 (60) 37 (54.4) 46 (62.2)   A 0.78 (0.71 – 0.85) 0.74 (0.67 – 0.82) 0.79 (0.72 – 0.86)  
 (rs904856) AG 27 (36) 27 (39.7) 25 (33.8)   G 0.22 (0.15 – 0.29) 0.26 (0.18 – 0.33) 0.21 (0.14 – 0.28)  
  GG 3 (4) 4 (5.9) 3 (4.1)        
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 




Table 3.19 Genotypic and allelic distribution profile of UGT1A4 (UCSC RefSeq: NM_007120) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
41 IVS1+346T>G TT 61 (82.4) 47 (67.1) 28 (40) 150 (74.3) T 0.90 (0.85 – 0.95) 0.82 (0.76 – 0.88) 0.60 (0.52 – 0.68) 0.86 (0.83 – 0.90) 
 (rs13401281) TG 11 (14.9) 21 (30) 28 (40) 48 (23.8) G 0.10 (0.05 – 0.15) 0.18 (0.12 – 0.24)‡ 0.40 (0.32 – 0.48)§ 0.14 (0.10 – 0.17) 
  GG 2 (2.7) 2 (2.9) 14 (20) 4 (2.0)      
42 IVS1+361C>T CC 42 (56.8) 37 (54.4) 44 (60.3)   C 0.75 (0.68 – 0.82) 0.73 (0.65 – 0.80) 0.77 (0.71 – 0.84)  
 (rs12466779) CT 27 (36.5) 25 (36.8) 25 (34.2)   T 0.25 (0.18 – 0.32) 0.27 (0.20 – 0.35) 0.23 (0.16 – 0.29)  
  TT 5 (6.8) 6 (8.8) 4 (5.5)        
43 IVS1+382G>C GG 42 (56) 37 (54.4) 43 (59.7)   G 0.73 (0.66 – 0.80) 0.74 (0.67 – 0.82) 0.74 (0.66 – 0.81)  
 (rs12463641) GC 26 (34.7) 27 (39.7) 20 (27.8)   C 0.27 (0.20 – 0.34) 0.26 (0.18 – 0.33) 0.26 (0.19 – 0.34)  
  CC 7 (9.3) 4 (5.9) 9 (12.5)        
44 IVS1+414A>G AA 41 (56.2) 36 (53.7) 42 (58.3) 124 (61.4) A 0.74 (0.67 – 0.81) 0.72 (0.65 – 0.80) 0.76 (0.69 – 0.83) 0.78 (0.74 – 0.82) 
 (rs12468356) AG 26 (35.6) 25 (37.3) 26 (36.1) 69 (34.2) G 0.26 (0.19 – 0.33) 0.28 (0.20 – 0.35) 0.24 (0.17 – 0.31) 0.22 (0.18 – 0.26) 
  GG 6 (8.2) 6 (9) 4 (5.6) 9 (4.5)      
45 IVS1-145C>T
#
 CC 79 (100) 73 (100) 76 (96.2)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.97 (0.95 – 1.00)  
  CT 0 (0) 0 (0) 2 (2.5)   T 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.03 (0.00 – 0.05)  
  TT 0 (0) 0 (0) 1 (1.3)        
46 966A>G
#
 AA 80 (100) 76 (100) 74 (94.9)   A 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.97 (0.95 – 1.00)  
  AG 0 (0) 0 (0) 4 (5.1)   G 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)‡ 0.03 (0.00 – 0.05)§  
  GG 0 (0) 0 (0) 0 (0)        
47 IVS2+15T>C TT 73 (91.3) 78 (100) 77 (98.7) 191 (94.6) T 0.96 (0.92 – 0.99) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.97 (0.96 – 0.99) 
 (rs4148327) TC 7 (8.8) 0 (0) 1 (1.3) 11 (5.4)  C 0.04 (0.01 – 0.08)† 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)§ 0.03 (0.01 – 0.04) 
  CC 0 (0) 0 (0) 0 (0) 0 (0.0)      
48 IVS2+18C>T CC 80 (100) 75 (97.4) 77 (100)   C 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00)  
  CT 0 (0) 2 (2.6) 0 (0)   T 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00)  
  TT 0 (0) 0 (0) 0 (0)        
49 IVS2+307A>G AA 46 (58.2) 47 (61) 55 (71.4) 128 (63.4) A 0.77 (0.71 – 0.84) 0.77 (0.71 – 0.84) 0.84 (0.79 – 0.90) 0.80 (0.76 – 0.84) 
 (rs1018124) AG 30 (38) 25 (32.5) 20 (26) 67 (33.2) G 0.23 (0.16 – 0.29) 0.23 (0.16 – 0.29) 0.16 (0.10 – 0.21) 0.20 (0.16 – 0.24) 
  GG 3 (3.8) 5 (6.5) 2 (2.6) 7 (3.5)      
50 IVS2-183C>G
#
 CC 78 (98.7) 76 (97.4) 80 (100)   C 0.99 (0.98 – 1.01) 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00)  
  CG 1 (1.3) 2 (2.6) 0 (0)   G 0.01 (-0.01 – 0.02) 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00)  
  GG 0 (0) 0 (0) 0 (0)        
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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Table 3.19 Genotypic and allelic distribution profile of UGT1A4 (UCSC RefSeq: NM_007120) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
51 IVS2-86C>T
#
 CC 77 (100) 76 (98.7) 75 (97.4)   C 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.99 (0.97 – 1.00)  
  CT 0 (0) 1 (1.3) 2 (2.6)   T 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.01 (0.00 – 0.03)  
  TT 0 (0) 0 (0) 0 (0)        
52 IVS2-82T>C TT 68 (86.1) 67 (85.9) 61 (77.2) 177 (87.6) T 0.92 (0.87 – 0.96) 0.93 (0.89 – 0.97) 0.88 (0.83 – 0.93) 0.93 (0.91 – 0.96) 
 (rs2302538) TC 9 (11.4) 11 (14.1) 17 (21.5) 23 (11.4) C 0.08 (0.04 – 0.13) 0.07 (0.03 – 0.11) 0.12 (0.07 – 0.17)§ 0.07 (0.04 – 0.09) 
  CC 2 (2.5) 0 (0) 1 (1.3) 2 (1.0)      
53 IVS2-37T>C
#
 TT 79 (100) 73 (98.6) 72 (96)   T 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.98 (0.96 – 1.00)  
  TC 0 (0) 1 (1.4) 3 (4)   C 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.02 (0.00 – 0.04)§  
  CC 0 (0) 0 (0) 0 (0)        
54 1094C>T CC 75 (98.7) 23 (100) 23 (100)   C 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  CT 1 (1.3) 0 (0) 0 (0)   T 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  TT 0 (0) 0 (0) 0 (0)        
55 *339G>C GG 2 (2.5) 1 (1.3) 3 (3.8)   G 0.13 (0.08 – 0.19) 0.15 (0.09 – 0.21) 0.15 (0.09 – 0.20)  
  GC 17 (21.5) 22 (27.5) 17 (21.8)   C 0.87 (0.81 – 0.92) 0.85 (0.79 – 0.91) 0.85 (0.80 – 0.91)  
  CC 60 (75.9) 57 (71.3) 58 (74.4)        
56 *440G>C GG 2 (2.6) 1 (1.3) 3 (4) 5 (2.5) G 0.14 (0.08 – 0.19) 0.15 (0.10 – 0.21) 0.15 (0.09 – 0.20) 0.14 (0.10 – 0.17) 
 (rs8330) GC 17 (22.1) 22 (28.2) 16 (21.3) 45 (22.3) C 0.86 (0.81 – 0.92) 0.85 (0.79 – 0.90) 0.85 (0.80 – 0.91) 0.86 (0.83 – 0.90) 
  CC 58 (75.3) 55 (70.5) 56 (74.7) 152 (75.2)      
57 *+851C>A CC 56 (71.8) 41 (56.9) 57 (80.3) 130 (64.4) C 0.83 (0.77 – 0.89) 0.74 (0.66 – 0.81) 0.88 (0.83 – 0.93) 0.79 (0.76 – 0.83) 
 (rs17862880) CA 18 (23.1) 24 (33.3) 11 (15.5) 61 (30.2) A 0.17 (0.11 – 0.23)† 0.26 (0.19 – 0.34)‡ 0.12 (0.07 – 0.17) 0.21 (0.17 – 0.24) 
  AA 4 (5.1) 7 (9.7) 3 (4.2) 11 (5.4)      
58 *+857C>T CC 9 (11.7) 18 (24.7) 15 (19.2) 25 (12.4) C 0.31 (0.24 – 0.38) 0.45 (0.36 – 0.53) 0.37 (0.29 – 0.44) 0.36 (0.32 – 0.41) 
 (rs4148329) CT 30 (39) 29 (39.7) 27 (34.6) 97 (48.0) T 0.69 (0.62 – 0.76)† 0.55 (0.47 – 0.64) 0.63 (0.56 – 0.71) 0.64 (0.59 – 0.68) 
  TT 38 (49.4) 26 (35.6) 36 (46.2) 80 (39.6)      
59 *+1291C>A
#
 CC 79 (100) 75 (100) 75 (100)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  CA 0 (0) 0 (0) 0 (0)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  AA 0 (0) 0 (0) 0 (0)        
60 *+1292G>A
#
 GG 78 (98.7) 76 (100) 75 (100)   G 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  GA 1 (1.3) 0 (0) 0 (0)   A 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  AA 0 (0) 0 (0) 0 (0)        
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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Table 3.19 Genotypic and allelic distribution profile of UGT1A4 (UCSC RefSeq: NM_007120) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 














 AA 78 (98.7) 74 (96.1) 78 (100)   A 0.99 (0.98 – 1.01) 0.98 (0.96 – 1.00) 1.00 (1.00 – 1.00)  
  AG 1 (1.3) 3 (3.9) 0 (0)   G 0.01 (-0.01 – 0.02) 0.02 (0.00 – 0.04) 0.00 (0.00 – 0.00)  
  GG 0 (0) 0 (0) 0 (0)        
62 *+1556C>T
#
 CC 79 (100) 76 (97.4) 78 (100)   C 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00)  
  CT 0 (0) 2 (2.6) 0 (0)   T 0.00 (0.00 – 0.00)† 0.01 (0.00 – 0.03)‡ 0.00 (0.00 – 0.00)  
  TT 0 (0) 0 (0) 0 (0)        
63 *+1833C>T
#
 CC 2 (2.6) 1 (1.3) 3 (3.8)   C 0.13 (0.08 – 0.18) 0.15 (0.09 – 0.20) 0.16 (0.10 – 0.21)  
  CT 16 (20.5) 21 (26.6) 19 (23.8)   T 0.87 (0.82 – 0.92) 0.85 (0.80 – 0.91) 0.84 (0.79 – 0.90)  
    TT 60 (76.9) 57 (72.2) 58 (72.5)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese (N=80) vs Malays (N=80). 
‡ denotes P < 0.05, Malays (N=80) vs Indians (N=80). 
§ denotes P < 0.05, Chinese (N=80) vs Indians (N=80). 
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3.4.1.2 LD Pattern of UGT1A4 
Pairwise LD analysis performed for each ethnic group (Figs 3.10A – C) revealed high 
linkage disequilibrium between polymorphisms located in the 5′ upstream region. 
Almost complete linkage was observed between the six polymorphisms located in 
the 5′ upstream region, -2650A>G (rs17868334), -2583T>C (rs17863791), -2484C>A 
(rs17868335), -2341G>A (rs17863792), -2273A>C (rs17864696) and -2228A>G 
(rs17874943) (│D'│ = 1, R2 ≥ 0.97) across all three ethnicities. In addition, strong 
linkage was found between these polymorphisms in the distal and proximal 5′ 
upstream regions, -1973A>G (rs1875263), -1268T>C (rs3806591), -457C>T 
(rs3732221), -419G>A (rs3732220), -219C>T (rs3732219) and -163G>A (rs3732218) 
(│D'│ ≥0.86, R2 ≥0.73) in all three ethnicities. Other polymorphisms located in the 5′ 
region which displayed strong LD among all ethnicities were -1180G>A (rs869283) 
with -2170C>T (rs6744284), -1846C>T (rs1875263) and -1531C>T (rs3806592) 
(│D'│ ≥0.92, R2 ≥0.81).  
Similarly, the synonymous polymorphism 804G>A (rs3732217) was observed to be 
in tight linkage with SNPs in intron 1, namely IVS1+43C>T (rs2011219), 
IVS1+243G>C (rs904855), IVS1+314A>G (rs904856), IVS1+361C>T (rs12466779) 
and IVS1+414A>G (rs12468356) (│D'│≥0.93, R2 ≥0.84) in all ethnicities. At the 3′ 
region, three variants, *339G>C, *440G>C (rs8330) and *+1833C>T were in high LD 
among Chinese, Malays and Indians (│D'│≥0.95, R2 ≥0.85).  
Pairwise LD matrix revealed the presence of three, four and five LD blocks as 
defined by Gabriel et al (467) in the healthy Chinese, Malay and Indian ethnic groups 
(Figs 3.10A – C). Block 1 of Chinese and Malay was similar and included 18 
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promoter SNPs [-2650A>G (rs17868334) till -163G>A (rs3732218)]. However, these 
SNPs in the promoter region were separated into three blocks in the Indian subjects.  
The second block in Chinese population and fourth block in Indian population 
consisted of 804G>A (rs3732217) in exon 1, eight SNPs in intron 1 and 
IVS2+307A>G (rs1018124). In the Malay population, these polymorphisms were 
separated into two blocks, LD blocks 2 and 3, with the breakpoint at IVS1+346T>G 
(rs13401281). With regards to Chinese LD block 3, it was similar to Malay LD block 4 
and Indian block 5 comprising of polymorphisms at the 3′ end of the gene which 
were *339G>C, *440G>C (rs8330), *+851C>A  (rs17862880), *+857C>T (rs4148329) 
and *+1833C>T.  
The overall inter-block linkage was relatively strong. Within the Chinese ethnic group, 
blocks 1 and 2 were strongly linked with multiallelic |D′| of 0.89. However, linkage 
between blocks 2 and 3 was weak with a multiallelic |D′| of 0.60. Similar pattern was 
observed in the Malay population (Block 1 vs Block 2, |D′| = 0.90, Block 2 vs Block 3, 
|D′| = 0.98, Block 3 vs Block 4, |D′| = 0.68). Likewise, high and moderate linkages 
between blocks 3 and 4 (Block 3 vs Block 4, |D′| = 0.92) as well as blocks 4 and 5 
(Block 4 vs Block 5, |D′| = 0.59) were observed respectively in the Indian population. 
However, weak linkages within blocks 1 to 3 were observed in the Indian cohort 
(Block 1 vs Block 2, |D′| = 0.22, Block 2 vs Block 3, |D′| = 0.20). 
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Fig 3.10 LD matrix for UGT1A4 polymorphisms in (A) Chinese, (B) 
Malays, and (C) Indians. 
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3.4.1.3 Genetic Profile of UGT1A4 tag-SNPs in Asian Breast Cancer Patients 
As the polymorphisms across the entire gene were found to be in high LD, tag-SNPs 
were selected to represent polymorphisms across the gene using the exhaustive 
search algorithm in TAGster program (423). The selection criteria of R2 ≥ 0.80 and 
MAF ≥ 0.05 were employed. A total of 14, 10 and 13 tag-SNPs were selected for 
Chinese, Malay and Indian healthy populations respectively. Since, the patient 
population consisted of patients from the three ethnicities, a multi-population tag-
SNP approach was adopted. Tag-SNPs representing the genetic profiles of all three 
ethnicities were selected via a two-stage exhaustive search process. A total of 16 
tag-SNPs [-2170C>T (rs6744284), -1973A>G (rs1875263), -1548A>G (rs3806593), -
1531C>T (rs3806592), 142T>G (*3, rs2011425), 448T>C (rs12468274), 471T>C 
(rs2011404), IVS1+196T>C (rs871514), IVS1+346T>G (rs13401281), IVS1+414A>G 
(rs12468356), IVS2+15T>C (rs4148327), IVS2+307A>G (rs1018124), IVS2-82T>C 
(rs2302538), *440G>C (rs8330), *+851C>A (rs17862880), and *+857C>T 
(rs4148329)] were identified via this approach and were genotyped in the patient 
cohort. In addition, seven other polymorphisms which have been reported to harbour 
functional impact were also genotyped in the patients: -419G>A (rs3732220), -
219C>T (rs3732219), -163G>A (rs3732218), 30G>A (rs61764026), 70C>A (*2, 
rs6755571), 173C>T, 804G>A (rs3732217). The frequencies of these 
polymorphisms in the patient cohort were not found to differ significantly from that of 
the healthy ethnic groups (Table 3.19).  
Among the Asian breast cancer cohort, two LD blocks with moderate inter-block 
linkage were observed (Block 1 vs Block 2, |D′| = 0.51) between the 16 tag-SNPs 
and seven functional polymorphisms (Fig 3.11). Block 1 which was the larger of the 
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two blocks comprised of 12 SNPs located in the 5′ upstream region, exon 1, introns 1 
and 2. In contrast, block two consisted of only three polymorphisms in the 3′ region 
of the gene.  
  
 
Fig 3.11 LD matrix for UGT1A4 functional and tag-SNPs in Asian breast cancer 
patient patients (N=202). 
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3.4.1.4 Genotypic-phenotypic Associations of UGT1A4 Polymorphic Variants  
Non-parametric statistical analyses of the phenotypic effects of the 16 tag-SNPs as 
well as five functional polymorphisms on plasma concentrations of tamoxifen, 
tamoxifen-N-glucuronide (Tam-N-Gluc) and (Z)-4-OHT were performed. Two of the 
functional polymorphisms, 70C>A (*2, rs6755571) and 173C>T, were not analysed 
as there were only one and two heterozygous carriers of the respective 
polymorphisms. However, the median and range of the parameters in each genotype 
group are listed in Table 3.20 for reference. In addition, the effects of these 
polymorphisms on MRTAM-N-Gluc/TAM were also examined.  
Among the 21 polymorphisms, thirteen polymorphisms were significantly associated 
with variations in plasma Tam-N-Gluc concentration and MRTAM-N-Gluc/TAM (Table 3.20). 
More than 1.5-fold higher median plasma concentration of TAM-N-Gluc was 
observed in patients carrying the heterozygous or homozygous variant genotype of 
142T>G (*3, rs2011425) compared to patients who were wild-type [TT vs TG vs GG: 
0.85 (0.15 – 11.09) vs 1.3 (0.17 – 9.20) vs 1.36 (0.19 – 5.00) ng/ml, P = 0.005]. 
Likewise, patients harbouring one or two copies of the variant allele of 142T>G (*3, 
rs2011425) were found to exhibit 1.5- to 1.9-fold higher MRTAM-N-Gluc/TAM as compared 
with patients harbouring the two copies of the wild-type alleles [TT vs TG vs GG: 
0.42 (0.11 – 2.87) vs 0.79 (0.19 – 3.60) vs 0.63 (0.28 – 1.66) , P < 0.001]. Similar 
significant associations with variations in Tam-N-Gluc level and MRTAM-N-Gluc/TAM 
across different genotype groups were also observed for -1973A>G (rs1875263), -
1548A>G (rs3806593), -419G>A (rs3732220), -219C>T (rs3732219), -163G>A 
(rs3732218), 448T>C (rs12468274), 804G>A (rs3732217), IVS1+196T>C 
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(rs871514), IVS1+414A>G (rs12468356) and IVS2+307A>G (rs1018124) (P ≤ 0.013, 
Table 3.20).  
At the 3′ downstream region of UGT1A4, approximately 1.5-fold difference in the 
MRTAM-N-Gluc/TAM was observed between individuals carrying wild-type and 
homozygous variant genotypes of *+851C>A (rs17862880), and *+857C>T 
(rs4148329) (P ≤ 0.008, Table 3.20). However, only *+857C>T (rs4148329) was 
associated with difference in plasma levels of Tam-N-Gluc. No significant 
associations between the UGT1A4 polymorphisms and steady state concentrations 











Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202). 





CC (N=151) CT (N=45) TT (N=6) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.38 (39.18 – 463.20) 192.08 (95.87 – 454.15) 171.08 (130.29 – 275.92) 0.961 0.641 0.704 0.901 
       [0.65 (-23.99 – 24.74)] [12.31 (-47.68 – 70.52)] [12.65 (-44.49 – 68.59)]  
(Z)-4-OHT 2.68 (0.47 – 7.17) 2.89 (0.85 – 6.51) 2.21 (1.76 – 4.49) 0.761 0.453 0.748 0.763 
       [0.07 (-0.38 – 0.48)] [0.27 (-0.70 – 1.26)] [0.15 (-0.70 – 1.35)]  
Tam-N-Gluc 1.01 (0.15 – 11.09) 1.05 (0.26 – 5.49) 1.03 (0.54 – 1.53) 0.506 0.891 0.907 0.800 
       [-0.08 (-0.31 – 0.16)] [-0.05 (-0.48 – 0.57)] [0.02 (-0.45 – 0.84)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.50 (0.11 – 3.60) 0.55 (0.13 – 1.87) 0.60 (0.20 – 0.93) 0.422 0.558 0.748 0.632 
              [-0.04 (-0.13 – 0.06)] [-0.06 (-0.31 – 0.26)] [-0.03 (-0.28 – 0.33)]   
-1973A>G 
(rs1875263) 
AA (N=126) AG (N=66) GG (N=10) AA vs AG AA vs GG AG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 202.13 (47.62 – 463.20) 179.12 (39.18 – 454.15) 217.82 (92.82 – 319.81) 0.038 0.828 0.549 0.119 
       [21.65 (1.21 – 43.71)] [6.14 (-47.52 – 59.67)] [-15.78 (-73.25 – 37.08)]  
(Z)-4-OHT 2.72 (0.70 – 7.17) 2.60 (0.47 – 5.80) 2.60 (1.67 – 4.96) 0.447 0.848 0.634 0.719 
       [0.14 (-0.22 – 0.49)] [-0.06 (-0.76 – 0.79)] [-0.20 (-0.90 – 0.66)]  
Tam-N-Gluc 0.87 (0.18 – 4.45) 1.15 (0.15 – 11.09) 1.67 (0.62 – 5.00) 0.060 0.007 0.208 0.013 
       [-0.24 (-0.52 – 0.01)] [-0.69 (-1.30 – -0.16)] [-0.43 (-1.08 – 0.35)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.44 (0.13 – 2.09) 0.61 (0.11 – 3.60) 0.77 (0.52 – 1.66) <0.001 0.001 0.197 <0.001 
       [-0.20 (-0.31 – -0.09)] [-0.35 (-0.59 – -0.20)] [-0.16 (-0.44 – 0.12)]  




Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 





AA (N=127) AG (N=64) GG (N=11) AA vs AG AA vs GG AG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.59 (47.62 – 463.20) 181.90 (39.18 – 454.15) 220.8 (92.82 – 319.81) 0.036 0.634 0.193 0.084 
       [21.93 (1.64 – 44.39)] [-12.85 (-60.49 – 36.86)] [-37.24 (-84.05 – 17.53)]  
(Z)-4-OHT 2.74 (0.70  – 7.17) 2.60 (0.47 – 5.80) 2.57 (1.67 – 4.96) 0.333 0.897 0.600 0.607 
       [0.18 (-0.19 – 0.54)] [-0.03 (-0.67 – 0.78)] [-0.18 (-0.87 – 0.64)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.27 (0.17 – 11.09) 1.79 (0.62 – 5.00) 0.003 0.004 0.338 0.001 
       [-0.39 (-0.66 – -0.12)] [-0.74 (-1.30 – -0.24)] [-0.35 (-0.99 – 0.40)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.41 (0.11 – 2.09) 0.79 (0.19 – 3.60) 0.65 (0.52 – 1.66) <0.001 0.001 0.642 <0.001 
       [-0.28 (-0.40 – -0.17)] [-0.3 (-0.46 – -0.17)] [-0.06 (-0.31 – 0.27)]  
-1531C>T 
(rs3806592) 
CC (N=154) CT (N=44) TT (N=4) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.36 (39.18 – 463.20) 192.39 (95.87 – 454.15) 171.08 (130.29 – 258.84) 0.971 0.550 0.526 0.828 
       [0.51 (-23.92 – 24.67)] [20.28 (-47.19 – 93.47)] [18.88 (-44.52 – 77.78)]  
(Z)-4-OHT 2.66 (0.47 – 7.17) 2.90 (0.85 – 6.51) 2.21 (1.96 – 3.54) 0.983 0.358 0.502 0.683 
       [0.00 (-0.45 – 0.42)] [0.33 (-0.62 – 1.63)] [0.36 (-0.65 – 1.84)]  
Tam-N-Gluc 1.00 (0.15 – 11.09) 1.05 (0.26 – 5.49) 1.03 (0.80 – 1.53) 0.404 0.740 0.911 0.680 
       [-0.09 (-0.34 – 0.14)] [-0.11 (-0.59 – 0.73)] [-0.03 (-0.51 – 0.94)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.50 (0.11 – 3.60) 0.56 (0.13 – 1.87) 0.60 (0.56 – 0.65) 0.350 0.325 0.551 0.427 
       [-0.04 (-0.14 – 0.06)] [-0.12 (-0.32 – 0.31)] [-0.06 (-0.28 – 0.37)]  




Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-419G>A (rs3732220) GG (N=126) GA (N=66) AA (N=10) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.49 (47.62 – 463.20) 181.90 (39.18 – 454.15) 222.28 (92.82 – 319.81) 0.047 0.532 0.171 0.095 
       [20.51 (0.37 – 42.66)] [-17.08 (-67.87 – 36.86)] [-41.78 (-89.05 – 16.71)]  
(Z)-4-OHT 2.72 (0.70 – 7.17) 2.60 (0.47 – 5.80) 2.60 (1.67 – 4.96) 0.353 0.809 0.559 0.610 
       [0.17 (-0.19 – 0.52)] [-0.09 (-0.77 – 0.79)] [-0.21 (-1.00 – 0.63)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.25 (0.17 – 11.09) 1.87 (0.62 – 5.00) 0.003 0.003 0.208 0.001 
       [-0.37 (-0.63 – -0.12)] [-0.89 (-1.40 – -0.31)] [-0.45 (-1.17 – 0.36)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.40 (0.11 – 2.09) 0.74 (0.19 – 3.60) 0.66 (0.52 – 1.66) <0.001 <0.001 0.415 <0.001 
       [-0.26 (-0.38 – -0.16)] [-0.33 (-0.55 – -0.19)] [-0.09 (-0.35 – 0.23)]  
-219C>T (rs3732219) CC (N=126) CT (N=66) TT (N=10) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.49 (47.62 – 463.20) 181.90 (39.18 – 454.15) 222.28 (92.82 – 319.81) 0.047 0.532 0.171 0.095 
       [20.51 (0.37 – 42.66)] [-17.08 (-67.87 – 36.86)] [-41.78 (-89.05 – 16.71)]  
(Z)-4-OHT 2.72 (0.70 – 7.17) 2.60 (0.47 – 5.80) 2.60 (1.67 – 4.96) 0.353 0.809 0.559 0.610 
       [0.17 (-0.19 – 0.52)] [-0.09 (-0.77 – 0.79)] [-0.21 (-1.00 – 0.63)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.25 (0.17 – 11.09) 1.87 (0.62 – 5.00) 0.003 0.003 0.208 0.001 
       [-0.37 (-0.63 – -0.12)] [-0.89 (-1.40 – -0.31)] [-0.45 (-1.17 – 0.36)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.40 (0.11 – 2.09) 0.74 (0.19 – 3.60) 0.66 (0.52 – 1.66) <0.001 <0.001 0.415 <0.001 
       [-0.26 (-0.38 – -0.16)] [-0.33 (-0.55 – -0.19)] [-0.09 (-0.35 – 0.23)]  





Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-163G>A (rs3732218) GG (N=126) GA (N=66) AA (N=10) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.49 (47.62 – 463.20) 181.90 (39.18 – 454.15) 222.28 (92.82 – 319.81) 0.047 0.532 0.171 0.095 
       [20.51 (0.37 – 42.66)] [-17.08 (-67.87 – 36.86)] [-41.78 (-89.05 – 16.71)]  
(Z)-4-OHT 2.72 (0.70 – 7.17) 2.60 (0.47 – 5.80) 2.60 (1.67 – 4.96) 0.353 0.809 0.559 0.610 
       [0.17 (-0.19 – 0.52)] [-0.09 (-0.77 – 0.79)] [-0.21 (-1.00 – 0.63)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.25 (0.17 – 11.09) 1.87 (0.62 – 5.00) 0.003 0.003 0.208 0.001 
       [-0.37 (-0.63 – -0.12)] [-0.89 (-1.40 – -0.31)] [-0.45 (-1.17 – 0.36)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.40 (0.11 – 2.09) 0.74 (0.19 – 3.60) 0.66 (0.52 – 1.66) <0.001 <0.001 0.415 <0.001 
       [-0.26 (-0.38 – -0.16)] [-0.33 (-0.55 – -0.19)] [-0.09 (-0.35 – 0.23)]  
30G>A (rs61764026) GG (N=197) GA (N=5)     GG vs GA       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 193.37 (39.18 – 454.15) 236.7 (129.29 – 463.20)   0.270    
       [-43.9 (-123.19 – 35.24)]    
(Z)-4-OHT 2.66 (0.47 – 7.13) 4.40 (2.05 – 7.17)   0.167    
       [-1.00 (-2.76 – 0.36)]    
Tam-N-Gluc 1.01 (0.15 – 11.09) 0.71 (0.32 – 9.20)   0.929    
       [-0.02 (-3.59 – 0.71)]    
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.52 (0.11 – 2.87) 0.3 (0.21 – 3.60)   0.606    
       [0.06 (-0.60 – 0.35)]    





Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 





CC (N=201) CA (N=1)             
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 198.14 (39.18 – 463.20) 206.81        
(Z)-4-OHT 2.66 (0.47 – 7.17) 5.51        
Tam-N-Gluc 1.01 (0.15 – 11.09) 1.73        
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.52 (0.11 – 3.60) 0.84        
142T>G (*3, 
rs2011425) 
TT (N=129) TG (N=61) GG (N=12) TT vs TG TT vs GG TG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.59 (39.18 – 463.20) 186.57 (39.87 – 454.15) 197.41 (68.32 – 319.81) 0.086 0.585 0.800 0.222 
       [18.73 (-2.8 – 41.36)] [16.01 (-31.05 – 65.80)] [-7.66 (-55.54 – 45.56)]  
(Z)-4-OHT 2.70 (0.47 – 7.17) 2.76 (0.70 – 5.80) 2.51 (1.13 – 4.96) 0.618 0.540 0.688 0.758 
       [0.10 (-0.28 – 0.46)] [0.23 (-0.38 – 1.02)] [0.20 (-0.53 – 0.94)]  
Tam-N-Gluc 0.85 (0.15 – 11.09) 1.30 (0.17 – 9.20) 1.36 (0.19 – 5.00) 0.002 0.124 0.976 0.005 
       [-0.41 (-0.69 – -0.14)] [-0.38 (-1.01 – 0.10)] [0.01 (-0.64 – 0.71)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.42 (0.11 – 2.87) 0.79 (0.19 – 3.60) 0.63 (0.28 – 1.66) <0.001 0.019 0.835 <0.001 
       [-0.26 (-0.39 – -0.16)] [-0.23 (-0.39 – -0.04)] [0.03 (-0.22 – 0.31)]  







Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
173C>T CC (N=200) CT (N=2)             
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 199.19 (39.18 – 463.20) 172.56 (130.29 – 214.84)       
(Z)-4-OHT 2.67 (0.47 – 7.17) 2.98 (2.43 – 3.54)       
Tam-N-Gluc 1.01 (0.15 – 11.09) 1.44 (0.80 – 2.08)       
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.52 (0.11 – 3.60) 0.79 (0.62 – 0.97)       
448T>C (rs12468274) TT (N=124) TC (N=69) CC (N=9) TT vs TC TT vs CC TC vs CC 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 203.81 (47.62 – 463.20) 177.9 (39.18 – 454.15) 223.76 (92.82 – 319.81) 0.015 0.395 0.076 0.025 
       [25.96 (5.32 – 48.50)] [-23.14 (-73.50 – 31.13)] [-48.55 (-103.44 – 5.33)]  
(Z)-4-OHT 2.75 (0.85 – 7.17) 2.57 (0.47 – 5.80 2.57 (1.67 – 4.96) 0.121 0.837 0.439 0.278 
       [0.27 (-0.07 – 0.62)] [-0.06 (-0.84 – 0.83)] [-0.34 (-1.20 – 0.56)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.24 (0.17 – 11.09) 1.79 (0.62 – 5.00) 0.011 0.005 0.214 0.002 
       [-0.32 (-0.59 – -0.07)] [-0.82 (-1.41 – -0.26)] [-0.46 (-1.25 – 0.35)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.40 (0.11 – 2.09) 0.70 (0.19 – 3.60) 0.65 (0.52 – 1.66) <0.001 0.002 0.568 <0.001 
       [-0.26 (-0.37 – -0.15)] [-0.29 (-0.50 – -0.13)] [-0.07 (-0.34 – 0.27)]  





Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
471T>C (rs2011404)     
TT + 
TC 
(N=14) CC (N=188) TT + TC vs CC       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen   182.70 (113.26 – 346.43) 200.36 (39.18 – 463.20) 0.538    
       [-13.45 (-49.77 – 28.93)]    
(Z)-4-OHT   3.00 (1.40 – 5.87) 2.65 (0.47 – 7.17) 0.596    
       [0.22 (-0.51 – 1.04)]    
Tam-N-Gluc   0.78 (0.28 – 3.53) 1.05 (0.15 – 11.09) 0.225    
       [-0.20 (-0.56 – 0.11)]    
Plasma Concentration of Analytes (ng/ml) 
MRTam-N-Gluc/TAM (x100)   0.40 (0.19 – 1.87) 0.53 (0.11 – 3.600) 0.263    
       [-0.09 (-0.24 – 0.06)]    
804G>A (rs3732217) GG (N=123) GA (N=69) AA (N=10) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 203.67 (47.62 – 463.20) 177.9 (39.18 – 454.15) 233.4 (92.82 – 319.81) 0.013 0.322 0.040 0.017 
       [26.22 (5.76 – 49.02)] [-24.82 (-70.65 – 26.31)] [-53.12 (-100.99 – -4.70)]  
(Z)-4-OHT 2.76 (0.85 – 7.17) 2.57 (0.47 – 5.80) 2.78 (1.67 – 4.96) 0.109 0.772 0.376 0.246 
       [0.28 (-0.06 – 0.63)] [-0.10 (-0.82 – 0.74)] [-0.36 (-1.13 – 0.42)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.24 (0.17 – 11.09) 1.67 (0.62 – 5.00) 0.010 0.005 0.275 0.003 
       [-0.32 (-0.59 – -0.07)] [-0.69 (-1.28 – -0.24)] [-0.39 (-1.01 – 0.36)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.40 (0.11 – 2.09) 0.70 (0.19 – 3.60) 0.64 (0.45 – 1.66) <0.001 0.003 0.802 <0.001 
       [-0.26 (-0.37 – -0.16)] [-0.26 (-0.42 – -0.10)] [-0.04 (-0.27 – 0.28)]  






Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 





TT (N=79) TC (N=96) CC (N=27) TT vs TC TT vs CC TC vs CC 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 207.36 (47.62 – 463.20) 189.89 (39.18 – 390.50) 192.69 (49.45 – 454.15) 0.083 0.584 0.549 0.225 
       [18.93 (-2.45 – 40.56)] [8.24 (-21.71 – 43.29)] [-9.38 (-38.82 – 22.24)]  
(Z)-4-OHT 2.81 (1.01 – 7.17) 2.69 (0.47 – 6.80) 2.41 (0.70 – 5.51) 0.150 0.239 0.951 0.283 
       [0.27 (-0.09 – 0.63)] [0.27 (-0.19 – 0.84)] [0.02 (-0.49 – 0.58)]  
Tam-N-Gluc 0.75 (0.15 – 4.45) 1.10 (0.17 – 11.09) 1.55 (0.23 – 5.49) 0.011 <0.001 0.054 <0.001 
       [-0.26 (-0.46 – -0.05)] [-0.63 (-1.04 – -0.33)] [-0.39 (-0.79 – 0.00)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.35 (0.11 – 2.09) 0.56 (0.13 – 3.60) 0.67 (0.29 – 1.80) <0.001 <0.001 0.030 <0.001 
       [-0.18 (-0.27 – -0.10)] [-0.34 (-0.48 – -0.23)] [-0.17 (-0.32 – -0.01)]  
IVS1+346T>G 
(rs13401281) 
TT (N=150) TG (N=48) GG (N=4) TT vs TG TT vs GG TG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.28 (39.18 – 463.20) 192.39 (49.45 – 454.15) 207.65 (168.00 – 258.84) 0.750 0.699 0.655 0.876 
       [4.21 (-20.04 – 26.84)] [-12.75 (-82.61 – 63.23)] [-14.6 (-72.29 – 57.95)]  
(Z)-4-OHT 2.66 (0.47 – 7.17) 2.97 (0.70 – 6.80) 2.39 (2.04 – 2.66) 0.733 0.388 0.430 0.656 
       [-0.07 (-0.54 – 0.34)] [0.33 (-0.39 – 1.58)] [0.61 (-0.57 – 1.88)]  
Tam-N-Gluc 0.95 (0.15 – 11.09) 1.08 (0.23 – 5.49) 1.18 (0.89 – 1.53) 0.194 0.430 0.810 0.342 
       [-0.15 (-0.39 – 0.08)] [-0.23 (-0.71 – 0.57)] [-0.06 (-0.63 – 1.10)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.47 (0.11 – 3.60) 0.56 (0.13 – 1.87) 0.62 (0.37 – 0.73) 0.082 0.460 0.864 0.183 
       [-0.09 (-0.19 – 0.01)] [-0.09 (-0.34 – 0.29)] [-0.02 (-0.25 – 0.40)]  




Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 





AA (N=124) AG (N=69) GG (N=9) AA vs AG AA vs GG AG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 202.13 (47.62 – 463.20) 177.9 (39.18 – 454.15) 223.76 (92.82 – 319.81) 0.017 0.395 0.076 0.029 
       [25.27 (4.61 – 47.28)] [-23.35 (-73.90 – 30.36)] [-48.55 (-103.44 – 5.62)]  
(Z)-4-OHT 2.75 (0.85 – 7.17) 2.60 (0.47 – 5.80) 2.57 (1.67 – 4.96) 0.135 0.816 0.467 0.305 
       [0.26 (-0.08 – 0.61)] [-0.07 (-0.84 – 0.83)] [-0.34 (-1.20 – 0.58)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.24 (0.17 – 11.09) 1.79 (0.62 – 5.00) 0.009 0.005 0.220 0.002 
       [-0.33 (-0.59 – -0.07)] [-0.82 (-1.42 – -0.26)] [-0.45 (-1.25 – 0.35)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.40 (0.11 – 2.09) 0.70 (0.19 – 3.60) 0.65 (0.52 – 1.66) <0.001 0.002 0.589 <0.001 
       [-0.26 (-0.37 – -0.15)] [-0.29 (-0.50 – -0.13)] [-0.07 (-0.34 – 0.27)]  
IVS2+15T>C 
(rs4148327) 
TT (N=191) TC (N=11)     TT vs TC       
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 193.37 (39.18 – 463.20) 226.01 (68.32 – 406.95)   0.230    
       [-29.83 (-90.66 – 21.50)]    
(Z)-4-OHT 2.63 (0.47 – 7.17) 3.35 (1.13 – 3.98)   0.689    
       [-0.14 (-0.88 – 0.60)]    
Tam-N-Gluc 1.01 (0.15 – 11.09) 0.85 (0.19 – 4.26)   0.892    
       [0.03 (-0.45 – 0.48)]    
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.52 (0.11 – 3.60) 0.38 (0.14 – 1.50)   0.371    
       [0.06 (-0.09 – 0.27)]    




Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 





AA (N=128) AG (N=67) GG (N=7) AA vs AG AA vs GG AG vs GG 
Overall P 
value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.49 (39.87 – 463.20) 186.57 (39.18 – 454.15) 220.80 (92.82 – 273.48) 0.079 0.945 0.466 0.203 
       [19.05 (-2.47 – 39.89)] [-2.79 (-54.35 – 62.84)] [-22.86 (-74.85 – 44.20)]  
(Z)-4-OHT 2.72 (0.85 – 7.17) 2.63 (0.47 – 5.80) 2.46 (1.67 – 4.96) 0.291 0.835 0.963 0.577 
       [0.19 (-0.17 – 0.55)] [0.11 (-0.76 – 1.17)] [-0.04 (-1.07 – 0.93)]  
Tam-N-Gluc 0.85 (0.15 – 4.45) 1.27 (0.19 – 11.09) 1.55 (0.62 – 2.83) 0.002 0.038 0.625 0.003 
       [-0.40 (-0.67 – -0.13)] [-0.55 (-1.23 – -0.02)] [-0.21 (-0.87 – 0.68)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.42 (0.11 – 2.09) 0.79 (0.19 – 3.60) 0.65 (0.52 – 1.66) <0.001 0.012 0.890 <0.001 
       [-0.27 (-0.38 – -0.16)] [-0.26 (-0.44 – -0.08)] [-0.02 (-0.31 – 0.36)]  
IVS2-82T>C 
(rs2302538) 
TT (N=177) TC (N=23) CC (N=2) TT vs TC TT vs CC TC vs CC 
Overall P 
value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 200.33 (39.18 – 463.20) 189.43 (63.30 – 454.15) 188.64 (170.46 – 206.81) 0.628 0.794 0.920 0.863 
       [9.75 (-29.29 – 44.36)] [7.48 (-68.97 – 128.88)] [4.60 (-107.16 – 149.35)]  
(Z)-4-OHT 2.70 (0.47 – 7.17) 2.43 (1.11 – 5.05) 3.59 (1.67 – 5.51) 0.144 0.869 0.689 0.341 
       [0.36 (-0.13 – 0.88)] [-0.37 (-3.52 – 2.47)] [-0.51 (-3.85 – 1.55)]  
Tam-N-Gluc 0.98 (0.17 – 11.09) 1.15 (0.15 – 9.20) 2.28 (1.73 – 2.83) 0.243 0.074 0.367 0.119 
       [-0.22 (-0.76 – 0.13)] [-1.21 (-2.34 – 0.48)] [-0.90 (-2.39 – 3.77)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.50 (0.13 – 2.87) 0.67 (0.11 – 3.60) 1.25 (0.84 – 1.66) 0.050 0.068 0.317 0.032 
       [-0.17 (-0.44 – 0.00)] [-0.59 (-1.37 – 0.09)] [-0.46 (-1.36 – 1.00)]  




Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
*440G>C (rs8330) GG (N=5) GC (N=45) CC (N=152) GG vs GC GG vs CC GC vs CC 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 306.72 (171.63 – 390.50) 181.46 (44.27 – 406.95) 200.36 (39.18 – 463.20) 0.023 0.039 0.235 0.050 
       [102.77 (15.23 – 185.53)] [89.41 (4.12 – 169.56)] [-13.87 (-38.05 – 8.82)]  
(Z)-4-OHT 2.33 (1.40 – 5.87) 2.60 (0.85 – 5.80) 2.69 (0.47 – 7.17) 0.639 0.617 0.870 0.871 
       [-0.28 (-1.33 – 1.34)] [-0.30 (-1.50 – 1.24)] [-0.03 (-0.41 – 0.34)]  
Tam-N-Gluc 1.53 (0.55 – 4.26) 0.94 (0.15 – 5.00) 1.02 (0.17 – 11.09) 0.109 0.139 0.402 0.220 
       [0.68 (-0.14 – 3.12)] [0.66 (-0.26 – 2.91)] [-0.10 (-0.33 – 0.11)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.44 (0.32 – 1.71) 0.53 (0.11 – 1.80) 0.52 (0.13 – 3.60) 0.528 0.614 0.711 0.806 
       [0.09 (-0.24 – 0.76)] [0.06 (-0.24 – 0.70)] [-0.02 (-0.11 – 0.08)]  
*+851C>A 
(rs17862880) 
CC (N=130) CA (N=61) AA (N=11) CC vs CA CC vs AA CA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 195.76 (44.27 – 406.95) 200.33 (39.18 – 463.20) 206.81 (49.45 – 255.98) 0.862 0.318 0.394 0.610 
       [2.01 (-21.37 – 24.17)] [25.57 (-21.74 – 81.36)] [21.18 (-24.9 – 86.19)]  
(Z)-4-OHT 2.72 (0.85 – 7.13) 2.66 (0.47 – 7.17) 2.37 (0.70 – 5.51) 0.915 0.612 0.589 0.863 
       [-0.02 (-0.37 – 0.36)] [0.20 (-0.72 – 1.05)] [0.27 (-0.84 – 1.08)]  
Tam-N-Gluc 0.90 (0.15 – 4.45) 1.17 (0.17 – 11.09) 1.26 (0.19 – 9.20) 0.057 0.205 0.772 0.101 
       [-0.21 (-0.45 – 0.01)] [-0.38 (-0.89 – 0.21)] [-0.10 (-0.79 – 0.63)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.44 (0.11 – 2.09) 0.60 (0.17 – 2.87) 0.67 (0.30 – 3.60) 0.016 0.018 0.324 0.008 
       [-0.12 (-0.24 – -0.02)] [-0.23 (-0.48 – -0.04)] [-0.12 (-0.40 – 0.13)]  




Table 3.20 Effect of UGT1A4 tag-SNPs on plasma concentrations of tamoxifen and its metabolites (ng/ml), and metabolic ratio (N=202) (Continued). 





CC (N=25) CT (N=97) TT (N=80) CC vs CT CC vs TT CT vs TT 
Overall P 
value 
Plasma Concentration of Analytes (ng/ml) 
Tamoxifen 213.89 (49.45 – 390.50) 200.23 (39.18 – 463.20) 191.22 (47.62 – 404.23) 0.623 0.916 0.515 0.770 
       [7.29 (-27.49 – 39.51)] [1.75 (-33.40 – 33.99)] [-7.11 (-28.21 – 15.23)]  
(Z)-4-OHT 2.57 (0.70 – 5.87) 2.63 (0.47 – 7.17) 2.79 (0.85 – 7.13) 0.847 0.752 0.862 0.951 
       [-0.07 (-0.60 – 0.47)] [-0.11 (-0.68 – 0.46)] [-0.03 (-0.39 – 0.32)]  
Tam-N-Gluc 1.26 (0.15 – 9.20) 1.10 (0.17 – 11.09) 0.80 (0.18 – 4.45) 0.387 0.051 0.031 0.039 
       [0.18 (-0.23 – 0.66)] [0.41 (0.00 – 0.84)] [0.21 (0.02 – 0.42)]  
Plasma Metabolic Ratio (MR) 
MRTam-N-Gluc/TAM (x100) 0.59 (0.11 – 3.60) 0.58 (0.14 – 2.87) 0.40 (0.13 – 2.09) 0.495 0.018 0.002 0.003 
       [0.07 (-0.11 – 0.27)] [0.18 (0.03 – 0.40)] [0.13 (0.05 – 0.23)]  




In view of the high LD between the polymorphisms, haplotypic analyses were carried 
out. LD matrix indicated that two major blocks segregated the polymorphisms (Fig 
3.11). Hence, haplotypic analyses were performed separately for the two LD blocks. 
Before haplotypic analysis using the haploGLM package in R software, plasma 
concentration of tamoxifen was square-root-transformed while all other parameters 
were ln-transformed to ensure conformity with requirement of normally distributed 
data. Haplotypes significantly associated with the parameters were subjected to 
subsequent adjustment with covariates. LD block 1 which consisted of 12 
polymorphisms was associated with alterations in plasma Tam-N-Gluc concentration 
and MRTAM-N-Gluc/TAM but not plasma concentrations of tamoxifen or (Z)-4-OHT. As 
indicated in Table 3.21, LD block 1 comprised of three major haplotypes, of which 
the most frequent variant haplotype H2 (frequency: 0.18) was correlated with higher 
plasma concentration of Tam-N-Gluc and MRTAM-N-Gluc/TAM. After adjustment for 
significant covariates including age, height, weight and menopausal status of 
patients, the associations remained significant (Table 3.22). In contrast, haplotypic 
combinations of the three SNPs in the 3′ region of the gene were not found to 
influence the plasma concentrations of the analytes and MRTAM-N-Gluc/TAM (Table 3.21). 
Subsequently, patients were classified according to their diplotypic status for H2 in 
LD block 1. The median MRTAM-N-Gluc/TAM was 1.5-fold higher among patients carrying 
H1/H2 compared to patients carrying the wild-type (H1/H1) haplotype pairs but 
similar between individuals carrying one or two copies of the H2 haplotype (Fig 3.12). 
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Table 3.21 Effects of UGT1A4 Haplotypes on the plasma concentrations of analytes and metabolite ratio (MR). 


























































































































































































































































































































(Intercept of GLM) 14.40 2.08 3.70 1.73 0.29 0.08 0.06 0.04 < 0.0001 < 0.0001 <0.001 < 0.0001 
H1 
L
 A C G C G T T G T T A A 0.61             
H2 G C A T A G C A C T G G 0.18 -0.43 0.39 0.46 -0.03 0.39 0.11 0.08 0.05 0.266 < 0.0001 <0.001 0.620 
H3 A T G C G T T G C G A A 0.12 -0.11 0.22 0.22 -0.03 0.46 0.13 0.10 0.06 0.806 0.080 0.026 0.672 
Hrare * * * * * * * * * * * * 0.09 -0.82 0.06 0.21 -0.16 0.68 0.19 0.15 0.09 0.229 0.754 0.155 0.074 
            























































































































































































































































(Intercept of GLM) 14.44 2.36 3.98 1.69 0.69 0.19 0.16 0.09 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
H1 
L
 G C C          0.14             
H2 C C T          0.63 -0.16 -0.11 -0.09 0.00 0.40 0.11 0.09 0.05 0.699 0.343 0.311 0.997 
H3 C A C          0.20 -0.47 0.11 0.19 -0.01 0.45 0.13 0.10 0.06 0.304 0.385 0.067 0.827 
Hrare * * *          0.02 0.59 0.29 0.18 0.07 1.01 0.28 0.23 0.13 0.559 0.304 0.427 0.624 
† Plasma concentrations of tamoxifen and (Z)-4-OHT were square-root-transformed; Tam-N-Gluc concentration and MRTAM-N-Gluc/TAM were multiplied by factors of 10 and 10000 before ln-
transformation.  



























































































































































































































































(Intercept of GLM) 1.97 2.33 1.66 0.37 0.238 < 0.0001 
H1 
L
 A C G C G T T G T T A A 0.61       
H2 G C A T A G C A C T G G 0.18 0.41 0.47 0.10 0.08 < 0.0001 < 0.0001 
H3 A T G C G T T G C G A A 0.12 0.19 0.18 0.12 0.10 0.132 0.064 
Hrare * * * * * * * * * * * * 0.09 0.06 0.21 0.18 0.14 0.739 0.138 
Covariates:                     
Age              0.03 0.01 0.01 0.01 0.012 0.016 
Weight              − 0.01 − 0.00 − 0.005 
Height              -0.01 − 0.01 − 0.440 − 
Menopausal Status                           -0.02 − 0.18 − 0.911 − 
† Tam-N-Gluc concentration was multiplied by a factor of 10 before ln-transformation and the GLM model for Tam-N-Gluc concentration  was adjusted for  
age, height and menopausal status; MRTAM-N-Gluc/TAM  was multiplied by a factor of 10000 before ln-transformation and the GLM model for MRTAM-N-Gluc/TAM  
was adjusted for age and weight. 
‡ Haplotype H1 refers to the wild-type haplotype. 
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Fig 3.12 Effects of UGT1A4 LD block 1 H2 
haplotype pairs on plasma concentrations of 




UGT1A4 belongs to the UGT1A family of phase I drug metabolizing enzymes 
involved in the conjugation of a wide range of substrates. Like other UGT1A genes, 
UGT1A4 has been reported to be highly polymorphic in the Caucasians, Japanese 
and Koreans (352-356). In the present study, the genetic catalogue of UGT1A4 
polymorphisms in the healthy Chinese, Malays and Indians were established with 80 
subjects in each ethnicity. The exons with the exon-intron junctions as well as the 5′ 
upstream and 3′ downstream regions were screened in our healthy subjects 
revealing a total of 61 polymorphisms. Of these variants, 17 SNPs were novel while 
14 polymorphisms were located in the exons.  
Among the 14 exonic SNPs, only two were located between exons 2 and 5 which 
encode the highly conserved, putative UDPGA-binding domain, transmembrane 
domain and C-terminus of UGT1A enzymes (342, 468). Furthermore, these two 
polymorphisms were ethnic specific with only 5.1% of the ethnic Indians being 
heterozygous for 966A>G (exon 2, I323V) and absent in Chinese and Malays. With 
regard to 1094C>T (exon 4, P365L), the heterozygous genotype was observed in 
1.3% of the ethnic Chinese subjects but was absent in the ethnic Malays and Indians. 
Of note, the polymorphism 1094C>T leads to an amino acid change of P365L at the 
UGT signature sequence. As these SNPs lie in the region common to all UGT1A 
genes, their functional effects may not be limited to UGT1A4. 
The polymorphisms found in exon 1 were generally of low frequencies and 
polymorphic in specific population with the exception of 142T>G (*3, rs2011425), 
448T>C (rs12468274), 471T>C (rs2011404) and 804G>A (rs3732217). Amongst 
which, the transversion 142T>G (*3, rs2011425) was the only nonsynonymous SNP 
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with relatively high variant allelic frequencies ranging from 0.20 to 0.24 across the 
three ethnicities and has been widely investigated. Another nonsynonymous 
polymorphism, 70C>A (*2, rs6755571), which has been previously reported in 8% of 
the Caucasian population(352) was found to be absent in our Chinese and Malay 
populations, consistent with published reports in Koreans and Japanese (353, 356). 
The SNP was however present in two healthy Indian subjects and one Indian patient 
as heterozygous genotypes. Interestingly, 70C>A (*2, rs6755571) and 142T>G (*3, 
rs2011425) have also been found to co-exist in the German Caucasians (360). 
However, this observation was not replicated in subsequent studies involving 
Caucasian subjects carried out by Benoit-Biancamano et al (352) and Thomas et al 
(356). Likewise, linkage between 70C>A (*2, rs6755571) and 142T>G (*3, 
rs2011425) transversion was poor in our Asian populations. 
In line with previous studies in the East Asians and Caucasians (341, 352, 353), high 
LD was observed among the polymorphic variants in the 5′ upstream region, exon 1 
and intron 1, especially in the Malay population. Interestingly, high linkage was also 
observed among polymorphisms in the 3′ region. However, the LD between the 5′ 
and 3′ regions was generally poor. This linkage pattern was found to be highly similar 
to that of the Japanese and Han Chinese (341, 353). As the exons 2 to 5 were 
shared among all the UGT1A isoforms, SNPs present in exons 2 to 5 and the 3′ 
region are not expected to be in high LD with polymorphisms in the promoter region 
and exon 1 of the gene which uniquely define the various UGT1A isoforms.  
Based on the LD (quantified by R2) between polymorphisms, tag-SNPs were chosen 
to reduce the genotyping burden in the patient subjects. Using the exhaustive search 
algorithm, a relatively small number of 16 tag-SNPs were selected to represent all 61 
SNPs along the length of UGT1A4 gene across all three populations. It has been 
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reported previously by Woo et al (222) that tag-SNPs selected via LD-based 
methods are able to capture majority of the haplotype diversity. In addition, the low 
frequency exonic polymorphisms which can potentially influence the enzyme activity 
of UGT1A4 were also genotyped in the Asian patients. 
Analyses of the individual polymorphisms showed that several polymorphisms were 
significantly associated with alterations in the plasma level of Tam-N-Gluc and 
MRTAM-N-Gluc/TAM but not plasma levels of tamoxifen and (Z)-4-OHT. Closer 
examination of the LD between these polymorphisms indicated high linkage between 
them and two LD blocks according to the definition of Gabriel et al (467) were 
inferred. Thus, haplotypic associations between the inferred haplotypes in each LD 
block and the phenotypic parameters were performed. Haplotype-specific GLM 
analyses indicated that haplotype H2 in LD block 1 was significantly associated with 
higher plasma concentration of Tam-N-Gluc. Higher MRTAM-N-Gluc/TAM was also 
associated with the haplotype, indicating higher rate of tamoxifen N-glucuronidation. 
The H2 haplotype was a haplotypic combination of 12 SNPs: -1548G, -1531C, -419A, 
-219T, -163A, 142G, 448C, 804A, IVS1+196C, IVS1+346T, IVS1+414G and 
IVS2+307G. Among these polymorphisms, 142T>G (*3, rs2011425) is the most 
widely investigated functional SNP in UGT1A4. Sun et al (134) has previously 
reported higher glucuronidation rates of tamoxifen and (Z)-4-OHT in cell lines 
overexpressing variant forms of UGT1A4 enzyme including UGT1A4.2 and 
UGT1A4.3. The variant UGT1A4.3 but not UGT1A4.2 was found to exhibit higher 
glucuronidating activities against tamoxifen and 4-OHT. This phenotypic effect of 
142T>G (*3, rs2011425) has been proven in vivo among the German breast cancer 
patients (118). In the present study, it was showed that 142T>G (*3, rs2011425) 
seemed to exert similar effects in the Asian patients. Furthermore, the effects of 
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142T>G (*3, rs2011425) were mediated through haplotypic combinations with other 
polymorphisms located in the 5′ upstream and intronic regions.  
Of note, the SNPs in the 5′ upstream region have been demonstrated to alter the 
transcriptional activity of UGT1A4. Both -219C>T (rs3732219) and -163G>A 
(rs3732218) have been (362) associated with decreased AhR-regulated expression 
of UGT1A4 in the reporter gene constructs. In a separate study, -204G>A, was 
associated with lower glucuronidation of N-OH-PhIP in Caucasian liver samples 
(352). These promoter variants were observed to be in LD with 142T>G (*3, 
rs2011425). However, it was proven otherwise by Benoit-Biancamano et al (352) 
who demonstrated limited effects on UGT1A4 transcriptional activity when -163G>A 
(rs3732218) was present as a haplotypic construct with -457C>T (rs3732221), -
419G>A (rs3732220) and -219C>T (rs3732219). It should be noted that Benoit-
Biancamano et al (352) only examined the proximal promoter region of UGT1A4 
(approximately 500 base pair upstream of the translational start site). In our Asian 
ethnic populations, 142T>G (*3, rs2011425) was not only found to be in moderate to 
high linkage (|D′| ≥ 0.82, R2 ≥ 0.55) with these promoter variants. Moderate LD 
between 142T>G (*3, rs2011425) and polymorphisms in the distal 5′ promoter region 
[-2650A>G (rs17868334), -2583T>C (rs17863791), -2484C>A (rs17868335), -
2341G>A (rs17863792), -2273A>C (rs17864696) and -2228A>G] was also observed 
in the Chinese (|D′| ≥ 0.84, R2 ≥ 0.60) and Malay (|D′| ≥ 0.91, R2 ≥ 0.58) subjects 
while higher LD was observed among the Indian (|D′| ≥ 0.80, R2 ≥ 0.89) subjects. 
The in vivo effects of these SNPs which were in tight linkage would likely be due to 
the impact that these SNPs exert in combination as a haplotype. Hence, the 
mechanistic basis of the haplotypic effects of these SNPs should be examined in 
subsequent in vitro studies.  
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Although UGT1A4 polymorphisms were found to significantly impact the plasma 
levels of Tam-N-Gluc and MRTAM-N-Gluc/TAM, an inverse trend was not observed with 
plasma concentration of tamoxifen. It has been previously estimated that 92% and 
7% tamoxifen undergoes N-demethylation and 4-hydroxylation to form NDM and (Z)-
4-OHT respectively (119). The remaining 1% of tamoxifen undergoes N-oxidation, α-, 
3-, 3′- and 4′-hydroxylation in addition to N-glucuronidation (118). Examination of the 
plasma concentration of Tam-N-Gluc found that it was generally present at plasma 
concentrations 2- to 3- fold lower than (Z)-4-OHT in the patients although the 
concentration of Tam-N-Gluc did exceed that of (Z)-4-OHT in certain patients. Hence, 
N-glucuronidation is likely to contribute to less than 1% of tamoxifen metabolism and 
direct impact of UGT1A4 polymorphisms on the variations in plasma concentrations 
of tamoxifen might be minimal. 
Besides the effects on tamoxifen concentrations, Sun et al has previously reported 
an increase rate in the N-glucuronidation of (Z)-4-OHT by UGT1A4.3 variant protein 
compared to the wild-type UGT1A4.1 protein (134). However, no association 
between UGT1A4 polymorphisms and plasma concentrations of (Z)-4-OHT was 
observed in the Asian patients. Interestingly, the levels of (Z)-4-OHT-N-Gluc were 
below the quantification limit in more than 90% of all patients suggesting that N-
glucuronidation was not a major route of elimination for (Z)-4-OHT, in contrary to 
previous findings by Ogura et al (130). Hence, the effect of UGT1A4 on the 
disposition of (Z)-4-OHT would likely be minor.  
In summary, UGT1A4 was found to be highly polymorphic in our three healthy Asian 
populations and the SNPs were in high LD across various populations. Haplotype H2 
in LD block 1 which comprised of the functional polymorphism, 142T>G (*3, 
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rs2011425), was associated with higher glucuronidation of tamoxifen to form Tam-N-
Gluc, consistent with previous studies. As 142T>G (*3, rs2011425) was present in 
haplotypic combination with other polymorphisms, the mechanistic basis of the 
observed effects should be further investigated. However, N-glucuronidation is a 
minor metabolic pathway of tamoxifen compared to N-demethylation or 4-
hydroxylation. Hence, the relevance of these findings on the treatment outcome of 
tamoxifen remains to be determined. 
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3.4.2 UDP glucuronosyltransferase 2 family, polypeptide B7 (UGT2B7) 
3.4.2.1 Genetic Profile of UGT2B7 
A total of 77 polymorphisms were uncovered during the screening of the 5′ upstream 
(up to approximately 2.5 kbp), exonic, exon-intron boundaries and 3′ downstream 
regions (up to approximately 2.0 kbp) of UGT2B7 gene (Fig 3.13). Thirty 
polymorphisms were novel and are indicated in Table 3.24 while the putative 
funcitons of these polymorphism are listed in Table 3.23. Approximately 30% of the 
variants (N=23) were excluded from subsequent analyses due to MAF of 1% or less 
in all three healthy populations, or less than 2% in one healthy population. Thus, a 
final number of 54 polymorphic variants were included in subsequent analysis. 
Majority of the variants were found in the non-coding regions with only twelve SNPs 
located in the six exons with seven of which being synonymous. They were found in 
exons 1, 2, 4 and 5. Among the other polymorphisms, 20 variants were found in the 
5′ upstream region, 31 were in the introns, one was in the 3′ UTR and 13 in the 3′ 
downstream region. The genotypic and allelic frequencies of these polymorphic 
variants are listed in Table 3.24. All polymorphisms conformed to the Hardy-
Weinberg equilibrium. 
Significant variations in the genotypic distributions of 22 SNPs were observed 
between ethnic groups (Table 3.24). Twelve polymorphisms, of which three were 
found in the exons, were observed to be significantly different between the healthy 
Indians and the Chinese or Malays. The frequency of the non-synonymous 
transversion, 211G>T, was 15- and 9-fold higher in the Chinese and Malays, 
respectively, compared to the Indians. The converse was true for both 735A>G 
(rs28365062) and 1062C>T (rs4348159). Besides, two polymorphisms in intron 4 
 264
and two variants in 3′ downstream region were found to be 1.1- to 1.8-fold higher in 
the healthy Malay compared to the Indian populations. Similarly, IVS4+186C>A, 
IVS4-154C>G (rs4588522), IVS5-107G>A (rs7658752) and *+1493C>T were 
present at significantly lower frequencies in the Indians compared to Chinese while 
IVS4-95G>A (rs10022440) was present at higher frequency in the Indians than the 
Chinese. 
 
Fig 3.13 Polymorphisms present in UGT2B7 gene (UCSC RefSeq: NM_001074.2). 
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Table 3.23 Functional effects of UGT2B7 polymorphisms.  
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
-2457G>T  5′ Upstream Promoter/regulatory region Deletion of GATA-1 and SRY binding site 
-2390_-2067delALU(325bp)  5′ Upstream ALU element – 
-1859G>A  5′ Upstream Upstream with no known function – 
-1852C>G rs6600879 5′ Upstream Upstream with no known function – 
-1684C>T rs4554144 5′ Upstream Upstream with no known function – 
-1681T>C rs73823857 5′ Upstream Upstream with no known function – 
-1570C>T rs4538548 5′ Upstream Upstream with no known function – 
-1568C>T rs6600883 5′ Upstream Upstream with no known function – 
-1306A>G rs4455491 5′ Upstream Upstream with no known function – 
-1299T>C rs11940220 5′ Upstream Upstream with no known function – 
-1273G>C  5′ Upstream Upstream with no known function – 
-1112T>C rs11940316 5′ Upstream Upstream with no known function – 
-900G>A rs7438135 5′ Upstream Promoter/regulatory region Disrupts AP-1 binding site 
-854delT  5′ Upstream Promoter/regulatory region Deletion of SRY binding site 
-573G>A  5′ Upstream Upstream with no known function – 
-327A>G rs7662029 5′ Upstream Promoter/regulatory region Disrupts binding site for SRY 
-161T>C rs7668258 5′ Upstream Upstream with no known function – 
-138G>A rs73823859 5′ Upstream Promoter/regulatory region Creates binding sites for SRY and HFH-2 
-125T>C rs7668282 5′ Upstream Promoter/regulatory region Disrupts binding site for CdxA 
-96A>C  5′ UTR Upstream with no known function – 
211G>T rs12233719 Exon 1 Missense (conservative) polymorphism; Splicing 
regulation 
A71S; Predicted to be benign with a score of 0.119 
372A>G rs28365063 Exon 1 Exonic synonymous polymorphism R124R 
IVS1+9_IVS1+10insT  Intron 1 Intronic with no known function – 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software was restricted to 
SNPs in the 3′ untranslated region. 
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Table 3.23 Functional effects of UGT2B7 polymorphisms. (continued) 
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
IVS1-470T>C rs28375964 Intron 1 Intronic with no known function – 
IVS1-314A>G rs62298861 Intron 1 Intronic enhancer Creates binding site for STATx 
IVS1-300C>A rs72643000 Intron 1 Intronic enhancer Affects binding site for CdxA 
IVS1-292C>T  Intron 1 Intronic enhancer Creation of binding sites for Brn-2, CdxA and S8 
IVS1-181C>T rs73823860 Intron 1 Intronic with no known function – 
IVS1-78T>C rs7439326 Intron 1 Intronic enhancer Creates binding site for CdxA 
IVS1-49A>G  rs7438244 Intron 1 Intronic enhancer Affects binding of CRE-BP, Oct-1, CdxA and c-Ets-1 
735A>G rs28365062 Exon 2 Exonic synonymous polymorphism; Splicing 
regulation 
T245T; Creates binding site for SRp55; Disrupts 
binding site for Exonic Splicing Enhancer 
763G>A  Exon 2 Missense (conservative) polymorphism V255I; Predicted to be benign with a score of 0.001 
801A>T rs7438284 Exon 2 Exonic synonymous polymorphism P267P 
802T>C rs7439366 Exon 2 Missense (conservative) polymorphism; Splicing 
regulation 
H268Y; Predicted to be benign with a score of 0.049; 
Affects binding of Srp40 and SRp55 
855C>A rs34661811 Exon 2 Exonic synonymous polymorphism; Splicing 
regulation 
A285A; Creates binding site for Srp40; Disrupts 
binding site for Exonic Splicing Enhancer 
IVS2+115G>A rs7441750 Intron 2 Intronic enhancer Creates binding site for AML-1a 
IVS2+148G>A rs7441774 Intron 2 Intronic with no known function – 
IVS2-281A>G  Intron 2 Intronic enhancer Deletion of Sox-5 binding site 
IVS3+169_IVS3+170insT rs72601809  Intron 3 Intronic enhancer Creates binding sites for HFH-2 
IVS3+187_IVS3+192delTAAG  Intron 3 Intronic enhancer Creation of Nkx-2 binding site 
1054C>T  Exon 4 Exonic nonsynonymous polymorphism R352W; Predicted to be possibly damaging with a 
score of 0.672 
1059C>G  rs4292394 Exon 4 Exonic synonymous polymorphism; Splicing 
regulation 
L353L; Creates SF2/ASF binding site 
1062C>T  rs4348159 Exon 4 Exonic synonymous polymorphism; Splicing 
regulation 
Y354Y; Creates binding site for exonic splicing 
silencer; Disrupts binding site for exonic splicing 
enhancer 
1065G>C  Exon 4 Exonic synonymous polymorphism; Splicing 
regulation 
K355K; Creation of additional binding sites for Srp40 
and exonic splicing enhancer 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software was restricted to 
SNPs in the 3′ untranslated region. 
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Table 3.23 Functional effects of UGT2B7 polymorphisms. (continued) 
SNPs rs ID Location 
Putative effects predicted by software 
Possible Functional Effects Descriptions 
IVS4+64A>T rs4337789 Intron 4 Intronic with no known function – 
IVS4+155delA  Intron 4 Intronic enhancer Disruption of CdxA binding site 
IVS4+186C>A rs72853597 Intron 4 Intronic with no known function – 
IVS4+259A>T rs6600892 Intron 4 Intronic enhancer Creates binding sites for GATA-1, -2, -3 and cEBPa; Affects 
binding of c-Ets-1 
IVS4-296C>A rs4521414 Intron 4 Intronic with no known function – 
IVS4-182C>T  Intron 4 Intronic with no known function – 
IVS4-181A>G  rs4314345 Intron 4 Intronic with no known function – 
IVS4-176G>T  Intron 4 Intronic enhancer Creation of deltaE binding site 
IVS4-174A>G  Intron 4 Intronic with no known function – 
IVS4-173T>C rs58997816 Intron 4 Intronic with no known function – 
IVS4-154C>G rs4588522 Intron 4 Intronic enhancer Creates binding site for E4BP4 
IVS4-129C>T  rs4364327 Intron 4 Intronic with no known function – 
IVS4-95G>A rs10022440 Intron 4 Intronic enhancer Disrupts binding site for CdxA 
IVS4-45A>G  Intron 4 Intronic with no known function – 
1191C>T rs57913007 Exon 5 Exonic synonymous polymorphism A397A 
IVS5+31T>C  Intron 5 Intronic with no known function – 
IVS5+187delA  Intron 5 Intronic with no known function – 
IVS5+227A>T rs35402056 Intron 5 Intronic enhancer Affects binding site for CdxA 
IVS5-107G>A rs7658752 Intron 5 Intronic enhancer Creates binding site for GATA-1 
*220G>A  3′ Untranslated Region Downstream with no known function – 
*229A>G   3′ Untranslated Region Downstream with no known function – 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software was restricted to 
SNPs in the 3′ untranslated region. 
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Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
1 -2457G>T
#
 GG 79 (98.8) 80 (100.0) 80 (100.0)   G 
0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  
GT 1 (1.3) 0 (0.0) 0 (0.0)   T 
0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  
TT 0 (0.0) 0 (0.0) 0 (0.0)    




wt/wt 6 (7.5) 5 (6.2) 13 (16.2)   wt 
0.26 (0.19 – 0.33) 0.28 (0.21 – 0.34) 0.34 (0.26 – 0.41)  
  
wt/delALU 30 (37.5) 34 (42.5) 28 (35.0)   delALU 
0.74 (0.67 – 0.81) 0.73 (0.66 – 0.79) 0.66 (0.59 – 0.74)  
  
delALU/delALU 44 (55.0) 41 (51.3) 39 (48.8)    
    
3 -1859G>A
#
 GG 79 (98.8) 76 (95.0) 80 (100.0)   G 
0.99 (0.98 – 1.01) 0.97 (0.94 – 1.00) 1.00 (1.00 – 1.00)  
  
GA 1 (1.3) 3 (3.8) 0 (0.0)   
A 0.01 (-0.01 – 0.02) 0.03 (0.00 – 0.06) 0.00 (0.00 – 0.00)  
  
AA 0 (0.0) 1 (1.2) 0 (0.0)    
    
4 -1852C>G CC 6 (7.5) 5 (6.2) 13 (16.2)   C 
0.26 (0.19 – 0.33) 0.28 (0.21 – 0.34) 0.35 (0.28 – 0.42)  
 
(rs6600879) CG 30 (37.5) 34 (42.5) 30 (37.5)   G 
0.74 (0.67 – 0.81) 0.73 (0.66 – 0.79) 0.65 (0.58 – 0.72)  
  
GG 44 (55.0) 41 (51.3) 37 (46.3)    
    
5 -1684C>T CC 7 (8.8) 5 (6.2) 13 (16.2)   C 0.26 (0.19 – 0.33) 0.28 (0.21 – 0.34) 0.35 (0.28 – 0.42)  
 
(rs4554144) CT 28 (35.0) 34 (42.5) 30 (37.5)   T 
0.74 (0.67 – 0.81) 0.73 (0.66 – 0.79) 0.65 (0.58 – 0.72)  
  
TT 45 (56.3) 41 (51.3) 37 (46.3)    
    
6 -1681T>C TT 80 (100.0) 79 (98.8) 78 (97.5)   T 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.99 (0.97 – 1.00)  
 
(rs73823857) TC 0 (0.0) 1 (1.2) 2 (2.5)   C 
0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.01 (0.00 – 0.03)  
  
CC 0 (0.0) 0 (0.0) 0 (0.0)    
    
7 -1570C>T CC 6 (7.5) 5 (6.2) 13 (16.2)   C 0.26 (0.19 – 0.33) 0.28 (0.21 – 0.34) 0.34 (0.27 – 0.42)  
 
(rs4538548) CT 30 (37.5) 34 (42.5) 29 (36.3)   T 0.74 (0.67 – 0.81) 0.73 (0.66 – 0.79) 0.66 (0.58 – 0.73)  
  
TT 44 (55.0) 41 (51.3) 38 (47.5)    
    
8 -1568C>T CC 7 (8.8) 5 (6.2) 13 (16.2)   C 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.34 (0.27 – 0.42)  
 
(rs6600883) CT 29 (36.3) 34 (42.5) 29 (36.3)   T 0.73 (0.66 – 0.8) 0.73 (0.66 – 0.79) 0.66 (0.58 – 0.73)  
  
TT 44 (55.0) 41 (51.3) 38 (47.5)    
    
9 -1306A>G AA 8 (10.0) 5 (6.2) 13 (16.2)   A 0.28 (0.21 – 0.35) 0.28 (0.21 – 0.34) 0.36 (0.28 – 0.43)  
 
(rs4455491) AG 29 (36.3) 34 (42.5) 31 (38.8)   G 0.72 (0.65 – 0.79) 0.73 (0.66 – 0.79) 0.64 (0.57 – 0.72)  
  
GG 43 (53.8) 41 (51.3) 36 (45.0)    
    
10 -1299T>C TT 6 (7.5) 5 (6.2) 13 (16.2)   T 0.25 (0.18 – 0.32) 0.28 (0.21 – 0.34) 0.35 (0.28 – 0.42)  
 
(rs11940220) TC 28 (35.0) 34 (42.5) 30 (37.5)   C 0.75 (0.68 – 0.82) 0.73 (0.66 – 0.79) 0.65 (0.58 – 0.72)  
    CC 46 (57.5) 41 (51.3) 37 (46.3)            
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
11 -1273G>C
#
 GG 77 (96.3) 77 (96.3) 80 (100.0)   
G 0.98 (0.96 – 1.00) 0.98 (0.96 – 1.00) 1.00 (1.00 – 1.00)  
  
GC 3 (3.8) 3 (3.7) 0 (0.0)   C 
0.02 (0.00 – 0.04) 0.02 (0.00 – 0.04) 0.00 (0.00 – 0.00)  
  
CC 0 (0.0) 0 (0.0) 0 (0.0)    
    
12 -1112T>C TT 6 (7.5) 5 (6.2) 14 (17.5)   T 0.28 (0.21 – 0.34) 0.28 (0.21 – 0.35) 0.36 (0.28 – 0.43)  
 
(rs11940316) TC 32 (40.0) 35 (43.8) 29 (36.2)   C 0.73 (0.66 – 0.79) 0.72 (0.65 – 0.79) 0.64 (0.57 – 0.72)  
  
CC 42 (52.5) 40 (50.0) 37 (46.3)    
    
13 -900G>A GG 6 (7.5) 5 (6.2) 13 (16.2)   G 0.27 (0.20 – 0.34) 0.27 (0.20 – 0.34) 0.34 (0.26 – 0.41)  
 
(rs7438135) GA 31 (38.7) 33 (41.3) 28 (35.0)   A 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.80) 0.66 (0.59 – 0.74)  
  
AA 43 (53.8) 42 (52.5) 39 (48.8)    
    
14 -854delT
#
 wt/wt 78 (97.5) 80 (100.0) 80 (100.0)   wt 
0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  
wt/delT 2 (2.5) 0 (0.0) 0 (0.0)   
delT 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  
delT/delT 0 (0.0) 0 (0.0) 0 (0.0)    
    
15 -573G>A
#
 GG 79 (98.8) 78 (97.5) 79 (98.8)   
G 0.99 (0.98 – 1.01) 0.99 (0.97 – 1.00) 0.99 (0.98 – 1.01)  
  
GA 1 (1.3) 2 (2.5) 1 (1.2)   A 0.01 (-0.01 – 0.02) 0.01 (0.00 – 0.03) 0.01 (-0.01 – 0.02)  
  
AA 0 (0.0) 0 (0.0) 0 (0.0)    
    
16 -327A>G AA 6 (7.5) 5 (6.2) 13 (16.2)   A 
0.25 (0.18 – 0.32) 0.26 (0.19 – 0.33) 0.34 (0.27 – 0.42)  
 
(rs7662029) AG 28 (35.0) 32 (40.0) 29 (36.3)   G 
0.75 (0.68 – 0.82) 0.74 (0.67 – 0.81) 0.66 (0.58 – 0.73)  
  
GG 46 (57.5) 43 (53.8) 38 (47.5)    
    
17 -161T>C TT 6 (7.5) 5 (6.2) 12 (15.0) 11 (5.4) T 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.34 (0.27 – 0.42) 0.26 (0.22 – 0.30) 
 
(rs7668258) TC 31 (38.7) 34 (42.5) 31 (38.7) 83 (41.7) C 0.73 (0.66 – 0.8) 0.73 (0.66 – 0.79) 0.66 (0.58 – 0.73) 0.74 (0.70 – 0.78) 
  
CC 43 (53.8) 41 (51.3) 37 (46.3) 108 (53.5)  
    
18 -138G>A GG 80 (100.0) 80 (100.0) 79 (98.8) 202 (100.0) G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 
 
(rs73823859) GA 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 
  
AA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
    
19 -125T>C TT 67 (83.8) 60 (75.0) 66 (82.5) 166 (82.2) T 0.91 (0.86 – 0.95) 0.85 (0.79 – 0.91) 0.91 (0.86 – 0.95) 0.91 (0.88 – 0.94) 
 
(rs7668282) TC 11 (13.7) 16 (20.0) 13 (16.3) 35 (17.3) C 0.09 (0.05 – 0.14) 0.15 (0.09 – 0.21) 0.09 (0.05 – 0.14) 0.09 (0.06 – 0.12) 
  
CC 2 (2.5) 4 (5.0) 1 (1.2) 1 (0.5)  
    
20 -96A>C
#
 AA 80 (100.0) 80 (100.0) 79 (98.8)   
A 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  
AC 0 (0.0) 0 (0.0) 1 (1.2)   C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
    CC 0 (0.0) 0 (0.0) 0 (0.0)            
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
21 211G>T GG 58 (72.5) 66 (82.5) 79 (98.8) 152 (75.2) G 0.85 (0.79 – 0.91) 0.91 (0.87 – 0.96) 0.99 (0.98 – 1.01) 0.86 (0.83 – 0.90) 
 
(rs12233719) GT 20 (25.0) 14 (17.5) 1 (1.2) 45 (22.3) T 0.15 (0.09 – 0.21) 0.09 (0.04 – 0.13)
‡ 0.01 (-0.01 – 0.02)§ 0.14 (0.10 – 0.17) 
  
TT 2 (2.5) 0 (0.0) 0 (0.0) 5 (2.5)  
    
22 372A>G AA 53 (66.3) 55 (68.8) 60 (75.0) 123 (60.9) A 0.82 (0.76 – 0.88) 0.83 (0.77 – 0.88) 0.86 (0.81 – 0.92) 0.77 (0.73 – 0.82) 
 
(rs28365063) AG 25 (31.2) 22 (27.5) 18 (22.5) 67 (33.2) G 0.18 (0.12 – 0.24) 0.18 (0.12 – 0.23) 0.14 (0.08 – 0.19) 0.23 (0.18 – 0.27) 
  
GG 2 (2.5) 3 (3.7) 2 (2.5) 12 (5.9)  
    
23 IVS1+9_IVS1+10insT wt/wt 80 (100.0) 80 (100.0) 75 (93.8)   wt 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.97 (0.94 – 1.00)  
  
wt/insT 0 (0.0) 0 (0.0) 5 (6.2)   insT 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)
‡ 0.03 (0.00 – 0.06)§  
  
insT/insT 0 (0.0) 0 (0.0) 0 (0.0)    
    
24 IVS1-470T>C TT 43 (53.8) 41 (51.3) 37 (46.3)   
T 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.79) 0.65 (0.58 – 0.72)  
 
(rs28375964) TC 31 (38.7) 34 (42.5) 30 (37.5)   C 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.35 (0.28 – 0.42)  
  
CC 6 (7.5) 5 (6.2) 13 (16.2)    
    
25 IVS1-314A>G AA 73 (91.3) 72 (90.0) 55 (68.8)   
A 0.96 (0.92 – 0.99) 0.95 (0.92 – 0.98) 0.84 (0.78 – 0.89)  
 
(rs62298861) AG 7 (8.7) 8 (10.0) 24 (30.0)   G 0.04 (0.01 – 0.08) 0.05 (0.02 – 0.08)
‡ 0.16 (0.11 – 0.22)§  
  
GG 0 (0.0) 0 (0.0) 1 (1.2)    
    
26 IVS1-300C>A CC 80 (100.0) 80 (100.0) 78 (97.5)   
C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00)  
 
(rs72643000) CA 0 (0.0) 0 (0.0) 2 (2.5)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03)  
  
AA 0 (0.0) 0 (0.0) 0 (0.0)    
    
27 IVS1-292C>T
#
 CC 79 (98.8) 80 (100.0) 80 (100.0)   C 
0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  
CT 1 (1.2) 0 (0.0) 0 (0.0)   T 
0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  
TT 0 (0.0) 0 (0.0) 0 (0.0)    
    
28 IVS1-181C>T CC 80 (100.0) 80 (100.0) 79 (98.8)   
C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
 
(rs73823860) CT 0 (0.0) 0 (0.0) 1 (1.2)   T 
0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  
TT 0 (0.0) 0 (0.0) 0 (0.0)    
    
29 IVS1-78T>C TT 6 (7.5) 5 (6.2) 13 (16.2) 11 (5.5) T 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.36 (0.28 – 0.43) 0.26 (0.22 – 0.30) 
 
(rs7439326) TC 31 (38.7) 34 (42.5) 31 (38.8) 83 (41.1) C 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.79) 0.64 (0.57 – 0.72) 0.74 (0.70 – 0.78) 
  
CC 43 (53.8) 41 (51.3) 36 (45.0) 108 (53.5)  
    
30 IVS1-49A>G AA 6 (7.5) 5 (6.2) 13 (16.2)   A 
0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.35 (0.28 – 0.42)  
 
(rs7438244) AG 31 (38.7) 34 (42.5) 30 (37.5)   G 
0.73 (0.66 – 0.80) 0.73 (0.66 – 0.79) 0.65 (0.58 – 0.72)  
    GG 43 (53.8) 41 (51.3) 37 (46.3)            
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
31 735A>G AA 73 (91.3) 72 (90.0) 55 (68.8)   A 0.96 (0.92 – 0.99) 0.95 (0.92 – 0.98) 0.84 (0.78 – 0.89)  
 (rs28365062) AG 7 (8.7) 8 (10.0) 24 (30.0)   G 0.04 (0.01 – 0.08) 0.05 (0.02 – 0.08)‡ 0.16 (0.11 – 0.22)§  
  GG 0 (0.0) 0 (0.0) 1 (1.2)         
32 763G>A
#
 GG 80 (100.0) 80 (100.0) 79 (98.8)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  GA 0 (0.0) 0 (0.0) 1 (1.2)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)        
33 801A>T AA 6 (7.5) 5 (6.2) 13 (16.2)   A 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.35 (0.28 – 0.42)  
 (rs7438284) AT 31 (38.7) 34 (42.5) 30 (37.5)   T 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.79) 0.65 (0.58 – 0.72)  
  TT 43 (53.8) 41 (51.3) 37 (46.3)           
34 802T>C TT 6 (7.5) 5 (6.2) 14 (17.5) 11 (5.5) T 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.36 (0.28 – 0.43) 0.26 (0.21 – 0.30) 
 (*2, rs7439366) TC 31 (38.7) 34 (42.5) 29 (36.2) 81 (40.3) C 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.79) 0.64 (0.57 – 0.72) 0.74 (0.70 – 0.79) 
  CC 43 (53.8) 41 (51.3) 37 (46.3) 109 (54.3)         
35 855C>A CC 80 (100.0) 80 (100.0) 79 (98.8)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
 (rs34661811) CA 0 (0.0) 0 (0.0) 1 (1.2)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  AA 0 (0.0) 0 (0.0) 0 (0.0)           
36 IVS2+115G>A GG 6 (7.5) 5 (6.2) 13 (16.2)   G 0.27 (0.20 – 0.34) 0.27 (0.20 – 0.34) 0.36 (0.28 – 0.43)  
 (rs7441750) GA 31 (38.7) 33 (41.3) 31 (38.8)   A 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.80) 0.64 (0.57 – 0.72)  
  AA 43 (53.8) 42 (52.5) 36 (45.0)           
37 IVS2+148G>A GG 6 (7.5) 6 (7.5) 13 (16.2)   G 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.35) 0.36 (0.28 – 0.43)  
 (rs7441774) GA 31 (38.7) 33 (41.2) 31 (38.8)   A 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79) 0.64 (0.57 – 0.72)  
  AA 43 (53.8) 41 (51.3) 36 (45.0)           
38 IVS2-281A>G
#
 AA 78 (97.5) 80 (100.0) 80 (100.0)   A 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  AG 2 (2.5) 0 (0.0) 0 (0.0)   G 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  GG 0 (0.0) 0 (0.0) 0 (0.0)           
39 IVS3+169_ wt/wt 6 (7.5) 5 (6.2) 13 (16.2)   wt 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.35) 0.36 (0.28 – 0.43)  
 IVS3+170insT wt/insT 31 (38.7) 35 (43.8) 31 (38.8)   insT 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79) 0.64 (0.57 – 0.72)  
 (rs72601809) insT/insT 43 (53.8) 40 (50.0) 36 (45.0)           
40 IVS3+187_ wt/wt 67 (83.8) 60 (75) 66 (82.5)   wt 0.91 (0.86 – 0.95) 0.84 (0.79 – 0.90) 0.91 (0.86 – 0.95)  
 IVS3+192delTAAG
#
 wt/delTAAG 11 (13.7) 15 (18.8) 13 (16.3)   delTAAG 0.09 (0.05 – 0.14) 0.16 (0.10 – 0.21) 0.09 (0.05 – 0.14)  
    delTAAG/delTAAG 2 (2.5) 5 (6.2) 1 (1.2)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 




Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
41 1054C>T
#
 CC 79 (98.8) 80 (100.0) 80 (100.0)   C 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  CT 1 (1.2) 0 (0.0) 0 (0.0)   T 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)           
42 1059C>G CC 5 (6.2) 5 (6.2) 14 (17.5)   C 0.26 (0.19 – 0.33) 0.28 (0.21 – 0.35) 0.39 (0.32 – 0.47)  
 (rs4292394) CG 32 (40.0) 35 (43.8) 35 (43.8)   G 0.74 (0.67 – 0.81) 0.72 (0.65 – 0.79) 0.61 (0.53 – 0.68)  
  GG 43 (53.8) 40 (50.0) 31 (38.7)           
43 1062C>T CC 73 (91.3) 72 (90.0) 55 (68.8) 180 (89.1) C 0.96 (0.92 – 0.99) 0.95 (0.92 – 0.98) 0.84 (0.78 – 0.89) 0.94 (0.92 – 0.97) 
 (rs4348159) CT 7 (8.7) 8 (10.0) 24 (30.0) 21 (10.4) T 0.04 (0.01 – 0.08) 0.05 (0.02 – 0.08)‡ 0.16 (0.11 – 0.22)§ 0.06 (0.03 – 0.08) 
  TT 0 (0.0) 0 (0.0) 1 (1.2) 1 (0.5)       
44 1065G>C
#
 GG 80 (100.0) 80 (100.0) 79 (98.8)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  GC 0 (0.0) 0 (0.0) 1 (1.2)   C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)           
45 IVS4+64A>T AA 6 (7.5) 5 (6.2) 14 (17.5)   A 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.35) 0.39 (0.31 – 0.46)  
 (rs4337789) AT 31 (38.7) 35 (43.8) 34 (42.5)   T 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79) 0.61 (0.54 – 0.69)  
  TT 43 (53.8) 40 (50.0) 32 (40.0)           
46 IVS4+155delA
#
 wt/wt 6 (7.5) 5 (6.2) 14 (17.5)   wt 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.35) 0.38 (0.31 – 0.46)  
  wt/delA 31 (38.7) 35 (43.8) 33 (41.3)   delA 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79) 0.62 (0.54 – 0.69)  
  delA/delA 43 (53.8) 40 (50.0) 33 (41.2)           
47 IVS4+186C>A
#
 CC 34 (42.5) 43 (53.8) 45 (56.3) 86 (42.6) C 0.62 (0.54 – 0.69) 0.73 (0.66 – 0.80) 0.76 (0.69 – 0.82) 0.64 (0.59 – 0.69) 
  CA 31 (38.8) 31 (38.7) 31 (38.7) 86 (42.6) A 0.38 (0.31 – 0.46) 0.27 (0.20 – 0.34) 0.24 (0.18 – 0.31)§ 0.36 (0.31 – 0.41) 
  AA 15 (18.7) 6 (7.5) 4 (5.0) 30 (14.9)        
48 IVS4+259A>T AA 41 (51.3) 34 (42.5) 49 (61.3) 102 (50.5) A 0.69 (0.62 – 0.77) 0.61 (0.54 – 0.69) 0.78 (0.72 – 0.85) 0.70 (0.66 – 0.75) 
 (rs6600892) AT 29 (36.2) 30 (37.5) 27 (33.8) 79 (39.1) T 0.31 (0.23 – 0.38) 0.39 (0.31 – 0.46)‡ 0.22 (0.15 – 0.28) 0.30 (0.25 – 0.34) 
  TT 10 (12.5) 16 (20.0) 4 (5.0) 21 (10.4)      
49 IVS4-296C>A CC 7 (8.7) 5 (6.2) 15 (18.7)   C 0.28 (0.21 – 0.34) 0.28 (0.21 – 0.35) 0.4 (0.32 – 0.48)  
 (rs4521414) CA 30 (37.5) 35 (43.8) 34 (42.5)   A 0.73 (0.66 – 0.79) 0.72 (0.65 – 0.79)‡ 0.6 (0.52 – 0.68)  
  AA 43 (53.8) 40 (50.0) 31 (38.8)          
50 IVS4-182C>T
#
 CC 79 (98.8) 80 (100.0) 80 (100.0)   C 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  CT 1 (1.2) 0 (0.0) 0 (0.0)   T 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
    TT 0 (0.0) 0 (0.0) 0 (0.0)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 




Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
51 IVS4-181A>G AA 6 (7.5) 5 (6.2) 14 (17.5)   A 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.34) 0.39 (0.32 – 0.47)  
 (rs4314345) AG 31 (38.7) 34 (42.5) 35 (43.8)   G 0.73 (0.66 – 0.80) 0.73 (0.66 – 0.79) 0.61 (0.53 – 0.68)  
  GG 43 (53.8) 41 (51.3) 31 (38.7)           
52 IVS4-176G>T
#
 GG 80 (100.0) 78 (97.5) 80 (100.0)   G 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 1.00 (1.00 – 1.00)  
  GT 0 (0.0) 2 (2.5) 0 (0.0)   T 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03) 0.00 (0.00 – 0.00)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)           
53 IVS4-174A>G
#
 AA 79 (98.8) 80 (100) 80 (100.0)   A 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  AG 1 (1.2) 0 (0.0) 0 (0.0)   G 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  GG 0 (0.0) 0 (0.0) 0 (0.0)           
54 IVS4-173T>C TT 72 (90.0) 72 (90.0) 75 (93.8) 188 (93.1) T 0.95 (0.92 – 0.98) 0.95 (0.92 – 0.98) 0.97 (0.94 – 1.00) 0.96 (0.94 – 0.98) 
 (rs58997816) TC 8 (10.0) 8 (10.0) 5 (6.2) 13 (6.4) C 0.05 (0.02 – 0.08) 0.05 (0.02 – 0.08) 0.03 (0.00 – 0.06) 0.04 (0.02 – 0.06) 
  CC 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)         
55 IVS4-154C>G CC 6 (7.5) 5 (6.2) 14 (17.5) 13 (6.4) C 0.25 (0.18 – 0.32) 0.28 (0.21 – 0.35) 0.39 (0.32 – 0.47) 0.27 (0.23 – 0.32) 
 (rs4588522) CG 28 (35.0) 35 (43.8) 35 (43.8) 84 (41.6) G 0.75 (0.68 – 0.82) 0.72 (0.65 – 0.79) 0.61 (0.53 – 0.68)§ 0.73 (0.68 – 0.77) 
  GG 46 (57.5) 40 (50.0) 31 (38.7) 105 (52.0)        
56 IVS4-129C>T CC 6 (7.5) 5 (6.2) 14 (17.5)   C 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.35) 0.39 (0.32 – 0.47)  
 (rs4364327) CT 31 (38.7) 35 (43.8) 35 (43.8)   T 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79) 0.61 (0.53 – 0.68)  
  TT 43 (53.8) 40 (50.0) 31 (38.7)        
57 IVS4-95G>A GG 80 (100.0) 79 (98.8) 73 (91.3) 202 (100.0) G 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.95 (0.92 – 0.98) 1.00 (1.00 – 1.00) 
 (rs10022440) GA 0 (0.0) 1 (1.2) 6 (7.5) 0 (0.0) A 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.05 (0.02 – 0.08)§ 0.00 (0.00 – 0.00) 
  AA 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0)        
58 IVS4-45A>G
#
 AA 79 (98.8) 80 (100.0) 79 (98.8)   A 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  AG 1 (1.2) 0 (0.0) 1 (1.2)   G 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  GG 0 (0.0) 0 (0.0) 0 (0.0)           
59 1191C>T CC 80 (100.0) 80 (100.0) 79 (98.8)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
 (rs57913007) CT 0 (0.0) 0 (0.0) 1 (1.2)   T 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)           
60 IVS5+31T>C
#
 TT 80 (100.0) 80 (100.0) 76 (95.0)   T 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.98 (0.95 – 1.00)  
  TC 0 (0.0) 0 (0.0) 4 (5.0)   C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)‡ 0.03 (0.00 – 0.05)§  
    CC 0 (0.0) 0 (0.0) 0 (0.0)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 




Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
61 IVS5+187delA wt/wt 80 (100.0) 80 (100.0) 79 (98.8)   wt 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  wt/delA 0 (0.0) 0 (0.0) 1 (1.2)   delA 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  delA/delA 0 (0.0) 0 (0.0) 0 (0.0)           
62 IVS5+227A>T AA 6 (7.5) 5 (6.2) 14 (17.5)   A 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.35) 0.39 (0.32 – 0.47)  
 (rs35402056) AT 31 (38.7) 35 (43.8) 35 (43.8)   T 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79) 0.61 (0.53 – 0.68)  
  TT 43 (53.8) 40 (50.0) 31 (38.7)           
63 IVS5-107G>A GG 6 (7.5) 6 (7.5) 16 (20.0)   G 0.26 (0.19 – 0.33) 0.29 (0.22 – 0.36) 0.41 (0.34 – 0.49)  
 (rs7658752) GA 30 (37.5) 34 (42.5) 34 (42.5)   A 0.74 (0.67 – 0.81) 0.71 (0.64 – 0.78) 0.59 (0.51 – 0.66)§  
  AA 44 (55.0) 40 (50.0) 30 (37.5)          
64 *229A>G
#
 AA 78 (97.5) 79 (98.8) 80 (100)   A 0.99 (0.97 – 1.00) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
  AG 2 (2.5) 1 (1.2) 0 (0.0)   G 0.01 (0.00 – 0.03) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
  GG 0 (0.0) 0 (0.0) 0 (0.0)        
65 *+296T>C TT 6 (7.5) 5 (6.2) 15 (18.7)   T 0.26 (0.19 – 0.33) 0.28 (0.21 – 0.35) 0.41 (0.34 – 0.49)  
 (rs6851533) TC 30 (37.5) 35 (43.8) 36 (45.0)   C 0.74 (0.67 – 0.81) 0.72 (0.65 – 0.79)‡ 0.59 (0.51 – 0.66)§  
  CC 44 (55.0) 40 (50.0) 29 (36.3)         
66 *+447T>C TT 6 (7.5) 5 (6.2) 16 (20.0)   T 0.26 (0.19 – 0.33) 0.28 (0.21 – 0.34) 0.42 (0.34 – 0.50)  
 (rs6600893) TC 30 (37.5) 34 (42.5) 35 (43.8)   C 0.74 (0.67 – 0.81) 0.73 (0.66 – 0.79)‡ 0.58 (0.50 – 0.66)§  
  CC 44 (55.0) 41 (51.3) 29 (36.2)         
67 *+692T>C
#
 TT 80 (100.0) 76 (95.0) 80 (100.0)   T 1.00 (1.00 – 1.00) 0.98 (0.95 – 1.00) 1.00 (1.00 – 1.00)  
  TC 0 (0.0) 4 (5.0) 0 (0.0)   C 0.00 (0.00 – 0.00)† 0.03 (0.00 – 0.05)‡ 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)         
68 *+1029G>C GG 6 (7.5) 4 (5.0) 14 (17.9) 14 (7.0) G 0.25 (0.18 – 0.32) 0.18 (0.12 – 0.23) 0.32 (0.25 – 0.39) 0.20 (0.16 – 0.24) 
 (rs7666195) GC 28 (35.0) 20 (25.0) 22 (28.2) 53 (26.4) C 0.75 (0.68 – 0.82) 0.83 (0.77 – 0.88)‡ 0.68 (0.61 – 0.75) 0.80 (0.76 – 0.84) 
  CC 46 (57.5) 56 (70.0) 42 (53.9) 134 (66.7)        
69 *+1271G>T
#
 GG 68 (85.0) 61 (76.3) 72 (90.0) 170 (84.6) G 0.91 (0.87 – 0.96) 0.85 (0.79 – 0.91) 0.94 (0.90 – 0.98) 0.92 (0.89 – 0.94) 
  GT 10 (12.5) 14 (17.5) 6 (7.5) 29 (14.4) T 0.09 (0.04 – 0.13) 0.15 (0.09 – 0.21) 0.06 (0.02 – 0.10) 0.08 (0.06 – 0.11) 
  TT 2 (2.5) 5 (6.2) 2 (2.5) 2 (1.0)         
70 *+1319C>T
#
 CC 6 (7.5) 5 (6.2) 16 (20.0) 13 (6.5) C 0.2 (0.14 – 0.26) 0.21 (0.14 – 0.27) 0.31 (0.24 – 0.38) 0.19 (0.15 – 0.23) 
  CT 20 (25.0) 23 (28.8) 18 (22.5) 51 (25.4) T 0.8 (0.74 – 0.86) 0.79 (0.73 – 0.86)‡ 0.69 (0.62 – 0.76) 0.81 (0.77 – 0.85) 
    TT 54 (67.5) 52 (65.0) 46 (57.5) 137 (68.2)           
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.24 Genotypic and allelic distribution profile of UGT2B7 (UCSC RefSeq: NM_001074) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
71 *+1493C>T
#
 CC 6 (7.5) 7 (8.7) 17 (21.2)   C 0.25 (0.18 – 0.32) 0.29 (0.22 – 0.36) 0.42 (0.34 – 0.50)  
  CT 28 (35.0) 32 (40.0) 33 (41.3)   T 0.75 (0.68 – 0.82) 0.71 (0.64 – 0.78) 0.58 (0.50 – 0.66)§  
  TT 46 (57.5) 41 (51.3) 30 (37.5)          
72 *+1784T>C
#
 TT 79 (98.8) 79 (98.8) 80 (100.0)   T 0.99 (0.98 – 1.01) 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00)  
  TC 1 (1.2) 1 (1.2) 0 (0.0)   C 0.01 (-0.01 – 0.02) 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00)  
  CC 0 (0.0) 0 (0.0) 0 (0.0)        
73 *+1955G>C
#
 GG 74 (92.5) 73 (91.3) 56 (70.0)   G 0.96 (0.93 – 0.99) 0.96 (0.92 – 0.99) 0.84 (0.79 – 0.90)  
  GC 6 (7.5) 7 (8.7) 23 (28.8)   C 0.04 (0.01 – 0.07) 0.04 (0.01 – 0.08)‡ 0.16 (0.10 – 0.21)§  
  CC 0 (0.0) 0 (0.0) 1 (1.2)         
74 *+1969C>T
#
 CC 33 (41.3) 45 (56.3) 49 (61.3) 85 (42.1) C 0.61 (0.54 – 0.69) 0.75 (0.68 – 0.82) 0.79 (0.73 – 0.86) 0.64 (0.59 – 0.69) 
  CT 32 (40.0) 30 (37.5) 29 (36.2) 88 (43.6) T 0.39 (0.31 – 0.46)† 0.25 (0.18 – 0.32) 0.21 (0.14 – 0.27)§ 0.36 (0.31 – 0.41) 
  TT 15 (18.7) 5 (6.2) 2 (2.5) 29 (14.4)      
75 *+2023C>T
#
 CC 80 (100.0) 80 (100.0) 78 (97.5)   C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00)  
  CT 0 (0.0) 0 (0.0) 2 (2.5)   T 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03)  
  TT 0 (0.0) 0 (0.0) 0 (0.0)           
76 *+2024C>G
#
 CC 7 (8.7) 5 (6.2) 15 (18.7)   C 0.27 (0.20 – 0.34) 0.28 (0.21 – 0.35) 0.42 (0.34 – 0.50)  
  CG 29 (36.3) 35 (43.8) 37 (46.3)   G 0.73 (0.66 – 0.80) 0.72 (0.65 – 0.79)‡ 0.58 (0.50 – 0.66)§  
  GG 44 (55.0) 40 (50.0) 28 (35.0)         
77 *+2251_*+2252ins[41]
a#
 wt/wt 6 (7.5) 5 (6.2) 15 (18.7)   wt 0.26 (0.19 – 0.33) 0.28 (0.21 – 0.35) 0.41 (0.34 – 0.49)  
  wt/ins 30 (37.5) 35 (43.8) 36 (45.0)   ins 0.74 (0.67 – 0.81) 0.72 (0.65 – 0.79)‡ 0.59 (0.51 – 0.66)§  
    ins/ins 44 (55.0) 40 (50.0) 29 (36.3)               
a. *+2251_*+2252ins[41] refers to insertion of the following 41 nucleotide bases, TTTACAAACCTTGAGCTAAATACAGAGTGCTGATTGGTGTA,  
between *+2251 and *+2252. 
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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3.4.2.2 LD Pattern of UGT2B7 
A total of 80 healthy subjects from the local Chinese, Malay and Indian populations 
were included in the analyses. Across all three ethnic groups, complete LD was 
observed between IVS1-314A>G (rs62298861), 735A>G (rs4348159) and 1062C>T 
(rs4348159) (│D′│= 1.00, R2 = 1.00). High LD was also found between the following 
SNPs in all three populations: *+1955G>C and IVS1-314A>G (rs62298861), 735A>G 
(rs4348159), 1062C>T (rs4348159) (│D′│≥ 0.95, R2 ≥ 0.85); -125T>C (rs7668282) 
and IVS3+187_IVS3+192delTAAG (│D′│= 1.00, R2 ≥ 0.95) (Figs 3.14A – C). 
The LD present among all SNPs except -1859G>A, -1273C>G, -125T>C 
(rs7668282), 211G>T (rs12233719), 372A>G (rs28365063), IVS1+9_IVS1+10insT, 
IVS1-314A>G (rs62298861), 735A>G (rs4348159), IVS3+187_IVS3+192delTAAG, 
1062C>T (rs4348159), IVS4+186C>A, IVS4+259A>T (rs6600892), IVS4-129C>T 
(rs4364327), *+1029G>C (rs7666195), *+1271G>T, *+1493C>T, *+1955G>C and 
*+1969C>T, was strong in all healthy ethnic groups especially the Chinese and 
Malays (Chinese and Malays:│D′│≥ 0.86, R2 ≥ 0.80 vs Indians:│D′│≥ 0.88, R2 ≥ 0.62) 
(Figs 3.14A – C). The extremely high LD among the SNPs led to the observation of 
one single LD block encompassing polymorphisms along the UGT2B7 gene across 
all three ethnicities. 
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Fig 3.14 LD matrix for UGT2B7 polymorphisms in (A) Chinese, 
(B) Malays, and (C) Indians. 
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3.4.2.3 Genetic Profile of UGT2B7 tag-SNPs in Asian Breast Cancer Patients 
Tag-SNPs representing polymorphisms across the gene were selected using the 
exhaustive search algorithm in TAGster program (423) using the selection criteria of 
R2 ≥ 0.80 and MAF ≥ 0.05. A total of 10, 11 and 12 tag-SNPs were selected for 
Chinese, Malay and Indian healthy populations respectively. Subsequently, 14 multi-
population tag-SNPs [-125T>C (rs7668282), 211G>T (rs12233719), 372A>G 
(rs28365063), IVS1-78T>C (rs7439326), 1062C>T (rs4348159), IVS4+186C>A, 
IVS4+259A>T (rs6600892), IVS4-173T>C (rs4588522), IVS4-154C>G (rs4588522), 
IVS4-95G>A (rs10022440), *+1029G>C (rs7666195), *+1271G>T, *+1319C>T, 
*+1969C>T] representing the genetic profiles of all three ethnicities were selected via 
a two-stage exhaustive search process. These tag-SNPs, together with three 
additional functional polymorphisms [-161T>C (rs7668258), -138G>A (rs73823859), 
802T>C (*2, rs7439366)] were genotyped in the patients. The frequencies of these 
polymorphisms in the patient cohort were not found to differ significantly from that of 
the healthy ethnic groups (Table 3.24). However, both IVS4-95G>A (rs10022440) 
and -138G>A (rs73823859) were not present in our patient (Table 3.24). 
LD matrix of the 15 polymorphisms genotyped in the Asian breast cancer patient 
cohort indicated the presence of three LD blocks with high inter-block linkage (Block 
1 vs Block 2: multiallelic │D′│= 0.94, Block 2 vs Block 3:│D′│= 0.78). Block 1 was 
made up of eight SNPs and spanned from the 5′ upstream region to intron 4 (Fig 
3.15). Blocks 2 and 3 were small LD blocks at the 3′ region of the gene and 
comprised of two SNPs each [Block 2: IVS4-95G>A (rs10022440) and *+1029G>C 
(rs7666195), Block 3: *+1319C>T and *+1969C>T].  
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Fig 3.15 LD matrix for UGT2B7 functional and tag-SNPs in Asian breast cancer 
patient patients (N=202). 
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3.4.2.4 Genotypic-phenotypic Associations of UGT2B7 Polymorphisms 
Association analyses of the phenotypic effect of the single SNPs were performed 
with respect to steady state plasma concentrations of (Z)-endoxifen, (E)-endoxifen, 
(Z)-4-OHT, the corresponding metabolites [(E)-N-desmethyltamoxifen-4-O-
glucuronide or (E)-NDM-4-O-Gluc, (Z)-N-desmethyltamoxifen-4-O-glucuronide or (Z)-
NDM-4-O-Gluc, (E)-tamoxifen-4-O-glucuronide or (E)-Tam-4-O-Gluc, respectively] 
and metabolic ratios [MRE-NDM-4-O-GLUC/Z-END, MRZ-NDM-4-O-GLUC/E-END, MRE-TAM-4-O-GLUC/Z-4-
OHT, respectively] (Table 3.25). Since IVS4-95G>A (rs10022440) and -138G>A 
(rs73823859) were not present in our patient cohort, no further investigations of 
these two SNPs were possible. 
The polymorphisms genotyped in the breast cancer patients were not found to be 
statistically associated with the plasma concentrations of the analytes or the MRs. 
Like UGT1A4, high LD was observed between the UGT2B7 polymorphisms and LD 
matrix revealed the presence of three LD blocks (Fig 3.15). Hence, haplotypic 
analyses using the haploGLM package were performed subsequently. All phenotypic 
parameters were ln-transformed except plasma concentration of (Z)-4-OHT which 
was square-root-transformed before analyses. The haplotypes within each of the 
three LD blocks were not significantly associated with variations in plasma 
concentrations of the analytes or the MRs (Tables 3.26 − 3.28). 
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Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-161T>C (rs7668258) TT (N=11) TC (N=83) CC (N=108) TT vs TC TT vs CC TC vs CC 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 22.23 (5.33 – 52.84) 14.22 (2.06 – 51.65) 16.57 (2.18 – 49.93) 0.462 0.680 0.243 0.442 
       [3.17 (-3.37 – 13.16)] [1.46 (-4.74 – 11.56)] [-1.43 (-3.99 – 0.93)]  
(E)-Endoxifen 0.21 (0.03 – 2.91) 0.19 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.295 0.356 0.838 0.590 
       [0.05 (-0.03 – 0.14)] [0.04 (-0.04 – 0.14)] [0.00 (-0.03 – 0.02)]  
(Z)-4-OHT 3.03 (1.63 – 6.80) 2.66 (0.85 – 7.13) 2.69 (0.47 – 7.17) 0.593 0.847 0.671 0.852 
       [0.24 (-0.66 – 1.29)] [0.13 (-0.64 – 1.21)] [-0.08 (-0.44 – 0.26)]  
(E)-NDM-4-O-Gluc 0.97 (0.18 – 3.97) 0.95 (0.07 – 29.78) 0.95 (0.17 – 18.42) 0.967 0.876 0.722 0.935 
       [-0.01 (-0.47 – 0.59)] [0.03 (-0.42 – 0.65)] [0.03 (-0.15 – 0.23)]  
(Z)-NDM-4-O-Gluc 0.28 (0.11 – 1.02) 0.25 (0.04 – 1.61) 0.26 (0.05 – 1.81) 0.712 0.491 0.850 0.833 
       [0.03 (-0.09 – 0.14)] [0.03 (-0.07 – 0.14)] [0.01 (-0.04 – 0.05)]  
(E)-Tam-4-O-Gluc 0.26 (0.09 – 0.88) 0.31 (0.05 – 8.14) 0.27 (0.05 – 4.70) 0.791 0.811 0.222 0.478 
       [-0.02 (-0.16 – 0.13)] [0.01 (-0.10 – 0.16)] [0.03 (-0.02 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 7.14 (2.66 – 10.70) 6.90 (2.20 – 80.56) 5.64 (2.56 – 52.14) 0.338 0.993 0.022 0.067 
       [-1.06 (-3.47 – 1.12)] [0.02 (-1.83 – 2.37)] [0.98 (0.15 – 1.93)]  
MRZ-NDM-4-O-GLUC/E-END 1.43 (0.09 – 10.79) 1.72 (0.04 – 22.60) 1.71 (0.09 – 35.41) 0.544 0.686 0.596 0.766 
       [-0.28 (-1.29 – 0.77)] [-0.18 (-1.04 – 0.88)] [0.09 (-0.28 – 0.46)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 12.74 (5.51 – 15.17) 11.71 (4.05 – 174.19) 9.93 (4.16 – 106.92) 0.277 0.862 0.035 0.092 
            [-1.80 (-5.87 – 1.46)] [0.23 (-2.87 – 3.34)] [1.70 (0.14 – 3.43)]  
-125T>C (rs7668282) TT (N=166) TC + CC (N=36)     TT vs TC + CC       
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.66 (2.06 – 52.84) 16.30 (2.18 – 42.23)   0.718    
       [-0.54 (-3.48 – 2.92)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.19 (0.03 – 0.45)   0.976    
       [0.00 (-0.03 – 0.04)]    
(Z)-4-OHT 2.64 (0.70 – 7.13) 2.87 (0.47 – 7.17)   0.637    
       [-0.11 (-0.58 – 0.34)]    
(E)-NDM-4-O-Gluc 0.96 (0.07 – 29.78) 0.89 (0.17 – 5.64)   0.974    
       [-0.01 (-0.25 – 0.24)]    




Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-125T>C (rs7668282) TT (N=166) TC + CC (N=36)     TT vs TC + CC       
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.71) 0.30 (0.05 – 1.81)   0.400    
       [-0.03 (-0.09 – 0.04)]    
(E)-Tam-4-O-Gluc 0.29 (0.05 – 8.14) 0.27 (0.07 – 1.50)   0.899    
       [0.00 (-0.07 – 0.07)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.21 (2.20 – 80.56) 5.99 (2.99 – 23.68)   0.910    
       [0.07 (-0.93 – 1.09)]    
MRZ-NDM-4-O-GLUC/E-END 1.67 (0.04 – 35.41) 2.09 (0.38 – 15.66)   0.214    
       [-0.30 (-0.87 – 0.19)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.49 (4.05 – 174.19) 10.86 (5.05 – 45.51)   0.967    
       [0.04 (-1.79 – 1.90)]    
211G>T (rs12233719) GG (N=152) GT (N=45) TT (N=5) GG vs GT GG vs TT GT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.01 (2.06 – 52.84) 16.99 (4.27 – 49.93) 10.55 (5.71 – 29.54) 0.743 0.576 0.686 0.828 
       [-0.51 (-3.80 – 2.61)] [1.6 (-8.97 – 11.94)] [2.25 (-9.54 – 12.92)]  
(E)-Endoxifen 0.19 (0.03 – 2.91) 0.18 (0.03 – 6.64) 0.19 (0.03 – 0.31) 0.326 0.767 0.544 0.577 
       [0.01 (-0.01 – 0.06)] [-0.01 (-0.13 – 0.10)] [-0.02 (-0.15 – 0.11)]  
(Z)-4-OHT 2.62 (0.47 – 7.17) 2.98 (1.01 – 6.20) 2.37 (1.22 – 4.66) 0.408 0.818 0.859 0.706 
       [-0.16 (-0.53 – 0.24)] [0.10 (-1.32 – 1.32)] [0.18 (-1.21 – 1.53)]  
(E)-NDM-4-O-Gluc 0.98 (0.07 – 29.78) 0.86 (0.16 – 18.42) 0.67 (0.21 – 2.68) 0.582 0.390 0.447 0.603 
       [0.06 (-0.15 – 0.28)] [0.28 (-0.60 – 0.94)] [0.23 (-0.70 – 0.93)]  
(Z)-NDM-4-O-Gluc 0.27 (0.04 – 1.61) 0.26 (0.05 – 1.81) 0.18 (0.15 – 0.65) 0.827 0.618 0.808 0.883 
       [0.01 (-0.05 – 0.06)] [0.03 (-0.15 – 0.18)] [0.02 (-0.17 – 0.20)]  
(E)-Tam-4-O-Gluc 0.29 (0.05 – 8.14) 0.27 (0.07 – 4.70) 0.33 (0.06 – 0.62) 0.639 0.638 0.759 0.815 
       [0.01 (-0.05 – 0.07)] [0.05 (-0.18 – 0.25)] [0.04 (-0.21 – 0.26)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.28 (2.20 – 80.56) 5.43 (2.42 – 52.14) 4.99 (2.74 – 9.08) 0.178 0.271 0.662 0.253 
       [0.62 (-0.29 – 1.61)] [1.26 (-1.18 – 4.27)] [0.64 (-1.86 – 3.76)]  
MRZ-NDM-4-O-GLUC/E-END 1.63 (0.09 – 35.41) 2.17 (0.04 – 21.57) 1.28 (0.91 – 5.75) 0.345 0.736 0.428 0.573 
       [-0.25 (-0.79 – 0.26)] [0.15 (-0.82 – 1.93)] [0.41 (-0.92 – 2.83)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.79 (4.16 – 174.19) 9.19 (4.05 – 106.92) 8.75 (4.52 – 15.79) 0.348 0.317 0.571 0.424 
       [0.83 (-0.89 – 2.52)] [1.98 (-3.12 – 7.48)] [1.10 (-4.46 – 7.11)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
372A>G (rs28365063) AA (N=123) AG (N=67) GG (N=12) AA vs AG AA vs GG AG vs GG 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 14.37 (2.06 – 52.84) 18.56 (2.18 – 51.65) 13.41 (5.71 – 35.33) 0.411 0.722 0.613 0.668 
       [-1.13 (-4.21 – 1.57)] [0.57 (-4.03 – 6.10)] [1.68 (-3.84 – 8.98)]  
(E)-Endoxifen 0.19 (0.03 – 2.91) 0.18 (0.03 – 6.64) 0.18 (0.03 – 0.31) 0.666 0.414 0.601 0.695 
       [0.00 (-0.02 – 0.04)] [0.02 (-0.02 – 0.11)] [0.01 (-0.04 – 0.11)]  
(Z)-4-OHT 2.60 (0.70 – 7.17) 2.98 (0.47 – 7.13) 2.55 (0.85 – 4.66) 0.342 0.847 0.623 0.617 
       [-0.17 (-0.53 – 0.21)] [0.06 (-0.61 – 0.88)] [0.18 (-0.52 – 1.12)]  
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 1.05 (0.16 – 5.90) 0.72 (0.21 – 18.42) 0.518 0.426 0.275 0.525 
       [-0.07 (-0.28 – 0.14)] [0.15 (-0.19 – 0.49)] [0.21 (-0.19 – 0.69)]  
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.61) 0.29 (0.05 – 1.81) 0.20 (0.08 – 1.71) 0.645 0.422 0.319 0.600 
       [-0.01 (-0.06 – 0.04)] [0.04 (-0.05 – 0.12)] [0.04 (-0.06 – 0.15)]  
(E)-Tam-4-O-Gluc 0.27 (0.05 – 8.14) 0.31 (0.05 – 1.83) 0.27 (0.06 – 4.70) 0.638 0.699 0.642 0.823 
       [-0.01 (-0.07 – 0.04)] [0.03 (-0.12 – 0.14)] [0.03 (-0.12 – 0.17)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.19 (2.20 – 80.56) 6.19 (2.31 – 24.58) 4.85 (2.74 – 52.14) 0.885 0.453 0.530 0.759 
       [0.07 (-0.87 – 0.92)] [0.60 (-0.92 – 2.40)] [0.64 (-1.15 – 2.47)]  
MRZ-NDM-4-O-GLUC/E-END 1.61 (0.09 – 35.41) 2.00 (0.04 – 21.57) 1.89 (0.87 – 9.74) 0.558 0.554 0.891 0.756 
       [-0.14 (-0.51 – 0.30)] [-0.21 (-1.50 – 0.59)] [-0.05 (-1.80 – 0.86)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.47 (4.16 – 174.19) 10.76 (4.05 – 45.51) 9.35 (4.52 – 106.92) 0.970 0.805 0.743 0.959 
       [-0.02 (-1.64 – 1.49)] [0.38 (-2.61 – 3.47)] [0.43 (-2.97 – 4.07)]  
IVS1-78T>C (rs7439326) TT (N=11) TC (N=83) CC (N=108) TT vs TC TT vs CC TC vs CC 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 22.23 (5.33 – 52.84) 14.22 (2.06 – 51.65) 16.57 (2.18 – 49.93) 0.462 0.680 0.243 0.442 
       [3.17 (-3.37 – 13.16)] [1.46 (-4.74 – 11.56)] [-1.43 (-3.99 – 0.93)]  
(E)-Endoxifen 0.21 (0.03 – 2.91) 0.19 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.295 0.356 0.838 0.590 
       [0.05 (-0.03 – 0.14)] [0.04 (-0.04 – 0.14)] [0.00 (-0.03 – 0.02)]  
(Z)-4-OHT 3.03 (1.63 – 6.80) 2.66 (0.85 – 7.13) 2.69 (0.47 – 7.17) 0.593 0.847 0.671 0.852 
       [0.24 (-0.66 – 1.29)] [0.13 (-0.64 – 1.21)] [-0.08 (-0.44 – 0.26)]  
(E)-NDM-4-O-Gluc 0.97 (0.18 – 3.97) 0.95 (0.07 – 29.78) 0.95 (0.17 – 18.42) 0.967 0.876 0.722 0.935 
       [-0.01 (-0.47 – 0.59)] [0.03 (-0.42 – 0.65)] [0.03 (-0.15 – 0.23)]  




Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS1-78T>C (rs7439326) TT (N=11) TC (N=83) CC (N=108) TT vs TC TT vs CC TC vs CC 
Overall P 
value 
(Z)-NDM-4-O-Gluc 0.28 (0.11 – 1.02) 0.25 (0.04 – 1.61) 0.26 (0.05 – 1.81) 0.712 0.491 0.850 0.833 
       [0.03 (-0.09 – 0.14)] [0.03 (-0.07 – 0.14)] [0.01 (-0.04 – 0.05)]  
(E)-Tam-4-O-Gluc 0.26 (0.09 – 0.88) 0.31 (0.05 – 8.14) 0.27 (0.05 – 4.70) 0.791 0.811 0.222 0.478 
       [-0.02 (-0.16 – 0.13)] [0.01 (-0.10 – 0.16)] [0.03 (-0.02 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 7.14 (2.66 – 10.70) 6.90 (2.20 – 80.56) 5.64 (2.56 – 52.14) 0.338 0.993 0.022 0.067 
       [-1.06 (-3.47 – 1.12)] [0.02 (-1.83 – 2.37)] [0.98 (0.15 – 1.93)]  
MRZ-NDM-4-O-GLUC/E-END 1.43 (0.09 – 10.79) 1.72 (0.04 – 22.60) 1.71 (0.09 – 35.41) 0.544 0.686 0.596 0.766 
       [-0.28 (-1.29 – 0.77)] [-0.18 (-1.04 – 0.88)] [0.09 (-0.28 – 0.46)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 12.74 (5.51 – 15.17) 11.71 (4.05 – 174.19) 9.93 (4.16 – 106.92) 0.277 0.862 0.035 0.092 
       [-1.80 (-5.87 – 1.46)] [0.23 (-2.87 – 3.34)] [1.70 (0.14 – 3.43)]  
802T>C (*2, rs7439366) TT (N=11) TC (N=81) CC (N=109) TT vs TC TT vs CC TC vs CC 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 22.23 (5.33 – 52.84) 14.24 (2.06 – 51.65) 16.45 (2.18 – 49.93) 0.474 0.672 0.300 0.509 
       [2.80 (-3.39 – 13.13)] [1.55 (-4.71 – 11.66)] [-1.27 (-3.80 – 1.08)]  
(E)-Endoxifen 0.21 (0.03 – 2.91) 0.19 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.289 0.358 0.818 0.585 
       [0.05 (-0.03 – 0.14)] [0.04 (-0.04 – 0.14)] [0.00 (-0.03 – 0.02)]  
(Z)-4-OHT 3.03 (1.63 – 6.80) 2.66 (0.85 – 7.13) 2.63 (0.47 – 7.17) 0.601 0.838 0.682 0.858 
       [0.24 (-0.66 – 1.29)] [0.13 (-0.64 – 1.22)] [-0.08 (-0.43 – 0.27)]  
(E)-NDM-4-O-Gluc 0.97 (0.18 – 3.97) 1.00 (0.07 – 29.78) 0.94 (0.17 – 18.42) 0.928 0.874 0.656 0.902 
       [-0.02 (-0.48 – 0.57)] [0.03 (-0.41 – 0.65)] [0.05 (-0.14 – 0.24)]  
(Z)-NDM-4-O-Gluc 0.28 (0.11 – 1.02) 0.26 (0.04 – 1.61) 0.26 (0.05 – 1.81) 0.770 0.481 0.749 0.811 
       [0.02 (-0.10 – 0.14)] [0.03 (-0.07 – 0.14)] [0.01 (-0.04 – 0.06)]  
(E)-Tam-4-O-Gluc 0.26 (0.09 – 0.88) 0.31 (0.05 – 8.14) 0.27 (0.05 – 4.70) 0.805 0.824 0.251 0.522 
       [-0.02 (-0.16 – 0.13)] [0.01 (-0.11 – 0.16)] [0.03 (-0.02 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 7.14 (2.66 – 10.70) 6.90 (2.20 – 80.56) 5.67 (2.56 – 52.14) 0.339 0.989 0.026 0.077 
       [-1.08 (-3.53 – 1.12)] [-0.02 (-1.84 – 2.34)] [0.97 (0.13 – 1.94)]  
MRZ-NDM-4-O-GLUC/E-END 1.43 (0.09 – 10.79) 1.81 (0.04 – 22.60) 1.67 (0.09 – 35.41) 0.495 0.692 0.479 0.677 
       [-0.30 (-1.34 – 0.75)] [-0.18 (-1.04 – 0.91)] [0.12 (-0.24 – 0.51)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 12.74 (5.51 – 15.17) 11.71 (4.05 – 174.19) 9.94 (4.16 – 106.92) 0.292 0.902 0.044 0.115 
       [-1.80 (-5.96 – 1.46)] [0.13 (-2.91 – 3.31)] [1.63 (0.05 – 3.38)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
 285
 
Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
1062C>T (rs4348159) CC (N=180) CT + TT (N=22) 
 
  CC vs CT + TT       
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.85 (2.06 – 52.84) 12.66 (5.44 – 42.23)   0.506    
       [1.03 (-2.45 – 5.05)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.20 (0.03 – 1.80)   0.991    
       [0.00 (-0.04 – 0.05)]    
(Z)-4-OHT 2.72 (0.47 – 7.17) 2.47 (0.85 – 5.87)   0.306    
       [0.26 (-0.28 – 0.79)]    
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 1.03 (0.33 – 2.08)   0.832    
       [0.03 (-0.24 – 0.32)]    
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.81) 0.27 (0.10 – 0.93)   0.864    
       [0.01 (-0.06 – 0.08)]    
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.28 (0.07 – 0.71)   0.698    
       [0.02 (-0.06 – 0.10)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.11 (2.20 – 80.56) 6.21 (2.99 – 17.89)   0.972    
       [0.02 (-1.29 – 1.31)]    
MRZ-NDM-4-O-GLUC/E-END 1.75 (0.04 – 22.60) 1.17 (0.37 – 35.41)   0.263    
       [0.28 (-0.21 – 0.85)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.59 (4.05 – 174.19) 9.89 (4.16 – 36.94)   0.951    
       [0.10 (-2.29 – 2.52)]    
IVS4+186C>A CC (N=86) CA (N=86) AA (N=30) CC vs CA CC vs AA CA vs AA 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.56 (2.18 – 52.84) 14.95 (2.06 – 49.93) 16.6 (5.22 – 42.10) 0.958 0.553 0.434 0.759 
       [0.08 (-2.42 – 2.70)] [-1.17 (-5.10 – 2.93)] [-1.40 (-5.10 – 2.15)]  
(E)-Endoxifen 0.19 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.19 (0.03 – 0.45) 0.653 0.648 0.459 0.737 
       [0.00 (-0.02 – 0.04)] [0.00 (-0.07 – 0.03)] [-0.01 (-0.08 – 0.02)]  
(Z)-4-OHT 2.75 (0.47 – 7.13) 2.62 (1.11 – 7.17) 2.66 (0.70 – 5.80) 0.821 0.875 0.668 0.923 
       [0.05 (-0.33 – 0.42)] [-0.04 (-0.60 – 0.49)] [-0.10 (-0.56 – 0.35)]  
(E)-NDM-4-O-Gluc 0.93 (0.16 – 18.42) 1.04 (0.07 – 29.78) 0.95 (0.21 – 4.81) 0.647 0.945 0.701 0.875 
       [0.05 (-0.16 – 0.26)] [-0.01 (-0.29 – 0.27)] [-0.06 (-0.32 – 0.21)]  




Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS4+186C>A CC (N=86) CA (N=86) AA (N=30) CC vs CA CC vs AA CA vs AA 
Overall P 
value 
(Z)-NDM-4-O-Gluc 0.27 (0.05 – 1.81) 0.26 (0.04 – 1.46) 0.25 (0.07 – 1.04) 0.474 0.570 0.916 0.730 
       [0.02 (-0.03 – 0.07)] [0.02 (-0.04 – 0.09)] [0.00 (-0.06 – 0.06)]  
(E)-Tam-4-O-Gluc 0.32 (0.05 – 4.70) 0.28 (0.07 – 8.14) 0.26 (0.05 – 1.22) 0.595 0.560 0.705 0.774 
       [0.02 (-0.04 – 0.08)] [0.02 (-0.05 – 0.12)] [0.01 (-0.05 – 0.08)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.49 (2.31 – 52.14) 5.81 (2.20 – 80.56) 5.79 (3.35 – 25.67) 0.381 0.335 0.945 0.556 
       [0.40 (-0.54 – 1.32)] [0.52 (-0.55 – 1.80)] [0.04 (-0.98 – 1.24)]  
MRZ-NDM-4-O-GLUC/E-END 1.99 (0.04 – 21.57) 1.63 (0.09 – 35.41) 1.60 (0.50 – 11.18) 0.495 0.292 0.492 0.520 
       [0.13 (-0.25 – 0.56)] [0.29 (-0.28 – 0.87)] [0.18 (-0.36 – 0.63)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 11.59 (4.05 – 106.92) 9.85 (4.16 – 174.19) 9.85 (4.52 – 37.05) 0.479 0.158 0.623 0.433 
       [0.59 (-1.03 – 2.31)] [1.48 (-0.57 – 3.69)] [0.42 (-1.23 – 2.66)]  
IVS4+259A>T (rs6600892) AA (N=102) AT (N=79) TT (N=21) AA vs AT AA vs TT AT vs TT 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 14.20 (2.06 – 52.84) 17.65 (4.27 – 51.65) 11.12 (2.18 – 35.33) 0.178 0.554 0.166 0.247 
       [-1.82 (-4.72 – 0.84)] [0.94 (-2.42 – 5.62)] [3.29 (-1.17 – 8.08)]  
(E)-Endoxifen 0.19 (0.03 – 2.91) 0.19 (0.03 – 6.64) 0.16 (0.03 – 0.31) 0.845 0.128 0.101 0.249 
       [0.00 (-0.03 – 0.03)] [0.03 (0.00 – 0.11)] [0.04 (0.00 – 0.12)]  
(Z)-4-OHT 2.51 (0.70 – 6.80) 3.00 (1.00 – 7.17) 2.60 (0.47 – 4.66) 0.098 0.882 0.241 0.206 
       [-0.29 (-0.65 – 0.07)] [0.04 (-0.49 – 0.70)] [0.37 (-0.22 – 1.07)]  
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 1.09 (0.16 – 5.90) 0.69 (0.17 – 18.42) 0.159 0.147 0.029 0.066 
       [-0.14 (-0.35 – 0.06)] [0.22 (-0.08 – 0.46)] [0.35 (0.03 – 0.68)]  
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.22) 0.30 (0.05 – 1.61) 0.19 (0.05 – 1.81) 0.181 0.327 0.095 0.167 
       [-0.03 (-0.08 – 0.02)] [0.04 (-0.04 – 0.11)] [0.07 (-0.01 – 0.15)]  
(E)-Tam-4-O-Gluc 0.27 (0.05 – 8.14) 0.34 (0.05 – 1.83) 0.21 (0.06 – 4.70) 0.142 0.202 0.070 0.104 
       [-0.04 (-0.10 – 0.01)] [0.05 (-0.03 – 0.13)] [0.09 (-0.01 – 0.18)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.24 (2.20 – 80.56) 6.19 (2.31 – 24.58) 4.70 (2.74 – 52.14) 0.775 0.224 0.172 0.385 
       [-0.12 (-1.02 – 0.74)] [0.72 (-0.48 – 2.14)] [0.87 (-0.43 – 2.33)]  
MRZ-NDM-4-O-GLUC/E-END 1.61 (0.09 – 35.41) 1.92 (0.04 – 21.57) 2.14 (0.38 – 9.79) 0.434 0.201 0.377 0.381 
       [-0.15 (-0.49 – 0.24)] [-0.44 (-1.43 – 0.25)] [-0.36 (-1.46 – 0.36)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.20 (4.16 – 174.19) 11.47 (4.05 – 37.39) 8.75 (4.52 – 106.92) 0.498 0.368 0.221 0.438 
       [-0.53 (-2.22 – 1.01)] [0.97 (-1.27 – 3.17)] [1.36 (-1.11 – 4.25)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS4-173T>C (rs4588522) TT (N=188) TC + CC (N=14) 
 
  TT vs TC + CC       
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.66 (2.06 – 52.84) 16.56 (7.16 – 50.26)   0.992    
       [-0.04 (-4.96 – 4.88)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.22 (0.03 – 2.91)   0.433    
       [-0.02 (-0.10 – 0.03)]    
(Z)-4-OHT 2.67 (0.47 – 7.17) 2.62 (0.85 – 6.51)   0.501    
       [0.26 (-0.45 – 0.91)]    
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 1.05 (0.26 – 3.8)   0.619    
       [-0.10 (-0.53 – 0.29)]    
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.81) 0.26 (0.09 – 0.81)   0.992    
       [0.00 (-0.11 – 0.09)]    
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.31 (0.11 – 0.88)   0.798    
       [-0.01 (-0.13 – 0.09)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.09 (2.20 – 80.56) 7.42 (2.66 – 16.65)   0.375    
       [-0.79 (-2.75 – 1.04)]    
MRZ-NDM-4-O-GLUC/E-END 1.74 (0.04 – 35.41) 1.40 (0.09 – 22.60)   0.373    
       [0.31 (-0.44 – 1.08)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.31 (4.05 – 174.19) 12.47 (5.42 – 27.79)   0.257    
       [-1.99 (-5.80 – 1.27)]    
IVS4-154C>G (rs4588522) CC (N=13) CG (N=84) GG (N=105) CC vs CG CC vs GG CG vs GG 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 16.78 (5.33 – 52.84) 13.87 (2.06 – 51.65) 16.7 (2.18 – 49.93) 0.596 0.833 0.343 0.608 
       [1.67 (-3.68 – 9.19)] [0.41 (-4.99 – 8.12)] [-1.13 (-3.70 – 1.18)]  
(E)-Endoxifen 0.21 (0.03 – 2.91) 0.19 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.209 0.209 0.961 0.429 
       [0.05 (-0.02 – 0.14)] [0.04 (-0.02 – 0.14)] [0.00 (-0.03 – 0.03)]  
(Z)-4-OHT 2.54 (1.63 – 6.80) 2.67 (0.85 – 7.13) 2.74 (0.47 – 7.17) 0.966 0.760 0.779 0.939 
       [-0.02 (-0.74 – 0.86)] [-0.08 (-0.73 – 0.79)] [-0.05 (-0.41 – 0.29)]  
(E)-NDM-4-O-Gluc 0.83 (0.18 – 3.97) 1.02 (0.07 – 29.78) 0.94 (0.17 – 18.42) 0.680 0.921 0.508 0.779 
       [-0.07 (-0.48 – 0.37)] [-0.02 (-0.41 – 0.39)] [0.06 (-0.13 – 0.26)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS4-154C>G (rs4588522) CC (N=13) CG (N=84) GG (N=105) CC vs CG CC vs GG CG vs GG 
Overall P 
value 
(Z)-NDM-4-O-Gluc 0.28 (0.11 – 1.02) 0.27 (0.04 – 1.61) 0.26 (0.05 – 1.81) 0.996 0.573 0.577 0.795 
       [0.00 (-0.10 – 0.10)] [0.02 (-0.07 – 0.11)] [0.02 (-0.03 – 0.06)]  
(E)-Tam-4-O-Gluc 0.25 (0.09 – 0.88) 0.32 (0.05 – 8.14) 0.27 (0.05 – 4.70) 0.459 0.962 0.140 0.316 
       [-0.05 (-0.16 – 0.08)] [0.00 (-0.11 – 0.11)] [0.04 (-0.01 – 0.10)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 7.14 (2.66 – 10.70) 6.94 (2.20 – 80.56) 5.62 (2.56 – 52.14) 0.262 0.962 0.017 0.052 
       [-1.12 (-3.29 – 0.80)] [0.05 (-1.67 – 1.97)] [1.04 (0.19 – 1.97)]  
MRZ-NDM-4-O-GLUC/E-END 1.42 (0.09 – 10.79) 1.75 (0.04 – 22.60) 1.74 (0.09 – 35.41) 0.282 0.412 0.536 0.519 
       [-0.40 (-1.32 – 0.37)] [-0.28 (-1.10 – 0.45)] [0.10 (-0.27 – 0.48)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 12.11 (5.51 – 15.17) 11.72 (4.05 – 174.19) 9.78 (4.16 – 106.92) 0.236 0.833 0.022 0.062 
       [-1.89 (-5.52 – 1.19)] [0.25 (-2.49 – 2.97)] [1.84 (0.24 – 3.56)]  
*+1029G>C (rs7666195) GG (N=14) GC (N=53) CC (N=134) GG vs GC GG vs CC GC vs CC 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.51 (5.33 – 52.84) 12.38 (2.06 – 48.73) 16.05 (2.18 – 51.65) 0.633 0.906 0.188 0.428 
       [1.27 (-3.40 – 8.48)] [-0.22 (-5.48 – 6.3)] [-1.82 (-4.67 – 0.81)]  
(E)-Endoxifen 0.21 (0.03 – 2.91) 0.18 (0.03 – 0.38) 0.19 (0.03 – 6.64) 0.263 0.459 0.383 0.465 
       [0.04 (-0.03 – 0.14)] [0.02 (-0.04 – 0.10)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.37 (1.63 – 6.80) 2.68 (1.00 – 5.14) 2.72 (0.47 – 7.17) 0.939 0.628 0.506 0.745 
       [-0.05 (-0.72 – 0.85)] [-0.15 (-0.77 – 0.58)] [-0.13 (-0.55 – 0.25)]  
(E)-NDM-4-O-Gluc 0.72 (0.18 – 3.97) 1.04 (0.07 – 29.78) 0.96 (0.17 – 18.42) 0.758 0.587 0.893 0.877 
       [-0.06 (-0.51 – 0.38)] [-0.08 (-0.44 – 0.27)] [-0.01 (-0.22 – 0.21)]  
(Z)-NDM-4-O-Gluc 0.28 (0.11 – 1.02) 0.27 (0.04 – 1.61) 0.26 (0.05 – 1.81) 0.913 0.860 0.865 0.977 
       [-0.01 (-0.12 – 0.09)] [0.01 (-0.08 – 0.09)] [0.01 (-0.05 – 0.06)]  
(E)-Tam-4-O-Gluc 0.24 (0.09 – 0.88) 0.31 (0.05 – 8.14) 0.28 (0.05 – 4.70) 0.568 0.687 0.520 0.737 
       [-0.04 (-0.18 – 0.08)] [-0.02 (-0.12 – 0.08)] [0.02 (-0.04 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.81 (2.66 – 10.70) 6.54 (2.20 – 80.56) 5.9 (2.56 – 52.14) 0.441 0.819 0.176 0.380 
       [-0.89 (-3.39 – 1.11)] [-0.16 (-1.74 – 1.49)] [0.68 (-0.33 – 1.83)]  
MRZ-NDM-4-O-GLUC/E-END 1.42 (0.09 – 10.79) 1.89 (0.36 – 21.57) 1.67 (0.04 – 35.41) 0.308 0.699 0.206 0.378 
       [-0.41 (-1.39 – 0.51)] [-0.15 (-0.92 – 0.68)] [0.28 (-0.16 – 0.72)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 11.38 (5.51 – 15.17) 11.1 (4.05 – 174.19) 10.2 (4.16 – 106.92) 0.379 0.885 0.204 0.411 
       [-1.65 (-6.02 – 1.62)] [-0.19 (-2.87 – 2.28)] [1.17 (-0.58 – 3.28)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
*+1271G>T GG (N=170) GT + TT (N=31) 
 
  GG vs GT + TT       
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.51 (2.06 – 52.84) 17.65 (2.18 – 42.19)   0.636    
       [-0.79 (-3.99 – 2.92)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.19 (0.03 – 0.45)   0.777    
       [0.00 (-0.03 – 0.05)]    
(Z)-4-OHT 2.62 (0.70 – 7.13) 3.18 (0.47 – 7.17)   0.335    
       [-0.25 (-0.74 – 0.27)]    
(E)-NDM-4-O-Gluc 0.96 (0.07 – 29.78) 0.90 (0.17 – 5.64)   0.834    
       [-0.03 (-0.29 – 0.24)]    
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.71) 0.29 (0.05 – 1.81)   0.344    
       [-0.03 (-0.11 – 0.04)]    
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.28 (0.07 – 1.50)   0.848    
       [-0.01 (-0.09 – 0.07)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.18 (2.20 – 80.56) 6.09 (2.99 – 23.68)   0.957    
       [0.04 (-1.04 – 1.12)]    
MRZ-NDM-4-O-GLUC/E-END 1.67 (0.04 – 35.41) 2.14 (0.38 – 15.66)   0.142    
       [-0.38 (-1.02 – 0.15)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.41 (4.05 – 174.19) 11.07 (5.05 – 45.51)   1.000    
       [0.00 (-2.05 – 2.00)]    
*+1319C>T CC (N=13) CT (N=51) TT (N=137) CC vs CT CC vs TT CT vs TT 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 16.78 (5.33 – 52.84) 12.09 (2.06 – 48.73) 16.18 (2.18 – 51.65) 0.390 0.891 0.104 0.256 
       [2.62 (-2.91 – 11.33)] [0.27 (-5.07 – 7.89)] [-2.14 (-5.11 – 0.45)]  
(E)-Endoxifen 0.21 (0.03 – 2.91) 0.18 (0.03 – 0.38) 0.19 (0.03 – 6.64) 0.137 0.244 0.381 0.295 
       [0.06 (-0.01 – 0.14)] [0.04 (-0.03 – 0.13)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.54 (1.63 – 6.80) 2.66 (1.00 – 5.14) 2.74 (0.47 – 7.17) 0.900 0.751 0.445 0.731 
       [0.09 (-0.68 – 0.97)] [-0.10 (-0.75 – 0.75)] [-0.15 (-0.57 – 0.23)]  
(E)-NDM-4-O-Gluc 0.83 (0.18 – 3.97) 0.95 (0.07 – 29.78) 0.97 (0.17 – 18.42) 0.953 0.756 0.712 0.905 
       [-0.01 (-0.48 – 0.45)] [-0.06 (-0.43 – 0.36)] [-0.04 (-0.25 – 0.19)]  




Table 3.25 Effect of UGT2B7 tag-SNPs on plasma concentrations of tamoxifen metabolites and metabolic ratios (N=202) (Continued). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
*+1319C>T CC (N=13) CT (N=51) TT (N=137) CC vs CT CC vs TT CT vs TT 
Overall P 
value 
(Z)-NDM-4-O-Gluc 0.28 (0.11 – 1.02) 0.24 (0.04 – 1.61) 0.26 (0.05 – 1.81) 0.852 0.726 0.983 0.952 
       [0.02 (-0.12 – 0.12)] [0.01 (-0.08 – 0.10)] [0.00 (-0.06 – 0.06)]  
(E)-Tam-4-O-Gluc 0.25 (0.09 – 0.88) 0.30 (0.05 – 8.14) 0.28 (0.05 – 4.70) 0.670 0.751 0.623 0.837 
       [-0.03 (-0.18 – 0.09)] [-0.02 (-0.12 – 0.09)] [0.02 (-0.05 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 7.14 (2.66 – 10.70) 6.77 (2.20 – 80.56) 5.91 (2.56 – 52.14) 0.409 0.751 0.164 0.350 
       [-1.05 (-3.70 – 1.08)] [-0.25 (-1.84 – 1.59)] [0.73 (-0.31 – 1.94)]  
MRZ-NDM-4-O-GLUC/E-END 1.42 (0.09 – 10.79) 1.89 (0.36 – 21.57) 1.67 (0.04 – 35.41) 0.174 0.436 0.239 0.310 
       [-0.56 (-1.72 – 0.30)] [-0.27 (-1.05 – 0.44)] [0.27 (-0.19 – 0.73)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 12.11 (5.51 – 15.17) 11.1 (4.05 – 174.19) 10.27 (4.16 – 106.92) 0.409 0.833 0.240 0.462 
       [-1.72 (-6.22 – 1.81)] [-0.29 (-2.99 – 2.35)] [1.10 (-0.66 – 3.29)]  
*+1969C>T CC (N=85) CT (N=88) TT (N=29) CC vs CT CC vs TT CT vs TT 
Overall P 
value 
Plasma Concentration of Analytes (ng/mL) 
(Z)-Endoxifen 15.71 (2.18 – 52.84) 14.24 (2.06 – 49.93) 16.75 (5.22 – 42.10) 0.806 0.582 0.353 0.700 
       [0.38 (-2.18 – 2.98)] [-1.05 (-5.17 – 3.02)] [-1.73 (-5.35 – 1.88)]  
(E)-Endoxifen 0.19 (0.03 – 4.88) 0.18 (0.03 – 6.64) 0.19 (0.03 – 0.39) 0.494 0.743 0.392 0.641 
       [0.00 (-0.02 – 0.04)] [0.00 (-0.06 – 0.03)] [-0.01 (-0.07 – 0.02)]  
(Z)-4-OHT 2.76 (0.47 – 7.13) 2.60 (1.11 – 7.17) 2.82 (0.70 – 5.80) 0.799 0.884 0.719 0.931 
       [0.05 (-0.32 – 0.43)] [-0.03 (-0.62 – 0.51)] [-0.09 (-0.57 – 0.36)]  
(E)-NDM-4-O-Gluc 0.95 (0.16 – 18.42) 0.98 (0.07 – 29.78) 0.99 (0.21 – 4.81) 0.413 0.868 0.426 0.620 
       [0.08 (-0.11 – 0.28)] [-0.02 (-0.32 – 0.28)] [-0.11 (-0.40 – 0.16)]  
(Z)-NDM-4-O-Gluc 0.28 (0.05 – 1.81) 0.26 (0.04 – 1.46) 0.25 (0.07 – 1.04) 0.326 0.560 0.929 0.600 
       [0.02 (-0.02 – 0.08)] [0.02 (-0.05 – 0.10)] [0.00 (-0.07 – 0.06)]  
(E)-Tam-4-O-Gluc 0.33 (0.05 – 4.70) 0.28 (0.07 – 8.14) 0.27 (0.05 – 1.22) 0.371 0.612 0.990 0.661 
       [0.03 (-0.03 – 0.09)] [0.02 (-0.06 – 0.12)] [0.00 (-0.07 – 0.07)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.50 (2.31 – 52.14) 5.81 (2.20 – 80.56) 5.67 (3.35 – 25.67) 0.200 0.382 0.801 0.393 
       [0.58 (-0.31 – 1.50)] [0.43 (-0.65 – 1.82)] [-0.15 (-1.16 – 1.07)]  
MRZ-NDM-4-O-GLUC/E-END 1.96 (0.04 – 21.57) 1.63 (0.09 – 35.41) 1.61 (0.49 – 10.53) 0.591 0.357 0.547 0.625 
       [0.10 (-0.28 – 0.52)] [0.27 (-0.31 – 0.87)] [0.16 (-0.37 – 0.64)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 11.71 (4.05 – 106.92) 9.78 (4.16 – 174.19) 10.27 (4.52 – 37.05) 0.242 0.190 0.930 0.348 
       [0.93 (-0.66 – 2.63)] [1.39 (-0.71 – 3.76)] [0.09 (-1.58 – 2.22)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.26 Effects of UGT2B7 Haplotypes on the O-glucuronidation of (Z)-Endoxifen. 
























































































































































































































(Intercept of GLM) 2.68 4.65 1.97 0.12 0.16 0.11 <0.001 <0.001 <0.001 
H1 
L
 T T G A T T C C 0.26          
H2 C T G A C C C A 0.35 0.03 -0.04 -0.07 0.08 0.11 0.08 0.666 0.751 0.361 
H3 C T T G C C C C 0.13 -0.01 -0.15 -0.14 0.10 0.14 0.10 0.928 0.296 0.155 
H4 C C G A C C C C 0.09 0.01 -0.04 -0.06 0.13 0.17 0.12 0.925 0.804 0.645 
H5 C T G G C C C C 0.09 0.07 0.10 0.03 0.12 0.17 0.12 0.554 0.548 0.801 
H6 C T G A C C T C 0.06 -0.04 -0.09 -0.05 0.14 0.19 0.13 0.780 0.642 0.702 
Hrare * * * * * * * * 0.02 -0.01 -0.06 -0.05 0.00 NA 0.00 <0.001 NA <0.001 












































































































































































(Intercept of GLM) 2.66 4.60 1.94 0.12 0.17 0.12 <0.001 <0.001 <0.001 
H1 
L
 C G       0.19          
H2 G C       0.72 0.04 -0.02 -0.06 0.07 0.10 0.07 0.636 0.829 0.423 
H3 C C       0.08 0.06 0.11 0.05 0.12 0.17 0.12 0.624 0.524 0.668 
Hrare * *             0.01 -0.31 -0.27 0.04 0.00 0.00 0.00 <0.001 <0.001 <0.001 











































































































































































(Intercept of GLM) 2.61 4.55 1.94 0.12 0.17 0.12 <0.001 <0.001 <0.001 
H1 
L
 C C       0.19          
H2 T C       0.45 0.06 0.03 -0.03 0.08 0.11 0.07 0.416 0.756 0.690 
H3 T T       0.36 0.07 0.00 -0.06 0.08 0.11 0.08 0.417 0.978 0.420 
Hrare * *             0.00 -0.14 -0.02 0.12 NA NA 0.00 NA NA <0.001 
† Plasma concentrations of (Z)-endoxifen ln-transformed; (E)-NDM-4-O-Gluc concentrations and MRE-NDM-4-O-Gluc/Z-END were multiplied by 
factors of 100 and 10000, respectively, before ln-transformation. 
‡ Haplotype H1 of each block refers to the wild-type haplotype.  
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Table 3.27 Effects of UGT2B7 Haplotypes on the O-glucuronidation of (E)-Endoxifen. 
























































































































































































































(Intercept of GLM) 2.69 3.34 5.26 0.20 0.14 0.19 <0.001 <0.001 <0.001 
H1 
L
 T T G A T T C C 0.26          
H2 C T G A C C C A 0.35 -0.01 -0.05 -0.04 0.14 0.09 0.13 0.954 0.574 0.736 
H3 C T T G C C C C 0.13 -0.03 -0.05 -0.02 0.17 0.12 0.17 0.860 0.679 0.913 
H4 C C G A C C C C 0.09 -0.11 0.09 0.20 0.21 0.15 0.21 0.620 0.519 0.333 
H5 C T G G C C C C 0.09 -0.11 0.01 0.12 0.21 0.14 0.21 0.616 0.942 0.568 
H6 C T G A C C T C 0.06 -0.05 -0.03 0.02 0.24 0.16 0.23 0.846 0.848 0.947 
Hrare * * * * * * * * 0.02 -0.06 0.00 0.06 NA 0.00 0.00 NA <0.001 <0.001 












































































































































































(Intercept of GLM) 2.71 3.34 5.24 0.21 0.14 0.20 <0.001 <0.001 <0.001 
H1 
L
 C G       0.19          
H2 G C       0.72 -0.05 -0.02 0.02 0.13 0.09 0.12 0.722 0.804 0.848 
H3 C C       0.08 0.04 0.03 -0.01 0.21 0.15 0.21 0.857 0.831 0.975 
Hrare * *       0.01 -0.53 -0.22 0.32 0.00 0.00 NA 0.000 0.000 NA 











































































































































































(Intercept of GLM) 2.65 3.31 5.26 0.21 0.14 0.20 <0.001 <0.001 <0.001 
H1 
L
 C C       0.19          
H2 T C       0.45 -0.02 0.04 0.06 0.13 0.09 0.13 0.870 0.689 0.651 
H3 T T       0.36 0.00 -0.04 -0.04 0.14 0.09 0.13 0.991 0.654 0.744 
Hrare * *       0.00 0.13 -0.04 -0.17 NA 0.00 NA NA 0.000 NA 
† Plasma concentrations of (E)-endoxifen and (Z)-NDM-4-O-Glucas well as MRZ-NDM-4-O-Gluc/E-END were multiplied by factor of 100 before ln-
transformation. 




Table 3.28 Effects of UGT2B7 Haplotypes on the O-glucuronidation of (Z)-4-OHT. 















































































































































































































(Intercept of GLM) 1.71 3.55 2.54 0.07 0.15 0.12 <0.001 <0.001 <0.001 
H1 
L
 T T G A T T C C 0.26          
H2 C T G A C C C A 0.35 -0.01 -0.09 -0.09 0.05 0.10 0.08 0.841 0.391 0.255 
H3 C T T G C C C C 0.13 -0.01 -0.13 -0.14 0.06 0.13 0.10 0.930 0.298 0.167 
H4 C C G A C C C C 0.09 0.00 -0.08 -0.07 0.08 0.16 0.12 0.957 0.604 0.548 
H5 C T G G C C C C 0.09 -0.01 -0.02 0.03 0.08 0.16 0.12 0.868 0.922 0.791 
H6 C T G A C C T C 0.06 -0.06 -0.14 -0.06 0.09 0.18 0.14 0.480 0.428 0.653 
Hrare * * * * * * * * 0.02 0.01 -0.02 -0.06 NA NA NA NA NA NA 



































































































































































(Intercept of GLM) 1.68 3.51 2.52 0.08 0.16 0.12 <0.001 <0.001 <0.001 
H1 
L
 C G       0.19          
H2 G C       0.72 0.01 -0.07 -0.08 0.05 0.09 0.07 0.895 0.474 0.300 
H3 C C       0.08 0.06 0.08 0.03 0.08 0.16 0.12 0.462 0.620 0.806 
Hrare * *       0.01 -0.14 -0.16 0.01 0.00 0.00 NA <0.001 <0.001 NA 


































































































































































(Intercept of GLM) 1.66 3.47 2.51 0.08 0.16 0.12 <0.001 <0.001 <0.001 
H1 
L
 C C       0.19          
H2 T C       0.45 0.03 -0.01 -0.03 0.05 0.10 0.07 0.566 0.914 0.642 
H3 T T       0.36 0.02 -0.05 -0.08 0.05 0.10 0.08 0.749 0.628 0.300 
Hrare * *       0.00 -0.05 0.12 0.15 NA 0.00 0.00 NA <0.001 <0.001 
† Plasma concentrations of (Z)-4-OHT were square-root-transformed; Plasma concentrations of (E)-Tam-4-O-Gluc and MRE-TAM-4-O-Gluc/Z-4-
OHT were multiplied by factors of 100 and 10000, respectively, before ln-transformation. 




Among the UGT2B family of enzymes, UGT2B7 is the highly expressed isoform in 
the liver and most widely investigated UGT2B isoform (333, 345, 351, 363). However, 
large inter-individual variabilities in the glucuronidation capacity of UGT2B7 are 
frequently observed and have been attributed to the presence of genetic variants 
along the UGT2B7 gene (351, 372). In the current study, the genetic profile of 
UGT2B7 was characterized in three Asian ethnic groups namely, Chinese, Malays 
and Indians (N=80 each). Following which, the functional effects of these 
polymorphic variants on the metabolism of tamoxifen metabolites were evaluated in 
Asian breast cancer patients receiving tamoxifen therapy. 
Screening of approximately 11.8 kilobases of the UGT2B7 gene in 240 Asian 
subjects revealed the highly polymorphic nature of UGT2B7 with 77 polymorphisms 
being uncovered. Among the five nonsynonymous polymorphisms, 802T>C (*2, 
rs7439366) is the most widely investigated functional polymorphism (366). The T to 
C transition causes a substitution of histidine for tyrosine at codon 268 which resides 
in the substrate binding domain. Hence, it has been postulated that the 
polymorphism may lead to altered substrate binding capacity and catalytic activity 
(366, 368). Besides 802T>C (*2, rs7439366), 211G>T (rs12233719) is another non-
synonymous SNP which is also present at high frequency in exon 1 (342). Although 
the functional impact of 211G>T (rs12233719) is not known, it has been reported to 
cause the substitution of the small, hydrophobic amino acid, alanine, for serine which 
contains a polar side chain at codon 70 within the substrate binding site (370). Hence, 
this polymorphism can potentially influence the binding affinity of the enzyme for its 
substrates. Despite 211G>T (rs12233719) not being present in the Caucasian 
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subjects, it previously reported at variant frequencies of 0.19 and 0.12 in the 
Japanese and Korean populations, respectively (367, 369, 370). It was also 
observed to be in perfect linkage with the synonymous SNP, 372A>G (rs28365063, 
R124R). In contrast, these two polymorphisms were found to be in moderate linkage 
in the Chinese (|D′|=0.89, r2=0.64) and poor linkage in the Malays (|D′|=0.60, r2=0.16) 
and Indians (|D′|=1.00, r2=0.04).  
Other non-synonymous polymorphisms are present along exon 2 (763G>A, V255I) 
and exon 4 (1054C>T, R352W; 1065G>C, K355N). Although these polymorphisms 
have potential functional impact by virtue of its location, the frequencies were very 
low at only 1% of the Chinese (1054C>T, R352W) or Indians (763G>A, V255I; 
1065G>C, K355N). In addition, seven other synonymous polymorphic variants in the 
coding regions were also observed.  
Despite differences in the SNP frequencies and the LD pattern, pairwise LD analysis 
revealed tight linkage between the SNPs to form one single block across three 
ethnicities, an observation analogous to that observed in the Caucasians (375). This 
is indicative of the low probability of recombination events in a relatively small gene 
like UGT2B7. Due to high linkage, the use of tag-SNPs representative of other 
polymorphisms along the gene is an effective and cost-saving approach. The 
number of tag-SNPs selected in each population was less than half of the original 
number of high frequency SNPs (N=54). Finally, 14 tag-SNPs representative of all 
ethnic groups were selected and genotyped in the Asian breast cancer patients.  
In the present study, no significant relationships between UGT2B7 polymorphic 
variants and the plasma concentrations of the analytes or the MRs were observed. 
Despite the high LD between the SNPs, no significant haplotypic association was 
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observed too. This was in agreement with Murdter et al (118) who reported no 
significant relationship between UGT2B7*2 (802T>C, rs7439366) and the O-
glucuronidation of 4-OHT and endoxifen. However, a non-significant trend of lower 
MRE-NDM-4-O-GLUC/Z-END and MRE-TAM-4-O-GLUC/Z-4-OHT associated with the functional 
polymorphism, 802T>C (*2, rs7439366). This was in contrary to previous findings 
reported by Blevins-Primeau et al who demonstrated progressive increase in the O-
glucuronidation rates of (Z)-4-OHT and (Z)-endoxifen in liver microsomes as the 
number of variant C allele increases (195). The discrepancy in the results between 
the two studies might be due to the linkage between 802T>C (*2, rs7439366) and 
other polymorphisms. In our Asian subjects, 802T>C (*2, rs7439366) was found to 
be in high linkage with SNPs present in the 5′ upstream and exons. Thus, the effects 
exerted by UGT2B7 in the in vivo system might be due to the haplotypic combination 
of polymorphisms.   
Indeed, Innocenti et al (375), reported an increase in the gene expression and 
glucuronidating capacity of UGT2B7 on morphine in Caucasian subjects carrying the 
variant alleles of IVS1+985A>G (rs62298861), IVS1+829T>C (rs28375964) and 
IVS1+1250A>G (rs7438244) as a haplotype with the wild-type alleles of seven other 
tag-SNPs [-45597G>T, -6682_-6683insGCAAAT, 372A>G (rs28365063), 
IVS1+9_IVS1+10insT, IVS1+999C>A (rs72643000), 801A>T (rs7438284), 
IVS4+185C>A (rs72853597)]. A 45% increase in the average plasma level of 
morphine-3-glucuronide was observed. Regression analysis revealed a significant 
association between IVS1+985A>G and UGT2B7 mRNA levels. Additionally, 
IVS1+9_IVS1+10insT was significantly associated with the formation of morphine-3-
glucuronide and morphine-6-glucuronide. However, both IVS1+985A>G (rs62298861) 
and IVS1+9_IVS1+10insT were either absent or present at low frequencies in our 
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Asian populations compared to the variant frequencies of 0.17 and 0.13 respectively 
in the Caucasians (375). Since the frequencies of the polymorphisms as well as the 
LD between the polymorphisms differ across ethnic groups, functional SNPs 
operative in the Asian populations are likely to differ from the Caucasians.  
With respect to the metabolism of tamoxifen, extra-hepatic isoforms of UGTs, 
besides UGT2B7, are also found to mediate O-glucuronidation of 4-OHT and 
endoxifen (129). Sun et al has reported that UGT1A8 and UGT1A10 are two of the 
extrahepatic UGTs that exhibit the highest glucuronidating capacities for (Z)-4-OHT 
and (Z)-endoxifen (129). Both UGT1A8 and UGT1A10 are ubiquitously expressed 
along the GI tract contributing to 56% to 64% of the overall expression of UGT1A 
enzymes (469). Unlike the other UGT1A and UGT2B isoforms of enzymes, the 
expression of UGT1A10 has not been found to display significant inter-individual 
variations or diversity across different regions of the small intestine (346). As an oral 
drug, GI tract is the first-pass barrier which tamoxifen needs to cross before entering 
the systemic circulation. Hence, presence of functional UGT1A8 and UGT1A10 
along the GI tract might confound observations of altered plasma levels of analytes 
due to differential UGT2B7 catalytic activity resulting from presence of genetic 
variations.  
In conclusion, UGT2B7 was highly polymorphic with 77 polymorphisms discovered 
along the 11 kilobases of the gene region. Tight linkage was observed among almost 
all polymorphisms leading to the selection of 14 tag-SNPs representative of the 
genetic profile across all three Asian ethnicities. However, the tag-SNPs and 
functional SNPs genotyped in the Asian patient population did not suggest an 
important role for UGT2B7 in determining the glucuronidation capacity for 4-OHT and 
endoxifen. This was probably due to the concurrent presence of functional activity of 
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other UGT isoforms (including UGT1A8 and UGT1A10) which can eliminate the 
clinical dose of tamoxifen without apparent effects from UGT2B7. However, both 
UGT1A8 and UGT1A10 were not investigated in this study. Subsequent studies 
should investigate the impact of the pharmacogenetics of UGT1A8 and UGT1A10 on 
the metabolism of tamoxifen active metabolites. 
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3.4.3 UDP glucuronosyltransferase 2 family, polypeptide B15 (UGT2B15) 
3.4.3.1 Genetic Profile of UGT2B15 
The exonic and exonic-intronic boundaries of UGT2B15 were screened for presence 
of polymorphic variants in 80 healthy subjects from each of the three healthy ethnic 
populations. Additionally, the 5′ upstream and 3′ downstream regions were 
sequenced and a total of 47 polymorphisms were identified. Seventeen of these 47 
polymorphisms were localized to the 5′ upstream and UTR regions while 8 and 3 
SNPs were found in the 3′ UTR and 3′ downstream region. In additional, 4 exonic 
and 15 intronic SNPs were also found (Fig 3.16). The putative functions of these 
polymorphisms were tabulated in Table 3.29. With the exception of 253G>T (*2, 
rs1902023) which was located in exon 1, other exonic SNPs were found in exons 6. 
Two polymorphisms in exon 6, 1336T>C and 1553G>A were found in only 1% of 
Indians and in 1% of Malays and Indians respectively (Table 3.30).  
Thirteen polymorphisms were found to be present at frequencies of 4% or less and 
mostly ethnic-specific (Table 3.30). Five SNPs were only found in the Indian 
population: -772T>C (rs34503711), -379C>G (rs79960668), -4C>G, IVS5-344_-
345insA and 1336T>C. Similarly three SNPs were polymorphic only in the Chinese 
(IVS5-722A>G, IVS5-150A>G and IVS5-46C>G). Polymorphisms present in the 3′ 
region of UGT2B15 were found to be significantly different across the three healthy 
ethnicities. The proportions of homozygous variant for 1568A>C (*4, rs4148269, 
exon 6) and *168C>T (rs3100, in 3′ UTR) were approximately 4.6-fold higher in the 
Indians compared to the Malays which were in turn about 4.8-fold higher than the 
Chinese. Conversely, the frequencies of *186A>T (rs4148271) and *+899G>A were 
higher in the Chinese compared to the Malays or Indians (Table 3.30). Besides, ten 
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SNPs [-1805T>C (rs62299491), -1137T>C (rs9994887), -772T>C (rs34503711), -
513T>C (rs62317005), IVS2-54T>C, IVS2-90C>G, IVS3+132A>C, IVS4-207insT 
(rs34449264), *+1041G>T and *+1067A>C] were found to be significantly different in 
the healthy Indian subjects compared to Chinese or Malay subjects (P ≤ 0.022). On 
the contrary, IVS2-95C>T, IVS3+135G>A, IVS5-416G>C and *+630C>G were found 
to be significantly different in the Chinese in comparison with Malays and Indians.  
 
Fig 3.16 Polymorphisms present in UGT2B15 gene (UCSC RefSeq: NM_001076).  
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Table 3.29 Functional effects of UGT2B15 polymorphisms.  
SNPs rs ID Location Putative effects predicted by software 
Possible Functional Effects Descriptions 
-2310A>T rs62298399 5′ Upstream Promoter/regulatory region Creates binding site for CP2 
-1844C>T rs7696472 5′ Upstream Upstream with no known function – 
-1805T>C rs62299491 5′ Upstream Upstream with no known function – 
-1577A>G rs7686914 5′ Upstream Promoter/regulatory region Creation of GATA binding sites 
-1409G>A rs7682027 5′ Upstream Upstream with no known function – 
-1395A>C rs13112099 5′ Upstream Promoter/regulatory region Creation of Nkx-2 binding site 
-1137T>C rs9994887 5′ Upstream Upstream with no known function – 
-818T>G rs1960773 5′ Upstream Promoter/regulatory region Disruption of c-Ets-1 binding site 
-772T>C rs34503711 5′ Upstream Upstream with no known function – 
-513T>C rs62317005 5′ Upstream Upstream with no known function – 
-508G>A rs1120265 5′ Upstream Promoter/regulatory region Creation of Tst-1 binding site 
-506T>A rs1580083 5′ Upstream Upstream with no known function – 
-497C>T rs76571221 5′ Upstream Promoter/regulatory region Disruption of CdxA binding site 
-477A>G rs78497667 5′ Upstream Upstream with no known function – 
-379C>G rs79960668 5′ Upstream Upstream with no known function – 
-378C>T rs75187800 5′ Upstream Upstream with no known function – 
-4C>G  5′ Upstream Promoter/regulatory region Disruption of c-Ets-1 binding site 
253G>T rs1902023 Exon 1 Missense (conservative) polymorphism Y85D; Predicted to be benign with a score of 0.000 
IVS2+56A>T rs2045100 Intron 2 Intronic with no known function – 
IVS2-95C>T  Intron 2 Intronic with no known function – 
IVS2-90C>G  Intron 2 Intronic enhancer Creates binding site for SRY 
IVS2-54T>C  Intron 2 Intronic with no known function – 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software 




Table 3.29 Functional effects of UGT2B15 polymorphisms. (continued) 
SNPs rs ID Location Putative effects predicted by software 
Possible Functional Effects Descriptions 
IVS2-33T>A  Intron 2 Intronic enhancer Creates binding site for IRF-2 
IVS3+129T>C  Intron 3 Intronic enhancer Affects binding of Tal-1b, CP2 and GATA-1, GATA-2 
IVS3+132A>C  Intron 3 Intronic with no known function – 
IVS3+135G>A  Intron 3 Intronic with no known function – 
IVS4-207insT rs34449264 Intron 4 Intronic with no known function – 
IVS5-793G>A  Intron 5 Intronic with no known function – 
IVS5-722A>G  Intron 5 Intronic enhancer Disrupts binding site for SRY 
IVS5-416G>T  Intron 5 Intronic with no known function – 
IVS5-344_345insA Intron 5 Intronic enhancer Creates binding site for HFH-2 
IVS5-226G>A  Intron 5 Intronic enhancer Disrupts binding sites for HSF and Creates site for CdxA 
IVS5-150A>G  Intron 5 Intronic enhancer Disrupts binding sites for Oct-1 
IVS5-84A>G  Intron 5 Intronic enhancer Disrupts binding sites for C/EBP 
IVS5-46C>G  Intron 5 Intronic enhancer Creates binding sites for C/EBPb and Pbx-1 
IVS5-14T>C rs4148268 Intron 5 Intronic enhancer Creation of GATA and CdxA binding sites 
1336T>C  Exon 6 Exonic synonymous 
polymorphism; Splicing 
regulation 
L446L; Creates binding sites for exonic splicing enhancer 
1553G>A  Exon 6 Missense (conservative) 
polymorphism; Splicing 
regulation 
R518Q; Predicted to be possibly damaging with a score of 
0.564; Creates binding sites for SC35 and exonic splicing 
enhancer 
1568A>C rs4148269 Exon 6 Missense (conservative) 
polymorphism; Splicing 
regulation 
K523T; Predicted to be benign with a score of 0.000; 
Creates binding sites for SF2/ASF and Srp40; Affects 
binding of exonic splicing enhancer  
*168C>T rs3100 3′ Untranslated Region Downstream with no known 
function 
– 
*186A>T rs4148271 3′ Untranslated Region Downstream with no known 
function 
– 
† FastSNP prediction was restricted to polymrophisms present in the 5′ upstream, exonic and intronic regions. Analyses using MicroInspector software was 
restricted to SNPs in the 3′ untranslated region. 
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Table 3.30 Genotypic and allelic profile of UGT2B15 (UCSC RefSeq: NM_001076). 
SN Polymorphisms Genotype 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
1 -2310A>T AA 42 (52.5) 45 (56.3) 45 (56.3) 107 (53.0) A 0.72 (0.65 – 0.79) 0.74 (0.68 – 0.81) 0.73 (0.66 – 0.80) 0.72 (0.67 – 0.76) 
 
(rs62298399) AT 31 (38.8) 29 (36.3) 27 (33.8) 75 (37.1) T 0.28 (0.21 – 0.35) 0.26 (0.19 – 0.32) 0.27 (0.20 – 0.34) 0.28 (0.24 – 0.33) 
  
TT 7 (8.8) 6 (7.5) 8 (10.0) 20 (9.9)     
2 -1844C>T CC 11 (13.9) 12 (15.0) 21 (26.3) 39 (19.3) C 0.45 (0.37 – 0.53) 0.43 (0.35 – 0.51) 0.54 (0.47 – 0.62) 0.43 (0.38 – 0.48) 
 
(rs7696472) CT 49 (62.0) 45 (56.3) 45 (56.3) 95 (47.0) T 0.55 (0.47 – 0.63) 0.57 (0.49 – 0.65) 0.46 (0.38 – 0.53) 0.57 (0.52 – 0.62) 
  
TT 19 (24.1) 23 (28.8) 14 (17.5) 68 (33.7)     
3 -1805T>C TT 79 (98.8) 75 (93.8) 63 (78.8) 197 (97.5) T 0.99 (0.98 – 1.01) 0.97 (0.94 – 1.00) 0.88 (0.83 – 0.93) 0.99 (0.97 – 1.00) 
 
(rs62299491) TC 1 (1.3) 5 (6.3) 15 (18.8) 4 (2.0) C 0.01 (-0.01 – 0.02) 0.03 (0.00 – 0.06)
‡ 0.12 (0.07 – 0.17)§ 0.01 (0.00 – 0.03) 
  
CC 0 (0.0) 0 (0.0) 2 (2.5) 1 (0.5)     
4 -1577A>G AA 16 (20.0) 14 (17.5) 23 (28.8) A 0.49 (0.41 – 0.56) 0.45 (0.37 – 0.53) 0.56 (0.49 – 0.64)  
 
(rs7686914) AG 46 (57.5) 44 (55.0) 44 (55.0) G 0.51 (0.44 – 0.59) 0.55 (0.47 – 0.63) 0.44 (0.36 – 0.51)  
  
GG 18 (22.5) 22 (27.5) 13 (16.3)     
5 -1409G>A GG 42 (52.5) 52 (65.0) 56 (70.0) 109 (54.0) G 0.74 (0.67 – 0.81) 0.81 (0.75 – 0.87) 0.85 (0.79 – 0.91) 0.73 (0.68 – 0.77) 
 
(rs7682027) GA 34 (42.5) 26 (32.5) 24 (30.0) 75 (37.1) A 0.26 (0.19 – 0.33) 0.19 (0.13 – 0.25) 0.15 (0.09 – 0.21)
§ 0.27 (0.23 – 0.32) 
  
AA 4 (5.0) 2 (2.5) 0 (0.0) 18 (8.9)     
6 -1395A>C AA 13 (16.5) 12 (15.2) 25 (31.3) 37 (18.3) A 0.46 (0.38 – 0.54) 0.43 (0.35 – 0.51) 0.55 (0.47 – 0.63) 0.42 (0.37 – 0.46) 
 
(rs13112099) AC 47 (59.5) 44 (55.7) 38 (47.5) 94 (46.5) C 0.54 (0.46 – 0.62) 0.57 (0.49 – 0.65) 0.45 (0.37 – 0.53) 0.58 (0.54 – 0.63) 
  
CC 19 (24.1) 23 (29.1) 17 (21.3) 71 (35.1)     
7 -1137T>C TT 13 (16.5) 15 (18.8) 31 (38.8) 38 (18.8) T 0.41 (0.33 – 0.49) 0.45 (0.37 – 0.53) 0.61 (0.53 – 0.68) 0.43 (0.38 – 0.47) 
 
(rs9994887) TC 39 (49.4) 42 (52.5) 35 (43.8) 96 (47.5) C 0.59 (0.51 – 0.67) 0.55 (0.47 – 0.63)
‡ 0.39 (0.32 – 0.47)§ 0.57 (0.53 – 0.62) 
  
CC 27 (34.2) 23 (28.8) 14 (17.5) 68 (33.7)     
8 -818T>G TT 10 (12.5) 13 (16.3) 21 (26.3) 38 (18.8) T 0.45 (0.37 – 0.53) 0.44 (0.37 – 0.52) 0.54 (0.47 – 0.62) 0.43 (0.38 – 0.47) 
 
(rs1960773) TG 52 (65.0) 45 (56.3) 45 (56.3) 96 (47.5) G 0.55 (0.47 – 0.63) 0.56 (0.48 – 0.63) 0.46 (0.38 – 0.53) 0.57 (0.53 – 0.62) 
  
GG 18 (22.5) 22 (27.5) 14 (17.5) 68 (33.7)     
9 -772T>C TT 80 (100.0) 80 (100.0) 73 (91.3) 200 (99.0) T 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.96 (0.92 – 0.99) 1.00 (0.99 – 1.00) 
 
(rs34503711) TC 0 (0.0) 0 (0.0) 7 (8.8) 2 (1.0) C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)
‡ 0.04 (0.01 – 0.08)§ <0.01 (0.00 – 0.01) 
  
CC 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)     
10 -513T>C TT 79 (98.8) 75 (93.8) 63 (78.8) T 0.99 (0.98 – 1.01) 0.97 (0.94 – 1.00) 0.88 (0.83 – 0.93)  
 
(rs62317005) TC 1 (1.3) 5 (6.3) 15 (18.8) C 0.01 (-0.01 – 0.02) 0.03 (0.00 – 0.06)
‡ 0.12 (0.07 – 0.17)§  
    CC 0 (0.0) 0 (0.0) 2 (2.5)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.30 Genotypic and allelic profile of UGT2B15 (UCSC RefSeq: NM_001076) (Continued). 
SN Polymorphisms Genotype 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
11 -508G>A GG 10 (12.5) 13 (16.3) 21 (26.3) 38 (18.8) G 0.45 (0.37 – 0.53) 0.44 (0.37 – 0.52) 0.54 (0.47 – 0.62) 0.43 (0.38 – 0.47) 
 
(rs1120265) GA 52 (65.0) 45 (56.3) 45 (56.3) 96 (47.5) A 0.55 (0.47 – 0.63) 0.56 (0.48 – 0.63) 0.46 (0.38 – 0.53) 0.57 (0.53 – 0.62) 
  
AA 18 (22.5) 22 (27.5) 14 (17.5) 68 (33.7)     
12 -506T>A TT 10 (12.5) 13 (16.3) 21 (26.3) 38 (18.8) T 0.45 (0.37 – 0.53) 0.44 (0.37 – 0.52) 0.54 (0.47 – 0.62) 0.43 (0.38 – 0.47) 
 
(rs1580083) TA 52 (65.0) 45 (56.3) 45 (56.3) 96 (47.5) A 0.55 (0.47 – 0.63) 0.56 (0.48 – 0.63) 0.46 (0.38 – 0.53) 0.57 (0.53 – 0.62) 
  
AA 18 (22.5) 22 (27.5) 14 (17.5) 68 (33.7)     
13 -497C>T CC 40 (50.0) 46 (57.5) 58 (72.5) 109 (54.0) C 0.73 (0.66 – 0.79) 0.78 (0.72 – 0.85) 0.85 (0.79 – 0.91) 0.73 (0.69 – 0.77) 
 
(rs76571221) CT 36 (45.0) 33 (41.3) 20 (25.0) 77 (38.1) T 0.28 (0.21 – 0.34) 0.22 (0.15 – 0.28) 0.15 (0.09 – 0.21)§ 0.27 (0.23 – 0.31) 
  
TT 4 (5.0) 1 (1.3) 2 (2.5) 16 (7.9)     
14 -477A>G AA 53 (66.3) 64 (80.0) 62 (77.5) 137 (67.8) A 0.82 (0.76 – 0.88) 0.89 (0.85 – 0.94) 0.88 (0.83 – 0.93) 0.81 (0.78 – 0.85) 
 
(rs78497667) AG 25 (31.3) 15 (18.8) 17 (21.3) 55 (27.2) G 0.18 (0.12 – 0.24) 0.11 (0.06 – 0.15) 0.12 (0.07 – 0.17) 0.19 (0.15 – 0.22) 
  
GG 2 (2.5) 1 (1.3) 1 (1.3) 10 (5.0)     
15 -379C>G CC 80 (100.0) 79 (100.0) 79 (98.8) C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
 
(rs79960668) CG 0 (0.0) 0 (0.0) 1 (1.3) G 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  
GG 0 (0.0) 0 (0.0) 0 (0.0)     
16 -378C>T CC 39 (48.8) 41 (51.9) 42 (52.5)  C 
0.72 (0.65 – 0.79) 0.75 (0.68 – 0.81) 0.73 (0.66 – 0.80)  
 
(rs75187800) CT 37 (46.3) 36 (45.6) 33 (41.3)  T 
0.28 (0.21 – 0.35) 0.25 (0.19 – 0.32) 0.27 (0.20 – 0.34)  
  
TT 4 (5.0) 2 (2.5) 5 (6.3)  
    
17 -4C>G
#
 CC 80 (100.0) 80 (100.0) 78 (98.7) C 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  
CG 0 (0.0) 0 (0.0) 1 (1.3) G 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  
GG 0 (0.0) 0 (0.0) 0 (0.0)     
18 253G>T GG 20 (25.3) 23 (28.8) 15 (19.0) 68 (33.7) G 0.56 (0.49 – 0.64) 0.56 (0.48 – 0.63) 0.47 (0.40 – 0.55) 0.57 (0.53 – 0.62) 
 
(*2, rs1902023) GT 49 (62.0) 43 (53.8) 45 (57.0) 96 (47.5) T 0.44 (0.36 – 0.51) 0.44 (0.37 – 0.52) 0.53 (0.45 – 0.60) 0.43 (0.38 – 0.47) 
  
TT 10 (12.7) 14 (17.5) 19 (24.1) 38 (18.8)     
19 IVS2+56A>T AA 43 (53.8) 38 (48.1) 55 (68.8) 107 (53.0) A 0.74 (0.67 – 0.81) 0.70 (0.63 – 0.77) 0.83 (0.77 – 0.88) 0.71 (0.67 – 0.76) 
 
(rs2045100) AT 32 (40.0) 35 (44.3) 22 (27.5) 74 (36.6) T 0.26 (0.19 – 0.33) 0.30 (0.23 – 0.37) 0.18 (0.12 – 0.23) 0.29 (0.24 – 0.33) 
  
TT 5 (6.3) 6 (7.6) 3 (3.8) 21 (10.4)     
20 IVS2-95C>T CC 22 (27.5) 25 (31.6) 30 (38.0) 41 (20.3) C 0.49 (0.42 – 0.57) 0.60 (0.52 – 0.68) 0.65 (0.58 – 0.73) 0.48 (0.43 – 0.53) 
  
CT 35 (43.8) 45 (57.0) 43 (54.4) 112 (55.4) T 0.51 (0.43 – 0.58)
† 0.40 (0.32 – 0.48) 0.35 (0.27 – 0.42)§ 0.52 (0.47 – 0.57) 
    TT 23 (28.8) 9 (11.4) 6 (7.6) 49 (24.3)           
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.30 Genotypic and allelic profile of UGT2B15 (UCSC RefSeq: NM_001076) (Continued). 
SN Polymorphisms Genotype 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
21 IVS2-90C>G CC 42 (52.5) 39 (49.4) 58 (73.4) 107 (53.0) C 0.74 (0.68 – 0.81) 0.72 (0.64 – 0.79) 0.86 (0.81 – 0.91) 0.73 (0.68 – 0.77) 
  
CG 35 (43.8) 35 (44.3) 20 (25.3) 79 (39.1) G 0.26 (0.19 – 0.32) 0.28 (0.21 – 0.36)
‡ 0.14 (0.09 – 0.19)§ 0.27 (0.23 – 0.32) 
  
GG 3 (3.8) 5 (6.3) 1 (1.3) 16 (7.9)     
22 IVS2-54T>C
#
 TT 69 (86.3) 64 (81) 50 (64.1) 161 (79.7) T 0.93 (0.89 – 0.97) 0.91 (0.86 – 0.95) 0.82 (0.76 – 0.88) 0.90 (0.87 – 0.93) 
  
TC 11 (13.8) 15 (19.0) 28 (35.9) 41 (20.3) C 0.07 (0.03 – 0.11) 0.09 (0.05 – 0.14)
‡ 0.18 (0.12 – 0.24)§ 0.10 (0.07 – 0.13) 
  
CC 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)     
23 IVS2-33T>A
#
 TT 80 (100.0) 73 (92.4) 68 (87.2) 197 (97.5) T 1.00 (1.00 – 1.00) 0.94 (0.90 – 0.97) 0.93 (0.89 – 0.97) 0.99 (0.98 – 1.00) 
  
TA 0 (0.0) 2 (2.5) 9 (11.5) 5 (2.5) A 0.00 (0.00 – 0.00)
† 0.06 (0.03 – 0.10)‡ 0.07 (0.03 – 0.11)§ 0.01 (0.00 – 0.02) 
  
AA 0 (0.0) 4 (5.1) 1 (1.3) 0 (0.0)     
24 IVS3+129T>C TT 40 (50.0) 46 (58.2) 59 (74.7)  T 
0.73 (0.66 – 0.80) 0.78 (0.72 – 0.85) 0.87 (0.81 – 0.92)  
  
TC 37 (46.3) 32 (40.5) 19 (24.1)  C 
0.27 (0.20 – 0.34) 0.22 (0.15 – 0.28) 0.13 (0.08 – 0.19)§  
  
CC 3 (3.8) 1 (1.3) 1 (1.3)  
    
25 IVS3+132A>C
#
 AA 78 (97.5) 75 (94.9) 62 (78.5) A 0.99 (0.97 – 1.00) 0.97 (0.95 – 1.00) 0.89 (0.84 – 0.94)  
  
AC 2 (2.5) 4 (5.1) 16 (20.3) C 0.01 (0.00 – 0.03) 0.03 (0.00 – 0.05)
‡ 0.11 (0.06 – 0.16)§  
  
CC 0 (0.0) 0 (0.0) 1 (1.3)     
26 IVS3+135G>A GG 17 (21.3) 23 (29.1) 25 (31.6) 41 (20.3) G 0.49 (0.41 – 0.56) 0.60 (0.52 – 0.68) 0.63 (0.55 – 0.70) 0.48 (0.43 – 0.53) 
  
GA 44 (55.0) 49 (62.0) 49 (62.0) 111 (55.0) A 0.51 (0.44 – 0.59)† 0.40 (0.32 – 0.48) 0.37 (0.30 – 0.45)§ 0.52 (0.47 – 0.57) 
  
AA 19 (23.8) 7 (8.9) 5 (6.3) 50 (24.8)     
27 IVS4-207insT
#
 wt/wt 56 (70.0) 41 (51.3) 23 (29.1)  wt 0.84 (0.79 – 0.90) 0.73 (0.66 – 0.80) 0.51 (0.43 – 0.59)  
 
(rs34449264) wt/insT 23 (28.8) 35 (43.8) 35 (44.3)  insT 0.16 (0.10 – 0.21)
† 0.27 (0.20 – 0.34)‡ 0.49 (0.41 – 0.57)§  
  
inst/insT 1 (1.3) 4 (5.0) 21 (26.6)  
    
28 IVS5-793G>A
#
 GG 80 (100.0) 80 (100.0) 77 (100.0) G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00)  
  
GA 0 (0.0) 0 (0.0) 0 (0.0) A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00)  
  
AA 0 (0.0) 0 (0.0) 0 (0.0)  
29 IVS5-722A>G
#
 AA 77 (96.3) 80 (100.0) 76 (100.0) A 0.98 (0.96 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  
AG 3 (3.8) 0 (0.0) 0 (0.0) G 0.02 (0.00 – 0.04) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  
GG 0 (0.0) 0 (0.0) 0 (0.0)    
30 IVS5-416G>T
#
 GG 41 (51.3) 55 (69.6) 65 (85.5) G 0.73 (0.66 – 0.79) 0.84 (0.78 – 0.90) 0.92 (0.88 – 0.96) 
  
GT 34 (42.5) 23 (29.1) 10 (13.2) T 0.28 (0.21 – 0.34)† 0.16 (0.10 – 0.22) 0.08 (0.04 – 0.12)§ 
    TT 5 (6.3) 1 (1.3) 1 (1.3)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.30 Genotypic and allelic profile of UGT2B15 (UCSC RefSeq: NM_001076) (Continued). 
SN Polymorphisms Genotype 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
31 IVS5-344_345insA
#
 wt/wt 80 (100.0) 79 (100.0) 78 (97.5)   wt 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.97 – 1.00) 
  
wt/insT 0 (0.0) 0 (0.0) 2 (2.5)   insT 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (0.00 – 0.03) 
  
insT/insT 0 (0.0) 0 (0.0) 0 (0.0)       
32 IVS5-226G>A
#
 GG 74 (100.0) 80 (100.0) 76 (100.0)   G 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  
GA 0 (0.0) 0 (0.0) 0 (0.0)   A 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  
AA 0 (0.0) 0 (0.0) 0 (0.0)       
33 IVS5-150A>G
#
 AA 74 (98.7) 80 (100.0) 77 (100.0)   A 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  
AG 1 (1.3) 0 (0.0) 0 (0.0)   G 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  
GG 0 (0.0) 0 (0.0) 0 (0.0)       
34 IVS5-84A>G
#
 AA 76 (100.0) 80 (100.0) 77 (100.0)   A 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  
AG 0 (0.0) 0 (0.0) 0 (0.0)   G 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  
GG 0 (0.0) 0 (0.0) 0 (0.0)       
35 IVS5-46C>G
#
 CC 75 (98.7) 80 (100.0) 78 (100.0)   C 0.99 (0.98 – 1.01) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  
CG 1 (1.3) 0 (0.0) 0 (0.0)   G 0.01 (-0.01 – 0.02) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  
GG 0 (0.0) 0 (0.0) 0 (0.0)       
36 IVS5-14T>C TT 73 (93.6) 76 (95.0) 76 (98.7)   T 0.96 (0.93 – 0.99) 0.96 (0.93 – 0.99) 0.99 (0.98 – 1.01) 
 
(rs4148268) TC 4 (5.1) 2 (2.5) 1 (1.3)   C 0.04 (0.01 – 0.07) 0.04 (0.01 – 0.07) 0.01 (-0.01 – 0.02) 
  
CC 1 (1.3) 2 (2.5) 0 (0.0)        
37 1336T>C
#
 TT 78 (100.0) 80 (100.0) 76 (98.7)   T 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01)  
  
TC 0 (0.0) 0 (0.0) 1 (1.3)   C 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02)  
  
CC 0 (0.0) 0 (0.0) 0 (0.0)        
38 1553G>A
#
 GG 80 (100.0) 79 (98.8) 79 (98.8)   G 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.99 (0.98 – 1.01)  
  
GA 0 (0.0) 1 (1.3) 1 (1.3)   A 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.01 (-0.01 – 0.02)  
  
AA 0 (0.0) 0 (0.0) 0 (0.0)        
39 1568A>C AA 56 (70.0) 39 (48.8) 22 (27.5) 117 (58.2) A 0.84 (0.79 – 0.90) 0.71 (0.64 – 0.78) 0.49 (0.42 – 0.57) 0.77 (0.73 – 0.81) 
 
(*4, rs4148269) AC 23 (28.8) 36 (45.0) 35 (43.8) 75 (37.3) C 0.16 (0.10 – 0.21)† 0.29 (0.22 – 0.36)‡ 0.51 (0.43 – 0.58)§ 0.23 (0.19 – 0.27) 
  
CC 1 (1.3) 5 (6.3) 23 (28.8) 9 (4.5)      
40 *168C>T CC 56 (70.0) 39 (50.0) 25 (31.3) 116 (57.7) C 0.84 (0.79 – 0.90) 0.72 (0.65 – 0.79) 0.51 (0.43 – 0.58) 0.77 (0.72 – 0.81) 
 
(rs3100) CT 23 (28.8) 34 (43.6) 31 (38.8) 76 (37.8) T 0.16 (0.10 – 0.21) 0.28 (0.21 – 0.35)‡ 0.49 (0.42 – 0.57)§ 0.23 (0.19 – 0.28) 
    TT 1 (1.3) 5 (6.4) 24 (30.0) 9 (4.5)           
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.30 Genotypic and allelic profile of UGT2B15 (UCSC RefSeq: NM_001076) (Continued). 
SN Polymorphisms Genotype 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
41 *186A>T AA 40 (50.0) 54 (69.2) 65 (81.3) 107 (53.2) A 0.72 (0.65 – 0.79) 0.85 (0.79 – 0.90) 0.89 (0.85 – 0.94) 0.74 (0.69 – 0.78) 
 
(rs4148271) AT 35 (43.8) 24 (30.8) 13 (16.3) 82 (40.8) T 0.28 (0.21 – 0.35)
† 0.15 (0.10 – 0.21)‡ 0.11 (0.06 – 0.15)§ 0.26 (0.22 – 0.31) 
  
TT 5 (6.3) 0 (0.0) 2 (2.5) 12 (6.0)     
42 *220G>A
#
 GG 80 (100.0) 77 (98.7) 77 (96.3) G 1.00 (1.00 – 1.00) 0.99 (0.98 – 1.01) 0.98 (0.96 – 1.00)  
  
GA 0 (0.0) 1 (1.3) 3 (3.8) A 0.00 (0.00 – 0.00) 0.01 (-0.01 – 0.02) 0.02 (0.00 – 0.04)  
  
AA 0 (0.0) 0 (0.0) 0 (0.0)     
43 *228G>T GG 79 (98.8) 75 (97.4) 62 (77.5) G 0.99 (0.98 – 1.01) 0.99 (0.97 – 1.00) 0.87 (0.82 – 0.92) 
 
(rs35791822) GT 1 (1.3) 2 (2.6) 15 (18.8) T 0.01 (-0.01 – 0.02) 0.01 (0.00 – 0.03)
‡ 0.13 (0.08 – 0.18)§ 
  
TT 0 (0.0) 0 (0.0) 3 (3.8)    
44 *291A>T
#
 AA 80 (100.0) 77 (100.0) 80 (100.0) A 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
  
AT 0 (0.0) 0 (0.0) 0 (0.0) T 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
  
TT 0 (0.0) 0 (0.0) 0 (0.0)     
45 *317C>T CC 79 (98.8) 75 (97.4) 61 (76.3) C 0.99 (0.98 – 1.01) 0.99 (0.97 – 1.00) 0.86 (0.81 – 0.92)  
 
(rs34930215) CT 1 (1.3) 2 (2.6) 16 (20.0) T 0.01 (-0.01 – 0.02) 0.01 (0.00 – 0.03)
‡ 0.14 (0.08 – 0.19)§  
  
TT 0 (0.0) 0 (0.0) 3 (3.8)     
46 *+630C>G
#
 CC 57 (72.2) 40 (50.0) 29 (36.3) 120 (59.7) C 0.85 (0.80 – 0.91) 0.72 (0.65 – 0.79) 0.63 (0.56 – 0.71) 0.78  (0.74 – 0.82) 
  
CG 21 (26.6) 35 (43.8) 43 (53.8) 73 (36.3) G 0.15 (0.09 – 0.20)
† 0.28 (0.21 – 0.35) 0.37 (0.29 – 0.44)§ 0.22 (0.18 – 0.26) 
  
GG 1 (1.3) 5 (6.3) 8 (10.0) 8 (4.0)     
47 *+888A>G
#
 AA 20 (25.0) 22 (27.5) 15 (19.0) 48 (23.9) A 0.55 (0.47 – 0.63) 0.54 (0.47 – 0.62) 0.37 (0.30 – 0.45) 0.47 (0.42 – 0.52) 
  
AG 48 (60.0) 43 (53.8) 29 (36.7) 93 (46.3) G 0.45 (0.37 – 0.53) 0.46 (0.38 – 0.53)
‡ 0.63 (0.55 – 0.70)§ 0.53 (0.48 – 0.58) 
  
AA 12 (15.0) 15 (18.8) 35 (44.3) 60 (29.9)     
48 *+899G>A
#
 GG 41 (51.3) 57 (72.2) 65 (82.3) 108 (53.7) G 0.73 (0.66 – 0.79) 0.85 (0.80 – 0.91) 0.91 (0.86 – 0.95) 0.74 (0.70 – 0.78) 
  
GA 34 (42.5) 21 (26.6) 13 (16.5) 82 (40.8) A 0.28 (0.21 – 0.34)
† 0.15 (0.09 – 0.20)‡ 0.09 (0.05 – 0.14)§ 0.26 (0.22 – 0.30) 
  
AA 5 (6.3) 1 (1.3) 1 (1.3) 11 (5.5)     
49 *+1041G>T
#
 GG 14 (17.5) 15 (19.0) 33 (42.9) G 0.46 (0.39 – 0.54) 0.46 (0.38 – 0.53) 0.62 (0.54 – 0.69)  
  
GT 46 (57.5) 42 (53.2) 29 (37.7) T 0.54 (0.46 – 0.61) 0.54 (0.47 – 0.62)
‡ 0.38 (0.31 – 0.46)§  
    TT 20 (25.0) 22 (27.8) 15 (19.5)               
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 
§ denotes P < 0.05, Chinese vs Indians. 
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Table 3.30 Genotypic and allelic profile of UGT2B15 (UCSC RefSeq: NM_001076) (Continued). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
50 *+1067A>C
#
 AA 20 (26.0) 23 (25.0) 16 (21.1) A 0.55 (0.47 – 0.63) 0.53 (0.46 – 0.60) 0.38 (0.30 – 0.46) 
  
AC 45 (58.4) 51 (55.4) 26 (34.2) C 0.45 (0.37 – 0.53) 0.47 (0.40 – 0.54)
‡ 0.62 (0.54 – 0.70)§  
  
CC 12 (15.6) 18 (19.6) 34 (44.7)     
51 *+1350A>G
#
 AA 78 (97.5) 78 (97.5) 59 (75.6) 198 (98.5) A 0.99 (0.97 – 1.00) 0.99 (0.97 – 1.00) 0.86 (0.80 – 0.91) 0.99 (0.98 – 1.00) 
  
AG 2 (2.5) 2 (2.5) 16 (20.5) 3 (1.5) G 0.01 (0.00 – 0.03) 0.01 (0.00 – 0.03)
‡ 0.14 (0.09 – 0.20)§ 0.01 (0.00 – 0.02) 
    GG 0 (0.0) 0 (0.0) 3 (3.8) 0 (0.0)           
# denotes novel polymorphism. 
† denotes P < 0.05, Chinese vs Malays. 
‡ denotes P < 0.05, Malays vs Indians. 





3.4.3.2 LD Pattern of UGT2B15 
Pairwise LD analyses indicated (Fig 3.17A − C) almost complete LD between the 
SNPs located in the 3′ region of the gene across all three ethnic groups: 1568A>C 
(*4, rs4148269) and *168C>T (rs3100) (|D′| ≥ 0.97 and R2 ≥ 0.90); *+888A>G with 
*+1041G>T and *+1067A>C (|D′| ≥ 0.97 and R2 ≥ 0.90). Four polymorphisms located 
in the 5′ upstream region, -818T>G (rs1960773), -508G>A (*2, rs1902023), -506T>A 
(rs1580083) and 253G>T (*2, rs1902023) (|D′| ≥ 0.92 and R2 ≥ 0.85), were also 
observed to be in very tight linkage across all three healthy ethnic populations.   
In addition, IVS4-207insA (rs34449264) was found to be in high LD with 1568A>C 
(*4, rs4148269) and *168C>T (rs3100) across all ethnicities (|D′| ≥ 0.87 and R2 ≥ 
0.71). The functional variant, 253G>T (*2, rs1902023) was found to exhibit moderate 
linkage with promoter SNPs including, -1844C>T (rs7696472), -1577A>G 
(rs7686914), -1395A>C (rs13112099) and -1137T>C (rs9994887) (|D′| ≥ 0.88 and R2 
≥ 0.66). 
LD matrices revealed the presence of 3 blocks in each ethnic group (Fig 3.17A − C). 
Blocks 1 and 2 of the Chinese and Indian population as well as block 1 of the Malay 
population consisted of polymorphisms in the 5′ gene region as well as 253G>T (*2, 
rs1902023). Conversely, block 3 of Chinese and Indians as well as Malay blocks 2 
and 3 were made up of SNPs in the 3′ terminal of the gene. Interblock linkage was 
low between LD blocks at the 5′ and 3′ region (multiallelic |D′| for Chinese block 1 vs 
2: 0.94, Chinese block 2 vs 3: 0.35; Malay block 1 vs 2: 0.36, Malay block 2 vs 3: 
0.59; Indian block 1 vs 2: 0.86, Indian block 2 vs 3: 0.34). 
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Fig 3.17 LD matrix for UGT2B15 polymorphisms in (A) Chinese, (B) 
Malays, and (C) Indians. 
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3.4.3.3 Genetic Profile of UGT2B15 tag-SNPs in Asian Breast Cancer Patients 
Tag-SNPs representing polymorphisms along the gene were selected using the 
exhaustive search algorithm (TAGster program) with the selection criteria of R2 ≥ 
0.80 and MAF ≥ 0.05. A total of 15, 17 and 19 tag-SNPs were selected for Chinese, 
Malay and Indian healthy populations. Subsequently, 20 multi-population tag-SNPs [-
2310A>T (rs62298399), -1805T>C (rs62299491), -1409G>A (rs7682027), -1137T>C 
(rs9994887), -508G>A (rs1120265), -497C>T (rs76571221), -477A>G (rs78497667), 
253G>T (*2, rs1902023), IVS2+56A>T (rs2045100), IVS2-95C>T, IVS2-90C>G, 
IVS2-54T>C, IVS2-33T>A, IVS3+135G>A, 1568A>C (*4, rs4148269), *186A>T 
(rs4148271), *+630C>G, *+888A>G, *+899G>A, and *+1350A>G] representing the 
genetic profiles of all three ethnicities were selected via a two-stage exhaustive 
search process. These 20 tag-SNPs and six additional functional SNPs [-1844C>T 
(rs7696472), -1395A>C (rs13112099), -818T>G (rs1960773), -772T>C (rs34503711), 
-506T>A (rs1580083), and *168C>T (rs3100)] were genotyped in the patient cohort. 
The frequencies of these variants were not found to differ significantly from that of 
the healthy ethnic groups (Table 3.30).  
The LD matrix of these 26 SNPs revealed the presence of three LD blocks among 
the UGT2B15 tag-SNPs and functional polymorphisms. The largest block is LD block 
1 which includes 10 SNPs in the 5′ upstream region and 253G>T (*2, rs1902023) 
(Fig 3.18). The second block was consisted of three polymorphic variants in intron 2 
[IVS2+56A>T (rs2045100), IVS2-95C>T and IVS2-90C>G] while third block 
comprised of five polymorphisms including one exonic SNP and four SNPs in the 3′ 
gene region [1568A>C (*4, rs4148269), *168C>T (rs3100), *186A>T (rs4148271), 
*+630C>G and *+888A>G]. Inter-block linkage between blocks 1 and 2 was high with 
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multiallelic |D′| of 0.92 while low linkage between blocks 2 and 3 was observed 
(multiallelic |D′| = 0.34). 
 
Fig 3.18 LD matrix for UGT2B15 functional and tag-SNPs in Asian breast cancer 
patient patients (N=202). 
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3.4.3.4 Genotypic-phenotypic Associations of UGT2B15 tag-SNPs  
Genotypic-phenotypic associations between the polymorphisms and the phenotypes 
were examined in 25 polymorphic variants. With respect to -772T>C (rs34503711), 
no association analysis was carried out as only two heterozygous carrier of this 
polymorphism were observed. As UGT2B15 catalyses similar reactions as UGT2B7 
in tamoxifen biochemical pathway (118, 129), phenotypic parameters examined were 
similar to UGT2B7, namely the steady state plasma concentrations of (Z)-endoxifen, 
(E)-endoxifen, (Z)-4-OHT, the corresponding metabolites [(E)-NDM-4-O-Gluc, (Z)-
NDM-4-O-Gluc, (E)-Tam-4-O-Gluc, respectively] and metabolic ratios [MRE-NDM-4-O-
GLUC/Z-END, MRZ-NDM-4-O-GLUC/E-END, MRE-TAM-4-O-GLUC/Z-4-OHT, respectively] (Table 3.31). 
No significant associations between the individual UGT2B15 polymorphisms and the 
phenotypic parameters were observed. Subsequently, haplotypic association 
analysis was performed on the transformed-parameters using the haploGLM 
package. A total of three LD blocks were observed (Fig 3.18) and haplotypic 
associations within each block were performed. The haplotypes derived from LD 
blocks 1 and 2 were not significantly associated with variations in plasma 
concentrations of the analytes or the MRs (Tables 3.32 − 3.34). The haplotype-
specific GLM indicated associations between LD block 3 and variations in plasma 
concentrations of (E)-endoxifen and MRZ-NDM-4-O-GLUC/E-END among patients carrying 
the H3 haplotype compared to the wild-type H1 haplotype. The relationships 
remained significant even after adjustment of significant covariates previously 
identified via univariate analyses which included CYP2D6 genotype and 
chemotherapy status (Table 3.35). However, pairwise comparisons between the 
copy numbers of the H3 haplotype did not yield any significant correlations (Fig 3.19). 
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A near significant correlation between subjects carrying the LD Block 3 H3 haplotype 
and lower plasma concentration of (E)-Tam-4-O-Gluc was observed (P = 0.057, 
Table 3.34). However, the relationship became non-significant after adjustment for 
confounding covariates (CYP2D6 genotype and age). 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-2310A>T (rs62298399) AA (N=107) AT (N=75) TT (N=20) AA vs AT AA vs TT AT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.40 (4.27 – 49.93) 16.75 (2.06 – 52.84) 13.02 (6.33 – 50.26) 0.655 0.796 0.559 0.826 
       [-0.57 (-3.31 – 1.94)] [0.58 (-3.17 – 4.85)] [1.28 (-3.09 – 6.31)]  
(E)-Endoxifen 0.18 (0.03 – 6.64) 0.19 (0.03 – 2.91) 0.21 (0.03 – 0.35) 0.972 0.150 0.238 0.376 
       [0.00 (-0.03 – 0.03)] [-0.03 (-0.08 – 0.01)] [-0.03 (-0.09 – 0.02)]  
(Z)-4-OHT 2.77 (0.70 – 6.35) 2.68 (0.47 – 7.17) 2.34 (1.67 – 6.51) 0.876 0.354 0.708 0.747 
       [0.03 (-0.36 – 0.40)] [0.22 (-0.34 – 0.70)] [0.10 (-0.45 – 0.72)]  
(E)-NDM-4-O-Gluc 0.89 (0.16 – 19.22) 1.04 (0.07 – 29.78) 0.99 (0.40 – 3.76) 0.475 0.905 0.852 0.786 
       [-0.07 (-0.27 – 0.14)] [-0.03 (-0.32 – 0.24)] [0.05 (-0.27 – 0.39)]  
(Z)-NDM-4-O-Gluc 0.25 (0.05 – 1.71) 0.29 (0.04 – 1.81) 0.26 (0.08 – 0.81) 0.258 0.910 0.310 0.442 
       [-0.03 (-0.08 – 0.02)] [0.01 (-0.06 – 0.08)] [0.04 (-0.04 – 0.12)]  
(E)-Tam-4-O-Gluc 0.29 (0.05 – 5.73) 0.28 (0.07 – 8.14) 0.26 (0.12 – 0.88) 0.854 0.884 0.967 0.978 
       [0.01 (-0.05 – 0.06)] [0.01 (-0.08 – 0.10)] [0.00 (-0.09 – 0.10)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.92 (2.31 – 80.56) 6.19 (2.20 – 61.11) 6.44 (3.50 – 17.54) 0.499 0.447 0.763 0.664 
       [-0.29 (-1.15 – 0.57)] [-0.51 (-1.83 – 0.93)] [-0.27 (-1.53 – 1.20)]  
MRZ-NDM-4-O-GLUC/E-END 1.88 (0.04 – 35.41) 1.76 (0.09 – 22.60) 1.42 (0.49 – 9.46) 0.169 0.216 0.093 0.137 
       [-0.28 (-0.75 – 0.14)] [0.30 (-0.24 – 0.88)] [0.55 (-0.08 – 1.72)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.47 (4.05 – 155.86) 10.51 (4.77 – 174.19) 11.67 (4.52 – 25.57) 0.667 0.592 0.855 0.834 
       [-0.30 (-1.85 – 1.16)] [-0.66 (-3.08 – 2.01)] [-0.37 (-2.79 – 2.34)]  
-1844C>T (rs7696472) CC (N=39) CT (N=95) TT (N=68) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 14.41 (5.33 – 43.05) 15.71 (2.06 – 52.84) 16.30 (4.27 – 50.26) 0.338 0.821 0.484 0.598 
       [1.38 (-1.76 – 4.66)] [0.40 (-3.06 – 3.98)] [-0.96 (-3.68 – 1.73)]  
(E)-Endoxifen 0.19 (0.03 – 0.43) 0.18 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.477 0.848 0.311 0.554 
       [0.01 (-0.02 – 0.05)] [0.00 (-0.05 – 0.04)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.84 (1.63 – 6.35) 2.63 (0.47 – 7.17) 2.64 (0.70 – 6.51) 0.253 0.465 0.681 0.525 
       [0.24 (-0.19 – 0.70)] [0.15 (-0.29 – 0.62)] [-0.08 (-0.48 – 0.29)]  
(E)-NDM-4-O-Gluc 0.87 (0.18 – 19.22) 1.04 (0.07 – 29.78) 0.89 (0.16 – 4.44) 0.536 0.806 0.420 0.669 
       [-0.07 (-0.32 – 0.18)] [0.02 (-0.21 – 0.25)] [0.08 (-0.13 – 0.30)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-1844C>T (rs7696472) CC (N=39) CT (N=95) TT (N=68) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.26 (0.08 – 1.14) 0.28 (0.04 – 1.71) 0.26 (0.05 – 1.81) 0.965 0.801 0.625 0.896 
       [0.00 (-0.06 – 0.07)] [0.01 (-0.05 – 0.08)] [0.01 (-0.04 – 0.06)]  
(E)-Tam-4-O-Gluc 0.28 (0.09 – 5.73) 0.31 (0.05 – 8.14) 0.26 (0.05 – 1.50) 0.885 0.457 0.324 0.579 
       [-0.01 (-0.08 – 0.06)] [0.03 (-0.04 – 0.09)] [0.03 (-0.03 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.09 (2.53 – 80.56) 6.48 (2.20 – 61.11) 5.52 (2.56 – 22.18) 0.257 0.627 0.047 0.125 
       [-0.62 (-1.83 – 0.48)] [0.28 (-0.79 – 1.32)] [0.91 (0.02 – 1.92)]  
MRZ-NDM-4-O-GLUC/E-END 1.88 (0.64 – 15.57) 1.97 (0.04 – 35.41) 1.46 (0.09 – 21.57) 0.292 0.836 0.264 0.419 
       [-0.21 (-0.73 – 0.21)] [0.04 (-0.46 – 0.55)] [0.24 (-0.18 – 0.67)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 9.92 (5.39 – 155.86) 11.10 (4.05 – 174.19) 9.11 (4.39 – 45.51) 0.253 0.614 0.066 0.155 
       [-1.07 (-3.26 – 0.68)] [0.40 (-1.41 – 2.15)] [1.57 (-0.13 – 3.35)]  
-1805T>C (rs62299491) TT (N=197) TC + CC (N=5)     TT vs TC + CC       
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.40 (2.06 – 52.84) 25.48 (16.78 – 28.46)   0.061    
       [-8.28 (-15.41 – 0.54)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.28 (0.09 – 0.31)   0.490    
       [-0.06 (-0.12 – 0.09)]    
(Z)-4-OHT 2.66 (0.47 – 7.17) 4.19 (1.81 – 4.25)   0.347    
       [-0.51 (-1.82 – 0.64)]    
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 1.48 (1.04 – 2.11)   0.079    
       [-0.55 (-1.02 – 0.09)]    
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.81) 0.34 (0.27 – 0.39)   0.237    
       [-0.07 (-0.16 – 0.10)]    
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.31 (0.24 – 0.64)   0.478    
       [-0.05 (-0.18 – 0.14)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.14 (2.20 – 80.56) 6.48 (3.90 – 10.70)   0.874    
       [-0.20 (-2.97 – 2.78)]    
MRZ-NDM-4-O-GLUC/E-END 1.72 (0.04 – 35.41) 1.43 (1.07 – 3.25)   0.969    
       [0.01 (-1.09 – 2.02)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.51 (4.05 – 174.19) 13.24 (6.67 – 15.17)   0.874    
       [-0.29 (-5.32 – 5.17)]    
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-1409G>A (rs7682027) GG (N=109) GA (N=75) AA (N=18) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 16.18 (2.18 – 51.65) 15.91 (2.06 – 52.84) 10.63 (5.33 – 43.05) 0.947 0.201 0.228 0.426 
       [0.08 (-2.52 – 2.62)] [2.42 (-1.37 – 7.23)] [2.34 (-1.60 – 7.36)]  
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.19 (0.03 – 4.88) 0.17 (0.03 – 0.43) 0.520 0.400 0.571 0.616 
       [0.00 (-0.01 – 0.04)] [0.02 (-0.03 – 0.09)] [0.01 (-0.04 – 0.07)]  
(Z)-4-OHT 2.68 (0.47 – 7.17) 2.81 (1.00 – 6.80) 2.33 (1.63 – 6.35) 0.540 0.516 0.263 0.554 
       [-0.11 (-0.46 – 0.26)] [0.18 (-0.35 – 0.76)] [0.30 (-0.25 – 0.84)]  
(E)-NDM-4-O-Gluc 1.00 (0.16 – 5.90) 0.96 (0.07 – 29.78) 0.66 (0.18 – 19.22) 0.752 0.243 0.285 0.478 
       [0.03 (-0.17 – 0.23)] [0.17 (-0.12 – 0.51)] [0.16 (-0.14 – 0.47)]  
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.81) 0.28 (0.07 – 1.71) 0.21 (0.08 – 1.02) 0.813 0.376 0.431 0.663 
       [-0.01 (-0.06 – 0.04)] [0.04 (-0.05 – 0.11)] [0.03 (-0.05 – 0.12)]  
(E)-Tam-4-O-Gluc 0.28 (0.05 – 1.83) 0.28 (0.05 – 8.14) 0.27 (0.09 – 5.73) 0.845 0.801 0.641 0.917 
       [-0.01 (-0.06 – 0.05)] [0.01 (-0.08 – 0.11)] [0.02 (-0.08 – 0.11)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.19 (2.20 – 25.67) 5.89 (2.31 – 61.11) 6.52 (2.53 – 80.56) 0.825 0.874 0.606 0.919 
       [0.12 (-0.75 – 1.03)] [-0.14 (-1.89 – 1.41)] [-0.32 (-2.06 – 1.32)]  
MRZ-NDM-4-O-GLUC/E-END 1.48 (0.09 – 22.6) 2.01 (0.04 – 14.30) 1.74 (0.66 – 35.41) 0.344 0.917 0.497 0.600 
       [-0.20 (-0.60 – 0.20)] [-0.04 (-0.66 – 0.65)] [0.16 (-0.47 – 0.97)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.92 (4.39 – 45.51) 10.13 (4.05 – 174.19) 9.81 (5.39 – 155.86) 0.663 0.994 0.846 0.910 
       [0.37 (-1.18 – 1.91)] [0.01 (-2.45 – 2.84)] [-0.17 (-3.03 – 2.28)]  
-1395A>C (rs13112099) AA (N=37) AC (N=94) CC (N=71) AA vs AC AA vs CC AC vs CC 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 14.22 (5.33 – 43.05) 15.75 (2.06 – 52.84) 16.42 (4.27 – 50.26) 0.747 0.905 0.619 0.871 
       [0.52 (-2.72 – 3.68)] [-0.22 (-3.93 – 3.28)] [-0.68 (-3.48 – 2.01)]  
(E)-Endoxifen 0.19 (0.03 – 0.43) 0.18 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.696 0.747 0.335 0.633 
       [0.00 (-0.03 – 0.04)] [0.00 (-0.05 – 0.03)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.77 (1.50 – 6.35) 2.63 (0.47 – 7.17) 2.68 (0.70 – 6.51) 0.543 0.798 0.708 0.823 
       [0.13 (-0.32 – 0.60)] [0.05 (-0.39 – 0.51)] [-0.08 (-0.47 – 0.30)]  
(E)-NDM-4-O-Gluc 0.84 (0.18 – 19.22) 1.04 (0.07 – 29.78) 0.89 (0.16 – 5.64) 0.355 0.859 0.446 0.593 
       [-0.11 (-0.35 – 0.15)] [-0.02 (-0.26 – 0.22)] [0.08 (-0.13 – 0.29)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-1395A>C (rs13112099) AA (N=37) AC (N=94) CC (N=71) AA vs AC AA vs CC AC vs CC 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.25 (0.08 – 1.14) 0.28 (0.04 – 1.71) 0.26 (0.05 – 1.81) 0.940 0.961 0.779 0.973 
       [0.00 (-0.06 – 0.07)] [0.00 (-0.06 – 0.08)] [0.01 (-0.04 – 0.06)]  
(E)-Tam-4-O-Gluc 0.27 (0.09 – 5.73) 0.30 (0.05 – 8.14) 0.27 (0.05 – 1.50) 0.713 0.796 0.442 0.738 
       [-0.01 (-0.08 – 0.06)] [0.01 (-0.06 – 0.08)] [0.02 (-0.03 – 0.08)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.89 (2.53 – 80.56) 6.43 (2.20 – 61.11) 5.77 (2.56 – 23.68) 0.402 0.662 0.109 0.264 
       [-0.45 (-1.65 – 0.68)] [0.26 (-0.85 – 1.36)] [0.72 (-0.15 – 1.68)]  
MRZ-NDM-4-O-GLUC/E-END 1.92 (0.64 – 15.57) 1.90 (0.04 – 35.41) 1.47 (0.09 – 21.57) 0.705 0.643 0.429 0.701 
       [-0.07 (-0.58 – 0.40)] [0.11 (-0.40 – 0.63)] [0.18 (-0.24 – 0.59)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 9.92 (5.39 – 155.86) 10.93 (4.05 – 174.19) 9.19 (4.39 – 45.51) 0.314 0.705 0.150 0.299 
       [-0.86 (-3.00 – 0.88)] [0.33 (-1.66 – 2.08)] [1.28 (-0.45 – 2.99)]  
-1137T>C (rs9994887) TT (N=38) TC (N=96) CC (N=68) TT vs TC TT vs CC TC vs CC 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.16 (5.33 – 43.05) 15.56 (2.06 – 52.84) 16.30 (4.27 – 50.26) 0.300 0.757 0.463 0.549 
       [1.52 (-1.58 – 5.01)] [0.55 (-2.95 – 4.18)] [-0.99 (-3.73 – 1.69)]  
(E)-Endoxifen 0.19 (0.03 – 0.43) 0.18 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.442 0.892 0.301 0.530 
       [0.01 (-0.02 – 0.05)] [0.00 (-0.05 – 0.04)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.89 (1.63 – 6.35) 2.62 (0.47 – 7.17) 2.64 (0.70 – 6.51) 0.215 0.433 0.669 0.474 
       [0.27 (-0.17 – 0.74)] [0.16 (-0.28 – 0.66)] [-0.09 (-0.48 – 0.29)]  
(E)-NDM-4-O-Gluc 0.91 (0.18 – 19.22) 1.04 (0.07 – 29.78) 0.89 (0.16 – 4.44) 0.604 0.772 0.436 0.701 
       [-0.06 (-0.30 – 0.19)] [0.03 (-0.21 – 0.27)] [0.08 (-0.13 – 0.29)]  
(Z)-NDM-4-O-Gluc 0.27 (0.08 – 1.14) 0.28 (0.04 – 1.71) 0.26 (0.05 – 1.81) 0.803 0.678 0.686 0.878 
       [0.01 (-0.06 – 0.08)] [0.02 (-0.05 – 0.09)] [0.01 (-0.04 – 0.06)]  
(E)-Tam-4-O-Gluc 0.29 (0.09 – 5.73) 0.30 (0.05 – 8.14) 0.26 (0.05 – 1.50) 0.933 0.443 0.331 0.582 
       [0.00 (-0.07 – 0.07)] [0.03 (-0.04 – 0.10)] [0.03 (-0.03 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.91 (2.53 – 80.56) 6.47 (2.20 – 61.11) 5.52 (2.56 – 22.18) 0.258 0.649 0.047 0.125 
       [-0.62 (-1.85 – 0.48)] [0.27 (-0.81 – 1.32)] [0.91 (0.02 – 1.92)]  
MRZ-NDM-4-O-GLUC/E-END 1.90 (0.64 – 15.57) 1.96 (0.04 – 35.41) 1.46 (0.09 – 21.57) 0.414 0.737 0.297 0.505 
       [-0.16 (-0.68 – 0.28)] [0.08 (-0.43 – 0.58)] [0.23 (-0.19 – 0.65)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 9.86 (5.39 – 155.86) 11.01 (4.05 – 174.19) 9.11 (4.39 – 45.51) 0.244 0.631 0.066 0.152 
       [-1.11 (-3.26 – 0.68)] [0.39 (-1.45 – 2.15)] [1.57 (-0.13 – 3.34)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-818T>G (rs1960773) TT (N=38) TG (N=96) GG (N=68) TT vs TG TT vs GG TG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.16 (5.33 – 43.05) 15.56 (2.06 – 52.84) 16.30 (4.27 – 50.26) 0.300 0.757 0.463 0.549 
       [1.52 (-1.58 – 5.01)] [0.55 (-2.95 – 4.18)] [-0.99 (-3.73 – 1.69)]  
(E)-Endoxifen 0.19 (0.03 – 0.43) 0.18 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.442 0.892 0.301 0.530 
       [0.01 (-0.02 – 0.05)] [0.00 (-0.05 – 0.04)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.89 (1.63 – 6.35) 2.62 (0.47 – 7.17) 2.64 (0.70 – 6.51) 0.215 0.433 0.669 0.474 
       [0.27 (-0.17 – 0.74)] [0.16 (-0.28 – 0.66)] [-0.09 (-0.48 – 0.29)]  
(E)-NDM-4-O-Gluc 0.91 (0.18 – 19.22) 1.04 (0.07 – 29.78) 0.89 (0.16 – 4.44) 0.604 0.772 0.436 0.701 
       [-0.06 (-0.30 – 0.19)] [0.03 (-0.21 – 0.27)] [0.08 (-0.13 – 0.29)]  
(Z)-NDM-4-O-Gluc 0.27 (0.08 – 1.14) 0.28 (0.04 – 1.71) 0.26 (0.05 – 1.81) 0.803 0.678 0.686 0.878 
       [0.01 (-0.06 – 0.08)] [0.02 (-0.05 – 0.09)] [0.01 (-0.04 – 0.06)]  
(E)-Tam-4-O-Gluc 0.29 (0.09 – 5.73) 0.30 (0.05 – 8.14) 0.26 (0.05 – 1.50) 0.933 0.443 0.331 0.582 
       [0.00 (-0.07 – 0.07)] [0.03 (-0.04 – 0.10)] [0.03 (-0.03 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.91 (2.53 – 80.56) 6.47 (2.20 – 61.11) 5.52 (2.56 – 22.18) 0.258 0.649 0.047 0.125 
       [-0.62 (-1.85 – 0.48)] [0.27 (-0.81 – 1.32)] [0.91 (0.02 – 1.92)]  
MRZ-NDM-4-O-GLUC/E-END 1.90 (0.64 – 15.57) 1.96 (0.04 – 35.41) 1.46 (0.09 – 21.57) 0.414 0.737 0.297 0.505 
       [-0.16 (-0.68 – 0.28)] [0.08 (-0.43 – 0.58)] [0.23 (-0.19 – 0.65)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 9.86 (5.39 – 155.86) 11.01 (4.05 – 174.19) 9.11 (4.39 – 45.51) 0.244 0.631 0.066 0.152 
       [-1.11 (-3.26 – 0.68)] [0.39 (-1.45 – 2.15)] [1.57 (-0.13 – 3.34)]  
-772T>C (rs34503711) TT (N=200) TC (N=2)             
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.75 (2.06 – 52.84) 15.68 (9.28 – 22.08)       
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.26 (0.21 – 0.30)       
(Z)-4-OHT 2.67 (0.47 – 7.17) 2.49 (1.67 – 3.31)       
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 1.30 (0.40 – 2.21)       
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.81) 0.55 (0.10 – 0.99)       
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.29 (0.12 – 0.47)       
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.15 (2.20 – 80.56) 7.16 (4.32 – 10.00)       
MRZ-NDM-4-O-GLUC/E-END 1.70 (0.04 – 35.41) 1.89 (0.49 – 3.30)       
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.52 (4.05 – 174.19) 10.68 (7.24 – 14.11)       




Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-508G>A (rs1120265) GG (N=38) GA (N=96) AA (N=68) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.16 (5.33 – 43.05) 15.56 (2.06 – 52.84) 16.30 (4.27 – 50.26) 0.300 0.757 0.463 0.549 
       [1.52 (-1.58 – 5.01)] [0.55 (-2.95 – 4.18)] [-0.99 (-3.73 – 1.69)]  
(E)-Endoxifen 0.19 (0.03 – 0.43) 0.18 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.442 0.892 0.301 0.530 
       [0.01 (-0.02 – 0.05)] [0.00 (-0.05 – 0.04)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.89 (1.63 – 6.35) 2.62 (0.47 – 7.17) 2.64 (0.70 – 6.51) 0.215 0.433 0.669 0.474 
       [0.27 (-0.17 – 0.74)] [0.16 (-0.28 – 0.66)] [-0.09 (-0.48 – 0.29)]  
(E)-NDM-4-O-Gluc 0.91 (0.18 – 19.22) 1.04 (0.07 – 29.78) 0.89 (0.16 – 4.44) 0.604 0.772 0.436 0.701 
       [-0.06 (-0.30 – 0.19)] [0.03 (-0.21 – 0.27)] [0.08 (-0.13 – 0.29)]  
(Z)-NDM-4-O-Gluc 0.27 (0.08 – 1.14) 0.28 (0.04 – 1.71) 0.26 (0.05 – 1.81) 0.803 0.678 0.686 0.878 
       [0.01 (-0.06 – 0.08)] [0.02 (-0.05 – 0.09)] [0.01 (-0.04 – 0.06)]  
(E)-Tam-4-O-Gluc 0.29 (0.09 – 5.73) 0.30 (0.05 – 8.14) 0.26 (0.05 – 1.50) 0.933 0.443 0.331 0.582 
       [0.00 (-0.07 – 0.07)] [0.03 (-0.04 – 0.10)] [0.03 (-0.03 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.91 (2.53 – 80.56) 6.47 (2.20 – 61.11) 5.52 (2.56 – 22.18) 0.258 0.649 0.047 0.125 
       [-0.62 (-1.85 – 0.48)] [0.27 (-0.81 – 1.32)] [0.91 (0.02 – 1.92)]  
MRZ-NDM-4-O-GLUC/E-END 1.90 (0.64 – 15.57) 1.96 (0.04 – 35.41) 1.46 (0.09 – 21.57) 0.414 0.737 0.297 0.505 
       [-0.16 (-0.68 – 0.28)] [0.08 (-0.43 – 0.58)] [0.23 (-0.19 – 0.65)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 9.86 (5.39 – 155.86) 11.01 (4.05 – 174.19) 9.11 (4.39 – 45.51) 0.244 0.631 0.066 0.152 
       [-1.11 (-3.26 – 0.68)] [0.39 (-1.45 – 2.15)] [1.57 (-0.13 – 3.34)]  
-506T>A (rs1580083) TT (N=38) TA (N=96) AA (N=68) TT vs TA TT vs AA TA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.16 (5.33 – 43.05) 15.56 (2.06 – 52.84) 16.30 (4.27 – 50.26) 0.300 0.757 0.463 0.549 
       [1.52 (-1.58 – 5.01)] [0.55 (-2.95 – 4.18)] [-0.99 (-3.73 – 1.69)]  
(E)-Endoxifen 0.19 (0.03 – 0.43) 0.18 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.442 0.892 0.301 0.530 
       [0.01 (-0.02 – 0.05)] [0.00 (-0.05 – 0.04)] [-0.01 (-0.05 – 0.01)]  
(Z)-4-OHT 2.89 (1.63 – 6.35) 2.62 (0.47 – 7.17) 2.64 (0.70 – 6.51) 0.215 0.433 0.669 0.474 
       [0.27 (-0.17 – 0.74)] [0.16 (-0.28 – 0.66)] [-0.09 (-0.48 – 0.29)]  
(E)-NDM-4-O-Gluc 0.91 (0.18 – 19.22) 1.04 (0.07 – 29.78) 0.89 (0.16 – 4.44) 0.604 0.772 0.436 0.701 
       [-0.06 (-0.30 – 0.19)] [0.03 (-0.21 – 0.27)] [0.08 (-0.13 – 0.29)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
 321
 
Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-506T>A (rs1580083) TT (N=38) TA (N=96) AA (N=68) TT vs TA TT vs AA TA vs AA 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.27 (0.08 – 1.14) 0.28 (0.04 – 1.71) 0.26 (0.05 – 1.81) 0.803 0.678 0.686 0.878 
       [0.01 (-0.06 – 0.08)] [0.02 (-0.05 – 0.09)] [0.01 (-0.04 – 0.06)]  
(E)-Tam-4-O-Gluc 0.29 (0.09 – 5.73) 0.30 (0.05 – 8.14) 0.26 (0.05 – 1.50) 0.933 0.443 0.331 0.582 
       [0.00 (-0.07 – 0.07)] [0.03 (-0.04 – 0.10)] [0.03 (-0.03 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.91 (2.53 – 80.56) 6.47 (2.20 – 61.11) 5.52 (2.56 – 22.18) 0.258 0.649 0.047 0.125 
       [-0.62 (-1.85 – 0.48)] [0.27 (-0.81 – 1.32)] [0.91 (0.02 – 1.92)]  
MRZ-NDM-4-O-GLUC/E-END 1.90 (0.64 – 15.57) 1.96 (0.04 – 35.41) 1.46 (0.09 – 21.57) 0.414 0.737 0.297 0.505 
       [-0.16 (-0.68 – 0.28)] [0.08 (-0.43 – 0.58)] [0.23 (-0.19 – 0.65)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 9.86 (5.39 – 155.86) 11.01 (4.05 – 174.19) 9.11 (4.39 – 45.51) 0.244 0.631 0.066 0.152 
       [-1.11 (-3.26 – 0.68)] [0.39 (-1.45 – 2.15)] [1.57 (-0.13 – 3.34)]  
-497C>T (rs76571221) CC (N=109) CT (N=77) TT (N=16) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.61 (4.27 – 49.93) 16.69 (2.06 – 52.84) 13.02 (6.33 – 50.26) 0.887 0.790 0.676 0.932 
       [-0.17 (-2.80 – 2.29)] [0.59 (-4.02 – 5.49)] [1.06 (-4.09 – 6.32)]  
(E)-Endoxifen 0.18 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.23 (0.03 – 0.35) 0.936 0.119 0.195 0.319 
       [0.00 (-0.03 – 0.03)] [-0.04 (-0.10 – 0.00)] [-0.03 (-0.11 – 0.01)]  
(Z)-4-OHT 2.77 (0.70 – 6.35) 2.60 (0.47 – 7.17) 2.51 (1.76 – 6.51) 0.448 0.756 0.706 0.727 
       [0.14 (-0.24 – 0.48)] [0.10 (-0.66 – 0.60)] [-0.13 (-0.76 – 0.56)]  
(E)-NDM-4-O-Gluc 0.90 (0.16 – 19.22) 1.02 (0.07 – 29.78) 0.99 (0.47 – 3.76) 0.654 0.859 0.980 0.904 
       [-0.04 (-0.24 – 0.16)] [-0.03 (-0.34 – 0.25)] [-0.01 (-0.32 – 0.37)]  
(Z)-NDM-4-O-Gluc 0.25 (0.05 – 1.71) 0.28 (0.04 – 1.81) 0.24 (0.08 – 0.81) 0.346 0.906 0.416 0.570 
       [-0.02 (-0.08 – 0.03)] [0.01 (-0.07 – 0.09)] [0.03 (-0.05 – 0.12)]  
(E)-Tam-4-O-Gluc 0.30 (0.05 – 5.73) 0.27 (0.07 – 8.14) 0.29 (0.14 – 0.88) 0.616 0.717 0.515 0.775 
       [0.01 (-0.04 – 0.07)] [-0.02 (-0.13 – 0.08)] [-0.03 (-0.15 – 0.07)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.77 (2.31 – 80.56) 6.25 (2.20 – 61.11) 6.87 (3.50 – 17.54) 0.503 0.387 0.611 0.607 
       [-0.29 (-1.11 – 0.55)] [-0.67 (-2.18 – 0.95)] [-0.44 (-1.98 – 1.20)]  
MRZ-NDM-4-O-GLUC/E-END 1.88 (0.04 – 35.41) 1.72 (0.09 – 22.6) 1.41 (0.55 – 9.46) 0.310 0.226 0.167 0.258 
       [-0.21 (-0.66 – 0.20)] [0.29 (-0.25 – 0.98)] [0.47 (-0.15 – 1.72)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.47 (4.05 – 155.86) 10.51 (4.77 – 174.19) 11.67 (4.52 – 25.57) 0.633 0.460 0.691 0.733 
       [-0.35 (-1.90 – 1.12)] [-1.04 (-3.73 – 2.06)] [-0.63 (-3.40 – 2.31)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
-477A>G (rs78497667) AA (N=137) AG (N=55) GG (N=10) AA vs AG AA vs GG AG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.71 (2.18 – 52.84) 16.42 (2.06 – 50.26) 13.02 (6.33 – 42.23) 0.738 0.908 0.730 0.926 
       [-0.43 (-3.17 – 2.28)] [0.38 (-5.89 – 7.26)] [0.97 (-5.46 – 7.50)]  
(E)-Endoxifen 0.19 (0.03 – 4.88) 0.19 (0.03 – 6.64) 0.21 (0.03 – 0.33) 0.852 0.408 0.594 0.734 
       [0.00 (-0.04 – 0.03)] [-0.02 (-0.10 – 0.04)] [-0.01 (-0.12 – 0.06)]  
(Z)-4-OHT 2.76 (0.47 – 7.13) 2.45 (1.11 – 7.17) 2.64 (1.76 – 5.87) 0.442 0.969 0.611 0.725 
       [0.15 (-0.26 – 0.51)] [-0.02 (-1.17 – 0.68)] [-0.18 (-1.20 – 0.58)]  
(E)-NDM-4-O-Gluc 0.95 (0.16 – 19.22) 0.97 (0.07 – 29.78) 1.05 (0.49 – 2.05) 0.945 0.561 0.513 0.823 
       [0.01 (-0.21 – 0.22)] [-0.13 (-0.48 – 0.28)] [-0.13 (-0.53 – 0.36)]  
(Z)-NDM-4-O-Gluc 0.26 (0.05 – 1.71) 0.28 (0.04 – 1.81) 0.26 (0.21 – 0.61) 0.612 0.788 0.796 0.860 
       [-0.01 (-0.07 – 0.04)] [-0.01 (-0.08 – 0.09)] [0.01 (-0.07 – 0.11)]  
(E)-Tam-4-O-Gluc 0.30 (0.05 – 5.73) 0.25 (0.07 – 8.14) 0.36 (0.14 – 0.82) 0.332 0.444 0.230 0.409 
       [0.03 (-0.03 – 0.08)] [-0.04 (-0.18 – 0.09)] [-0.07 (-0.21 – 0.06)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.14 (2.31 – 80.56) 6.09 (2.20 – 61.11) 7.65 (3.50 – 17.54) 0.695 0.352 0.167 0.502 
       [0.18 (-0.68 – 1.11)] [-0.99 (-2.98 – 1.19)] [-1.28 (-3.07 – 0.57)]  
MRZ-NDM-4-O-GLUC/E-END 1.77 (0.04 – 35.41) 1.66 (0.09 – 22.60) 1.44 (0.63 – 9.46) 0.312 0.644 0.460 0.522 
       [-0.23 (-0.65 – 0.24)] [0.16 (-0.63 – 1.08)] [0.33 (-0.47 – 1.77)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.76 (4.05 – 155.86) 9.78 (4.77 – 174.19) 12.43 (4.52 – 25.57) 0.649 0.415 0.283 0.590 
       [0.33 (-1.25 – 1.90)] [-1.46 (-5.26 – 2.59)] [-1.99 (-5.92 – 1.72)]  
253G>T (*2, rs1902023) GG (N=68) GT (N=96) TT (N=38) GG vs GT GG vs TT GT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 16.30 (4.27 – 50.26) 15.56 (2.06 – 52.84) 15.16 (5.33 – 43.05) 0.463 0.757 0.300 0.549 
       [0.99 (-1.69 – 3.73)] [-0.55 (-4.18 – 2.95)] [-1.52 (-5.01 – 1.58)]  
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.18 (0.03 – 4.88) 0.19 (0.03 – 0.43) 0.301 0.892 0.442 0.530 
       [0.01 (-0.01 – 0.05)] [0.00 (-0.04 – 0.05)] [-0.01 (-0.05 – 0.02)]  
(Z)-4-OHT 2.64 (0.70 – 6.51) 2.62 (0.47 – 7.17) 2.89 (1.63 – 6.35) 0.669 0.433 0.215 0.474 
       [0.09 (-0.29 – 0.48)] [-0.16 (-0.66 – 0.28)] [-0.27 (-0.74 – 0.17)]  
(E)-NDM-4-O-Gluc 0.89 (0.16 – 4.44) 1.04 (0.07 – 29.78) 0.91 (0.18 – 19.22) 0.436 0.772 0.604 0.701 
       [-0.08 (-0.29 – 0.13)] [-0.03 (-0.27 – 0.21)] [0.06 (-0.19 – 0.30)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
253G>T (*2, rs1902023) GG (N=68) GT (N=96) TT (N=38) GG vs GT GG vs TT GT vs TT 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.26 (0.05 – 1.81) 0.28 (0.04 – 1.71) 0.27 (0.08 – 1.14) 0.686 0.678 0.803 0.878 
       [-0.01 (-0.06 – 0.04)] [-0.02 (-0.09 – 0.05)] [-0.01 (-0.08 – 0.06)]  
(E)-Tam-4-O-Gluc 0.26 (0.05 – 1.50) 0.30 (0.05 – 8.14) 0.29 (0.09 – 5.73) 0.331 0.443 0.933 0.582 
       [-0.03 (-0.09 – 0.03)] [-0.03 (-0.10 – 0.04)] [0.00 (-0.07 – 0.07)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.52 (2.56 – 22.18) 6.47 (2.20 – 61.11) 5.91 (2.53 – 80.56) 0.047 0.649 0.258 0.125 
       [-0.91 (-1.92 – -0.02)] [-0.27 (-1.32 – 0.81)] [0.62 (-0.48 – 1.85)]  
MRZ-NDM-4-O-GLUC/E-END 1.46 (0.09 – 21.57) 1.96 (0.04 – 35.41) 1.90 (0.64 – 15.57) 0.297 0.737 0.414 0.505 
       [-0.23 (-0.65 – 0.19)] [-0.08 (-0.58 – 0.43)] [0.16 (-0.28 – 0.68)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 9.11 (4.39 – 45.51) 11.01 (4.05 – 174.19) 9.86 (5.39 – 155.86) 0.066 0.631 0.244 0.152 
       [-1.57 (-3.34 – 0.13)] [-0.39 (-2.15 – 1.45)] [1.11 (-0.68 – 3.26)]  
IVS2+56A>T (rs2045100) AA (N=107) AT (N=74) TT (N=21) AA vs AT AA vs TT AT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.80 (2.06 – 52.84) 15.00 (4.54 – 35.33) 16.18 (4.27 – 49.93) 0.239 0.870 0.319 0.422 
       [1.37 (-0.96 – 4.11)] [-0.46 (-5.60 – 4.13)] [-2.24 (-7.09 – 2.53)]  
(E)-Endoxifen 0.20 (0.03 – 0.45) 0.17 (0.03 – 6.64) 0.19 (0.03 – 0.45) 0.068 0.982 0.302 0.176 
       [0.02 (0.00 – 0.06)] [0.00 (-0.06 – 0.06)] [-0.02 (-0.10 – 0.02)]  
(Z)-4-OHT 2.76 (0.47 – 7.17) 2.59 (1.00 – 5.14) 3.54 (0.70 – 6.20) 0.450 0.895 0.404 0.658 
       [0.14 (-0.21 – 0.51)] [-0.07 (-0.72 – 0.65)] [-0.24 (-1.03 – 0.34)]  
(E)-NDM-4-O-Gluc 1.04 (0.07 – 29.78) 0.90 (0.17 – 18.42) 0.69 (0.16 – 3.80) 0.337 0.333 0.603 0.463 
       [0.10 (-0.10 – 0.29)] [0.18 (-0.18 – 0.48)] [0.08 (-0.28 – 0.39)]  
(Z)-NDM-4-O-Gluc 0.28 (0.04 – 1.37) 0.25 (0.06 – 1.81) 0.24 (0.05 – 0.71) 0.406 0.360 0.430 0.496 
       [0.02 (-0.03 – 0.07)] [0.04 (-0.04 – 0.12)] [0.03 (-0.06 – 0.10)]  
(E)-Tam-4-O-Gluc 0.29 (0.07 – 8.14) 0.29 (0.05 – 4.70) 0.27 (0.05 – 1.09) 0.760 0.228 0.298 0.468 
       [0.01 (-0.05 – 0.06)] [0.05 (-0.04 – 0.15)] [0.05 (-0.05 – 0.15)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.39 (2.20 – 80.56) 6.05 (2.31 – 52.14) 4.14 (2.56 – 16.65) 0.622 0.017 0.060 0.064 
       [0.21 (-0.75 – 1.10)] [1.45 (0.28 – 2.69)] [1.08 (-0.07 – 2.69)]  
MRZ-NDM-4-O-GLUC/E-END 1.63 (0.38 – 22.60) 1.98 (0.04 – 35.41) 1.48 (0.36 – 9.35) 0.290 0.392 0.149 0.292 
       [-0.22 (-0.65 – 0.20)] [0.24 (-0.29 – 0.83)] [0.46 (-0.19 – 1.43)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.81 (4.52 – 174.19) 10.75 (4.05 – 106.92) 7.77 (4.39 – 24.86) 0.766 0.031 0.110 0.122 
       [0.21 (-1.49 – 1.85)] [2.17 (0.18 – 4.34)] [1.80 (-0.40 – 5.06)]  




Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS2-95C>T CC (N=41) CT (N=112) TT (N=49) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 18.73 (4.27 – 49.93) 14.51 (2.18 – 51.65) 14.37 (2.06 – 52.84) 0.237 0.590 0.763 0.535 
       [1.94 (-1.25 – 5.38)] [1.37 (-3.28 – 5.50)] [-0.49 (-3.78 – 2.32)]  
(E)-Endoxifen 0.19 (0.03 – 0.45) 0.18 (0.03 – 6.64) 0.21 (0.03 – 0.43) 0.751 0.699 0.331 0.640 
       [0.00 (-0.03 – 0.05)] [0.00 (-0.06 – 0.04)] [-0.01 (-0.06 – 0.01)]  
(Z)-4-OHT 3.30 (0.70 – 6.20) 2.57 (0.47 – 7.17) 2.76 (1.11 – 6.80) 0.365 0.874 0.780 0.720 
       [0.22 (-0.26 – 0.70)] [0.06 (-0.53 – 0.61)] [-0.06 (-0.52 – 0.34)]  
(E)-NDM-4-O-Gluc 0.90 (0.16 – 5.64) 0.95 (0.19 – 18.42) 0.99 (0.07 – 29.78) 0.589 0.694 0.784 0.842 
       [0.07 (-0.19 – 0.34)] [0.06 (-0.25 – 0.38)] [-0.03 (-0.23 – 0.19)]  
(Z)-NDM-4-O-Gluc 0.26 (0.05 – 1.46) 0.26 (0.04 – 1.81) 0.27 (0.08 – 1.22) 0.947 0.947 0.994 0.999 
       [0.00 (-0.06 – 0.06)] [0.00 (-0.07 – 0.07)] [0.00 (-0.05 – 0.06)]  
(E)-Tam-4-O-Gluc 0.33 (0.05 – 1.28) 0.27 (0.05 – 4.70) 0.29 (0.07 – 8.14) 0.858 0.952 0.821 0.968 
       [0.01 (-0.06 – 0.08)] [0.00 (-0.08 – 0.09)] [-0.01 (-0.07 – 0.06)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.77 (2.56 – 25.67) 6.19 (2.20 – 52.14) 6.30 (3.27 – 80.56) 0.348 0.425 0.968 0.620 
       [-0.48 (-1.54 – 0.55)] [-0.54 (-1.63 – 0.59)] [-0.02 (-0.94 – 1.03)]  
MRZ-NDM-4-O-GLUC/E-END 1.95 (0.36 – 15.57) 1.62 (0.04 – 35.41) 1.76 (0.63 – 12.08) 0.984 0.947 0.917 0.995 
       [-0.01 (-0.48 – 0.49)] [0.01 (-0.55 – 0.56)] [0.02 (-0.44 – 0.44)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.47 (4.39 – 37.05) 11.00 (4.05 – 106.92) 9.92 (4.52 – 174.19) 0.561 0.694 0.968 0.850 
       [-0.54 (-2.50 – 1.32)] [-0.39 (-2.35 – 1.57)] [0.04 (-1.54 – 1.96)]  
IVS2-90C>G CC (N=107) CG (N=79) GG (N=16) CC vs CG CC vs GG CG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.80 (2.06 – 52.84) 14.60 (4.27 – 35.33) 23.16 (5.22 – 49.93) 0.150 0.391 0.067 0.140 
       [1.65 (-0.64 – 4.32)] [-2.36 (-9.26 – 3.08)] [-4.76 (-11.45 – 0.49)]  
(E)-Endoxifen 0.20 (0.03 – 0.45) 0.17 (0.03 – 6.64) 0.20 (0.03 – 0.45) 0.059 0.731 0.240 0.136 
       [0.02 (0.00 – 0.06)] [0.00 (-0.08 – 0.06)] [-0.03 (-0.12 – 0.02)]  
(Z)-4-OHT 2.76 (0.47 – 7.17) 2.54 (1.00 – 5.14) 3.63 (0.70 – 6.20) 0.333 0.340 0.049 0.203 
       [0.17 (-0.17 – 0.55)] [-0.43 (-1.35 – 0.46)] [-0.87 (-1.45 – 0.00)]  
(E)-NDM-4-O-Gluc 1.04 (0.07 – 29.78) 0.86 (0.16 – 18.42) 0.79 (0.21 – 3.8) 0.214 0.851 0.728 0.473 
       [0.12 (-0.07 – 0.30)] [0.03 (-0.49 – 0.44)] [-0.05 (-0.59 – 0.29)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS2-90C>G CC (N=107) CG (N=79) GG (N=16) CC vs CG CC vs GG CG vs GG 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.28 (0.04 – 1.37) 0.25 (0.05 – 1.81) 0.22 (0.07 – 0.71) 0.316 0.638 0.676 0.583 
       [0.03 (-0.02 – 0.07)] [0.02 (-0.08 – 0.12)] [0.02 (-0.10 – 0.10)]  
(E)-Tam-4-O-Gluc 0.29 (0.07 – 8.14) 0.27 (0.05 – 4.70) 0.31 (0.05 – 1.09) 0.559 0.798 0.968 0.839 
       [0.02 (-0.04 – 0.07)] [0.02 (-0.10 – 0.13)] [0.00 (-0.12 – 0.12)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.30 (2.20 – 80.56) 5.92 (2.31 – 52.14) 4.45 (2.56 – 16.65) 0.487 0.081 0.225 0.223 
       [0.30 (-0.61 – 1.15)] [1.21 (-0.14 – 2.64)] [0.78 (-0.50 – 2.60)]  
MRZ-NDM-4-O-GLUC/E-END 1.63 (0.38 – 22.60) 1.90 (0.04 – 35.41) 1.51 (0.50 – 6.52) 0.410 0.638 0.330 0.546 
       [-0.16 (-0.57 – 0.24)] [0.15 (-0.49 – 0.84)] [0.37 (-0.41 – 1.47)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.53 (4.52 – 174.19) 10.74 (4.05 – 106.92) 8.67 (4.39 – 24.86) 0.642 0.120 0.237 0.311 
       [0.35 (-1.28 – 1.88)] [1.89 (-0.51 – 4.46)] [1.42 (-1.07 – 4.90)]  
IVS2-54T>C TT (N=161) TC (N=41)     TT vs TC       
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 16.70 (2.06 – 52.84) 12.38 (2.18 – 42.19)   0.073    
       [2.51 (-0.23 – 5.83)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.16 (0.03 – 0.45)   0.162    
       [0.02 (0.00 – 0.07)]    
(Z)-4-OHT 2.82 (0.70 – 7.13) 2.43 (0.47 – 7.17)   0.032    
       [0.42 (0.04 – 0.87)]    
(E)-NDM-4-O-Gluc 1.00 (0.07 – 29.78) 0.89 (0.19 – 4.09)   0.259    
       [0.12 (-0.09 – 0.34)]    
(Z)-NDM-4-O-Gluc 0.28 (0.04 – 1.81) 0.23 (0.05 – 1.61)   0.057    
       [0.05 (0.00 – 0.10)]    
(E)-Tam-4-O-Gluc 0.29 (0.05 – 8.14) 0.24 (0.05 – 1.17)   0.255    
       [0.04 (-0.03 – 0.10)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.09 (2.20 – 80.56) 6.40 (2.31 – 17.97)   0.422    
       [-0.41 (-1.39 – 0.65)]    
MRZ-NDM-4-O-GLUC/E-END 1.69 (0.04 – 35.41) 1.90 (0.38 – 15.66)   0.966    
       [-0.01 (-0.52 – 0.41)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.35 (4.05 – 174.19) 11.71 (4.88 – 34.76)   0.396    
       [-0.77 (-2.59 – 1.02)]    
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS2-33T>A TT (N=197) TA (N=5)     TT vs TA       
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.40 (2.06 – 52.84) 25.48 (16.78 – 28.46)   0.061    
       [-8.28 (-15.41 – 0.54)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.28 (0.09 – 0.31)   0.490    
       [-0.06 (-0.12 – 0.09)]    
(Z)-4-OHT 2.66 (0.47 – 7.17) 4.19 (1.81 – 4.25)   0.347    
       [-0.51 (-1.82 – 0.64)]    
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 1.48 (1.04 – 2.11)   0.079    
       [-0.55 (-1.02 – 0.09)]    
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.81) 0.34 (0.27 – 0.39)   0.237    
       [-0.07 (-0.16 – 0.10)]    
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.31 (0.24 – 0.64)   0.478    
       [-0.05 (-0.18 – 0.14)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.14 (2.20 – 80.56) 6.48 (3.90 – 10.70)   0.874    
       [-0.20 (-2.97 – 2.78)]    
MRZ-NDM-4-O-GLUC/E-END 1.72 (0.04 – 35.41) 1.43 (1.07 – 3.25)   0.969    
       [0.01 (-1.09 – 2.02)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.51 (4.05 – 174.19) 13.24 (6.67 – 15.17)   0.874    
       [-0.29 (-5.32 – 5.17)]    
IVS3+135G>A GG (N=41) GA (N=111) AA (N=50) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 18.73 (4.27 – 49.93) 14.60 (2.18 – 51.65) 14.31 (2.06 – 52.84) 0.233 0.518 0.872 0.531 
       [1.94 (-1.27 – 5.35)] [1.53 (-3.01 – 5.69)] [-0.27 (-3.40 – 2.47)]  
(E)-Endoxifen 0.19 (0.03 – 0.45) 0.18 (0.03 – 6.64) 0.21 (0.03 – 0.43) 0.751 0.676 0.297 0.601 
       [0.00 (-0.03 – 0.05)] [0.00 (-0.06 – 0.04)] [-0.01 (-0.06 – 0.01)]  
(Z)-4-OHT 3.30 (0.70 – 6.20) 2.57 (0.47 – 7.17) 2.73 (1.11 – 6.80) 0.322 0.702 0.919 0.679 
       [0.23 (-0.23 – 0.70)] [0.12 (-0.49 – 0.67)] [-0.02 (-0.48 – 0.37)]  
(E)-NDM-4-O-Gluc 0.90 (0.16 – 5.64) 0.95 (0.19 – 18.42) 0.98 (0.07 – 29.78) 0.527 0.560 0.929 0.795 
       [0.08 (-0.18 – 0.34)] [0.08 (-0.22 – 0.39)] [-0.01 (-0.21 – 0.21)]  




Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
IVS3+135G>A GG (N=41) GA (N=111) AA (N=50) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.26 (0.05 – 1.46) 0.26 (0.04 – 1.81) 0.27 (0.08 – 1.22) 0.886 0.843 0.788 0.957 
       [0.00 (-0.06 – 0.06)] [0.01 (-0.06 – 0.07)] [0.01 (-0.05 – 0.06)]  
(E)-Tam-4-O-Gluc 0.33 (0.05 – 1.28) 0.27 (0.05 – 4.70) 0.28 (0.07 – 8.14) 0.720 0.744 0.958 0.929 
       [0.01 (-0.06 – 0.09)] [0.01 (-0.07 – 0.10)] [0.00 (-0.06 – 0.06)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 5.92 (2.56 – 25.67) 6.19 (2.20 – 52.14) 6.20 (3.27 – 80.56) 0.439 0.539 0.953 0.731 
       [-0.39 (-1.48 – 0.67)] [-0.40 (-1.46 – 0.70)] [0.04 (-0.90 – 1.07)]  
MRZ-NDM-4-O-GLUC/E-END 1.95 (0.36 – 15.57) 1.63 (0.04 – 35.41) 1.75 (0.49 – 12.08) 0.906 0.836 0.699 0.928 
       [-0.03 (-0.51 – 0.48)] [0.06 (-0.49 – 0.60)] [0.07 (-0.37 – 0.49)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.66 (4.39 – 37.05) 11.07 (4.05 – 106.92) 9.85 (4.52 – 174.19) 0.710 0.930 0.930 0.948 
       [-0.34 (-2.28 – 1.56)] [-0.10 (-2.06 – 1.81)] [0.09 (-1.45 – 2.05)]  
1568A>C (*4, 
rs4148269/rs138015312) 
AA (N=117) AC (N=75) CC (N=9) AA vs AC AA vs CC AC vs CC 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 16.18 (2.06 – 52.84) 14.24 (2.18 – 43.8) 16.87 (5.71 – 42.23) 0.458 0.883 0.598 0.721 
       [0.85 (-1.57 – 3.41)] [-0.3 (-7.87 – 6.19)] [-1.56 (-8.65 – 4.75)]  
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.18 (0.03 – 1.80) 0.19 (0.03 – 0.25) 0.118 0.316 0.655 0.218 
       [0.02 (0.00 – 0.06)] [0.05 (-0.03 – 0.13)] [0.01 (-0.06 – 0.10)]  
(Z)-4-OHT 2.76 (0.85 – 7.17) 2.54 (0.47 – 5.14) 3.20 (1.22 – 5.87) 0.170 0.943 0.548 0.377 
       [0.24 (-0.10 – 0.57)] [-0.05 (-1.05 – 0.86)] [-0.29 (-1.34 – 0.62)]  
(E)-NDM-4-O-Gluc 1.00 (0.07 – 29.78) 0.90 (0.17 – 5.64) 0.81 (0.22 – 2.05) 0.453 0.966 0.845 0.760 
       [0.08 (-0.11 – 0.27)] [-0.01 (-0.41 – 0.49)] [-0.03 (-0.49 – 0.44)]  
(Z)-NDM-4-O-Gluc 0.27 (0.05 – 1.81) 0.26 (0.04 – 1.61) 0.27 (0.16 – 0.93) 0.511 0.845 0.568 0.752 
       [0.02 (-0.03 – 0.06)] [-0.01 (-0.12 – 0.10)] [-0.03 (-0.14 – 0.09)]  
(E)-Tam-4-O-Gluc 0.29 (0.07 – 8.14) 0.27 (0.05 – 1.28) 0.38 (0.06 – 0.56) 0.182 0.708 0.410 0.355 
       [0.04 (-0.02 – 0.09)] [-0.03 (-0.15 – 0.14)] [-0.05 (-0.17 – 0.10)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.19 (2.53 – 80.56) 6.14 (2.20 – 23.68) 5.31 (2.81 – 12.04) 0.584 0.516 0.734 0.742 
       [0.25 (-0.63 – 1.11)] [0.62 (-1.21 – 2.62)] [0.29 (-1.48 – 2.70)]  
MRZ-NDM-4-O-GLUC/E-END 1.61 (0.04 – 14.30) 2.03 (0.37 – 22.60) 2.77 (0.87 – 35.41) 0.387 0.428 0.670 0.552 
       [-0.16 (-0.67 – 0.22)] [-0.38 (-1.87 – 0.53)] [-0.24 (-1.84 – 1.16)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.51 (4.16 – 174.19) 10.66 (4.05 – 37.39) 11.33 (4.52 – 27.50) 0.575 0.809 0.960 0.845 
       [0.39 (-1.12 – 1.91)] [0.47 (-3.18 – 4.47)] [0.25 (-3.98 – 4.24)]  




Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehmann Estimate (95% Confidence Interval)] 
†
 
*168C>T (rs3100) CC (N=116) CT (N=76) TT (N=9) CC vs CT CC vs TT CT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 16.30 (2.06 – 52.84) 14.23 (2.18 – 43.80) 16.87 (5.71 – 42.23) 0.355 0.909 0.568 0.618 
       [1.05 (-1.31 – 3.62)] [-0.26 (-7.82 – 6.37)] [-1.67 (-8.74 – 4.53)]  
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.18 (0.03 – 1.80) 0.19 (0.03 – 0.25) 0.079 0.296 0.696 0.158 
       [0.02 (0.00 – 0.07)] [0.06 (-0.03 – 0.13)] [0.01 (-0.06 – 0.10)]  
(Z)-4-OHT 2.77 (0.85 – 7.17) 2.50 (0.47 – 5.14) 3.20 (1.22 – 5.87) 0.118 0.970 0.520 0.285 
       [0.27 (-0.07 – 0.61)] [-0.03 (-1.04 – 0.87)] [-0.31 (-1.34 – 0.60)]  
(E)-NDM-4-O-Gluc 1.01 (0.07 – 29.78) 0.90 (0.17 – 5.64) 0.81 (0.22 – 2.05) 0.377 0.992 0.808 0.682 
       [0.09 (-0.10 – 0.28)] [0.00 (-0.41 – 0.50)] [-0.03 (-0.49 – 0.43)]  
(Z)-NDM-4-O-Gluc 0.27 (0.05 – 1.81) 0.26 (0.04 – 1.61) 0.27 (0.16 – 0.93) 0.524 0.840 0.578 0.762 
       [0.02 (-0.03 – 0.06)] [-0.01 (-0.12 – 0.10)] [-0.03 (-0.14 – 0.09)]  
(E)-Tam-4-O-Gluc 0.29 (0.07 – 8.14) 0.26 (0.05 – 1.28) 0.38 (0.06 – 0.56) 0.151 0.731 0.388 0.307 
       [0.04 (-0.01 – 0.09)] [-0.02 (-0.15 – 0.14)] [-0.05 (-0.17 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.19 (2.53 – 80.56) 6.15 (2.20 – 23.68) 5.31 (2.81 – 12.04) 0.631 0.528 0.710 0.768 
       [0.22 (-0.66 – 1.07)] [0.61 (-1.22 – 2.62)] [0.30 (-1.47 – 2.68)]  
MRZ-NDM-4-O-GLUC/E-END 1.61 (0.04 – 14.30) 2.03 (0.37 – 22.60) 2.77 (0.87 – 35.41) 0.273 0.405 0.710 0.441 
       [-0.22 (-0.74 – 0.18)] [-0.42 (-1.87 – 0.49)] [-0.21 (-1.82 – 1.19)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.49 (4.16 – 174.19) 10.71 (4.05 – 37.39) 11.33 (4.52 – 27.50) 0.623 0.819 0.943 0.876 
       [0.34 (-1.16 – 1.84)] [0.40 (-3.22 – 4.48)] [0.27 (-3.97 – 4.24)]  
*186A>T (rs4148271) AA (N=107) AT (N=82) TT (N=12) AA vs AT AA vs TT AT vs TT 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 14.41 (4.27 – 52.84) 16.72 (2.06 – 51.65) 13.18 (6.33 – 43.05) 0.601 0.627 0.489 0.733 
       [-0.62 (-3.21 – 1.92)] [1.28 (-3.72 – 6.41)] [1.85 (-3.62 – 7.95)]  
(E)-Endoxifen 0.18 (0.03 – 6.64) 0.19 (0.03 – 4.88) 0.15 (0.03 – 0.43) 0.505 0.163 0.088 0.230 
       [0.00 (-0.04 – 0.01)] [0.04 (0.00 – 0.13)] [0.05 (0.00 – 0.14)]  
(Z)-4-OHT 2.70 (0.70 – 7.17) 2.66 (0.47 – 7.13) 2.23 (1.50 – 4.96) 0.693 0.491 0.587 0.753 
       [0.07 (-0.28 – 0.43)] [0.20 (-0.48 – 0.88)] [0.18 (-0.63 – 0.80)]  
(E)-NDM-4-O-Gluc 0.95 (0.16 – 18.42) 0.95 (0.07 – 29.78) 1.19 (0.47 – 3.91) 0.643 0.784 0.475 0.789 
       [0.04 (-0.14 – 0.23)] [-0.07 (-0.45 – 0.34)] [-0.13 (-0.51 – 0.28)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehman Estimate (95% Confidence Interval)] 
†
 
*186A>T (rs4148271) AA (N=107) AT (N=82) TT (N=12) AA vs AT AA vs TT AT vs TT 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.26 (0.05 – 1.71) 0.26 (0.04 – 1.81) 0.28 (0.08 – 1.02) 0.621 0.839 0.774 0.866 
       [-0.01 (-0.06 – 0.04)] [0.01 (-0.09 – 0.11)] [0.02 (-0.08 – 0.13)]  
(E)-Tam-4-O-Gluc 0.31 (0.05 – 4.70) 0.25 (0.05 – 8.14) 0.37 (0.13 – 0.71) 0.106 0.788 0.319 0.227 
       [0.04 (-0.01 – 0.10)] [-0.02 (-0.15 – 0.10)] [-0.06 (-0.19 – 0.05)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.26 (2.42 – 52.14) 5.72 (2.20 – 80.56) 6.74 (4.47 – 24.58) 0.391 0.378 0.181 0.369 
       [0.34 (-0.48 – 1.23)] [-0.75 (-2.43 – 0.99)] [-1.07 (-2.74 – 0.66)]  
MRZ-NDM-4-O-GLUC/E-END 1.63 (0.09 – 35.41) 1.67 (0.04 – 22.60) 2.72 (0.55 – 12.08) 0.923 0.161 0.119 0.314 
       [0.02 (-0.34 – 0.38)] [-0.77 (-2.09 – 0.30)] [-0.78 (-2.06 – 0.26)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 11.11 (4.05 – 106.92) 9.78 (4.16 – 174.19) 10.79 (7.63 – 35.05) 0.311 0.459 0.200 0.356 
       [0.77 (-0.73 – 2.30)] [-1.21 (-3.91 – 2.31)] [-1.85 (-4.64 – 1.04)]  
*+630C>G CC (N=120) CG (N=73) GG (N=8) CC vs CG CC vs GG CG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 16.30 (2.06 – 52.84) 14.24 (2.18 – 43.8) 18.78 (5.71 – 42.23) 0.373 0.914 0.624 0.649 
       [1.02 (-1.37 – 3.61)] [-0.26 (-9.18 – 6.68)] [-1.56 (-10.73 – 5.13)]  
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.18 (0.03 – 1.80) 0.19 (0.03 – 0.25) 0.086 0.557 0.987 0.217 
       [0.02 (0.00 – 0.07)] [0.02 (-0.05 – 0.11)] [0.00 (-0.06 – 0.09)]  
(Z)-4-OHT 2.77 (0.85 – 7.17) 2.46 (0.47 – 5.14) 3.23 (1.22 – 5.87) 0.090 0.672 0.326 0.196 
       [0.29 (-0.05 – 0.63)] [-0.24 (-1.24 – 0.85)] [-0.58 (-1.54 – 0.52)]  
(E)-NDM-4-O-Gluc 1.01 (0.07 – 29.78) 0.90 (0.17 – 5.64) 0.78 (0.22 – 2.05) 0.451 0.708 0.862 0.725 
       [0.08 (-0.12 – 0.27)] [0.10 (-0.29 – 0.58)] [0.06 (-0.40 – 0.61)]  
(Z)-NDM-4-O-Gluc 0.28 (0.05 – 1.81) 0.26 (0.04 – 1.61) 0.26 (0.16 – 0.61) 0.506 0.755 0.962 0.784 
       [0.02 (-0.03 – 0.07)] [0.02 (-0.08 – 0.13)] [0.00 (-0.10 – 0.13)]  
(E)-Tam-4-O-Gluc 0.29 (0.07 – 8.14) 0.27 (0.05 – 1.28) 0.32 (0.06 – 0.56) 0.180 0.976 0.652 0.405 
       [0.04 (-0.02 – 0.09)] [-0.01 (-0.12 – 0.16)] [-0.02 (-0.15 – 0.13)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.21 (2.53 – 80.56) 6.14 (2.20 – 23.68) 5.08 (2.81 – 9.52) 0.655 0.266 0.393 0.528 
       [0.21 (-0.67 – 1.07)] [0.96 (-0.64 – 3.17)] [0.84 (-1.02 – 3.36)]  
MRZ-NDM-4-O-GLUC/E-END 1.61 (0.04 – 15.57) 2.04 (0.37 – 35.41) 2.12 (0.87 – 6.19) 0.319 0.804 0.849 0.604 
       [-0.21 (-0.74 – 0.20)] [-0.12 (-1.43 – 0.83)] [0.08 (-1.02 – 1.83)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.52 (4.16 – 174.19) 10.66 (4.05 – 37.39) 10.40 (4.52 – 15.86) 0.673 0.448 0.558 0.713 
       [0.29 (-1.23 – 1.85)] [1.27 (-2.21 – 5.23)] [1.14 (-2.61 – 5.50)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehman Estimate (95% Confidence Interval)] 
†
 
*+888A>G AA (N=48) AG (N=93) GG (N=60) AA vs AG AA vs GG AG vs GG 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.76 (4.27 – 52.84) 14.41 (2.06 – 51.65) 15.99 (2.18 – 43.8) 0.757 0.711 0.466 0.761 
       [-0.53 (-3.41 – 2.73)] [0.49 (-2.72 – 3.82)] [1.02 (-1.99 – 3.62)]  
(E)-Endoxifen 0.20 (0.03 – 6.64) 0.19 (0.03 – 4.88) 0.16 (0.03 – 0.43) 0.865 0.047 0.019 0.043 
       [0.00 (-0.03 – 0.04)] [0.04 (0.00 – 0.11)] [0.04 (0.00 – 0.09)]  
(Z)-4-OHT 2.87 (1.01 – 6.80) 2.81 (0.70 – 7.17) 2.44 (0.47 – 5.87) 0.824 0.113 0.101 0.179 
       [0.06 (-0.38 – 0.47)] [0.36 (-0.10 – 0.83)] [0.30 (-0.07 – 0.69)]  
(E)-NDM-4-O-Gluc 1.03 (0.16 – 5.29) 0.97 (0.07 – 29.78) 0.86 (0.19 – 3.91) 0.986 0.493 0.437 0.700 
       [0.00 (-0.25 – 0.24)] [0.08 (-0.14 – 0.35)] [0.09 (-0.11 – 0.30)]  
(Z)-NDM-4-O-Gluc 0.26 (0.05 – 1.14) 0.29 (0.06 – 1.81) 0.25 (0.04 – 1.61) 0.450 0.963 0.455 0.662 
       [-0.02 (-0.08 – 0.04)] [0.00 (-0.06 – 0.06)] [0.02 (-0.03 – 0.07)]  
(E)-Tam-4-O-Gluc 0.33 (0.07 – 1.23) 0.27 (0.05 – 8.14) 0.25 (0.05 – 1.01) 0.402 0.094 0.254 0.224 
       [0.03 (-0.05 – 0.09)] [0.06 (-0.01 – 0.13)] [0.03 (-0.02 – 0.09)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.29 (2.56 – 25.67) 6.17 (2.42 – 80.56) 5.68 (2.20 – 24.58) 0.944 0.565 0.430 0.721 
       [-0.05 (-1.08 – 1.11)] [0.35 (-0.8 – 1.67)] [0.34 (-0.57 – 1.26)]  
MRZ-NDM-4-O-GLUC/E-END 1.46 (0.09 – 14.30) 1.65 (0.04 – 15.66) 2.12 (0.38 – 35.41) 0.635 0.044 0.073 0.091 
       [-0.08 (-0.55 – 0.28)] [-0.61 (-1.43 – -0.01)] [-0.45 (-1.09 – 0.04)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 11.23 (4.39 – 37.05) 10.47 (4.05 – 174.19) 9.91 (4.52 – 35.05) 0.791 0.477 0.611 0.771 
       [0.27 (-1.48 – 2.34)] [0.72 (-1.35 – 3.06)] [0.39 (-1.29 – 1.94)]  
           
*+899G>A GG (N=108) GA (N=82) AA (N=11) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 14.51 (4.27 – 52.84) 16.70 (2.06 – 51.65) 13.83 (6.33 – 43.05) 0.653 0.707 0.584 0.813 
       [-0.53 (-3.03 – 2.01)] [1.18 (-4.75 – 6.35)] [1.58 (-4.75 – 7.74)]  
(E)-Endoxifen 0.18 (0.03 – 6.64) 0.19 (0.03 – 4.88) 0.16 (0.03 – 0.43) 0.607 0.272 0.188 0.412 
       [0.00 (-0.04 – 0.02)] [0.03 (-0.02 – 0.13)] [0.04 (-0.01 – 0.13)]  
(Z)-4-OHT 2.77 (0.70 – 7.17) 2.62 (0.47 – 7.13) 2.20 (1.50 – 4.96) 0.538 0.563 0.721 0.735 
       [0.11 (-0.24 – 0.47)] [0.18 (-0.56 – 0.88)] [0.13 (-0.77 – 0.78)]  
(E)-NDM-4-O-Gluc 0.93 (0.16 – 18.42) 0.95 (0.07 – 29.78) 1.26 (0.47 – 3.91) 0.688 0.521 0.295 0.639 
       [0.04 (-0.14 – 0.23)] [-0.15 (-0.57 – 0.28)] [-0.19 (-0.61 – 0.21)]  
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.31 Effect of UGT2B15 tag-SNPs on plasma concentrations of tamoxifen metabolites (ng/ml) and metabolic ratios (N=202). (Continued) 
Parameters Median (Range) P values [Hodges-Lehman Estimate (95% Confidence Interval)] 
†
 
*+899G>A GG (N=108) GA (N=82) AA (N=11) GG vs GA GG vs AA GA vs AA 
Overall 
P value 
(Z)-NDM-4-O-Gluc 0.26 (0.05 – 1.71) 0.26 (0.04 – 1.81) 0.28 (0.11 – 1.02) 0.685 0.790 0.852 0.900 
       [-0.01 (-0.06 – 0.04)] [-0.02 (-0.11 – 0.09)] [-0.01 (-0.1 – 0.11)]  
(E)-Tam-4-O-Gluc 0.31 (0.05 – 4.70) 0.25 (0.05 – 8.14) 0.39 (0.13 – 0.71) 0.112 0.548 0.212 0.190 
       [0.04 (-0.01 – 0.10)] [-0.05 (-0.18 – 0.08)] [-0.08 (-0.23 – 0.04)]  
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.26 (2.42 – 52.14) 5.72 (2.20 – 80.56) 7.08 (4.51 – 24.58) 0.479 0.229 0.119 0.292 
       [0.28 (-0.54 – 1.16)] [-1.02 (-2.81 – 0.81)] [-1.36 (-3.01 – 0.47)]  
MRZ-NDM-4-O-GLUC/E-END 1.62 (0.09 – 35.41) 1.67 (0.04 – 22.60) 2.37 (0.55 – 12.08) 0.951 0.190 0.184 0.397 
       [-0.01 (-0.38 – 0.35)] [-0.73 (-2.28 – 0.37)] [-0.67 (-2.19 – 0.37)]  
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 11.09 (4.05 – 106.92) 9.78 (4.16 – 174.19) 11.23 (7.63 – 35.05) 0.412 0.326 0.153 0.340 
       [0.61 (-0.82 – 2.20)] [-1.77 (-4.75 – 1.97)] [-2.22 (-5.30 – 0.80)]  
*+1350A>G AA (N=198) AG (N=3)     AA vs AG       
Plasma Concentration of Analytes (ng/ml) 
(Z)-Endoxifen 15.75 (2.06 – 52.84) 16.87 (14.22 – 25.48)   0.575    
       [-3.00 (-11.33 – 9.71)]    
(E)-Endoxifen 0.19 (0.03 – 6.64) 0.03 (0.03 – 0.31)   0.415    
       [0.10 (-0.12 – 0.24)]    
(Z)-4-OHT 2.67 (0.47 – 7.17) 2.09 (2.03 – 4.25)   0.704    
       [0.17 (-1.56 – 1.78)]    
(E)-NDM-4-O-Gluc 0.95 (0.07 – 29.78) 2.03 (1.25 – 2.11)   0.087    
       [-0.80 (-1.46 – 0.23)]    
(Z)-NDM-4-O-Gluc 0.26 (0.04 – 1.81) 0.41 (0.33 – 0.93)   0.098    
       [-0.18 (-0.66 – 0.07)]    
(E)-Tam-4-O-Gluc 0.28 (0.05 – 8.14) 0.56 (0.31 – 0.64)   0.147    
       [-0.18 (-0.41 – 0.11)]    
Plasma Metabolic Ratios (MRs) 
MRE-NDM-4-O-GLUC/Z-END (x100) 6.11 (2.20 – 80.56) 8.80 (8.27 – 12.04)   0.095    
       [-3.42 (-6.07 – 0.91)]    
MRZ-NDM-4-O-GLUC/E-END 1.70 (0.04 – 22.60) 15.57 (1.07 – 35.41)   0.133    
       [-13.83 (-33.66 – 0.63)]    
MRE-TAM-4-O-GLUC/Z-4-OHT (x100) 10.49 (4.16 – 174.19) 15.10 (14.67 – 27.5)   0.075    
       [-6.78 (-16.84 – 0.84)]    
† Hodges-Lehmann Estimate (95% Confidence Interval) available for pairwise comparisons only. 
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Table 3.32 Effects of UGT2B15 Haplotypes on the O-glucuronidation of (Z)-Endoxifen. 











































































































































































































































(Intercept of GLM) 2.73 4.44 1.71 0.10 0.14 0.10 <0.001 <0.001 <0.001 
H1 
L
 A T G C C G A A C A G 0.28          
H2 A C A A T T G T C A T 0.26 -0.04 0.04 0.08 0.08 0.11 0.08 0.634 0.727 0.314 
H3 T T G C C G A A T G G 0.18 0.00 0.07 0.08 0.09 0.12 0.08 0.967 0.540 0.349 
H4 A C G A T T G T C A T 0.15 0.02 0.19 0.17 0.10 0.14 0.09 0.831 0.178 0.082 
H5 T T G C C G A A T A G 0.08 -0.05 0.08 0.13 0.12 0.17 0.12 0.674 0.651 0.271 
Hrare * * * * * * * * * * * 0.06 0.09 0.21 0.13 0.20 0.28 0.19 0.656 0.442 0.514 
                                            





















































































































































































(Intercept of GLM) 2.90 4.85 1.95 0.14 0.19 0.13 <0.001 <0.001 <0.001 
H1 
L
 A C C         0.19          
H2 A T C         0.52 -0.12 -0.15 -0.03 0.09 0.12 0.08 0.177 0.235 0.761 
H3 T C G         0.27 -0.08 -0.16 -0.09 0.09 0.13 0.09 0.408 0.195 0.315 
Hrare * * *         0.02 -0.51 -0.88 -0.37 0.26 0.36 0.25 0.051 0.015 0.142 
                                            
































































































































































































(Intercept of GLM) 2.73 4.65 1.92 0.08 0.11 0.07 <0.001 <0.001 <0.001 
H1 
L
 A C A C A       0.46          
H2 A C T C G       0.26 -0.01 -0.01 0.00 0.08 0.11 0.07 0.888 0.919 0.999 
H3 C T A G G       0.22 -0.04 -0.15 -0.11 0.08 0.11 0.08 0.600 0.179 0.160 
Hrare * * * * *             0.06 0.06 -0.01 -0.06 0.16 0.22 0.15 0.721 0.978 0.679 
† Plasma concentrations of (Z)-endoxifen ln-transformed; (E)-NDM-4-O-Gluc concentrations and MRE-NDM-4-O-Gluc/Z-END were multiplied by factors of 100 and 
10000, respectively, before ln-transformation. 




Table 3.33 Effects of UGT2B15 Haplotypes on the O-glucuronidation of (E)-Endoxifen. 











































































































































































































































(Intercept of GLM) 2.61 3.25 5.24 0.18 0.12 0.17 <0.001 <0.001 <0.001 
H1 
L
 A T G C C G A A C A G 0.28          
H2 A C A A T T G T C A T 0.26 -0.02 0.01 0.03 0.14 0.09 0.13 0.907 0.895 0.831 
H3 T T G C C G A A T G G 0.18 -0.05 0.04 0.09 0.15 0.10 0.15 0.749 0.710 0.553 
H4 A C G A T T G T C A T 0.15 0.01 0.10 0.08 0.17 0.12 0.16 0.929 0.400 0.612 
H5 T T G C C G A A T A G 0.08 0.10 0.03 -0.07 0.21 0.14 0.20 0.635 0.844 0.726 
Hrare * * * * * * * * * * * 0.06 0.28 0.09 -0.19 0.34 0.23 0.33 0.412 0.699 0.568 





















































































































































































(Intercept of GLM) 2.70 3.51 5.42 0.24 0.16 0.23 <0.001 <0.001 <0.001 
H1 
L
 A C C         0.19          
H2 A T C         0.52 -0.03 -0.12 -0.09 0.15 0.10 0.15 0.834 0.235 0.540 
H3 T C G         0.27 -0.06 -0.10 -0.04 0.16 0.11 0.15 0.693 0.354 0.811 
Hrare * * *         0.02 0.06 -0.65 -0.71 0.45 0.30 0.43 0.890 0.032 0.099 
































































































































































































(Intercept of GLM) 2.92 3.33 5.02 0.13 0.09 0.12 <0.001 <0.001 <0.001 
H1 
L
 A C A C A       0.46          
H2 A C T C G       0.26 -0.18 0.00 0.18 0.13 0.09 0.12 0.146 0.984 0.138 
H3 C T A G G       0.22 -0.31 -0.06 0.25 0.13 0.09 0.13 0.020 0.529 0.051 
Hrare * * * * *             0.06 -0.43 0.05 0.48 0.26 0.18 0.26 0.107 0.781 0.062 
† Plasma concentrations of (E)-endoxifen and (Z)-NDM-4-O-Glucas well as MRZ-NDM-4-O-Gluc/E-END were multiplied by factor of 100 before ln-transformation. 




Table 3.34 Effects of UGT2B15 Haplotypes on the O-glucuronidation of (Z)-4-OHT. 









































































































































































































































 A T G C C G A A C A G 0.28          
H2 A C A A T T G T C A T 0.26 0.01 0.11 0.08 0.05 0.10 0.08 0.835 0.295 0.324 
H3 T T G C C G A A T G G 0.18 0.01 0.08 0.07 0.05 0.11 0.09 0.796 0.475 0.450 
H4 A C G A T T G T C A T 0.15 0.02 0.19 0.17 0.06 0.12 0.10 0.680 0.131 0.090 
H5 T T G C C G A A T A G 0.08 -0.01 0.10 0.13 0.07 0.15 0.12 0.906 0.510 0.279 
Hrare * * * * * * * * * * * 0.06 0.04 0.18 0.12 0.12 0.25 0.20 0.775 0.479 0.533 
                                            



















































































































































































 A C C         0.19          
H2 A T C         0.52 -0.04 -0.07 -0.03 0.05 0.11 0.09 0.485 0.504 0.727 
H3 T C G         0.27 -0.03 -0.13 -0.09 0.06 0.11 0.09 0.549 0.246 0.318 
Hrare * * *         0.02 -0.32 -0.71 -0.33 0.16 0.33 0.26 0.042 0.030 0.206 
                                            






























































































































































































 A C A C A       0.46          
H2 A C T C G       0.26 -0.05 -0.08 -0.01 0.05 0.09 0.07 0.256 0.384 0.850 
H3 C T A G G       0.22 -0.07 -0.19 -0.10 0.05 0.10 0.08 0.152 0.057 0.214 
Hrare * * * * *             0.06 0.00 -0.03 -0.05 0.10 0.20 0.15 0.976 0.878 0.740 
† Plasma concentrations of (Z)-4-OHT were square-root-transformed; Plasma concentrations of (E)-Tam-4-O-Gluc and MRE-TAM-4-O-Gluc/Z-4-OHT were multiplied 
by factors of 100 and 10000, respectively, before ln-transformation. 
‡ Haplotype H1 of block 1 refers to high frequency haplotype while haplotype H1 of blocks 2 and 3 refer to the wild-type haplotype.  
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Table 3.35 Effects of UGT12B15 Block 3 Haplotypes on the O-glucuronidation of (E)-Endoxifen after adjustment of 
covariates. 











































































































































































































(Intercept of GLM) 3.68 4.68 0.26 0.20 < 0.0001 < 0.0001 
H1 
L
 A C A C A 0.46       
H2 A C T C G 0.26 -0.26 0.22 0.12 0.12 0.039 0.077 
H3 C T A G G 0.22 -0.39 0.30 0.13 0.13 0.003 0.020 
Hrare * * * * * 0.06 -0.46 0.45 0.23 0.23 0.048 0.056 
CYP2D6       -0.31 − 0.10 − 0.001 − 
Chemotherapy 
status 
            − 0.36 − 0.19 − 0.059 
† (E)-Endoxifen concentration was multiplied by a factor of 100 before ln-transformation. GLM model for (E)-
Endoxifen concentration was adjusted for CYP2D6 status; MRZ-NDM-4-O-GLUC/E-END was multiplied by a factor of 100 
before ln-transformation.GLM model for MRZ-NDM-4-O-GLUC/E-END was adjusted for chemotherapy status. 
‡ Haplotype H1 of each block refers to the wild-type haplotype.  
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Fig 3.19 Effects of UGT2B15 LD block 3 H3 
haplotype pairs on plasma concentrations of (A) 




Several studies have indicated a prominent role for UGT2B15 in the metabolism of 
clinical drugs and maintenance of the depot of endogenous steroidal hormones (333, 
337). Although the UGT2B15 gene is highly polymorphic in the Japanese (378), few 
studies have comprehensively screened the UGT2B15 gene for possible functional 
polymorphic variants, especially in the Asian populations. In the current study, 240 
healthy Asian subjects were screened for the presence of UGT2B15 polymorphisms 
and the impact of selected polymorphisms were evaluated in Asian breast cancer 
patients receiving tamoxifen. 
Screening of the exonic and exon-intron boundaries in 80 healthy Chinese, Malay 
and Indian subjects revealed the presence of 19 polymorphisms majority of which in 
the intronic regions. The 5′ upstream and 3′ downstream regions were also screened 
and found to be highly polymorphic with 25 polymorphisms. Twenty-three of all 
polymorphisms were found to be novel and two of which were located in exons.  
The two novel exonic polymorphisms were of low frequency and located in exon 6, 
1336T>C and 1553G>A, were observed. The synonymous variant, 1336T>C, was 
observed in 1% of the Indian subjects while the non-synonymous polymorphism, 
1553G>A (R518Q), was observed in 1% of both Malay and Indian subjects. Although 
1553G>A occurred at low frequency, it can potentially cause a drastic change in 
activity of UGT2B15 by virtue of its location which is mapped onto the c-terminal 
domain of the enzyme (339). Furthermore the SNP leads to a change in amino acid 
from positively charged arginine to an uncharged amino acid, glutamine. This 
substitution could potentially influence the conformation of the UGT2B15 protein. 
 338
Previously, Court et al (380) also reported the presence of another non-synonymous 
variant, 1055C>T, in exon 4 of UGT2B15 in 2% of the Caucasian population but was 
not found in our Asian populations. 
Among the nonsynonymous variants, 253G>T (*2, rs1902023) transversion is the 
most widely investigated variant. It is highly frequent in the Caucasians and 
Japanese (368, 380) with variant allelic frequencies of 0.55 and 0.79 respectively. In 
our healthy Indians, the variant allelic frequency (MAF: 0.53) was highly similar to 
that of the Caucasians but higher than that observed in our healthy Chinese and 
Malays (MAF: 0.44). This nonsynonymous SNP has been shown to lead to a change 
in amino acid at codon 85 (D85Y) located in the substrate binding region of the 
enzyme which led to reductions in glucuronidation rates for its substrates (380). 
However, the extent of reduction in glucuronidation rate due to this polymorphism 
differs between substrates. With regards to S-oxazepam and narigenin, 5-fold and 
10-fold differences in the respective glucuronidation rates were observed with 
UGT2B15*2 (253G>T, rs1902023) as compared to UGT2B15*1 (380). 
A total of twenty tag-SNPs representative of the 34 polymorphisms were selected 
and genotyped in our patients, together with six functional SNPs. Genotypic 
association analyses did not reveal any significant difference between the selected 
polymorphisms and the plasma concentrations of the (E)- and (Z)-isomers of 4-OHT 
and endoxifen, as well as the corresponding glucuronides and MRs. Subsequent 
haplotypic association analyses indicated correlations between H3 haplotype of LD 
block 3 and lower plasma concentration of endoxifen and higher MRZ-NDM-4-O-GLUC/E-END. 
LD block three comprised of 1568A>C (*4, rs4148269) and four SNPs in the 3′ gene 
region [*168C>T (rs3100), *186A>T (rs4148271), *+630C>G and *+888A>G] (Table 
3.35). The haplotype associated with differential glucuronidation of (E)-endoxifen 
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was found to carry the variant alleles at all positions except *186A>T (rs4148271). 
The effect of UGT2B15 haplotypes observed was in concordance with that reported 
by Sun et al (384). The investigators observed an excessive expression of variant C 
allele over the A allele for the polymorphism, 1568A>C (*4, rs4148269), which has 
been attributed to linkage with *168C>T (rs3100) (384). Higher mRNA expression 
was observed with *168C>T (rs3100). As the SNP is located in the 3′ UTR of 
UGT2B15, the authors postulated that the presence of the T allele abolishes the 
binding site for miRNA that leads to degradation of UGT2B15 mRNA. However, no 
causative miRNA was identified. Thus, the higher O-glucuronidation activity 
observed with haplotype H3 in the LD block 3 might be due to the higher expression 
of UGT2B15 as reported by Sun et al (384). However, the haplotypic effects 
observed were modest and were not observed when diplotypic constitutions of 
individuals were considered.  
The reason for the non-observation of a haplotypic association in the plasma 
concentration of (Z)-NDM-4-O-Gluc was unclear. There seemed to be an 
accumulation of (Z)-NDM-4-O-Gluc independent of the activity of UGT2B15 which 
requires further clarification. Previously, the formation rate of (Z)-NDM-4-O-Gluc from 
(E)-endoxifen in liver microsomes were found to be much higher than the 
glucuronidating activity of UGT2B15 alone (130). This suggested the involvement of 
other UGT isoforms in the O-glucuronidation of (E)-endoxifen. Consistently, 
UGT1A10 and UGT2B7 were found to exhibit activity against (E)-endoxifen (129).  
In line with Murdter et al (118), UGT2B15*2 (253G>T, rs1902023) and its associated 
haplotypes were not found to contribute to variations in the plasma concentrations of 
the analytes. This was in contrast to that reported by Sun et al (383) who observed 
an excessive expression of the UGT2B15*1 allele compared to the UGT2B15*2 
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(253G>T, rs1902023) allele in liver microsomes. Subsequent search for putative 
functional polymorphisms revealed high reverse LD between UGT2B15*2 (253G>T, 
rs1902023) and seven polymorphisms in the promoter region [-1844C>T 
(rs7696472), -1577A>G (rs7686914), -1395A>C (rs13112099), -1137T>C 
(rs9994887), -818T>G (rs1960773), -508G>A (rs1120265) and -506T>A 
(rs1580083)]. To investigate the independent effect of these seven polymorphisms, 
reporter gene assays were conducted and both -1137C>T (rs9994887) and -818G>T 
(rs1960773) were identified to possibly influence the hepatic expression of UGT2B15. 
Furthermore, the Nrf2 transcription factor was shown to bind to the region in the 
vicinity of -818G>T (rs1960773) suggesting that the allelic effect of -818G>T 
(rs1960773) is likely to be mediated via the activity of Nrf2 (383).  
Other than the glucuronidation of (E)-endoxifen, no association with the 
glucuronidation of other (Z)-isomers of 4-OHT and endoxifen was observed. This is 
likely due to the lower activity of UGT2B15 against the (Z)-isomers compared to the 
(E)-isomers (129, 130). Although it has also been shown in liver microsomes that 
UGT2B15 catalyses the O-glucuronidation of (E)-4-OHT to (Z)-Tam-4-O-Gluc (130), 
the effect of UGT2B15 polymorphisms on this catalytic pathway was not examined 
as the plasma concentrations of (E)-4-OHT and (Z)-Tam-4-O-Gluc were found to be 
below the lower limit of quantification in 25.3% and 63.9% of the Asian patients 
respectively. This observation may also indicate that 4-OHT exists and is eliminated 
predominately in the (Z)-isomeric form. 
In the present study, 47 polymorphic variants were observed along UGT2B15. Like 
other UGT genes, high LD between the SNPs was observed. Although haplotypes in 
LD block 3 of the gene was associated with higher glucuronidation of (E)-endoxifen, 
the effects were modest and became not apparent upon consideration of the 
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haplotype pairs. The effects of this haplotype block on the O-glucuronidation of (E)-
endoxifen should be verified in subsequent in vitro setting as well as independent 
patient cohort. 
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3.4.4 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 (SULT1A1) 
3.4.4.1 Genetic Profile of SULT1A1 
Two functional polymorphic variants, 636G>A (*2, rs9282861) and 667A>G (*3, 
rs1801030), were genotyped in the Asian healthy subjects and patient cohort. The 
genotypic and allelic frequencies of these two SNPs in the study subjects are listed 
in Table 3.36. The polymorphism, SULT1A1*3 (667A>G, rs1801030), was absent in 
the three healthy ethnicities and patient population. In contrast, SULT1A1*2 
(636G>A, rs9282861) variant allele was found in approximately 7% to 10% of our 
study populations with marginally higher frequency in the Indian population. The 
genotypic distribution of SULT1A1*2 (636G>A, rs9282861) conformed to Hardy-
Weinberg equilibrium (HWE). 
3.4.4.2 Genotypic-phenotypic Associations Between SULT1A1 Polymorphisms and 
Steady State Concentrations of Tamoxifen Metabolites 
Table 3.37 shows the median (range) of plasma concentrations of tamoxifen and its 
metabolites with respective to the SULT1A1*2 (636G>A, rs9282861) genotypes of 
patients. Non-parametric Mann-Whitney U test was applied to compare the plasma 
concentrations between *1/*1 and *1/*2 genotype groups.  
The plasma concentrations of tamoxifen and the three other metabolites were not 
found to differ significantly between patients carrying the *1/*1 and *1/*2 genotypes 
(Table 3.37).  
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Table 3.36 Genotypic and allelic frequencies of SULT1A1*2 (638G>A, rs9282861) and *3 (667A>G, rs1801030) (UCSC RefSeq: NM_001055). 
SN Polymorphisms Genotypes 
Genotypic Frequencies, N (%) 
Alleles 









Chinese (N=80) Malays (N=80) Indians (N=80) Patients (N=202) 
1 638G>A GG 69 (86.3) 70 (87.5) 64 (82.1) 176 (87.1) G 0.93 (0.89 – 0.97) 0.94 (0.90 – 0.98) 0.90 (0.86 – 0.95) 0.94 (0.91 – 0.96) 
 
(*2; rs9282861) GA 11 (13.8) 10 (12.5) 13 (16.7) 26 (12.9) A 0.07 (0.03 – 0.11) 0.06 (0.02 – 0.10) 0.10 (0.05 – 0.14) 0.06 (0.04 – 0.09) 
  
AA 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 
2 667A>G AA 80 (100.0) 80 (100.0) 78 (100.0) 202 (100.0) A 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 1.00 (1.00 – 1.00) 
 
(*3; rs1801030) AG 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) G 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 
    GG 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)           
 
Table 3.37 Effects of SULT1A1*2 (638G>A; rs9282861) polymorphism on median (range) plasma concentrations (ng/ml) of tamoxifen and 
its analytes (N = 202). 
Parameters 
Median (Range)   
Pairwise P values  
[Hodges-Lehman 
Estimate (95% Confidence 
Interval)] 
*1/*1 *1/*2   
*1/*1 vs *1/*2 




Tamoxifen 200.36 (39.18 – 463.20) 170.00 (39.87 – 390.50)   0.196 
      [17.32 (-9.95 – 46.42)] 
NDM 364.50 (50.68 – 896.21) 331.88 (106.88 – 622.17)  0.064 
      [47.58 (-2.04 – 106.38)] 
4-OHT 2.65 (0.47 – 7.17) 3.29 (1.00 – 5.03)  0.855 
      [-0.05 (-0.62 – 0.43)] 
Endoxifen 15.66 (2.06 – 52.84) 16.82 (6.20 – 35.64)  0.774 




3.4.4.3 Discussion  
In the present study, we investigated the effect of SULT1A1*2 (638G>A, 
rs9282861) on the variations in plasma levels of tamoxifen and its metabolites. 
The pharmacogenetic study was preceded by the investigation of the genotypic 
distributions of SULT1A1*2 (638G>A, rs9282861) and SULT1A1*3 (667A>G, 
rs1801030) in our local healthy Asian populations namely Chinese, Malays and 
Indians. Among the local Asian ethnicities, no significant inter-ethnic variation of 
SULT1A1*2 (638G>A, rs9282861) was observed. However, compared to the 
allelic frequencies of 0.17 and 0.29 in the Japanese and Caucasians, 
respectively, the allelic frequencies of our Asian populations, ranging between 
0.06 and 0.10, were much lower (409, 470). Concerning SULT1A1*3 (667A>G, 
rs1801030), we discovered that none of the Asian populations carried this variant 
allele though it was present in African Americans and Caucasians at frequencies 
of 0.16 and 0.01 respectively (409). 
SULT1A1*2 (638G>A, rs9282861) refers to a missense polymorphism leading to 
the substitution of amino acid R213H (408). The resultant protein exhibits lower 
thermal stability and activity against its substrates (404). Hence, lower rates of 
sulfonation of 4-OHT and endoxifen would be expected in patients harbouring the 
variant SULT1A1*2 (638G>A, rs9282861) allele. Nagar et al (411) investigated 
the impact of SULT1A1 polymorphisms [SULT1A1*2 (638G>A, rs9282861) and 
SULT1A1*3 (667A>G, rs1801030)] on the metabolism of a range of substrates in 
breast cancer cell lines, MCF-7, stably expressing wild-type and variant forms of 
SULT1A1. Compared to SULT1A1.1 and SULT1A1.3, SULT1A1.2 variant 
enzyme was found to have lower Vmax across different compounds with 
substrate-dependent differences observed. Furthermore, low expression of the 
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SULT1A1*2 (638G>A, rs9282861) allozyme was also observed with SULT1A1.2 
protein exhibiting approximately 6-fold lower half-life than the SULT1A1.1 
enzyme due to the greater extent of ubiquitination of the SULT1A1.2 allozyme 
compared to SULT1A1.1 allozyme. Furthermore, the investigators observed an 
allele-dependent effect against 4-OHT for which cells expressing the SULT1A1.2 
variant protein had a significantly higher anti-estrogenic response compared to 
the wild-type protein (411). This is likely due to shorter half-life of the SULT1A1.2 
variant protein coupled with the reduction in sulfonating activity towards 4-OHT 
resulting in reduced elimination of 4-OHT via the sulfonation pathway.  
However, pairwise comparison of the steady state concentrations of tamoxifen 
and its metabolites in Asian breast cancer patients harbouring different 
genotypes of SULT1A1*2 (638G>A, rs9282861) did not reveal any significant 
difference in the median plasma concentrations of the analytes. The effect of 
SULT1A1*2 (638G>A, rs9282861) has only been previously examined in a 
cohort of Caucasian patients (140). The results of the present study coincided 
with the previous study and both differed from the results of the in vitro study 
conducted by Nagar et al (411). 
One possible reason for the discrepancy between the in vitro and in vivo studies 
might be due to the active metabolites of tamoxifen, 4-OHT and endoxifen, being 
subjected to glucuronidation in addition to sulfonation. The SULTs and UGTs are 
found to complement the activity of each other during the phase II catalysis of 
overlapping substrates. The sulfonating reaction mediated by SULT is of high 
affinity and low capacity and dominates when the substrate concentration is low 
(387-389). However, glucuronidation is the dominant eliminating mechanism 
when substrate concentration is high. Hence, in the in vivo system, 
 346
glucuronidation might prevail when the concentration of either 4-OHT or 
endoxifen exceeded the handling capacity of SULT. Unless the catalytic 
capacities of the UGTs were also impaired due to presence of genetic variants, 
the effect of defective alleles on the sulfonating capacity of SULT may not be 
apparent. It is interesting to note that the positive association demonstrated by 
Nagar et al (411) in the in vitro experiment was achieved in the absence of 
glucuronidating activity. Alternatively, the effect of SULT1A1*2 (638G>A, 
rs9282861) can be more directly investigated by comparing the plasma 
concentrations of the sulfonyl-conjugates of the active metabolites. However, this 
data was not available in the present study.  
In summary, SULT1A1*2 (638G>A, rs9282861) was found to be prevalent in the 
Asian populations but not SULT1A1*3 (667A>G, rs1801030). The functional 
polymorphism, SULT1A1*2 (638G>A, rs9282861), was not found to be a 
dominant factor influencing the exposure levels of the metabolites although 
functional impact of the polymorphism on 4-OHT has been proven in in vitro 
experiments (411). Future studies investigating the impact of SULT1A1*2 
(638G>A, rs9282861) on the disposition of tamoxifen should examine the plasma 
levels of sulfonates of the metabolites to more accurately quantify the 




Chapter 4: Conclusions 
The metabolic pathway of tamoxifen was found to be extremely complex with 29 
metabolites detected in our Asian breast cancer patients comprising mostly pre-
menopausal patients of Chinese ethnic background. The steady state plasma 
concentrations of tamoxifen and its metabolites were found to exhibit significant 
variations between individuals.  
Pharmacogenetic analyses of the phase I pharmacogenes (CYP1A2, 
CYP2C9/19, CYP2D6 and CYP3A5) identified CYP2D6 polymorphisms to be the 
major genetic determinants affecting the disposition of tamoxifen and its 
metabolites. The most prevalent CYP2D6 polymorphisms in the Asian breast 
cancer patients were CYP2D6*5 (CYP2D6del) and *10 (100C>T, rs1065852). 
The plasma concentrations of endoxifen and NDM were found to be lower and 
higher, respectively, among patients carrying the defective variant CYP2D6*5 
(CYP2D6del) and *10 (100C>T, rs1065852) alleles. Correspondingly, the MRZ-
END/NDM, indicating the relative formation of (Z)-endoxifen from NDM, was lower 
among patients carrying the variant genotypes CYP2D6*5/*10 or 
CYP2D6*10/*10 compared to patients who were wild-type. Although these 
CYP2D6 variant alleles were found to influence the MRZ-4-OHT/TAM, no association 
with the steady state plasma concentrations of the respective metabolites was 
observed. This indicated that CYP2D6 polymorphisms exert greater impact on 
the formation of (Z)-endoxifen via NDM, compared to the biosynthesis of (Z)-4-
OHT from tamoxifen, in agreement with available reports. 
Although CYP2C9*2 (430T>C, rs1799853) and *3 (1075A>C, rs1057910) were 
found to influence the plasma levels of (Z)-4-OHT in Caucasian breast cancer 
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patients, similar correlation was not observed in the Asian patients. The 
functional polymorphism, CYP3A5*3 (6986A>G, rs776746), was also not found 
to affect the disposition of tamoxifen and its metabolites. In addition, the genetic 
profiles of both CYP1A2 and CYP2C19 were elucidated in our healthy Asian 
populations. However, the tag-SNPs and functional polymorphisms of these two 
pharmacogenes were not found to significantly impact the plasma levels of 
analytes or the extent of formation of the metabolites. 
Subsequent analyses of the phase II analytes demonstrated more extensive 
glucuronidation of the (E)-isomers of the active metabolites compared to that of 
the (Z)-isomers, in line with previous findings. Pharmacogenetic investigations of 
the phase II pharmacogenes identified UGT1A4 but not UGT2B7 and UGT2B15 
to be an important determinant of the disposition of tamoxifen and its metabolites. 
The genetic profiles of these three genes were elucidated in our healthy 
populations (Chinese, Malays, Indians) and representative tag-SNPs were 
identified. All three genes were found to be highly polymorphic with high LD 
observed between polymorphisms. UGT1A4*3 (142T>G, rs2011425) and the 
associated haplotype [-1548G, -1531C, -419A, -219T, -163A, 142G, 448C, 804A, 
IVS1+196C, IVS1+346T, IVS1+414G and IVS2+307G] were associated with 
higher plasma concentration of Tam-N-Gluc and MRTAM-N-GLUC/TAM which indicated 
higher rate of formation of N-glucuronidation of tamoxifen. A decrease in plasma 
level of (E)-endoxifen and corresponding increase in MRZ-NDM-4-O-GLUC/E-END were 
observed in patients carrying the variant haplotype in UGT2B15 block 3 
comprising of UGT2B15*4 (1568A>C, rs4148269) and four other SNPs in the 3′ 
gene region [*168C>T (rs3100), *186A>T (rs4148271), *+630C>G and 
*+888A>G]. However, the effects observed were modest. Furthermore, variations 
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in plasma concentrations of the analytes or the MRs were not found to differ 
significantly with tag-SNPs or functional polymorphisms of UGT2B7 as well as 
SULT1A1*2 (638G>A; rs9282861). 
In addition, patients’ baseline characteristics including age, height and weight 
were correlated with plasma levels of the analytes. Despite the consistent 
associations between CYP2D6 genetics and tamoxifen metabolism, 
corresponding association with treatment outcome of tamoxifen has not been 
constantly achieved (471). As the present study is at a relatively early stage, the 
effect of CYP2D6 and other candidate genes on the treatment response to 
tamoxifen cannot be assessed at this stage due to the unavailability of outcome 
data. Nevertheless, this will be an inevitable part of future directions of this study.  
Currently, the scientific community is divided with regard to the impact CYP2D6 
genetics on treatment response among tamoxifen-treated patients due to the 
negative findings from two large retrospective studies: Breast International Group 
(BIG) 1-98 and Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical 
trials (308, 309). Supporters of these two studies claimed that these two trials 
provided strong evidence that CYP2D6 is not associated with tamoxifen efficacy 
and CYP2D6 genetic testing should not be implemented in clinical practice. They 
pointed out that these two trials are of good study design with long-term and 
detailed follow-up of patients as well as the inclusion of control groups (472). 
However, proponents of CYP2D6 testing has brought to the attention several 
methodological flaws in the study that can potentially invalidate the finding which 
include use of DNA from formalin-fixed paraffin-embedded (FFPE) tumor 
samples, HWE non-compliance of CYP2D6 genotypes and only CYP2D6*4 
(1846G>A, rs3892097) polymorphism was genotyped (473). Among these 
 350
factors, the most controversial part is regarding the use of DNA from FFPE 
source. 
As opposed to the DNA extracted from peripheral blood, the use of DNA from 
FFPE samples may contained somatic mutations such as deletion of 
chromosome 22q13, the region where CYP2D6 is localized, which do not reflect 
the true metabolizing status of the individual patient. Although there is a recent 
report which indicate high correlations between genotyping results obtained from 
tumor and germline DNA, genotyping of CYP2D6 copy number variations which 
is present in approximately 5% of the population could not be performed on the 
FFPE samples due to fragmentation of DNA (474). Hence, the assignment of 
CYP2D6 metabolic status using FFPE samples would not be accurate. 
Besides treatment outcome of tamoxifen-treated patients, the link between 
CYP2D6 genetics and hot flashes has also not been consistently demonstrated. 
Hot flashes is the most common adverse event associated with the use of 
tamoxifen treatment and has been used as a surrogate marker for the tamoxifen 
efficacy (78). It has been reported to affect as many as 50% of the treated 
women. In the present study population, 40.6% of the breast cancer patients 
reported experiencing grade 1 or 2 hot flashes during the course of treatment. It 
would be of interest to examine the association between the candidate genes 
along the tamoxifen biochemical pathway and the incidence as well as severity of 




Fig 4.1 Significance of present study. The present study indicated a correlation 
between UGT1A4 variant alleles and higher rate of tamoxifen glucuronidation. In 
addition, CYP2D6 activity was also implicated in variations in plasma levels of 
the active metabolites of tamoxifen (4-OHT and endoxifen). The implications of 
these findings on treatment response to tamoxifen remains unknown. 
 
Due to heterogeneity in study design among tamoxifen pharmacogenetics 
investigation, highly varied results have been reported in the literature. The 
present study clearly illustrates a link between the tamoxifen disposition and 
genetics of both CYP2D6 and UGT1A4 genetics. However, the impact of these 
two candidate genes on the efficacy of tamoxifen remains to be established (Fig 
4.1). Future analysis of the response and adverse effect data from this study 
would be well positioned to address these issues.  
 352
Chapter 5: Future Directions 
The present study had comprehensively investigated the effects of multiple 
phase I and II pharmacogenes on the metabolic profile of tamoxifen in a Asian 
patient cohort consisting mainly of Chinese subjects (83.2%). After Chinese, 
Malays and Indians are also the next major ethnic groups in the Singapore 
population. Hence, the effects of these pharmacogenes should be verified in 
subsequent cohorts of breast cancer patients from these smaller ethnic groups 
(Malays and Indians). In addition, the formation and elimination of each 
metabolite of tamoxifen are influenced by multiple enzymes. Future studies 
should investigating the combinative effects of these polymorphic variants on the 
disposition of tamoxifen in order to obtain a more accurate overview of tamoxifen 
pharmacogenetics. 
It was noted that much of the variabilities in the plasma concentrations of 
tamoxifen and its metabolites as well as the associated metabolic ratios remain 
unexplained after taking into account the significant factors (CYP2D6 and 
UGT1A4 polymorphisms). This suggests the involvement of others yet unknown 
factors in the metabolism of tamoxifen. It has been widely reported that the 
expression of drug metabolizing enzymes and transporters are regulated at the 
transcriptional level by nuclear transcription factors and post-transcriptional level 
by regulatory mechanisms such as miRNA. Besides the cis-acting genetic 
variations present in the candidate genes, future studies should establish the 
relative impact of these factors on the metabolism of tamoxifen. Further studies 
should also investigate the pharmacogenetic correlations with the therapeutic 
outcome of tamoxifen treatment in Asian breast cancer patients. 
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Despite being widely employed in clinical care for almost four decades, no 
consensus about the optimal therapeutic range for tamoxifen has been 
established. This can be partly attributed to the complex pharmacodynamics of 
tamoxifen with multiple metabolites exhibiting anti-estrogenic and weak 
aromatase inhibitory activity. The plasma concentrations for tamoxifen 
metabolites are also found to increase with age. Thus, future studies should 
evaluate the therapeutic ranges and pharmacokinetic-pharmacodynamic 
relationship of tamoxifen with consideration of the combinatorial effects of these 
active metabolites.  
Besides the candidate genes identified along the metabolic pathways of 
tamoxifen, there could be other genetic factors that contribute to the wide 
variabilities in the plasma concentrations of tamoxifen metabolites. To identify 
these novel putative targets which can influence the pharmacokinetics and 
treatment outcome of tamoxifen, genome-wide association study or GWAS 
studies can be conducted. In contrast to the approach adopted in the present 
study, the entire genome is interrogated during a GWAS analysis (475). The 
associations between polymorphic variants and the phenotypic parameters are 
then analysed for possible correlations. Hence, future GWAS study can be 
conducted to evaluate the difference in the the genetic profile among patients 
who are either having high plasma levels of active tamoxifen metabolites or 
favorable treatment response, compared to patients who have low plasma levels 
of active tamoxifen metabolites or poor response to tamoxifen.  
However, one prevailing problem with GWAS study is the non-reproducibility of 
the results (475). In the study of tamoxifen pharmacogenetics, a GWAS study 
has been conducted among Japanese breast cancer patients who were receiving 
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tamoxifen as adjuvant treatment (476). The study identified a novel association 
between recurrence-free survival and the genetic locus, C10orf11. Interestingly, 
CYP2D6 was not identified as a significant factor influencing survival. 
Nevertheless, the investigators further analysed the newly identified locus with 
CYP2D6 in relation to patient survival and found cumulative effects of these 
genetic loci on the recurrence-free survival of patients. Similarly, CYP2D6 was 
also not recognized as a significant factor in another study which performed 
genome-wide screening of SNPs in lymphoblastoid cell lines of Caucasian ethnic 
origin (477). However, the causative locus identified as genetic predictor of 
endoxifen sensitivity is USP7 which differs from that in the Japanese cohort. One 
possible reason for the varied observations is the difference in the endpoint 
measures considered in these two studies. In addition, the genotyping platforms 
employed are also different. Thus, future GWAS analysis in our Asian breast 
cancer patients may yield interesting results which deviate from that of the 
current reports.  
Nonetheless, a regression analysis should be performed subsequent to the 
genome-wide scan to delineate the relative contributions of the newly-identified 
genetic loci in comparison to the CYP2D6 which has been estimated to account 
for approximately 50% of the variations in endoxifen plasma concentrations. In 
summary, future research should position to unravel the mystery behind the 
factors influencing tamoxifen pharmacokinetics as well as the link between the 
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Appendix C: Post-hoc Power Analysis. 
Table C1. Post-hoc study power to detect various effect sizes (0.10 – 1.00) at variant allelic frequencies 
ranging from 0.10 to 0.90 for sample size of N=163. 
Effect size, d 
Power (1 - β err prob) at different variant allelic frequencies, q 
0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 
0.10 0.079 0.094 0.097 0.094 0.085 0.075 0.066 0.058 0.052 
0.15 0.116 0.150 0.158 0.150 0.131 0.107 0.085 0.067 0.055 
0.20 0.169 0.230 0.245 0.230 0.196 0.153 0.114 0.081 0.059 
0.25 0.238 0.332 0.354 0.332 0.280 0.213 0.151 0.099 0.064 
0.30 0.321 0.448 0.477 0.448 0.379 0.286 0.196 0.121 0.070 
0.35 0.414 0.569 0.603 0.569 0.487 0.370 0.250 0.147 0.078 
0.40 0.513 0.684 0.718 0.684 0.596 0.460 0.311 0.177 0.086 
0.45 0.611 0.784 0.815 0.784 0.698 0.552 0.379 0.212 0.096 
0.50 0.702 0.862 0.887 0.862 0.786 0.642 0.450 0.251 0.108 
0.55 0.782 0.918 0.937 0.918 0.857 0.724 0.523 0.293 0.120 
0.60 0.848 0.955 0.968 0.955 0.911 0.796 0.595 0.339 0.134 
0.65 0.899 0.977 0.985 0.977 0.947 0.856 0.664 0.387 0.149 
0.70 0.937 0.990 0.993 0.990 0.971 0.902 0.728 0.437 0.165 
0.75 0.962 0.996 0.997 0.996 0.985 0.936 0.786 0.488 0.182 
0.80 0.979 0.998 0.999 0.998 0.993 0.961 0.835 0.539 0.201 
0.85 0.988 0.999 1.000 0.999 0.997 0.977 0.877 0.590 0.221 
0.90 0.994 1.000 1.000 1.000 0.999 0.987 0.910 0.639 0.242 
0.95 0.997 1.000 1.000 1.000 0.999 0.993 0.936 0.686 0.264 
1.00 0.999 1.000 1.000 1.000 1.000 0.996 0.956 0.730 0.287 
† Shaded region indicates the effect size which can be detected with a power of at least 80% at the respective 
variant allelic frequencies. 
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Table C2. Post-hoc study power to detect various effect sizes (0.10 – 1.00) at variant allelic frequencies 
ranging from 0.10 to 0.90 for sample size of N=202. 
Effect size, d 
Power (1 - β err prob) at different variant allelic frequencies, q 
0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 
0.10 0.086 0.104 0.109 0.104 0.094 0.081 0.069 0.059 0.052 
0.15 0.132 0.175 0.185 0.175 0.152 0.121 0.093 0.070 0.055 
0.20 0.198 0.274 0.293 0.274 0.233 0.178 0.127 0.086 0.059 
0.25 0.282 0.397 0.424 0.397 0.337 0.252 0.172 0.106 0.064 
0.30 0.382 0.531 0.564 0.531 0.454 0.341 0.227 0.131 0.070 
0.35 0.490 0.662 0.697 0.662 0.576 0.440 0.292 0.162 0.078 
0.40 0.599 0.776 0.807 0.776 0.691 0.542 0.364 0.197 0.087 
0.45 0.701 0.864 0.889 0.864 0.790 0.642 0.442 0.237 0.097 
0.50 0.789 0.925 0.942 0.925 0.868 0.733 0.522 0.281 0.108 
0.55 0.860 0.962 0.973 0.962 0.923 0.811 0.601 0.329 0.120 
0.60 0.913 0.983 0.989 0.983 0.958 0.873 0.676 0.380 0.134 
0.65 0.949 0.993 0.996 0.993 0.979 0.919 0.745 0.434 0.149 
0.70 0.972 0.997 0.999 0.997 0.990 0.951 0.805 0.488 0.165 
0.75 0.986 0.999 1.000 0.999 0.996 0.972 0.856 0.543 0.183 
0.80 0.993 1.000 1.000 1.000 0.998 0.985 0.897 0.598 0.202 
0.85 0.997 1.000 1.000 1.000 0.999 0.992 0.929 0.650 0.222 
0.90 0.999 1.000 1.000 1.000 1.000 0.996 0.952 0.699 0.243 
0.95 1.000 1.000 1.000 1.000 1.000 0.998 0.969 0.746 0.265 
1.00 1.000 1.000 1.000 1.000 1.000 0.999 0.981 0.788 0.288 
† Shaded region indicates the effect size which can be detected with a power of at least 80% at the respective 
variant allelic frequencies. 
 
